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INTRODUCTION 
The goal of this study is the development and the assessment of 
clinically applicable selection criteria for rational antimicrobial 
drug utilization. 
Rational use of antimicrobial agents is of relevance as the choice 
of the drugs, the route of administration, the dose, and the 
duration of therapy can interfere with the bacterial flora of an 
individual patient, of a particular ward, of a total hospital, and 
of the environment. It has been shown that inappropriate use of 
antimicrobial agents has led to a decrease in the efficacy of these 
drugs . Since overuse of antibiotics is directly linked to the 
emergence of drug-resistant bacteria, this is a world wide public 
health problem. 
Apart from promoting the emergence of registant strains, overuse and 
inappropriate use of antimicrobial agents results in unnecessary 
toxicity in patients, and to a marked increase in costs with little 
or no therapeutic gain. For rational antimicrobial drug therapy, the 
choice of the drug, the route of administration, the dosage and dose 
interval, and the duration of treatment have to be tailored both to 
the specific indications and to the individual patient. To provide 
rational antimicrobial drug utilization, several elements should be 
considered. They can be classified into the following components: 
Pharmacokinetics, Epidemiology, Therapeutic team management, and 
Policy development and decision making. The first topic is concerned 
with the reaction properties of a drug. In the second, the factors 
involved in selecting a particular drug for a particular situation 
come into consideration. To achieve rational antimicrobial drug 
therapy, a means must be found to brinq into practice the knowledge 
that is obtained from the two first mentioned fields. Therapeutic 
team management achieves the direct application of this knowledge, 
while policy development and decision making provides an instrument 
to guide the team's functioning. 
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1 PHARMACOKINETICS 
1.1 Antimicrobial agents 
For programming an adequate dosage regimen, the kinetic parameters 
of antimicrobial agents should be taken into account. In addition, 
the kinetic parameters of the metabolites of these compounds are 
essential since the metabolite(s) may interfere with the usefulness 
of the active antimicrobial agent. 
1.2 Antimicrobial agents and impairment of pathways of drug 
elimination 
The elimination of a drug from the body may proceed by metabolic 
and/or renal elimination. Metabolic and renal dysfunction therefore 
are likely to interfere with their elimination. Thus, when 
considering the optimal use of antimicrobial agents, the functional 
status of the liver and the kidney must be taken into account. 
2 EPIDEMIOLOGY 
2.1 Drug data 
The appropriate choice of a drug is one condition of rational 
therapy. Besides understanding the pharmacokinetic properties (1.1 
and 1.2), knowledge concerning the activity of a drug, its clinical 
use, possible adverse effects and its mode of action is necessary. 
New knowledge in these areas may necessitate a reappraisal of 
current principles applied to the treatment of bacterial infections. 
2.2 Microorganism data 
Patterns of microorganisms and their susceptibility do change, and 
microorganisms can develop resistance. These factors require 
monitoring. Changes in these factors should be taken into account 
when maximal effectiveness of antimicrobial agents is desired. 
2.3 Patient data 
Monitoring on the patient level of the effects of the drug, drug 
therapy, therapeutic benefits and of the side effects are necessary. 
This monitoring consists of collecting data concerning the 
administration of the drug, the age and sex of the patient,and 
18 
possibly also further details about his li.'e and medical history. 
The assessment of rational antimicrobial diug utilization requires 
judgement on the patient level. Data that should be recorded 
concerning the patient with an infectious disease, include the 
nature and the site of infection, the causative microorganism and 
the susceptibility data for the microorganisms. Also it is strongly 
recommended that the outcome of the therapy on the individual 
patient level be recorded, giving such data as leucocyte counts, 
body temperature and presence of wound infections. This information 
can then be combined and analyzed to provide data on the ward level 
and hospital level. 
3 THERAPEUTIC TEAM MANAGEMENT 
3.1 Problem assessment 
Patient care has become more complex in all areas. Along with the 
increased technology and sophistication in procedures pharmaco-
therapy has shown a rapid development. It can be questioned whether 
one individual is still capable of coordinating all the various 
aspects that must be taken into consideration if quality health care 
is to be provided. 
3.2 Team concept solution 
This coordination can be achieved through an interdisciplinary team, 
engaged in a collaborative system of health care. Such a team would 
be capable of guiding therapeutic activity both for direct patient 
care, in the form of therapeutic decision making, and for indirect 
care, in the form of policy and procedure development. 
4 POLICY DEVELOPMENT AND DECISION MAKING 
4.1 Policies and procedures 
In order to promote and improve the quality of the services 
delivered, policies and procedures in health care are required to 
regulate the activities pertaining to the practice of medicine, 
pharmacy and allied health professions. 
4.2 Decision making 
In recent years efforts have been made to develop a more systematic 
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approach to decision making under the conditions of uncertainty as 
occur in the clinical setting. Algorithms,explicit descriptions of 
appropriate steps to be taken in the care of a patient with a 
particular problem, tend to promote consistency in the treatment. 
4.3 The strategy 
A prerequisite in any model of policy development and decision 
making is the assessment of the sequence of steps that must be 
carried out. It is important that the model be flexible so that 
continuous adaptations can be made in the light of current findings. 
Rational antimicrobial drug utilization can only be achieved when 
the knowledge obtained from the elements of pharmacokinetics and 
epidemiology are fully integrated in the therapeutic team management 
through policy development and decision making. In the following 
chapters these elements will be discussed in more detail. 
The appendix to this thesis contains reports related to each of 
these fields. 
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CHAPTER 1. 
PHARMACOKINETICS 
1.1 Antimicrobial agents 
Pharmacokinetics is the study of the rates of drug absorption, 
25 
distribution and elimination . Using the techniques of modern 
pharmacokinetics, the rates of change that take place during the 
course of these processes can be determined. Knowledge of such rates 
contributes to the formulation of adequate dosage regimens for 
treating infectious diseases ' ' 3 . 
Clinical pharmacokinetics, the application of pharmacokinetic 
principles to patient therapeutic management, contributes to a 
better understanding of the mechanisms of absorption, distribution 
and elimination, and therefore it will lead to optimum dosage and 
19 dose rates for an individual treatment . 
1.1.1 Dosage regimen 
The guiding principle of antibacterial therapy is to maintain the 
necessary antibiotic concentration in the biophase for the length of 
time necessary to kill the requisite number of microbes or to 
inhibit their generation, thus allowing the defense mechanism of the 
20 body to destroy them . 
The plasma concentration-time profile of the drug needs to be 
considered in order to program an adequate dosage regimen. Such a 
dosage regimen depends on the pharmacokinetic and biopharmaceutic 
properties of the chosen drug. 
In order to assess how adequately a particular regimen functions, 
pharmacokinetic properties such as half-life, the plasma 
concentration-time profiles resulting from different routes of 
administration, the bioavailability, the mechanisms of elimination, 
and the penetration capacity into the cerebrospinal fluid or sputum 
need to be taken into consideration ' . 
1.1.2 Plasma concentration 
In clinical practice, apart from the problem of whether the drug 
will be active against the pathogenic organism, the question remains 
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what concentration of this drug in the body can be considered 
effective, adequate and safe. Such α concentration should be 
maintained during the duration of therapy. Furthermore,it should be 
kept in mind that for the therapeutic effect, an adequate 
concentration of the drug at the site of infection must be 
maintained. Thus, knowledge of the concentrations of antimicrobial 
agents in the tissue fluids is of extreme importance . Because 
tissue fluid concentration measurements are difficult to carry out 
in patients, they have generally been evaluated by the use of wound 
exudates or by studying a similar infection induced in laboratory 
animals . 
The development of methods to meas'ir" tissue fluid concentration 
is an aspect that requires further investigation. Since, as 
discussed above, the drug concentration is of such importance, 
emphasis has been placed on the plasma level of antimicrobial 
agents. For some drugs (sulfonamides and trimethoprim) it is 
important to achieve a 'constant' steady state plasma concentration, 
in order to inhibit the generation of microbes. The level of this 
concentration is directly related to the dose and the scheduled 
dosage interval . 
For drugs like the aminoglycosides, it is regarded desirable to 
achieve peak and trough concentrations. For these drugs, it is usual 
to avoid a steady state plasma concentration, because the antibiotic 
drug should only be present in adequate concentrations in some 
phases of the logarithmic growth phase of the pathogen, and because 
adverse effects, such as nephrotoxicity and ototoxicity can thus be 
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avoided . 
1.1.3 Methods of analysis 
In the past years, increased attention has been focussed on the 
study of the pharmacokinetics of antimicrobial agents. With HPLC 
(High Performance Liquid Chromatography) it appears possible to 
perform rapid quantitative and qualitative analysis of antimicrobial 
drugs in body fluids. Further, simultaneous detection and 
measurement of the microbiologically active compound as well as the 
microbiologically active and inactive metabolites can be rapidly 
determined. These distinctions could not be achieved with the 
classic microbiologic assay procedures, since these procedures are 
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based only upon microbiological activity. Furthermore, factors 
interfering with the microbiologic assay, such as the pH of the 
culture medium, properties of eluentia, sterility in the handling of 
samples, do not interfere with these analytical (HPLC) 
methods .These methods will have a great impact on the study of 
penetration capacities of antimicrobial agents in body tissues. 
1.1.4 Experimental results 
1.1.4.1 Method development 
The research activities of the Clinical Pharmacy group in the field 
of antimicrobial agents started in 1977, when therapeutic drug 
monitoring of antimicrobial agents in the body fluids of man were 
first discussed with members of the Intensive Care Unit. 
The activities were primarily focussed on the development of 
physical analytical methods for the determination of antimicrobial 
agents. With the HPLC method a new technique was developed for the 
determination of cephalosporins , nitrofurantoins , penicillins 
and sulfonamides . 
The HPLC technique has been used to perform pharmacokinetic studies 
on beta-lactam antibiotic drugs ' ' , and in particular on the 
group of sulfonamides12'30'35'36 (Appendix I 1,2,3,4,5,6,7). 
HPLC methods have been compared with the microbiologic assay 
procedures. The usefulness of the HPLC method could be demonstrated 
in particular for the beta-lactam antibiotic drugs . 
1.1.4.2 Pharmacokinetic information obtained 
For several reasons the sulfonamides were selected to study 
pharmacokinetic properties. Sulfonamides are 'safe' compounds with 
moderate effects that can be tolerated by volunteers. The dose can 
be high enough to ensure accurate and confident measurement of 
pharmacokinetic data. These data were collected through an HPLC 
determination. This method discriminates between the parent drug and 
its metabolite. This could not be achieved with the classical 
methods of determination ' . In addition, the group of sulfonamides 
remains of relevance in clinical practice, not only in the 
development countries, but also in the western world . 
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A detailed survey has been given for the kinetic properties of the 
eleven most currently used sulfonamides, the N.-acetylsulfonamide 
derivatives and their metabolites (Appendix I 1,2). 
After establishing the plasma concentration-time curves and renal 
excretion rate-time profiles when a sulfonamide and its metabolite 
were consecutively administered, it became possible to elucidate the 
relationship between the structure of a sulfonamide and that of its 
metabolite with its mechanims of metabolism and renal excretion 
(Appendix 1 3 ) . 
When studying the kinetic fate of the N^-acetylsulfonamide 
derivatives after administration to man, the phenomenom of 
deacetylation of the metabolite into sulfonamide became evident. It 
is suggested that deacetylation is part of the acetylation-
deacetylation equilibrium of sulfonamides. That this acetylation-
deacetylation balance exists in man could be shown after the 
ingestion of N.-trideuteroacetylsulfamerazine. After the oral 
intake of this deuterated compound, its profile was followed using 
HPLC and mass-spectrometry. Specifically, N^-trideuteroacetylsulfa-
merazine, its deacetylated compound sulfamerazine, and the N.-
acetylsulfamerazine metabolite of sulfamerazine were detected and 
measured (Appendix 1 4 ) . The half-lives of N4-trideuteroacetylsulfa-
merazine (5.0 h) and N.-acetylsulfamerazine (23 h) as measured in 
this experiment, differ considerably. Both these half-lives had 
already been found after the intake of N.-acetylsulfamerazine as the 
parent compound. The biphasic profile of the plasma concentration-
time curve of N4-acetylsulfamerazine can now be explained as a 
metabolic equilibrium (acetylation-deacetylation) and not as a 
result of a two compartment model. Deacetylation of N.-acetylsulfa-
merazine results in the formation of sulfamerazine, which again 
becomes acetylated into N.-acetylsulfamerazine as soon as it is 
formed. 
When one considers a particular metabolic equilibrium, the result is 
the following series of metabolic oscillations: 
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When the intrinsic half-life of the metabolite is much shorter than 
that of the parent compound, a biphasic profile of the plasma 
concentration-time curve can be expected . 
A similar, biphasic shape of the plasma concentration-time curves 
has been described for diazepam metabolites. This occurence can be 
explained by such a metabolic equilibrium between glucuronidation-
deglucuronidation (Appendix 1 5 ) . 
To properly understand the pharmacokinetic profiles of drugs, it is 
important to know if an equilibrium exists . The data about the 
pharmacokinetic properties of sulfonamides and metabolites can be 
utilized as reference data, in order to adjust the drug dosage 
regimen in patients with impaired metabolic or elimination pathways 
(see 1.2.3.1 and 1.2.3.2). 
1.2 Antimicrobial agents and impairment of pathways of drug 
elimination 
In drug therapy, three variables are of importance, i.e. the drug 
choice, the drug dose and the dosage interval. 
When a particular drug has to be administered to a patient, in whom 
a specific mechanism of drug elimination is partly or totally 
deteriorated as a result of disease, one must have a full 
understanding of the elimination pathways of this drug. This 
anticipates the behaviour of the drug in the actual condition of the 
patient and prevents side effects resulting from an accumulation of 
the parent drug and possibly of its metabolite(s). 
The elimination of a drug from the body may proceed by mechanisms 
listed in table 1. 
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TABLE 1. SOME PATHWAYS AND PATHWAY COMBINATIONS OF DRDG ELIMINATION 
1. Renal elimination only. 
2. Metabolic elimination only. 
3. Metabolic- and renal elimination of the parent drug. 
4. Metabolic elimination of the parent drug and renal elimination of 
the metabolite. 
5. Metabolic- and renal elimination of the parent drug and renal 
elimination of the metabolite. 
Metabolic and renal dysfunction are therefore likely to interfere in 
the metabolism and/or renal elimination of drugs. 
1.2.1 The liver 
The liver has a limited capacity for responses to pathological 
insults. Chronic liver disease tends to present comparable 
pathophysiological and clinical symptoms irrespective of its 
aetiology . It has been shown that the clearance of some drugs, 
predominantly eliminated by hepatic clearance, was reduced in cases 
of liver disease ' . Chronic liver disease is a complex situation 
which remains subject to intensive research activities. In 
individual patients it is impossible to predict how dosage 
adaptation should be made . Subchronic therapy can best be adapted 
by taking into account how the drug is eliminated as determined by 
16 
clearance monitoring during the course of therapy . 
1.2.2 The kidney 
The elimination of drugs, excreted entirely or partly unaltered by 
the kidneys, is slower in patients with renal dysfunction than in 
о 25 
patients with normal renal function ' . Many guidelines have been 
prepared for drug action and pharmacokinetics during renal 
failure ' ' ' . Generally the guiding principle has been to modify 
the 'usual' dosage regimen in such a way that the resulting drug 
level is about the same as that in patients with normal renal 
Q 
function . In this respect, individual drug elimination parameters 
have been estimated based upon the patient's creatinine clearance or 
serum creatinine concentration ' ' ' . 
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The elimination rate fraction is determined by nomograms; these 
describe the elimination rate of the drug as a fraction of its 
normal elimination rate constant. The usual parameters for the 
detection of kidney failure are an increase of serum creatinine 
concentration and a reduced creatinine clearance. To detect kidney 
failure in an early phase, new parameters such as the renal 
excretion rate or apparent renal clearance of the beta-2-micro-
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globulin and alanine-amino-peptidase have been suggested ' ' * . 
Their value is presently subject to intensive research activities. 
For the rational use of antimicrobial agents in patients with 
impaired kidney function, it is essential to know what the effects 
of all degrees of altered renal function would have on the behaviour 
of each drug to be used. However, quite often the basic 
pharmacokinetic mechanisms of the drug are far from well understood, 
even in patients with normal kidney function. 
1.2.3 Experimental results 
1.2.3.1 Sulfonamides 
Elimination of various sulfonamides from the human body occurs by 
12 36 
metabolism (acetylation) and renal excretion of the metabolite ' 
(Appendix I 1,3). For sulfamethoxazole, it has been demonstrated 
that its kinetic parameters, such as half-life, remain unaffected in 
patients with impaired kidney function, whose creatinine clearance 
remains over 15 ml/min (Appendix I 6). When creatinine clearance 
falls below 15 ml/min, the half-life of sulfamethoxazole is 
increased up to 40 h ( Appendix I 6). This increase in half-life is 
not caused by inhibition of the renal excretion of the compound 
itself, but results from the fact that the metabolite cannot be 
excreted. This inhibition results in a shift of the metabolic 
equilibrium, and deacetylation of the metabolite influences the 
measured half-life of the parent sulfonamide (see 1.2.3.2 and 
Appendix I 6,7). 
1.2.3.2 N.-acetylsulfonamide metabolites 
N.-acetylsulfonamide metabolites are eliminated from the body 
predominantly by renal excretion (Appendix I 3). Acetylated 
metabolites of sulfonamides are devoid of antibacterial activity, 
1Θ yet they retain the toxic potentials of the parent drugs 
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In contrast to sulfamethoxazole, the elimination rate of N¿-
acetylsulfamethoxazole is proportional to creatinine clearance. In 
patients with impaired kidney function, an increase of up to 40 
hours in half-life could be measured instead of the usual half-life 
of approximately 12 hours found in patients with normal kidney 
function. Extension of the half-life of the metabolite to 40 hours, 
causes the compound to accumulate. When the metabolite N4-
acetylsulfamethoxazole cannot be excreted, the deacetylation to 
sulfamethoxazole influences the half-life of the latter compound, 
which adopts the half-life of the metabolite. The same phenomenon is 
shown for sulfametrole (Appendix I 6,7). 
1.2.4 Conclusion 
In patients with an impaired kidney function, a thorough knowledge 
of metabolic and renal clearance of the administered drug is 
necessary. Reduction of the dose and/or an increase in the dosage 
interval seems to be the most appropriate method to avoid 
accumulation of a drug or its metabolite. As has been mentioned 
(1.2.3.1), the half-life of sulfamethoxazole remains unchanged in 
kidney impairment if creatinine clearance is more than 15 ml/min, as 
its route of elimination, metabolism by acetylation, remains 
unaffected. The same holds for sulfametrole. 
However, the half-lives of N.-acetylsulfamethoxazole and N4-
acetylsulfametrole are highly affected by kidney failure (1.2.3.2). 
The kinetics of both the parent drug and its metabolite(s) must be 
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considered when dosing a patient with renal impairment . For 
instance, dosing a patient solely with sulfamethoxazole and 
neglecting to consider the kinetics of its metabolite could be 
dangerous. Conversely, avoidance of the side effects of its 
metabolite by a dosage reduction of sulfamethoxazole may represent 
undertreatment of the patient and lead to therapeutic failure. In 
this instance, a change in the choice of the drug to a structural 
analogue such as sulfamethizole or sulfaethidole with almost 
identical intrinsic effects, but with more suitable kinetic 
parameters, is a third alternative to compensate for the reduction 
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of one pathway of elimination (Appendix 1 7 ) . If none of the 
foregoing is plausible, a last alternative may be to select a drug 
from a completly different class of compounds, taking into account 
the previously mentioned precautions. However, the benefit-risk 
balance of each drug used in treating an individual patient should 
be known so that problems, such as those revealed during the 
investigation of the sulfonamides, can be identified (Appendix I 7). 
As has been shown with this example, a working knowledge of 
pharmacokinetics is an essential component for establishing 
selection criteria for antimicrobial drug utilization· 
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CHAPTER 2 
EPIDEMIOLOGY 
2.1 Introduction 
Epidemiology has been defined as the study of the distribution of 
29 
the determinants of disease in human populations . It involves 
collecting, recording, analysing and evaluating data on disease in 
human populations. In recent years, epidemiological methods have 
also been utilized for recording drug efficacy, the adverse effects 
of drugs and the emergence of resistant pathogens in the 
environment. 
To rationalize antimicrobial drug therapy, it is necessary to 
collect data about drugs, microorganisms, and patients. Analysis of 
such data is an essential element in the rational choice of drug 
therapy in particular situations. Epidemiological monitoring 
consists of making routine observations on health and environmental 
parameters, and recording and transmitting these data . 
2.2 Drug data 
2.2.1 Methods 
In order to rationalize antimicrobial therapy, it is necessary to be 
well informed about the efficacy, activity and safety of the 
individual antimicrobial agents. 
In recent years, the antimicrobial approach to infections has been 
subjected to a fundamental change. For example, advances have been 
made in the diagnosis and treatment of anaerobic infections, in the 
policy of combining antibacterial drugs, in prophylactic 
antimicrobial drug therapy, and in the shortening of the period in 
which antibiotics are administered for both prophylaxis and 
treatment . 
Continuous evaluation, reappraisal, and review of literature data 
with respect to drug use is a prerequisite for selecting an 
appropriate drug. In this manner other uses have been found for 
metronidazole. Originally, this drug was introduced in 1960 for the 
treatment of vaginitis caused by Trichomonas Vaginalis. Recently, 
this drug has been found to be very effective in treating anaerobic 
infections"
 m 
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Another example is the rapid change in the policy of antimicrobial 
therapy in patients with urinary tract infections. In this field, 
large variations were noted in duration of treatment and the choice 
of drugs used. An investigation and evaluation of the situation has 
resulted in changes in drug therapy, both in its duration and in the 
choice of drugs. 
Attention has been focussed on the course of drug therapy. The use 
of short courses of antibiotics for uncomplicated urinary tract 
infections has been supported by several studies ' ' ' ' . Such 
treatment involves administering either a single dose or a short 
term course of an antibiotic. A single dose treatment regimen has 
several advantages over more prolonged antibiotic therapy. The 
microbiological flora of the rectum, vagina and periurethral area 
are less likely to be altered by a single dose. Side effects and 
drug costs are usually reduced . 
Several authors have compared the merits of using only trimethoprim 
13 22 instead of trimethoprim/sulfonamide combinations ' . Since 1973, 
trimethoprim is used as a single drug to treat urinary tract 
infections in Finland. In 1978, trimethoprim has been released for 
use as a single drug in other countries, including The United 
States, Great Britain, and The Netherlands. 
2.2.2 Experimental results 
Recent literature has been reviewed concerning the diagnosis, 
treatment and prevention of urinary tract infections. Factors 
affecting the choice of drug and recent studies concerning the 
duration of therapy are detailed (Appendix II 1). In this review, 
attention has been focussed on the use of trimethoprim. 
The history and antibacterial properties for trimethoprim are 
outlined, indications for the clinical use of this drug are 
presented and possible new uses are considered (Appendix II 2).For 
acute urinary tract infections, promising results with single doses 
of trimethoprim were obtained . In this study a commercially 
available dip-inoculum technique was used to determine the quantity 
of bacteriuria. The validity of the inoculum technique was 
demonstrated in a comparison with routine bacteriological counts^. 
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2.3 Microorganism data 
Once the relationship of microorganisms to infectious disease was 
understood, an intensive search was initiated to study 
antimicrobial therapy. In recent years, remarkable progress has been 
made in the development and clinical use of antimicrobial agents. 
However, many microorganisms are capable of developing resistance to 
many of the antimicrobial agents. The rate of development and the 
nature of this resistance varies widely. Some strains of 
microorganisms become drug tolerant, others inactivate the drug by 
enzymic action, while others initially sensitive to the drug, become 
increasingly resistant during the period that the drug is 
administered. Drug resistance in some instances is transmissible by 
Plasmids, leading to the situation that microorganisms become 
resistant to a drug without having come in contact with that drug^ . 
In recent years, it has become clear that inappropriate use of 
antibiotics is a major factor in the development of resistance. 
In 1974, Simmons and Stolley presented a comnentary on misuse of 
antibiotics. They suggested that 'hundreds of thousands of patients 
may be unnecessarily exposed to the hazards of antibiotics because 
of their inappropriate use'. In several intensive monitoring 
studies, this statement could be confirmed8'21'30'36. 
2.3.1 Use of antimicrobial agents 
Antimicrobial agents are used to prevent infection (prophylaxis) and 
to treat confirmed bacterial infection (therapy). 
2.3.1.1 Antimicrobial prophylaxis 
The topic of antibiotic prophylaxis continues to be important. It 
has been estimated that more than one third of antimicrobial 
utilization is to prevent infection . Prophylaxis is much more 
likely to be successful if one knows the bacterium, or at least the 
group of bacteria, that has the highest probability of causing the 
infection that is to be prevented. Careful record keeping of all 
pathogens isolated in the laboratory, with their antibiotic 
sensitivities, is important. Data, such as patterns of 
microorganisms found in various locations, and clustering of 
resistant strains, must be subject to epidemiological monitoring. 
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This data accumulation facilitates the search not only for the most 
likely causative microorganisms, but also for the choice of the most 
appropriate drug. An effective prophylactic regimen should be 
directed against the most likely infecting organisms, but it should 
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not be active against every potential pathogen . The antibacterial 
spectrum should be narrow so that there is minimal disturbance of 
the patient's normal flora . 
Despite 40 years of extensive investigation, many questions remain 
unresolved about prophylactic use of antibiotics during surgical 
treatment. Clinical trials on this subject have also generated 
confusion and left the clinician with few firmly established 
guidelines. Berger et al , have demonstrated the inadequate design 
of most clinical trials that examine antimicrobial prophylaxis in 
surgical procedures. Berger et al , established as standards for 
adequate design: prospective design, concurrent controls, 
randomization, double-blind procedure, diagnostic criteria, 
consideration of the extent of disease and underlying disease, 
tabulation of complications of prophylaxis and statistical analysis. 
Most of the 157 studies analysed concerning antimicrobial 
prophylaxis failed to fulfill even half of the methodological 
standards. They concluded that the basis for much controversy in 
this field might be the violation of these fundamental principles in 
selection and comparison of experimental subjects in the clinical 
investigations of antimicrobial prophylaxis as used in surgical 
procedures . 
2.3.1.2 Antimicrobial therapy 
The purpose of antimicrobial therapy is to treat confirmed and 
established bacterial infections. Because of the severity of the 
infection, it is not always possible to wait for microbiological 
data. In the case of a life threatening infection, where a bacterial 
cause is suspected, therapy is initiated with an antimicrobial drug 
that provides broad coverage. 
The definitive choice of the antibacterial drug is based upon 
microbial isolation and in vitro susceptibility tests. The 
microbiological basis for standard antimicrobial therapy is a 
susceptibility test, performed by disc diffusion techniques. In this 
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test, a suspension of the bacterial strain adjusted to a standard 
density is swabbed on agar and antibiotic discs are placed on the 
surface of the plate. After incubation for 18 to 24 hours at 350C, 
the diameter of the zone of inhibition around each disc is roughly 
proportional to the susceptibility of the organism to the 
antimicrobial agent in the disc. Zone diameters specified for each 
antimicrobial agent distinguish 'resistant', 'intermediate' and 
'sensitive' bacterial strains. 
These characterizations are based on zone sizes found with many 
strains of rapidly growing bacteria, the results of quantitative 
tube dilution tests with the same strains, and the blood 
concentrations of antimicrobial agents obtained with reconmended 
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doses . Such susceptibility data contribute in the selection of a 
drug for practical therapy. 
For the evaluation of a new drug, or for research purposes, other 
parameters are also used , such as the minimal inhibitory 
concentration (MIC), the minimal bactericidal concentration (MBC) 
and the minimal antibiotic concentration (NAC). The most frequently 
utilized parameter for measuring the efficacy of an antibiotic is 
the minimal inhibitory concentration (MIC). 
It is realized that, depending on the method applied, various 
factors, such as pH, protein-binding,ion content, antagonists, 
inoculum size etc., may influence the results of such a test. 
Standard methods must be used in every laboratory to facilitate 
interpretation of the results, for it has been shown that MIC 
differs notably from test system to test system, and that the 
laboratory values may also differ from the actual MIC at the 
38 infection site in the patient . 
Even when disc susceptibility tests are carefully performed 
according to standard procedures, other factors such as the 
condition of the patient (neutropenia, imnunoeuppression), the 
virulence of the organism, the severity and site of the infection, 
as well as the dose and route of administration of the antimicrobial 
agent are important variables. The patient's response to the drug is 
the ultimate test of its effectiveness; a poor response to a drug 
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used against a 'susceptible' organism may indicate that effective 
concentrations of the drug are not reaching the organism, and that 
26 surgical drainage or larger doses may be needed . On the individual 
patient level, the reporting of laboratory culture and antimicrobial 
susceptibility data as a part of the daily routine is of great value 
for the appropriate treatment with effective antimicrobial agents. 
2.3.2 Infection control programs 
Day to day requests for routine bacteriological data are used to 
support therapeutic decisions. Such data are generally delivered to 
the attending physician. At a later date they are compiled in 
retrospective surveys made by the bacteriologist. 
It has been shown that information important to all health care 
workers can be obtained through routine data processing of all 
positive cultures f reati a particular geographical area, together with 
the strains and their susceptibility patterns. In the United States 
the Joint Commission on Accreditation of Hospitals (JCAH) has 
provided a major impetus and been a support for the development of 
infection control programs. In their report, three standards are 
outlined. 
In the JCAH infection control standard I, nine basic elements are 
mentioned that should be included in an active hospital wide 
32 infection control program . 
1. Definition of nosocomial infections. 
2. A practical system for data collection and analysis. 
3. Written policies and procedures for asepsis, isolation and 
sanitation, with ongoing review. 
4. Specific indications for isolation, with provisions for 
ensuring high quality patient care. 
5. Written procedures for prevention, surveillance and control of 
environment related infection problems. 
6. Provision for the necessary laboratory support. 
7. Participation in the employee health program. 
Θ. Employee orientation and in-service education. 
9. Coordination of the medical staff on procedures resulting from 
antibiotic reviews. 
According to the JCAH standards, the medical staff, not the 
infection control practitioner or committee, is responsible for 
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monitoring antibiotic usage. However, the functions of the infection 
control committee are to review and evaluate the medical staff's 
findings and to work with the medical staff in determining and 
implementing any action that should be taken. 
Standard 2 deals with the responsibility for monitoring the 
infection control program. Such a program must be vested in a 
multidisciplinary (hospital) committee. The membership categories 
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that are required, recommended, and consultative are outlined . 
Finally, standard 3 deals with specific written infection control 
policies and procedures for all services throughout the hospital. 
Recently, a proposal for a nationwide control program in the 
Netherlands has been published . 
This proposal is based on the results of the SENIC project (Study on 
the Efficacy of Nosocomial Infection Control) coordinated by the 
Center for Infectious Diseases of the Centers for Disease Control, 
Atlanta, USA (CDC). 
2.3.3 Experimental results 
The patient drug profile including the bacteriological 
determinations was monitored on a daily basis by this author on 
medical wards, such as the ICU and the neurological ward. For the 
continuing education and assessment of appropriate antimicrobial 
usage, reports about antibiotic susceptibility and resistance trends 
were regularly discussed. These data were valuable for the 
preparation, introduction and maintenance of guidelines for rational 
antimicrobial usage that will be discussed in chapter 3 (Appendix 
III 1,2,3). 
2.4 Patient data 
On the individual patient level, systems have been developed to 
monitor the benefits or adverse effects of drug therapy. 
The essential components of this system are records for each patient 
stating which drug or drugs are administered and what 'reactions• 
are exhibited. These are usually supplemented by other information 
containing at least the age and sex of the patient, and possibly 
further . details about his life and medical history so that the 
relevance for epidemiological collection is improved . 
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In hospitals, such clinical records about one patient are now 
34 generally collected in a single medical record . 
Finney10 distinguishes between three objectives for ascertainment of 
records : 
1.Ascertainment by patient,where the purpose le to follow the 
history of all patients individually. 
2.Ascertainment by drug, where the purpose is to record all use 
of any specific set of drugs. 
3.Ascertainment by event, where the purpose is to record all 
incidents of specific events, such as thromboses, birth 
abnormalities, sudden deaths, etc. 
Such data are not only indispensable for retrospective case control 
studies, but they are relevant for prospective clinical trials, and 
treatment planning. For both retrospective and prospective studies, 
completeness and accuracy of records are a prerequisite. 
Individual patient files should contain the medical history and 
current diagnosis of the patient, including the results from 
treatment of previous illnesses, clinical data, reported adverse 
reactions. The rationale used in making the choice of drug, its dose 
and dosage interval, duration etc. should be mentioned. The 
indication for diagnostic tests and operations should be outlined, 
as well as results of x-rays, laboratory tests, and bacteriological 
data. These data should be collected in such a way, that easy 
retrieval is possible. For the retrospective and prospective study 
of the efficacy of antimicrobial agents in prophylaxis and therapy, 
data such as the site of infection, the causative microorganism, its 
susceptibility to antimicrobial drugs and the results of therapy 
including leucocyte counts, body temperature, number of 
postoperative wound infections, should be registered. 
2.4.1 Medication profile 
Accurate medication records are of the foremost importance for 
prospective and retrospective drug monitoring. The written records 
made by doctors when prescribing medication and those used by the 
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nurses when administering the individual doses to patients need to 
be straight forward. 
g 
Investigations such as those carried out in Aberdeen »have revealed 
the need for designing prescription forms which would provide 
complete records of drug therapy on a form, that is easily 
interpreted by the nurse. 
The procedure was improved by providing space to record the actual 
drug administration on the same form used for prescribing.The 
storage of this document independently from the medical record in 
the pharmacy, grouped per ward, per medical specialty and per time 
unit, opens up a wide variety of opportunities to study drug usage 
in the hospital. Such studies, all based on this readily available 
information, influence supply and prescribing policies and audit the 
12 
effects of these policies . 
The programs of hospital based drug utilization research as carried 
out at the Sint Radboud Hospital, Nijmegen, have been described 
extensively12'17'18'19'20'23. 
2.4.2 Population monitoring 
Each individual during his lifetime generates a large number of 
records pertaining to birth, marriage and death and, of course, 
medical events, such as drugs prescribed, vaccinations, hospital 
admission etc. Record linkage refers to the centralization of 
different records about a single person. When applied to medical 
records, it is a valuable aid to medical research, patient care and 
health service management . Record linkage for drug surveillance 
programs has been used in the United Kingdom for the analysis of 
associations between drugs and events . 
2.4.3 Drug utilization monitoring 
The continuous recording of drugs obtained on prescription by 
identified individuals has provided valuable information which 
cannot be obtained from drug sales figures or prescription studies, 
based on non-identified samples. 
The motives and methods for the analysis of recorded data, as well 
as the results from such analysis on the hospital, local, regional, 
national, and international level have been extensively 
described2'4'6'31. 
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Differences in the prescribing habits for antibiotics within the 
Nordic countries have been reported. It has been estimated that in 
Iceland 10 to 60% more antibiotics are prescribed than in the other 
Nordic countries, based upon the number of antibiotic prescriptions 
per 1000 inhabitants per day . These differences could not be 
explained by a higher incidence of infections. Moreover, antibiotic 
drug use in Iceland, discounting hospital use, was 3 times greater 
in urban areas than in rural areas. Although differences in age 
distribution and social group composition explain a considerable 
part, Olafsson indicates that the distinctions are partly due to 
the form of patient contact and to the doctor's working habits, for 
example whether he prescribed by telephone. 
The level (ward, hospital,etc.) at which the drug utilization 
research occurs, influences the impact of the results. Local and 
hospital generated drug utilization studies are of particular value 
as they involve small groups of concerned individuals rather than 
large national or international 'bodies', in which an individual 
health worker often cannot recognize his contribution. Physicians 
and pharmacists can gain an insight into the actual prescribing 
practices for drugs by drug utilization reports and thus have an 
influence on the prescribing policy. Changes that occur in 
utilization patterns can be monitored and reported within a few 
weeks. Thus the effects of the monitoring have an immediacy about 
them. This is a great advantage over other more cumbersome and time 
consuming methods of data collection, analysis, and interpretation, 
which quickly lose their impact because of their lack of actual 
12 
relevance to a recent situation . 
2.4.4 Experimental results 
Activities in this area have dealt with the introduction and mainte-
nance of a drug distribution system. At the Sint Radboud Hospital,a 
standard form for prescribing and recording drug administrations was 
introduced in 1972. Its primary aim was to increase the efficiency 
and safety of drug handling procedures in the hospital. It has 
allowed the collection of data in order to examine and compare 
prescribing variations among wards, medical specialties, and 
20 hospitals (Appendix II 3). By linking medical records and 
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medication profiles, guidelines for the rationalization of 
prescribing could be designed and introduced in the hospital ' . 
The method of record linkage has been used extensively for the 
rationalization of antimicrobial prescribing practice, as will be 
outlined in chapter 3. 
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CHAPTER 3. 
THERAPEUTIC TEAM MANAGEMENT 
3.1 Problem assessment 
Patient care has become increasingly complex in all areas· In 
addition to the increased sophistication in technology of medical 
care, the rapid development in pharmacotherapy has had an influence 
on the role of the physician in selecting the drug therapy . The 
process of safe and effective pharmacotherapy by an individual 
physician has several components: correctly assessing the initial 
and changing needs, selecting the most appropriate drug, selecting 
an appropriate formulation, dose,route and dosage regimen; supplying 
appropriate information to the patient and surveilling the outcome 
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of therapy .These processes require decisions based upon the 
physician's knowledge of medicine, pathology, pharmacology, 
pharmacokinetics, and therapeutics. 
In the last 50 years, there has been a remarkable increase in the 
number of drugs used in medical practice. It has also become evident 
that drugs are frequently not used to their full potential nor 
37 
according to generally accepted therapeutic criteria . This can be 
accounted, for in part, by the bewilderingly large choice of drugs 
available. All these factors have an effect on the quality of care 
that is to be provided. The term 'quality of care' can only be 
defined in relation to what is considered 'good' medical care, which 
is in turn based on the current goals and objectives of the health 
19 care system 
Eagle states: 'quality is easy to recognize when it is either 
present or absent but very difficult to define objectively for 
evaluation of the intermediate range'. 
Poor quality care, by definiton is anything less than what may be 
regarded as 'necessary', but also excessive treatment is interpreted 
as poor quality, because the procedures performed are inappropriate 
19 
and potentially harmful . During the last decade, analysis of the 
poor performance of health care organizations in meeting the 
national demand for high quality health care has suggested that a 
primary cause is the fragmentary approach each profession has taken 
1B 27 
while providing health care ,°'·". 
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3.2 Tentative solution 
Studies have advocated team delivery of care as an efficient and 
effective mode of supplying health care ' ' . This team is to be 
an interdisciplinary one, engaged in a collaborative system of 
providing health care. 
The care is both direct, in the form of therapeutic decision making, 
and indirect, in the form of policy and procedure development to 
1 θ guide therapeutic activity 
3.2.1 Teamconcept 
Each team must develop a sense of teamwork. Webster defines team­
work as:'joint action by a group of people in which each person 
subordinates his individual interests and opinions to the unity and 
efficiency of the group; coordinated efforts'. This definition of 
teamwork indicates that each member of the team should be utilized 
to his highest level of competence, and that no member could force a 
decision by rank. Interprofessional relationships are not legally 
derived partnerships, but rather stem from the reciprocal 
recognition of dedicated practitioners that each seeks to provide 
1β 
competent and effective medical care . 
The team composition should change as the specific type of care that 
is to be provided, changes. For success and acceptance of the 
decisions of the team, it is important that appropriate authority is 
provided for each team program. This authority varies within the 
organization depending on its size, and on the patient population. 
Wherever this authority is centered, it provides legitimacy and a 
sense of program continuity. It also assures the provision of needed 
resources and sanctions required to maintain the program . 
3.2.1.1 Patient care 
In direct patient care, interprofessional teams communicate and 
function through a formalized network of structures that exchange 
information consistently, as in medical rounds, in Intravenous Team 
11 21 Programs and in Intensive Care Teams ' . 
The primary function of a pharmacist in such teams is to monitor the 
patient's total drug therapy, with regard to the individuals' 
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response to drug therapy, talcing his individual biochemical 
parameters into account· 
The pharmacist is able to serve as a drug consultant to physicians 
by promoting safe and effective use of drugs and providing 
information about drugs and adverse effects. 
Depending upon the nature of the medical unit, other professionals 
also assist the practicing physician and the nurse in providing 
services. In the Intensive Care Unit of the Sint Radboud Hospital 
the support of a clinical bacteriologist proved highly valuable. He 
supplies daily information about the cultured causative 
microorganisms and their susceptibility patterns, and gives advice 
on appropriate treatment. All members of the team should participate 
in the day to day activities according to standard policy and 
procedures as established by the hospital. 
3.2.1.2 Indirect care 
In indirect care, the objective is to develop policies and 
procedures to guide therapeutic management. 
In hospitals, several committees concerned with therapeutic 
management and quality of care can be found, such as the Comnittees 
on Pharmacy and Therapeutics, Infection Control and Medical Audit. 
In order to assess the quality of care, the criteria or standards to 
be utilized and applied should be prospectively determined. As 
defined by the National Professional Standards Review Organizations 
(PSRO) Council, criteria are 'predetermined elements against which 
aspects of the quality of a medical service may be compared'. They 
are developed by professionals relying on professional expertise and 
on the professional literature . As such criteria should be used 
throughout the whole hospital, it is important that committee 
members be selected from members of the hospital staff. This will 
add strength and authority to the committee and its decisions. 
Moreover, for a hospital-wide program, it is indispensable that such 
a committee be a formal element of the organization, charged with 
the responsibility of formulating the policies . 
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3.2.2 Antimicrobial usage control 
The increasing incidence of antibiotic misuse and its accompaning 
impact on infections, has not only attracted considerable attention 
in medical literature, but also in the media. There is a consensus 
that the effective use of antimicrobial agents can be 
improved9'24'26'28'31. 
Papers have been published describing policies, procedures and 
models for improving the use of antimicrobial agents. In such 
studies a true interdisciplinary effort can be noted in which 
pharmacists, physicians, microbiologists and other health 
professionals with a common interest in infection control seek to 
promote a program of rational antimicrobial selection and 
^4,5,8,9,16,24,31. 
In the United States, every accredited hospital is required to have 
an infection control committee, which is responsable for the 
establishment of retrospective and prospective reviews of 
antimicrobial drug therapy and subsequent implementation of 
effective control programs to promote the rational use of these 
agents . 
In the Netherlands, most hospitals have a Pharmacy and Therapeutic 
Committee and an Antimicrobial Policy Committee. However in most 
cases, retrospective and prospective reviews of antimicrobial 
therapy is not actively pursued. 
3.2.2.1 Program approach 
Several possible approaches have been recommended to improve 
antimicrobial use. It is important to stress that one single 
approach will not ensure effectiveness in all hospitals. 
In the review and control of antimicrobial usage in hospitalized 
patients. Counts discriminates between more authorative methods and 
a collaborative approach. 
1. These authorative methods are 
- Required consultation. 
Certain antibiotics are placed in a restricted category. 
Before such a drug can be prescribed, consultation with an 
infectious disease clinician is required . 
50 
This control mechanism obviously depends on the availability of 
someone to act as consultant. 
- Omission from Formulary. 
The Pharmacy and Therapeutic Committee and Antimicrobial Policy 
Committee have the responsibility of deciding which antibiotics 
to add or remove from the Hospital Formulary. However, a mere 
list of formulary drugs gives no guarantee that the drugs will 
be used rationally. 
- Written justification. 
Writing a justification for ordering a particular antimicrobial 
drug will lead to a decrease in its use. This approach has been 
used for new antibiotics as soon as they became commercially 
available. Such an approach requires that usage be reviewed to 
determine rationality of use. 
- Automatic 'stop orders'. 
An automatic stop order may be helpful in decreasing drug 
usage. It requires the physician to continually review the 
drugs that the patient is receiving, and to decide whether 
treatment is still indicated. 
- Required cultures. 
Requiring that cultures be obtained prior to the prescribing of 
antibiotics is a method with many problems. For example there 
is no consensus whether a urinary culture is required for a 
first-time urinary tract infection in a young woman with a 
urinary Gram's stain suggesting Gram-negative rods in 
g 
substantial numbers . 
In other situations, desirability of cultures is also open to 
discussion. 
2.Collaborative method. 
It is much more likely that a collaborative approach will 
result in achieving the objectives of all parties concerned. 
Such an approach uses the talents of the medical staff, as well 
as those of the Infection Control Committee, Pharmacy and 
Therapeutics Committee,the nurses, the pharmacists, and the 
microbiologists. It consists of the following: 
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- Gathering of antibiotic use and cost data. 
In general, data on drug use and costs can be provided by the 
pharmacy department without much difficulty. 
These data, depending on the retrieval system of the 
pharmacy, can be provided on various levels: the total 
hospital,the medical specialty or a particular ward. 
- Establishment of criteria for antibiotic usage. 
The most important activity of this approach is the 
establishment of criteria for rational antibiotic usage. It 
is important that the prescribing physicians and the 
Infection Control Committee reach an agreement, since only 
then will the guidelines be accepted and adhered to. 
The method for preparation and introduction of guidelines is 
described in 3.2.2.2 and 3.2.2.3 
- Assessment of the present situation. 
Based on the guidelines, the current information on 
antimicrobial drug prescription can be collected. Such base-
line data are important to determine if and to what extent 
inappropriate use of antibiotics occurs. Information must 
also be collected regarding post-operative wound infections 
and the resulting drug therapy. 
- Follow-up studies. 
If a deliberate program of rationalization is to reduce or 
eliminate the use of a particular drug, surveillance studies 
can assess the success or failure of such a program over a 
period of time. Performing follow-up studies is important to 
determine if the previously detected antibiotic abuse has 
been corrected. 
A utilization review without feedback is incomplete and 
valueless. A regular review of antibiotic use in hospitalized 
patients can be obtained by periodic review of pharmacy drug 
use and cost data, review of nosocomial infection rates and 
outbreaks, and a regular report of antibiotic-resistance 
g 
patterns of bacteria isolated from patients in the hospital . 
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3.2.2.2 Preparation of guidelines on the ward level 
Before a formal multidisciplinary Antimicrobial Therapeutics 
Committee is instituted in the hospital, it frequently occurs that a 
department head feels the responsibility to develop an infection 
control program for his unit. In such a situation, the 
collaborative voluntary efforts of a bacteriologist, a pharmacist 
and the medical staff of the individual unit form a precondition if 
the program is to be a success (Appendix III 1,2). 
The preparation of infection control guidelines requires time, 
patience and perseverance. The most important facet of the 
guidelines is the establishement of criteria to determine whether 
the use of antibiotics in a particular situation is acceptable or 
nonacceptable. The series of articles from the Veterans 
Administration ad hoc Interdisciplinary Advisory Committee on 
Antimicrobial Drug Usage is helpful and can provide reference 
guidelines . In the preparation of the guidelines, allowance can be 
made for the specific activities of the unit 6' 1 4' 1 5' 2 0 ' 2 2» 2 5. once 
the guidelines are prepared, accepted and implemented, a 
retrospective study is necessary to follow the adherance to and the 
о 
effects of these guidelines on the individual patient level . 
3.2.2.3 Preparation of guidelines on the hospital level 
Once antibiotic monitoring has been performed on an individual ward 
or department level and proper analysis has detected inappropriate 
antibiotic use, policies and procedures can be established to 
promote rational use of these drugs. It is clear that initiatives 
and results reported on the ward level will encourage discussions on 
this subject in various hospital committees such as the Pharmacy and 
Therapeutics Committee, the Infection Control Committee as well as 
informally among the medical staff. This can result in a proposal to 
institute a multidisciplinary conroittee. Thereafter, the goals and 
objectives for such a committee should be prepared to develop and 
implement guidelines for rational antimicrobial therapy. 
It is recommended that members of this Antimicrobial Therapeutics 
Committee should also include peer representatives from the medical 
staff, as well as from the microbiology and pharmacy departments. 
Membership of such a committee may vary between hospitals. 
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# 
In the Sint Radboud Hospital, the membership of a bacteriologist, a 
clinical pharmacist, a clinical pharmacologist, a pediatrician and a 
29 surgeon has proven valuable in preparing guidelines (Appendix III 
3). Every member of this committee is charged with a specific task. 
The bacteriologist, who chaires the committee, coordinates the whole 
project. He prepares proposals for guidelines of both prophylaxis 
and therapy, which are discussed in the committee prior to 
submitting the proposal to the individual department. Further he 
provides the data about antibiotic susceptibility and resistance 
trends. 
The clinical pharmacist is responsible for collecting data about the 
use of antimicrobial agents on the hospital level and on an 
individual ward level, and in some cases, also on an individual 
patient level. Furthermore, he compares the drugs chosen by this 
committee with those selected by the Committee of Pharmacy and 
Therapeutics. 
The clinical pharmacologist, a physician from the department of 
Internal Medicine, coordinates contact with his colleagues in the 
Internal Medicine Departments. He discusses, alone or accompanied by 
another committee member, the proposals pertaining to the individual 
departments. 
The pediatrician is charged with assessing the guidelines, the 
recommended drugs, and drug doses as they apply to children. 
The surgeon coordinates all the proposals for guidelines concerning 
the use of antimicrobial agents in surgical, neurosurgical, and 
orthopedic operations. He discusses these with his colleagues in the 
surgical departments. 
Each member critically considers current practices, new trends in 
therapeutic approaches, evaluations of new drugs and dosage 
regimens, and the ultimate text of the guidelines. 
In addition, the committee seeks the advice of consulting members: 
this considerably strengthens the quality of the coinnittee's policy 
recommendations. 
The following actions were taken. 
A general plan and a schedule for the development and implementation 
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of the guidelines was discussed within the committee. The program 
began by making an inventory of the infection control programs 
already operational in the various departments, wards or units· 
An initial responsibility of the committee was to review and revise 
the current policies and procedures. 
The criteria and guidelines of these units were compared with 
recently published articles, such as the series published by the 
Veterans Administration . 
Adaptation or modification of the guidelines for individual 
hospital departments were readily accepted as infection control 
involves very few absolutes. Problems of understaffing can make it 
difficult or even impossible to implement certain procedures. In 
such a situation, it is important to know what the compromises and 
alternatives are, why they have been introduced and what risks are 
30 involved . 
For those departments, wards or units where no formal policy or 
procedure had been established, the committee took the initiative. 
It was essential that the committee first draw up a priority list of 
the departments for which guidelines would be proposed. 
Two different approaches were used for the preparation of guidelines 
for departments without formal procedures. 
1. The department head developed his unit's program. 
The committee's role was then to provide the head with up to date 
and relevant advice. 
Further, the committee would make recommendations relying on its 
expertise in epidemiology and infection control and its 
experience gained through the making of other guidelines. 
The final approval by the medical staff of the unit would then 
follow. 
2. Members of the committee, in consultation with the head of the 
department, prepared a proposal. It was important to reassure the 
head of the department that the conmittee was not interfering 
with his department. 
The proposal was further discussed by the medical staff of the 
department and the final program was approved by the staff. 
The approval of the program and the implementation of the guidelines 
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is a collaborative effort of the heads of departments, the Infection 
Control Committee, the medical staff, the Pharmacy and Therapeutics 
Committee and the hospital administration· 
3.2.3 Drug utilization review 
It is generally agreed that all aspects of an infection control 
program must be reviewed on an annual basis and if required, 
revised. Review without feedback or without information aimed at 
increasing the understanding of the prescribers is incomplete and 
without value. 
In the USA, an Infection Control Committee can be given the 
responsibility for the establishment of retrospective and 
prospective reviews of antimicrobial drug therapy . 
Drug utilization review has been defined as a 'dynamic process aimed 
first at rational prescribing and the consequent improvement in the 
quality of health care and second at minimizing needless 
39 7 
expenditures . Brodie and Smith have suggested a more detailed 
definition:'Drug utilization review is an authorized,structured and 
continuing program that reviews analyzes and interprets patterns, 
(rates and costs) of drug usage in a given health delivery system 
against predetermined standards'. 
The nature of the data collection and processing system is not 
specified in this definition. This allows delegation of activities 
to local administrative units and problem solving 'on the spot' by 
the practitioners . 
3.2.4 Uniform data elements 
Drug utilization review is becoming widely accepted as an integral 
part of medical practice , However, currently available information 
on the various factors of drug use is collected from a variety of 
sources that cover the entire spectrum of drug distribution, ranging 
from manufacturing data1 and third party data , to hospital data 
etc. Several studies have pointed out the need for uniform data 
elements in drug use and for the standardization of data collection 
if data from various institutions are to be compared2'3'13'16'17'23, 
In hospitals for example, many parameters have been used. Some 
parameters of major importance are categorized in table 2,together 
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with information regarding time needed to gather the data, the 
information value, the linkage to patient data, and the use for 
interhospital comparison. 
From this table it can be seen that only the percentage of patients 
receiving a defined drug therapy and the defined daily dose(DDD) per 
100 bed days are relevant units of comparison in interhospital 
studies. These are described below: 
-Percent of patients receiving defined treatment. 
Several studies using data acquired directly from patient records, 
have utilized the percentage of patients receiving a 
defined(antimicrobial) drug therapy28'35,38. 
However, patient record linked drug surveillance programs are time 
consuming. Only a rather limited quantity of patient data can be 
treated properly by manual methods, since individual patient charts 
must be assessed, analyzed and categorized. 
Such intensive monitoring, however, remains important as it gives 
information on the rationality of drug prescribing on the 
individual patient level. 
Recently, a computer assisted medical record audit system for 
antibiotic use review in ambulatory care has been described . This 
system seems to offer most advantages of a complete medical record 
audit with less expenditure of professional time . 
-DDD(defined daily dose) per 100 bed days. 
A new parameter has been introduced by Scandinavian researchers to 
3 23 
report the use of drugs in a society ' . They were concerned about 
the marked increase in drug consumption and related costs. The 
original purpose of the DDD was to study drug consumption on a 
large scale and was therefore expressed as DDD per 1000 inhabitants 
per 24 hours. In order to study the drug utilization patterns at 
the hospital level, ward level or individual patient level, the DDD 
was related to the number of bed days. The parameter DDD per 100 
bed days is promoted by the WHO Drug Utilization Research Group, as 
the unit of comparison in drug utilization research in hospitals. 
The DDD per 100 bed days has proven to be a suitable indicator of 
drug utilization in a hospital and a suitable parameter for 
therapeutic audit2'16(Appendix III 4,5). 
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TABLE 2. USEFULNESS OF PARAMETERS USED IN DRUG UTILIZATION RESEARCH IN HOSPITALS 
Parameter speed of gathering information 
information value 
linkage to possibility of 
patient data making interhospital 
available comparison 
remarks 
-cost of drug therapy rapid little price variation in 
-time 
-preparation 
-country 
-units of drug dispensed rapid 
іл 
β 
-weight of substance 
little 
slow intermediate no 
variations in concentration 
-quantitation problems 
-difficulty of separating acti 
substances in combined drugs 
-percent of patients 
receiving defined 
treatment 
slow/rapid* high yes yes -per individual drug 
-per individual therapy 
-as an absolute figure 
-Defined Daily Doses 
per 100 bed days 
slow/rapid* high yes yes -per individual drug 
-per individual treatment 
-per individual drug group 
-overall use 
-as a probability 
depending on data processing systems used 
3.3 Experimental resulte 
The promotion of rational antimicrobial therapy has been carried out 
both for direct patient care as well as for indirect care. 
In daily practice, rational antimicrobial therapy has been applied 
to direct patient care in the Intensive Care Unit of the Sint 
Radboud Hospital. The patient care consists of monitoring the 
patient's total drug therapy with regard to drug therapy response 
and the biochemical parameters of individual patients. Continuing 
education programs for the physicians and nurses in this unit were 
organized. 
For indirect care, guidelines for antimicrobial drug utilization 
were prepared for the General Surgical Unit and the Urological 
Unit (Appendix III 2). Intensive collaboration with the chief and 
staff physicians of the General Surgical Unit and the Urological 
Unit have led to the acceptance of guidelines and their application. 
The effects of the acceptance of guidelines on the patient ( fewer 
post-operative wound infections) as well as on the costs (decreased) 
were established' (Appendix III 1,2). 
For the General Surgical Unit a reduction in total antimicrobial 
drug use could be observed from 64 to 29 DDDs per 100 bed days(-55%) 
in the period 1976-1980 (Appendix III 5). 
For the Urological Unit a reduction could be noticed from 95 to 41 
DDDs per 100 bed days (-57%)(Appendix III 5). 
In both the Surgical and Urological Units, the quality of patient 
care as based upon the incidence of post-operative wound infections 
4 5 
was concoiranitently improved ' . 
The experience gained during these studies proved highly valuable 
when the author participated in a hospital comnittee to prepare 
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guidelines for antimicrobial agents . For the whole hospital a 
reduction in antimicrobial drug use could be assessed from 44 to 33 
DDDs per 100 bed days(-25%) in the period 1976-198017 (Appendix 
III 5). 
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CHAPTER 4. 
4 Policy development and decision making 
4.1 Introduction 
The stimulus to develop or change policies and procedures in health 
care can arise from different sources. 
For example, governmental health authorities make recomnendations 
for a national approach in the treatment of patients with venereal 
diseases to prevent an outbreak of penicillinase forming 
25 
gonococces . Another example is the incentive to control costs 
which generated selection procedures to control the increasing use 
of expensive blood products such as albumin. This can result in 
guidelines for proper use, contributing to decrease of costs . 
Also, scarcity of a drug product can require that priorities be set 
to determine the indications when the drug should be administered. 
This has been the case for Interferon. 
And evidently, the practitioners themselves see areas in which the 
quality of health care and their performance can be improved. 
Whatever the source, the common goal is to regulate the activities 
pertaining to the practice of medicine, pharmacy and allied health 
professions in order to promote and improve the quality of the 
services delivered at acceptable costs. In this respect the term 
'need' has been defined as whatever is required to maintain a 
service or a product at a satisfactory, achievable or acceptable 
level of availability24. 
This level varies with time, and it is necessary to identify 
variables in order to monitor the accepted quality, effectiveness 
and efficiency of health care. 
4.1.1 Needs assessment 
Needs assessment is the process by which one realizes and identifies 
18 
needs and decides which should receive priority . 
Traditionally, such decisions are made on the basis of accumulated 
observations, data, information,or knowledge together with 
experience and intuition. 
Needs assessment then makes it possible to avoid the arbitrary 
assertion of value, and instead, to make a reliable and valid 
63 
assertion of the quality of performance. 
4.1.2 Decision making 
In recent years efforts have been made to develop a more systematic 
approach to decision making . This systematic approach to decision 
28 
making under conditions of uncertainty is called decision analysis 
and is suited to the clinical setting ' . Gremy and Goldberg 2 
describe medicine as a discipline of action. When dealing with a 
patient, the doctor must be continually in a position to identify 
the patient's condition (diagnosis), to make a reasonable prediction 
of its future course (prognosis) and to suggest actions interfering 
with the normal process of disease, some of which will mainly serve 
to support the diagnosis (diagnostic acts or investigations), while 
others may improve the patient's condition (therapeutic acts). With 
regard to decision making, one is interested in optimizing the 
process, to examine the one which gives the 'best' result with the 
1 12 
'lowest' risk and/or cost ' . 
In this process, algorithms (explicit descriptions of appropriate 
steps to be taken in the care of a patient with a particular 
problem) tend to ensure the consistency of the treatment. 
An algorithm indicates appropriate history, physical examination and 
laboratory data to be obtained and makes precise recommendations for 
diagnosis and/or treatment, based on the data which have been 
obtained . In addition, Christensen-Szalanski et al suggest also a 
(computer) audit and feedback over the performance. In recent years, 
algorithms have been used for diagnosis 2,5,7,8,27,29
 > f o r 
treatment ' ' ' ,for the assessment of adverse drug 
reactions ' and also for audit purposes . 
An example of such an algorithm is given in figure 1. This algorithm 
12 is a 'decision tree' (flow scheme) for patient management in 
2β possible urinary tract infections (day 1 through 3) . In this 
decision tree, possibilities are given for deciding which strategy 
to follow. It states whether a culture of the urine should be taken 
for bacterial growth, or a treatment should be started with an 
antibiotic, and if so which drug to prescribe and what dosage 
regimen. 
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Order 
Culture 
and 
Sensitivity 
Do Not 
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Antibiotic 
A 
Antibiotic В 
No 
1 Antibiotic . 
Antibiotic A 
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кхГмоі 
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ot Saoaitlve г^У^" 
Culture ReaulC Negative 
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Sensitive A and В 
oC 
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Heeult 
Sensitive A Only 
Sensitive Д Only 
< 
oC 
I ¡lot Sensitive 
oC 
Culture Heeult Negative 
•oC 
Sensitive A and В <*c 
Culture 
Result 
Sensitive A Only 
Sensitive В Only 
« 
oÇw^ 
l Hot Sensitive 
Culture Result Negstlve 
oC 
•oC 
Ho Antibiotic 
oC 
Figure 1. A decision tree for a patient with possible urinary tract 
infection (days 1 through 3)(Froin ref.nr.28; with 
permission) 
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The consequences of the decision to make a culture or to start 
treatment are outlined step by step. This visualizes the normal 
thought process. It should be kept in mind that this is just one of 
a series of choices to be made in the whole chain that starts with 
the complaints of a patient and that after the physician's decision 
of what is the most appropriate strategy for this individual 
12 patient, it ends as shown in table 3 , with the patient's assertion 
that the complaints have been resolved to his satisfaction or wish. 
TABLE 3. ASSESSMENT OF THE STRATEGY 
Reason for consultation 
—&• Collection of clinical data 
Formulation of hypotheses 
Interpretation of data 
Evaluation of hypotheses 
NO · only one valid YES 
hypothesis I 
Planning of Therapy 
Outcome of Therapy 
3 22 
In this strategy, the following elements can be classified ' . 
1. Subjectives 
Reason for consultation, such as fever,pain, flushing. 
2. Objectives 
Collection of clinical data, such as temperature, culture. 
3. Assessment 
Formulation of hypothesis, interpretation of data and evaluation 
of hypothesis. 
4. Plan 
Deciding what is the moat appropriate strategy for an individual 
patient. 
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This SOAP scheme has proven to be effective in general practice for 
registering problem-oriented data 14 
4.2 The choice of the strategy 
Various factors influence the strategy and the choice to be made by 
the doctor. 
In the case of possible urinary tract infections (such as given in 
figure 1) the decision is highly dependent on sex and age of the 
patient. In the following paragraph, a proposal is given for a 
rational approach for treating urinary tract infections. 
After an initial classification based upon sex and age, a decision-
tree for treating urinary tract infections (UTI) in males and 
females of different ages is constructed (Table 4 and 4.2.1.1 
4.2.1.5). 
4.2.1 Urinary Tract Infections 
TABLE 4 CLASSIFICATION 
MALES-
Suspicion of UTI' 
FEMALES-
- 0-2 
- 2-5 
I— 5-15 
-> 15 
— 0-2 
— 2-5 
• 5-15 
·— > 15 
The classification based on age groups stem from discussions with 
members of the Department of Urology. 
In this decision tree, choices are made based upon probabilities, 
experience, knowledge and intuition. The classification based on sex 
and age, stems from the experience that females have a higher 
probability for a UTI than man2 . 
The choice of the drug stems from the world wide experience that 
E.Coli has the highest probability of being the causative 
microorganism. Depending on the local situation, the drug of first 
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choice can be established. The gained experience of succes and 
failure should be documented and used for the continuous evaluation 
of the policy. 
This will lead to an up to date system for the choice of the most 
successful strategy. 
In this decision tree, various elements require further 
justification. Such justification can only be demonstrated by 
research activities in which the urologist, pharmacist and 
bacteriologist work together. In the case of short term therapy such 
a collaborative study has been carried out. 
It was shown that trimethoprim alone is highly effective in treating 
the most likely causative microorganisms of UTI, and that it is safe 
4 9 and inexpensive ' . 
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4.2.1.1 Suspicion of Urinary Tract Infection 
Male«, Femalei, Age Group 0 - 2 yean 
tuipicion culture Siientitlvlty (c&a) sediment, gram Main 
infection present · urol. examination • appr. treatment 
infection not present—appr. treatment 
io 
4.2.1.2 Suspicion of Urinary Tract Infection 
Male·, Females, Age Group 2 · 5 yean 
suspicion sediment — 
gram stain 
dlpslide 
• short term . 
treatment 
evaluation 
effective — sediment follow up* -
dipslide 
persistent — urol. e x a m l n " appr. treatment 
effective 
not effective 
I 
* the follow up consists of post Infection monitoring after one week, one month, 
followed by every three months until two years after the initial infection 
* · urological examination includes rontgenologic evaluation 
4 2.1.3 Sutpicion of Uriniry Tract Infection 
Mile·, Fetnilí«, Aga Group S - 1 6 y u n 
< 
i effective — lediment — follow up' dlpdide first осаігелсе^—sediment — ihortterm— evaluetlon^ _ 
treatment \ | 
not effective 
I 
> 1 peryeer/^ 
pentstem —- c&K choce 10 day» ^—evaluatton 
treatment 
female» 
mele*— urol. eumm** epfv. treatment 
effective — sediment — follow up' 
dlptllde < 
penlstem—urol examinât юл4 
-appr treatment 
-J 
О 
poft infection monitoring after one weeh. β week* and 6 months 
* including röntgsnoioflic evaluation 
4.2.1 4 Suspicion of Urinary Tract Infection 
Mai«, Ao· Group > 15 yean 
uspiclon 
firn осшгепсе sediment — short term - evaluatl 
ram stain treatment 
dipslide 
> 1 per year — urol. examln·* —— appr. treatment 
< follow up* 
perslitem — cto — - choic* —10days —evaluation • 
sediment treatment 
effective ^—followup·« 
paniftant—urol. емагтйп — appr .treatment 
post infection monitoring after 1 «wek, β weeks and 3 months 
* Includes rontgenologic evaluation 
4 2 1 5 Suipfckm of Urinary Tract Infection 
Females, Ao· Group > 16 yean 
iregnam— cea _— 
•adlment 
cholea — ihort t*rm ^ ^ «valuation 
not р г ц р а т tadimam гіюп te-m ^ ^ evaluation 
^ а т ctain traatmant 
dipriid« 
affectiv· — f o l l o w up* 
panlitant — c t e c h o t e a — 1 0 day· — evaluations 
Mdimant traatmant 
a follow u p* ^^ 
pamftant— efts c h o i a — 1 0 d a y » evaluation 
Mdimant traatmant 
в ^—fol low up" < ^ 
not effective 
_J 
not effective — игЫ ажатш' 
e f f e c t i v e ^ follow up1 
< 
ef facti 
< 
aÉjnormal-_ appr treatment 
normal— maintenance dote 
long term p-ophylun 
noteffactiv· 
I 
penittent— urol а ж а т т * * * appr treatment*' 
poet infectton monitorino after 1 week, β weak· and 3 month» 
includes lonogrephic evalualion 
include· röntgenotogu: evduation 
* may include malntenane· doea, оссааюпаі dma 
4.3 Strategy for rational antimicrobial drug utilization 
An assessment of the sequence of steps that must be carried out is a 
prerequisite in any model of policy development and decision making. 
In the model, prepared to achieve a rationalized antimicrobial 
policy in the Sint Radboud Hospital, the following sequence of steps 
was developed: 
1.Gathering of signals for a change of policy. 
2.Study of relevant literature by a multidisciplinary team. 
B.Evaluation of new trends, and assessment of strategy. 
4.Assessment of actual drug prescription based on efficiency, 
safety and costs. 
5.Preparation of guidelines by a multidisciplinary team. 
6.Discussion of the guidelines with the Head(s) of the 
Department(s), the medical staff and the nurses. 
7.Adaptation of the guidelines, obtain final approval. 
8.Establishing criteria for the assessment of efficiency, safety 
and costs of the new approach. 
9.Introducing the guidelines in current practice. 
10.Monitoring closely the adherence to the guidelines (task of the 
Head of the Department or his delegate). 
11.Reviewing with a retrospective study the effects of the 
guidelines bases on criteria for efficiency, safety and costs. 
12.Reporting the results to the Head of the Department, the medical 
staff and the nurses. 
13.Evaluating the obtained results. 
14.Adaptation of the program based on the evaluation. 
15.Restudying and reviewing. 
4.4 Conclusion 
It is important that the model be flexible so that continuous 
adaptation can be made in light of current findings. Whatever the 
situation, the guiding principle should be based on voluntary 
compliance,interest and scientific approach with provision for 
efficient and safe care without incurring unacceptable expense. The 
program given describes how such a policy can be developed. This 
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policy development is not limited to the prescribing practice and 
use of antimicrobial agents; it can be applied to rationalize 
utilization of any drug. 
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SUMMARY TS ENGLISH 
The goal of this study is the development and the assessment of 
clinically applicable selection criteria for rational antimicrobial 
drug utilization. 
The elements that play a part are classified into the following 
components: Pharmacokinetics, Epidemiology, Therapeutic team 
management, and Policy development and decision making» These 
components are outlined in the introduction to the thesis· The 
thesis itself is arranged in chapters reflecting these components. 
The appendix contains the manuscripts upon which this thesis is 
based. 
CHAPTER 1 
Pharmacokinetics 
In the introduction to this chapter the relevance of measuring and 
following the plasma concentration of antimicrobial agents and their 
renal excretion in urine are discussed. 
How essential these data are is explained by means of the 
pharmacokinetics of sulfonamides. With High Performance Liquid 
Chromatography (HPLC) the pharmacokinetic properties of the 
sulfonamides and their N.-acetylsulfonamide metabolites and 
derivatives in both healthy volunteers and in patients were studied 
(Appendix I 1,2). 
It became possible to elucidate the relationship between the 
structure of a sulfonamide and its metabolite with its mechanism of 
metabolism and renal excretion (Appendix 1 3 ) . 
When studying the kinetic fate of the N.-acetylsulfonamide 
derivatives after administration to man, the phenomenon of 
deacetylation of the metabolite into sulfonamide became evident. 
After intake of labelled N.-acetylsulfamerazine , in which the 
hydrogen atoms of the acetyl group were replaced by deuterium, it 
could be shown that there exists an acetylation-deacetylation 
equilibrium in man (Appendix 1 4 ) . 
The knowledge of the elimination characteristics (Appendix I 5) with 
that of the metabolic equilibria was used to assess the effects of 
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kidney impairment on the kinetic properties of sulfonamides and 
their metabolites (Appendix I 6,7). 
For sulfamethoxazole it has been demonstrated that in patients with 
impaired kidney function, whose creatinine clearance remains over 15 
ml/min its kinetic parameters remain unaffected. In contrast, the 
elimination rate of the N4- acetylmetabolite is proportional to 
creatinine clearance, leading to accumulation when an unaltered 
dosage regimen of the sulfonamide is administered. An extension of 
up to 40 hours of the half-life could be measured, instead of a 
half-life of about 12 hours in patients with normal kidney function 
( Appendix I 6). When creatinine clearance falls below 15 ml/min, 
also the half-life of sulfamethoxazole is increased up to 40 hours. 
This increase in half-life of sulfamethoxazole is not caused by 
inhibition of the renal excretion of the compound itself, but 
results from the fact that the metabolite cannot be excreted. This 
inhibtion results in a shift of the metabolic equilibrium, and 
deacetylation of the metabolite influences the measured half-life of 
the parent sulfonamide (Appendix I 6). 
In patients with impaired kidney function, the kinetics of both the 
parent drug and its metabolite(s) must be considered when dosing a 
patient with a sulfonamide, whose elimination depends on metabolic 
conversion. For instance, dosing a patient solely with 
sulfamethoxazole and neglecting to consider the kinetics of its 
metabolite will lead to the accumulation of the metabolite. The 
metabolites themselves exert no antibacterial activity, yet they 
retain the toxic potentials. Conversely, avoidance of the side 
effects of the metabolite by a dosage reduction may represent under-
treatment of the patient. In this instance a change in the choice of 
drug to a structural analogue such as sulfamethizole or 
sulfaethidole is an alternative to compensate for the reduction of 
one pathway of elimination (Appendix I 7). The dosage regimens of 
these drugs in individual patients can be established by using the 
creatinine clearance as a guide. 
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CHAPTER 2 
Epidemiology 
In the introduction to this chapter the relevance of 
collectingjanalyzingjrecording, and evaluating data to rationalize 
antimicrobal drug therapy is described. In this respect, it appears 
useful to collect data about drugs, microorganisms and patients. 
The drug level 
For drugs, data are collected about the efficacy, activity and 
safety. From experimental results, the efficacy of trimethoprim in 
patients with urinary tract infections could be demonstrated. 
Special emphasis has been placed on short term therapy with 
trimethoprim in patients with acute, uncomplicated urinary tract 
infections (Appendix II 1). The pharmacokinetic properties of 
trimethoprim are described and established , and possible clinical 
uses are discussed ( Appendix II 2). 
The microorganism level 
It is indispensable in order to rationalize antimicrobial drug 
selection to collect data on microorganisms and their susceptibility 
patterns in respect to antimicrobial agents, and changes in these 
susceptibility patterns. The application of antimicrobial agents in 
the prevention and treatment of established bacterial infections is 
discussed. An Infection Control Program, already in practice in the 
United States of America, as developed by the Joint Coiranission on 
Accreditation of Hospitals (JCAH), is described. 
The patient level 
In order to formulate a rationalized policy, it is reconmended that 
data on drug utilization on the patient level be recorded. It is 
also necessary to collect data about the effects of drugs on the 
individual patient level. The linkage of data on drug use and the 
effects of these drugs on the individual patient provides the 
possibility of gaining insight into the prescribing policy of 
physicians. The drug distribution system as introduced in the Sint 
Radboud Hospital in 1972 enabled the recording of prescribed and 
administered drugs on the individual patient level ( Appendix II 3). 
The linkage of such data on drug use with the medical records of the 
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individual patient is used to design guidelines for the rationa-
lization of drug prescribing, as will be discussed in Chapter 3. 
CHAPTER 3 
Therapeutic team management 
Recent years have shown a rapid development in health care, and 
patient care has become increasingly complex in all areas. Apart 
from the sophistication in technology, also a vast increase in the 
arsenal of drugs has been seen. It is questioned whether one 
individual is still capable of coordinating all the various aspects 
that must be taken into consideration if the quality of health care 
is to be kept. Studies have advocated team management of care as an 
efficient and effective mode for supplying and maintaining good 
quality health care. The team can function both directly, on the 
individual patient level, as well as indirectly by contributing to 
the development of guidelines for rationalized drug use. In addition 
to the introduction of guidelines in general, it is important to 
consider the several possible approaches to improve antimicrobial 
drug use. 
A discrimination is made between more authorative methods and a 
collaborative approach. The later approach was chosen in the Sint 
Radboud Hospital and is described. The method for preparation of 
guidelines on the ward and the hospital level is outlined. In this 
respect, the function of the Antimicrobial Therapeutics Committee is 
described. Membership and the specific tasks of the members are 
discussed. In addition to the introduction of guidelines, it is 
generally agreed that all aspects of an infection control program 
must be reviewed. One of the aspects is the drug utilization review. 
In hospitals many parameters have been used to assess drug 
utilization, and several studies have pointed out the need for 
uniform data elements. It has been discussed in this thesis that 
only the percentage of patients receiving defined treatment and the 
Defined Daily Dose (DDD) per 100 bed days are relevant units of 
comparison in inter hospital studies. In this thesis, a method using 
the DDD concept to measure antimicrobial drug use on the ward level 
was developed by looking at the drug supply records of the ward. 
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Drug utilization data were expressed as the number of DDDs by 
recalculating their use according to the guidelines of a committee 
within the World Health Organization. These DDDs were related to the 
number of bed days, and the parameter of DDDs per 100 bed days was 
chosen as a unit of comparison. An active program has been 
established to rationalize antimicrobial prescribing on the surgical 
and urological wards and in the hospital (Appendix III 1,2,3,). 
Medical records and drug utilization survey per individual patient 
were linked for the surgical and urological unit ( Appendix III 
1,2,4). For the General Surgical Unit a reduction in total 
antimicrobial drug use could be observed from 64 to 29 DDDs per 100 
bed days ( -55%) in the period 1976-1980 ( Appendix III 5). For the 
Urological Unit a reduction could be noticed from 95 to 41 DDDs per 
100 bed days(-57%)(Appendix III 5). In both the Surgical and 
Urological Units , the quality of patient care as based upon the 
incidence of post operative wound infections, was conconmitently 
improved ( Appendix III 1,2). For the whole hospital a reduction in 
antimicrobial drug use from 44 to ЭЗ DDDs per 100 bed days (-25%) 
in the period 1976-1980 could be noted ( Appendix III 5). Thus, the 
first goal of maintaining the quality of care with a decreased use 
of antimicrobial agents was achieved. It could even be shown that 
the quality of care improved. 
CHAPTER 4 
Policy development and decision making 
The need to develop or change policies and procedures can arise 
from different sources. The common goal is to regulate the 
activities pertaining to the practice of medicine, pharmacy and 
allied health professions in order to promote and improve the 
quality of services delivered. In recent years, efforts have been 
made to develop a more systematic approach in the process of needs 
assessment and decision making. The systematic approach to decision 
making under conditions of uncertainty is called decision analysis. 
This process tends to ensure the consistency of decisions by giving 
step to step descriptions of the strategy. These descriptions are 
called algorithms and they have proven effective for assessment of 
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diagnosis,treatment, adverse drug reactions and for audit purposes. 
The strategy chosen is outlined for a rational approach in treatment 
of urinary tract infections in males and females. After an initial 
classificaton, based upon the sex and age , a decision tree for 
urinary tract infections is constructed. 
The choice of the strategy is based upon probability, 
experience,knowledge and intuition. 
The sequence of steps that were followed in the model developed to 
achieve a rationalized antimicrobial policy in the hospital are 
described. 
It is important that the model be flexible so that continuous 
adaptations can be made in the light of current findings. The 
program given, describes how such a policy can be developed. It is 
not limited to the prescribing practice and to the use of 
antimicrobial agents; it can be applied to rationalize utilization 
of any drug. 
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SUMMARY IN DUTCH 
Het doel van de studie, beschreven in dit proefschrift, is het 
ontwikkelen en vaststellen van kriteria voor het rationaliseren van 
het gebruik van antimicrobiële middelen. De verschillende elementen 
die hierbij een rol spelen, kunnen worden ingedeeld in de volgende 
eenheden, farmacokinetiek, epidemiologie, therapie team beleid en 
beleidsontwikkeling en besliskunde. In de inleiding van het 
proefschrift worden deze onderzoeksgebieden nader beschreven. Aan 
elk van deze eenheden wordt een hoofdstuk gewijd. Als addendum 
volgen een aantal publikaties, die de basis van dit proefschrift 
hebben gevormd. 
HOOFDSTUK 1 
Farmacokinetiek 
In de inleiding van dit hoofdstuk wordt ingegaan op het meten en het 
volgen van plasma concentraties en uitscheidings-karakteristieken in 
de urine van antimicrobiële middelen. De essentie van deze gegevens 
wordt toegelicht aan het voorbeeld van de kinetiek van Sulfonamiden. 
Met hoge druk vloeistof chromatografie (HPLC) is onderzoek 
uitgevoerd naar de farmacokinetische eigenschappen van Sulfonamiden 
en N.-acetylsulfonamide metabolieten en derivaten, bij proefpersonen 
en patiënten ( Appendix I 1,2 ). Het werd mogelijk de relatie tussen 
de structuur van een sulfonamide en zijn metaboliet met betrekking 
tot het mechanisme van metabolisme en renale uitscheiding op te 
helderen ( Appendix 1 3 ) . Tijdens de bestudering van de intrensieke 
eigenschappen van de N.-acetylsulfonamide derivaten werd aangetoond 
dat een aantal van deze stoffen over konden gaan in het niet 
geacetyleerde of gedeacetyleerde sulfonamide. Verondersteld wordt 
dat er een evenwicht bestaat tussen de acetylering en de 
deacetylering van Sulfonamiden. Door labelling van de 
waterstofatomen van de acetyl groep van N.-acetylsulfamerazine met 
deuterium, en na inname van deze verbinding, kon worden aangetoond 
dat een dergelijk evenwicht bij de mens bestaat ( Appendix 1 4 ). 
Met de aldus verkregen kennis en het begrip van 
uitscheidingskarakteristieken en metabole evenwichten (Appendix I 5) 
werd de invloed van een verminderde nierfunctie onderzocht op de 
kinetische eigenschappen van Sulfonamiden en N.-acetylsulfonamide 
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metabolieten ( Appendix I 6,7 ). Voor sulfamethoxazole kon worden 
aangetoond dat de kinetische eigenschappen onveranderd bleven bij 
patiënten met een verminderde nierfunctie tot een kreatinine klaring 
van 15 ml/min. Dit in tegenstelling tot het gedrag van de 
metaboliet,die wel afhankelijk blijkt van de kreatinine klaring. 
Zoals kan worden verwacht treedt akkumulatie op van de metaboliet 
bij patiënten met een verminderde nierfunctie. Een verlenging van de 
halfwaardetijd tot 40 uur kon worden gemeten in plaats van een 
halfwaarde tijd van 12 uur bij patiënten zonder verminderde 
nierfunctie (Appendix 1 6 ) . Wanneer de kreatinine klaring tot onder 
de 15 ml/min daalt, wordt ook de halfwaardetijd van sulfamethoxazole 
verlengd tot 40 uur. Deze verlenging in halfwaardetijd wordt niet 
veroorzaakt door remming van de renale klaring van de sulfonamide 
zelf, maar ontstaat omdat de metaboliet niet kan worden 
uitgescheiden. Deze remming veroorzaakt een verschuiving van het 
metabole evenwicht, en de deacetylering van de metaboliet beïnvloedt 
de gemeten halfwaardetijd van de oorspronkelijke sulfonamide 
(Appendix 1 6 ) . Bij patiënten met verminderde nierfunktie is het 
noodzakelijk de kinetische eigenschappen van zowel moederverbinding 
als metaboliet te kennen, wanneer een sulfonamide wordt toegediend 
waarvan de eliminatie afhankelijk is van metabole omzetting. Wanneer 
immers alleen rekening gehouden wordt met de kinetische 
eigenschappen van sulfamethoxazole zelf, zal de metaboliet 
kumuleren. De metaboliet heeft echter geen antibacteriële 
aktiviteit, terwijl wel schadelijke bijwerkingen worden 
toegeschreven aan zijn aanwezigheid. Anderzijds leidt vermindering 
van de dosering om de bijwerkingen van de metaboliet te vermijden 
tot een mogelijke onderdosering voor de patient. Voorgesteld wordt 
dat als alternatief een keuze gemaakt wordt uit struktuur analoga, 
zoals sulfamethizol of sulfaethidol, om te kompenseren voor het 
gedeeltelijk uitvallen van een uitscheidings route (Appendix I 7). 
De dosering van deze Sulfonamiden kan met behulp van de kreatinine 
klaring van de individuele patient worden bepaald. 
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HOOFDSTUK 2 
Epidemiologie 
In de inleiding van dit hoofdstuk wordt ingegaan op het belang van 
het verzamelen, analyseren en evalueren van gegevens. Om 
antimicrobiële middelen rationeel te gebruiken is het nodig gegevens 
te verzamelen over geneesmiddelen, microorganismen en patiënten. 
Het geneesmiddel 
Het is van belang gegevens te verzamelen over effectiviteit, werk-
zaamheid en veiligheid van geneesmiddelen. Uit onderzoek kon de 
effectiviteit van trimethoprim bij patiënten met urineweginfecties 
worden aangetoond, waarbij vooral gekeken is naar kortdurende 
behandeling met trimethoprim bij akute ongekompliceerde 
urineweginfekties ( Appendix II 1 ). De kinetiek van trimethoprim 
werd beschreven en mogelijkheden werden aangegeven om dit 
geneesmiddel ook voor andere klinische indicaties te gebruiken dan 
de huidige ( Appendix II 2 ). 
Het microorganisme 
Het verzamelen van gegevens over microorganismen, de gevoeligheden 
van antimicrobiële middelen ten opzichte van microorganismen, en 
veranderingen in deze gevoeligheidspatronen, is essentieel om een 
rationeel beleid te kunnen voeren. Ingegaan wordt op de toepassing 
van antimicrobiële middelen ter voorkoming of ter behandeling van 
bacteriële infecties. Een uiteenzetting van een infectiebeheer 
programma wordt beschreven, naar voorbeeld van de Joint Conmission 
on Accreditation of Hospitals (JCAH), zoals dat in de Verenigde 
Staten van Amerika reeds funktioneert. 
De patient 
Om een rationeel beleid te kunnen formuleren, is het essentieel de 
gegevens over het gebruik van geneesmiddelen per individuele patient 
te kunnen verzamelen. Tevens is het nodig de effecten van de genees-
middelen bij de individuele patient vast te leggen. Het koppelen van 
gegevens over geneesmiddelengebruik en de effecten van 
geneesmiddelen op verschillend nivo (patient, afdeling, ziekenhuis, 
etc) biedt de mogelijkheid inzicht te krijgen in het 
voorschrijfgedrag van artsen. 
Θ3 
Een geneesmiddelen distributie systeem zoals in het Sint 
Radboudziekenhuis sinds 1972 funktioneert, biedt de mogelijkheid tot 
op het nivo van de individuele patient de voorgeschreven en toege-
diende geneesmiddelen vast te leggen ( Appendix II 3 ). Het 
koppelen van gegevens over toegediende geneesmiddelen met de 
medische gegevens van individuele patiënten, heeft geleid tot het 
opstellen van richtlijnen om tot rationeel geneesmiddelen gebruik te 
kunnen komen, zoals in hoofdstuk 3 wordt beschreven. 
HOOFDSTUK 3 
Therapie-team beleid 
De laatste jaren heeft de gezondheidszorg zich snel ontwikkeld en 
patiënten zorg is veel ingewikkelder geworden. Nieuwe 
onderzoeksmethodieken zijn ontwikkeld en verfijnd. Tevens is het 
arsenaal van geneesmiddelen sterk uitgebreid. De vraag wordt 
opgeroepen of één individu in staat is om alle aspekten te overzien, 
onder handhaving van de kwaliteit van de zorg. Stromingen in de 
gezondheidszorg pleiten voor een meer gespreide verantwoordelijkheid 
om de kwaliteit van handelen op hoog nivo te kunnen blijven 
garanderen, tegen aanvaardbare kosten. 
Zo'η team kan op het nivo van de individuele patient funktioneren, 
maar kan ook in de vorm van indirekte zorg een bijdrage leveren bij 
het voorbereiden van richtlijnen om tot rationeel geneesmiddelen 
gebruik te komen. Ingegaan wordt op de verschillende mogelijkheden 
om een rationeel gebruik van antimicrobiële middelen te realiseren. 
Een onderscheid wordt gemaakt tussen een benadering gebaseerd op 
verplichting versus samenwerking. Beschreven wordt welke keus in het 
Sint Radboudziekenhuis is gemaakt, en op welke wijze richtlijnen 
zijn opgesteld op afdelings- en ziekenhuisnivo. 
In dit opzicht, wordt de funktie van een Antibiotica Beleids 
Kommissie beschreven. De funktie van de leden en de taken binnen de 
kommissie worden genoemd. Naast het invoeren van richtlijnen, wordt 
algemeen geaksepteerd dat alle onderdelen van een infektiebeheer-
programma regelmatig moeten worden beoordeeld. Een van de onderdelen 
betreft de overzichten over het gebruik van geneesmiddelen. Voor dit 
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doel zijn verschillende parameters in ziekenhuizen in gebruik, en 
vele studies hebben gewezen op de behoefte tot uniformering. 
In dit proefschrift wordt aangetoond dat alleen het percentage 
patiënten dat een vastgestelde behandeling ondergaat en de parameter 
gemiddelde dag dosering (DDD) per 100 bed dagen, zinnige 
vergei!jkingseenheden zijn tussen ziekenhuis studies. Een methode is 
ontwikkeld om gebruikmakend van het DDD koncept het gebruik van 
antimicrobiële middelen op afdelingsnivo te volgen. In dit koncept 
wordt het gebruik van geneesmiddelen, na omrekening volgens 
richtlijnen van een werkgroep van de wereld gezondheidsorganisatie, 
uitgedrukt in een aantal dagdoseringen. Deze dagdoseringen worden 
gerelateerd aan het aantal bed dagen. Het aantal dagdoseringen per 
100 bed dagen wordt als eenheid van vergelijking gebruikt. 
Op de afdelingen Chirurgie en Urologie en op ziekenhuisnivo, is 
aktief gewerkt om het antibiotica gebruik te rationaliseren. 
(Appendix III 1,2,3). Patiëntengegevens en geneesmiddelenoverzichten 
per individuele patient zijn voor de chirurgische en urologische 
afdeling gekoppeld (Appendix III 1,2,4). 
Voor de afdeling Algemene Heelkunde bleek het mogelijk het 
antibiotica gebruik in de periode 1976-1980 met 55% (van 64 tot 29 
DDDs per 100 bed dagen)te doen dalen (Appendix III 5). 
Voor de Urologische afdeling bleek een daling mogelijk van 57% (van 
95 tot 41 DDDs per 100 bed dagen (Appendix III 5). 
Op zowel de Heelkundige als de Urologische afdeling is de kwaliteit 
van patiëntenzorg verbeterd, uitgaande van het aantal post-
operatieve wondinfekties (Appendix III 1,2). 
Voor het gehele ziekenhuis kan een daling in het gebruik van 
antimicrobiële middelen worden vastgesteld van 44 tot 33 DDDs per 
100 bed dagen (-25%) in de periode 1976-1980(Appendix III 5). Dus 
het eerste doel om de kwaliteit van zorg te garanderen bij een 
verminderd antibiotica gebruik werd bereikt. Het bleek zelfs 
mogelijk vast te stellen dat de kwaliteit van de zorg was verbeterd. 
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HOOFDSTUK 4 
Beleidsontwikkeling en besliskunde 
De behoefte om een beleid en procedures te ontwikkelen kan van 
verschillende bronnen afkomstig zijn. Het gemeenschappelijk doel is 
de aktiviteiten met betrekking tot de uitoefening van de 
geneeskunde, artsenijbereidkunde en aanverwante disciplines te 
reguleren met als gedachte de kwaliteit van de dienstverlening zeker 
te stellen en te verbeteren. Recentelijk is getracht het proces van 
behoeftevaststelling en besluitvorming meer systematisch te 
benaderen. Deze systematische benadering onder omstandigheden van 
onzekerheden, heet besliskunde. Door stapsgewijs de strategie te 
beschrijven wordt getracht een duidelijke lijn te brengen in de 
beslissingen. 
Deze beschrijvingen worden algorithmen genoemd. Ze hebben aangetoond 
effektief te zijn voor het vaststellen van diagnoses, behandelingen, 
bijwerkingen en voor toetsingsdoeleinden. 
Een dergelijke strategie wordt aan de hand van een voorbeeld met 
betrekking tot een rationele benadering van urineweg infekties bij 
mannen en vrouwen toegelicht. Na een eerste indeling op basis van 
geslacht en leeftijd wordt een beslisboom voor urineweg infekties 
opgebouwd. De gekozen strategie houdt rekening met elementen 
verkregen uit waarschijnlijkheid, ervaring, kennis en intuïtie. 
Stap voor stap is beschreven hoe een rationeel geneesmiddelen 
gebruik gerealiseerd kan worden. Het is belangrijk dat het model 
flexibel is om kontinue aanpassingen mogelijk te maken. Het gegeven 
programma beschrijft op welke wijze dit beleid kan worden 
ontwikkeld. Het is niet beperkt tot het voorschrijven en gebruik van 
antimicrobiële middelen; het is toepasbaar voor het rationeel 
gebruik van ieder geneesmiddel. 
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Introduction and History 
The discovery of the antibacterial activity of some sulfamyl-containing 
dyes in the early 1930s initiated a new era in the treatment of infections. 
In 1935, Domagk [20, 21] discovered that prontosil (fig. 1), a sulphonamide 
radical containing azodye, protected mice against streptococcal infections 
and rabbits against staphylococcal infections. Fuller [31] demonstrated, by 
isolating sulphanilamide from the urine of patients treated with prontosil, 
that prontosil was metabolized in the body to form sulphanilamide, having 
'in vivo' and 'in vitro' bacteriostatic effects on susceptible organisms [13]. 
Woods [93] and Fildes [26] demonstrated that the sulphonamides are anti­
metabolites of p-aminobenzoic acid (PABA) (fig. 2). The determination of 
the structure of folic acid (fig. 3) by Angier et al. [3] showed the integral part 
of PABA in its structure. Nowadays it is generally accepted that the sulphon­
amides interfere in the folic acid synthesis by competitive antagonism of 
PABA, and this results in a bacteriostatic effect of sulphonamides on grow­
ing organisms. 
Chemical Structure of Sulphonamides 
The general term 'sulphonamides' has been used for derivatives of 
sulphanilamide (fig. 4). The nomenclature for sulphanilamide derivatives is 
based on the following numbering system: substituents on the nitrogen of 
the sulphonamide nitrogen (amide group) are called Ni substituents; sub­
stituents on the amino-nitrogen are called N4 substituents [19]. Substitution 
at the N1 and N4 positions of sulphonamides will result in compounds that 
vary widely in their pharmacokinetic behaviour. 
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Fig. I. Structure of Prontosil and its 'in vivo' reduction to sulphonamide. 
Fig. 2. Structure of p-aminobenzoic acid. 
Fig. 3. Structure of folic acid. 
Fig. 4. Structure of sulphanilamide. 
Substitution at the Ni Position. Depending on the nature of the sub­
stituent these groups may consist of acyclic derivatives such as sulpha-
cetamide and heterocyclic derivatives, comprised of a 5-membered ring such 
as sulphaethidole, sulphafurazole, sulphamethizole, sulphamethoxazole, sul-
phametrole, sulphathiazole or a 6-membered ring such as sulphadiazine, 
sulphadimidine, sulphamerazine and sulphapyridine. Acetylation of these 
compounds at their Ni position will lead to tasteless derivatives that are 
used in liquid oral preparations (e.g. Ni-acetyl sulphafurazole). After oral 
intake of the Ni-acetyl compounds, Ni-deacetylation results in formation 
of the parent compound [84]. 
Substitution at the N4 Position. Blocking the N4 nitrogen in sulphon­
amides by a group which is not removed in vivo destroys the activity. If 
substitution takes place with groups which may be removed or converted 
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in vivo to the free amine, the substances are active to the extent to which they 
are converted to compounds containing a free amino group [30]. This is the 
case with the locally acting compounds used mainly for preoperative reduc­
tion of bacterial counts in the gut in patients undergoing surgery, parti­
cularly in the intestinal tract [SI]. These drugs are rarely used and include 
drugs such as phthalylsulphathiazole. Reeves et al. [61] do not consider 
these drugs useful for either symptomatic intestinal infections, or in prepar­
ing the bowel for surgery. N4-Acetyl derivatives are known to be devoid of 
antibacterial activity [30, 56]. However, after oral intake of N4-acetylsulpha-
pyridine and N4-acetyIsulphadiazine the corresponding 'parent' sulphon-
amides have been detected [85]. This phenomenon was already shown for 
N4-acetyl sulphadimidine in 1947 by Krebs et al. [42]. Therefore, it seems 
likely that there should exist an equilibrium in the acetylation-deacetylation 
of sulphonamides [36, 88]. 
Methods of Determination 
Most pharmacokinetic data available in the literature are obtained by 
the spectrophotometric method, based on the method originally described 
for sulphanilamide by Bratton and Marshall [9]. This method was modified 
by Rieder [66]. These methods enable the measurement of either the 'total 
sulphonamide' concentration, or the free (active) drug level. It should be 
noted that the term 'free sulphonamide' levels refers to the concentration 
of both plasma protein bound and unbound sulphonamide, since the assay 
procedure eliminates the protein-binding effect [58]. The introduction and 
use of high-performance liquid chromatography (HPLC) has led to a new 
era of analysis and new fields in application in the pharmacokinetics of 
sulphonamides. Several HPLC procedures have been reported recently for 
the analysis of sulphonamides in biological fluids and they are discussed by 
Perry [58]. HPLC has an advantage over the spectrophotometric assay 
method, in that it is able to determine the parent drug and the metabolites, 
specifically and selectively [80]. HPLC is now the method of choice for the 
determination of sulphonamides and their metabolites in biological samples. 
Pharmacokinetics 
Classification Based on Half-Life of Elimination 
The sulphonamides and metabolites vary in their pharmacokinetic pro­
perties. This has led to the use of these drugs for various clinical purposes. 
Classification based on absorption and half-life (Τ'Λ) of elimination has 
proven to be most logical and clinically relevant [74]. 
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Ultrashort-acting Τ'Λ less than 4 h 
Short-acting Τ'Λ between 4 and 8 h 
Medium long-acting Τ'Λ between 8 and 16 h 
Long-acting T'/i between 16 and 60 h 
Ultralong-acting Τ 'Λ longer than 60 h 
pH Effect. The influence of pH on the solubility, the absorption and 
urinary excretion of sulphonamides and their metabolites can be anticipated. 
Urinary pH normally varies between 5 and 8, and some of the sulphonamides 
show variable pharmacokinetic properties such as Τ г of elimination, and 
percentage of excretion under different pH conditions, so that it is neces­
sary to study pharmacokinetic properties under fixed pH conditions. Urine 
can be maintained alkaline (pH 7-8) by regular intake of 10 g of sodium 
bicarbonate per day. An acidic urine (pH 5-6) can be achieved by the 
intake of 8 g of ammonium chloride per day [81]. This pH-dependent 
phenomenon will be discussed for each particular sulphonamide. 
pH and Solubility. The solubility of sulpha drugs and their metabolites 
has been studied by many authors who have noted a strong dependency of 
solubility on pH of the solvent for all sulpha drugs except for sulphanil-
amide itself [43]. The solubility is a factor influencing the formation of 
sulphonamide urinary concretions [6]. This is regarded as an important 
factor since the mechanical irritation to renal tubule cells by crystallization 
of the parent sulpha drug or its metabolite may only occur if the concen­
tration of the compound is higher than its solubility. Lehr [45] has suggested 
administering three sulphonamides together, since each drug retains its 
individual solubility, thus reducing the risk of renal complications. The 
influence of the pH is shown in table I, in which the sulphonamides and 
metabolites are listed in sequence of their solubility at pH values of 5.5 and 
7. The solubilities were determined using the HPLC method to measure the 
maximum concentration. 
pH and Absorption. Absorption of some of the most commonly used 
sulphonamides is increased by the administration of its sodium salt or by 
the simultaneous administration of sodium bicarbonate [59] but alkaliniza-
tion hardly increase the amount absorbed [37]. 
pH and Renal Excretion. The rate of renal elimination of sulphonamides 
is increased by the administration of sodium bicarbonate [41]. Dettli et al. [18] 
claimed that the influence of alkalinization on the rate of elimination in-
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Table I. Solubility of sulphonamides in mg/1 at 250C (room temperature) 
Compound pH5.5 pH7.0 
Sulphadiazine 
N4-Acetylsulphadiazine 
Sulphadimidine 
N4-Acetylsulphadimidine 
Ni,N4-Diacetylsulphadimidine 
Sulphadoxine 
N4-Acety!suIphadoxine 
Sulphaethidole 
N4-Acetylsulphaethidole 
Sulphafurazole 
N4-Acetylsulphafurazole 
Ni>N4-Diacetylsu]phafurazole 
Sulphamerazine 
N4-Acetylsulfamerazine 
Sulphamethizole 
N4-AcetyIsulphamethizole 
Sulphamethoxazole 
N4-Acetylsulphamethoxazole 
Ni-Acetylsulphamethoxazole 
Sulphametrole 
N4-Acetylsulphametrole 
Ni-Acetylsulphametrole 
Ni>N4-Diacetylsulphametrole 
Sulphapyridine 
N4-Acetylsulphapyridine 
Sulfisomidine 
N4-Acetylsulfisomidine 
Sulphathiazole 
N4-Acetylsulphathiazole 
265 
411 
438 
752 
11.8 
186 
221 
489 
392 
1,533 
250 
12.3 
238 
585 
1.555 
200 
300 
115 
66 
460 
1,100 
34 
22.7 
120 
313 
1,580 
53 
4,565 
54 
950 
1,620 
7,000 
1,340 
9.3 
2,387 
3,420 
7,110 
7,850 
4,724 
6,893 
5.2 
840 
2,300 
5,022 
3,000 
1.900 
1,000 
66 
1,700 
6,000 
24 
20.5 
200 
440 
2,480 
128 
130,868 
233 
Data according to Hekster et al. [37] and Vree et al. [unpublished results]. 
creases with decreasing values of the pKa' of a weak acid, due to the sup-
pression of the non-ionic tubular reabsorption of acid medicaments from 
the alkaline primary urine. This phenomenon was also observed by Bräun-
lich and Splinter [10] in long-acting sulphonamides. The influence of the pH 
is only apparent for the parent compound and not for the N4-acetyl me-
tabolites [81]. 
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Protein Binding 
Protein binding of sulphonamides in plasma is predominantly to al­
bumin. Protein binding varies between 20% (sulphadiazine), 80% (sulpha-
furazole) and 94% (sulphaethidole). Long-acting sulphonamides in general 
are highly bound (90% and more). The importance of the protein binding of 
sulphonamides is found in the fact that only the non-protein-bound fraction 
possesses an antibacterial effect. The protein binding is weak and reversed 
by dilution. In general, the N4-acetyl metabolites are bound to a somewhat 
greater extent than the parent compound [34, 89]. Protein binding varies 
widely with the structure and it appears that an increase in lipophilicity 
parallels an increase in binding [1]. The percentage of binding of each sul-
phonamide bound does not seem constant, and depends on the serum con­
centration of the drug [35, 44]; the lower the concentration, the higher the 
binding. In severe renal failure binding is decreased, a phenomenon not 
totally accounted for by low levels of plasma albumin [2]. 
Absorption 
Except for the sulphonamides which are relatively poor absorbed and 
predominantly used for their local effect within the gastro-intestinal tract, 
the sulphonamides are rapidly absorbed. Maximal plasma concentrations 
are reached within 1-3 h after an oral dose. Absorption is adequate, as more 
than 90% can be found in the urine as parent compound plus metabolite 
after six times the Τ 'Δ of the compounds. Absorption is influenced by the 
pH in the stomach as mentioned before. 
Distribution 
After absorption, the sulphonamides become widely distributed through­
out the body, and penetrate into various body tissues and fluids. They also 
cross the placenta and enter the fetal circulation. The apparent volume of 
distribution of the commonly used sulphonamides are in the order of 10-30 
litres, corresponding to 15-40% of total body volume [62]. Sulphonamides 
may be detected in the urine, saliva, sweat and bile, in the cerebrospinal, 
peritoneal, ocular and synovial fluids and in pleura and other effusions [51]. 
Reeves and Wilkinson [62] have reviewed the penetration into various 
body tissues and fluids. They conclude that in bacterial infections, which 
are located extracellularly and in situations where there is no active trans­
port or shift of pH, such as the CSF or synovial fluid, the concentration of 
sulphonamide attained by passive diffusion will approach the non-protein-
bound (free) concentration in serum. Where there is a shift to acid pH 
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plasma, sulphonamide concentrations are low and the compounds may have 
a less important therapeutic role compared with that of trimethoprim. 
Metabolism 
Sulphonamides are metabolized to a varying extent in tissues, primarily 
in the liver. Metabolism mainly involves acetylation on the para amino group 
(known as N4-acetylation) and to a lesser extent Ni-glucuronidation. To a 
vary small extent C-hydroxylation of phenyl and heterocyclic rings and of 
alkyl substituents, as well as 0 and ring N dealkylation takes place [1]. 
This depends on the lipid solubility and accessibility to the mixed function 
oxidase cytochrome P-450. N4-Acetylation is claimed to lead to the forma­
tion of inactive products 'in vivo' and 'in vitro', but hydroxylation by in­
testinal bacteria may occur in vivo to some extent with a resulting return of 
potency as in the case of phthalylsulphathiazole [89]. It is generally accepted 
that both parent compound and acetylated forms of sulphonamides may 
contribute to adverse effects such as renal complications and crystalluria 
[43, 46]. 
Phenotyped Acetylation 
It has been known for nearly two decades that the acetylation of certain 
drugs shows a bimodal character which is genetically controlled. The bio­
chemical basis lies in the enzyme step in the liver which transfers acetyl 
groups from acetyl coenzyme A to the acceptor drug molecule [25]. Patients 
can be classified as 'slow' and 'fast' acetylators, the acetylator phenotype 
having been determined from the isoniazid plasma Τ г or by measuring the 
ratio of acetylated and unchanged sulphapyridine [72]. Sulphadimidine is 
also used to detect the acetylator phenotype [24]. Vree et al. [87] surveyed 
the different methods of phenotyping. They showed that the 'slow-fast' 
acetylator differences did not hold through a series of sulphonamides. This 
complicates the use of one compound as a predictor for another compound, 
with a unimodal type of acetylation. Vree et al. [87] suggested determining 
the phenotype of each drug itself to establish the optimal dosage regimen for 
each individual patient. 
Excretion 
The final route of elimination (about 90% or more) of sulphonamides 
and their N4-acetyl metabolites is by renal excretion [62]. Different sulphon­
amides are handled by the kidney in different ways, depending on their 
chemical structure. Besides glomerular filtration, sulphonamides are gener-
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ally also substrates for the tubular anion transport reactions which excrete 
hippurates, carboxylic acids, sulphonates and glucurontdes [15]. N^Acetyl 
metabolites have, in general, higher renal clearance values than their cor-
responding parent sulphonamides, and are excreted to a large extent by 
tubular excretion [86]. The pH of the urine has been shown to have a marked 
influence on the renal clearance of these drugs. This phenomenon indicates 
that the sulphonamide is substantially reabsorbed by the kidney tubules. 
Protein binding regulating the free concentration of the sulphonamides in 
plasma may influence the renal excretion by limiting the amount that can 
be excreted per unit of time. 
Renal Clearance 
The renal clearance (Kr, ml/min) is the proportionality constant be-
tween the renal excretion rate dQ/dt (ßg/min) and the plasma concentration 
CA (ßg/ml). For the calculation of the Kr, the average renal excretion rate is 
divided by the mean plasma concentration during the measured time interval. 
From each urine and corresponding plasma sample the renal clearance con-
stant is calculated, as has been shown in several studies. 
Sulphadiazine 
Introduction 
Sulphadiazine (fig. 5) was introduced in 1939 as a single compound. 
Since 1979 the drug has been mainly used in combination with trimetho-
prim in a fixed composition of 410 mg of Sulphadiazine and 90 mg of tri-
methoprim. This combination is known under its generic name co-trimazine. 
General properties of sulphadiazine such as protein binding and molecular 
weight are given in table II. 
Fig. 5. Structure of sulphadiazine. 
Pharmacokinetic Properties 
The pharmacokinetic parameters measured in different studies show 
considerable variations. Previous studies have shown Τ'Λ values around 
16 h and up to 30 h [74], but recent investigations have given values around 
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Table //. General properties of sulphadiazine and its metabolite N4-acetylsulphadiazine 
Compound Molecular 
weight 
Sulphadiazine 250.28 
Rj-Acetylsulphadiazine 292.30 
pKa 
6.40 
5.86 
Protein 
binding, % 
50 
57 
Data according to Avery [4], Reeves and Wilkinson [62], Astra Sweden [personal 
cation] and Vree et al. [unpublished data]. 
Vd, I/kg 
0.36 
0.13 
communi-
10-15 h [23, 86]. Apart from possible differences between the particular 
studies, Ekstrôm et al. [23] mentioned two possibilities for this discrepancy, 
namely biopharmaceutical properties of the tablets and the assay method. 
Classification 
Based on the T'/i of elimination as determined in the study of Vree et al. 
[86], using a HPLC method (Τ'/ί of 10-12 h), sulphadiazine can be classified 
as a medium long-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubility of sulphadiazine at pH values 5.5 and 
7.0 is given in table III. The concentrations are given in mg 1 at 25CC 
(room temperature). 
Table III. Influence of the pH on the solubility of sulphadiazine and Na-acetylsulpha-
diazine 
Compound Solubility 
pH5.5 
Sulphadiazine 265 
N4-Acetylsulphadiazine 411 
in mg/l at 250C 
pH7.0 
950 
1,620 
Data according to Hekster et al. [3η and Vree et al. [82]. 
pH and Absorption, Metabolism and Renal Excretion. Although many 
studies have been carried out concerning the pharmacokinetic characteri­
zation of sulphadiazine, two variables have not been taken into account; 
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Fig. 6. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
diazine (SD) and its metabolite N4-acetyIsuIphadiazine (N4-SD) in a typical 'fast' (a) and 
'slow' (b) acetylator. Note that in the 'fast' acetylator, Ni-acetylsulphadiazine reaches 
a higher maximum plasma concentration than in the 'slow' acetylator. Both experiments 
were conducted under acidic urinary pH conditions. The amount of unchanged sulpha-
diazine excreted is comparable ('fast' 27.4% and 'slow' 34.3%), while the amount of N4-
acetylsulphadiazine excreted in the 'fast' acetylator is higher (38.3%) than in the 'slow' 
acetylator (20.4%) [from ref. 8η. 
firstly the influence of the urine pH and secondly the effects of the differences 
between 'fast' and 'slow' acetylators of sulphadiazine. Figure 6 shows the 
differences in the plasma concentration-time and renal excretion rate-time 
profiles of sulphadiazine and its metabolite N4-acetyl sulphadiazine in a 
typical 'fast' and 'slow' acetylator. 
Both experiments were carried out under acidic urine pH conditions. 
The maximum plasma concentration of N4-acetyl sulphadiazine in 'fast' 
acetylators is about 4/ig/ml, while in 'slow' acetylators it is about l.S/ig/ml. 
The amount of N4-acetyl sulphadiazine excreted in the urine is higher in 
'fast' acetylators, as expressed as the percentage of the dose, being 38.3% 
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Table IV. Influence of urinary pH and acetylation phenotype on Τ'Λ and renal excretion 
of sulphadiazine and Ki-acetylsulphadiazme. Data according to Vree et al. [87] 
Subjects Acetylation pH of the Τ % sulpha-T'AN^acetyl- % excreted as 
type urine diazine, h sulpha-
diazine, h sulpha- N^-acetyl-
n = 4 
n=2 
n = 2 
'fast' 
'slow* 
'slow' 
5.38 ± 0.25 9.75 ± 1.71 14.50 ± 2.52 
5.89 7.0 9.0 
7.43 6.5 8.0 
diazine sulphadiazine 
28.05 ±2.77 28.83 ±8.46 
45.00 28.35 
70.80 14.50 
±SEM. 
in this 'fast' acctylator and 20.4% in this 'slow' acetylator. It can be noted 
that the Τ'Λ is about 10-12 h in both 'fast' and 'slow' acetylators, whereas 
the Τ г of the metabolite is about 1.5 times that of the parent drug. Some 
different pharmacokinetic parameters of sulphadiazine obtained from a 
group of volunteers are summarized in table IV. 
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Fig. 7. Percentage Ni-acetylsulphadiazine-time profile in a group of'fast' (n=4) and 
'slow' (n=4) acetylators. In this case 'fast' and 'slow' acetylators can be distinguished in 
the final stage of elimination, 15-30 h after administration of the drug [from ref. 87]. 
Renal Clearance 
Differences in renal clearance data for sulphadiazine as found in the 
literature, varying from 15.9 ml/min [8] to 45 ml/min [55], are difficult to 
explain. In these studies the pH effects and differences between the 'slow' 
and 'fast' acetylators were not taken into account. Vree et al. [87] determined 
the renal clearance (the method was described in the introduction) for 'fast' 
acetylators (n = 4) at pH of 5.38 ± 0.25 to be 6.32 ± 0.40 ml/min. In 'slow' 
acetylators (n=4) the Kr was determined as 18.40 ± 8.15. The renal clear-
ance of the metabolite was 40-60 ml/min in this group of volunteers with 
an outlier of 107 ml/min. 
Metabolism 
Sulphadiazine is metabolized in the liver to N4-acetylsulphadiazine, but 
the extent of acetylation, regarded as the percentage of the dose of N4-
acetylsulphadiazine excreted in the urine (25.13 ± 9.61%; η = 8), is much 
lower than the percentage of the dose excreted as N4-acetylsulphametho-
xazole (48.15 ± 13.58%; η = 13) and N4-acetylsulphametrole (64.85 ± 
13.58%; η = 8) [37, 81]. Figure 7 shows the percentage N4-acetylsulpha-
diazine-time profile in both 'fast' and 'slow' acetylators. In the final elimi­
nation process, 'fast' acetylators exhibit a percentage of N4-acetylsulpha-
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diazine of 19 ± 3.5%, while 'slow' acetylators give a value of 14 ± 3.5%. 
The Τ'Λ of the residual curve for both 'fast' and 'slow' acetylators is 6.5 h. 
In this case it is possible to distinguish between 'fast' and 'slow' acetylators 
after a period of 15-30 h after administration of the drug. 
Sulphadiazine and Kidney Impairment 
A good relationship has been observed between the endogenous cre­
atinine clearance and the plasma Τ'Λ of sulphadiazine, indicating that the 
active drug is eliminated partly by renal handling [54]. Bergan et al. [8] have 
confirmed these findings and they suggest that the parallel slopes of the Τ'Λ 
versus the creatinine clearance regression lines of both active and total sul­
phadiazine and trimethoprim is a strong point in favour of the combination 
of sulphadiazine with trimethoprim compared to sulphamethoxazole or sul-
phametrole. The Τ'Λ of elimination of sulphamethoxazole and sulpha-
metrole is not significantly influenced by kidney impairment [38, 67]. Re­
examination of the data of Ohnhaus and Spring [54] revealed that the Τ Vi 
of elimination of sulphadiazine in a group of patients with a creatinine 
clearance varying from 100 to 18 ml/min was 12.56 ± 3.18 h. In their data, 
patients with a creatinine clearance varying from 8 to 12 ml/min have a T'A 
of elimination of 34.02 ± 8.47 h [54]. Their conclusion that the active sul­
phadiazine is eliminated mainly as a result of renal handling is questionable, 
as they have plotted the renal clearance of creatinine versus the T'/i of 
sulphadiazine, which is the sum of metabolic conversion to N4-acetylsulpha-
diazine and renal excretion of sulphadiazine. Acetylation is the main me­
tabolic route and also for sulphamethoxazole and sulphametrole the major 
pathway in the elimination. The Τ 'Λ of elimination of these two parent 
sulphonamides remains constant since it is virtually independent of kidney 
function. The contribution of the renal excretion of sulphadiazine to the 
total elimination is higher than in the case of sulphamethoxazole and sulpha­
metrole. Therefore, the Τ Vi of elimination of sulphadiazine ceases to be as 
independent of the kidney function. When the latter falls below a 'threshold' 
function of about 18 ml/min [54], the increase in the Τ'Λ of elimination of 
sulphadiazine becomes visible. 
In contrast to N4-acetylsulphamethoxazole and N4-acetylsulphametrole, 
the deacetylation of N4-acetylsulphadiazine into sulphadiazine is visible in 
healthy volunteers (see chapter N4-acetylsulphadiazine). It may be postu­
lated that in patients with kidney impairment, N4-acetylsulphadiazine is 
excreted less, and that the equilibrium of acetylation-deacetylation of sul­
phadiazine is changed in such a way that the amount of sulphadiazine 
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formed from N4-acetylsulphadiazine contributes sufficiently to increase the 
Τ Vi of elimination of sulphadiazine in patients with a kidney function be­
low a creatinine clearance of 20 ml/min. 
N4-Acetylsulphadiazi ne 
N4-Acetylsulphadiazine is the acetylated metabolite of sulphadiazine 
(fig. 8). General properties of N4-acetylsulphadiazine such as pK
a
, molecular 
weight, etc., are given in table II. 
C H 3 - C - N ^ O > | - N - < N O > 
Fig. 8. Structure of N4-acetylsulphadiazine. 
Pharmacokinetic Properties 
Classification 
The intrinsic Τ 'Λ of elimination of N4-acetylsulphadiazine is about 5 h 
in the alpha phase but is increased to 20 h in the final (beta) elimination 
phase (fig. 9). 
pH Effects 
pH and Solubility. The solubility of N4-acetylsulphadiazine at pH values 
5.5 and 7.0 is given in table III. 
Absorption, Metabolism and Renal Excretion 
Figure 9 shows the plasma concentration-time curve and renal excretion 
rate-time profile of N4-acetylsulphadiazine and its metabolite sulphadiazine 
in a volunteer after an oral dose of 778 mg of N4-acetylsulphadiazine. This 
volunteer was phenotyped as a 'slow' acetylator of sulphadimidine. The 
initial Τ 'Λ of elimination of N4-acetylsulphadiazine is 5 h, but after 24 h 
the final elimination Τ 'Λ is increased to 20 h. N4-Acetylsulphadiazine is 
deacetylated into sulphadiazine that can be detected in plasma. Its Τ'Λ is 
about 14 h. The slope of the curve suggests an equilibrium between acety-
lation and deacetylation, reached after 24 h. In urine, N4-acetylsulpha-
diazine is excreted for about 40% unchanged. A small extent (1%) of the 
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Fig. 9. Plasma concentration-time and renal excretion rate-time profiles of 778 mg 
Nj-acetylsulphadiazine (N4) and its metabolite sulphadiazine (S) in a 'slow' acetylator. 
The Τ Vi of N4-acetylsulphadiazme is 5h, and increases in the final stage of the elimi­
nation curve to 20 h, due to acetylation of its metabolite sulphadiazine. 
dose is excreted as its metabolite sulphadiazine. The different pharmaco­
kinetic parameters of N4-acetylsulphadiazine obtained for 2 volunteers are 
summarized in table V. 
Renal Clearance of Ni-Acetylsulphadiazine 
As shown in table V, the renal clearance of N4-acetylsulphadiazine is 
about 60 ml/min. 
Deacetylation 
N4-Acetylsulphadiazine is deacetylated into sulphadiazine, being de­
tected in plasma and urine of healthy volunteers. 
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Table V. Some pharmacokinetic parameters of N^-acetylsulphadiazine in man. Data ac­
cording to Vree et al. [85] 
Subjects 
π=2 
N4=N4-Acetylsulphadiazine 
renal clearance; T,/i = 5; 20 
T'/iN^h T'AS.h 
5; 20 14; 20 
%N4 %S 
40 1 
K
r
 N4, ml/min 
60 
; S=sulphadiazme; % = percent of the dose excreted; K
r
= 
'alpha* phase 5 h, 'beta' phase 20 h. 
N-i-Acetylsulphadiazine and Kidney Impairment 
As discussed in the chapter on sulphadiazine, the fact that N4-acetyl-
sulphadiazine is deacetylated seems of great importance to explain its be­
haviour in patients with impaired kidney function. With the impaired renal 
clearance of N^acetylsulphadiazine, the deacetylation contributes signifi­
cantly to the plasma concentration of sulphadiazine, thus giving rise to an 
increase of the Τ 'Λ of elimination. This increase of the Τ '/ι of elimination 
of the parent compound is not caused by an impaired renal excretion, but 
by an increased amount of deacetylation per unit of time. 
Sulphadimidine (Sulphamethazine) 
Introduction 
Sulphadimidine was introduced in 1942 as a single compound. The 
drug is listed in the selection of essential drugs [91]. The structure and general 
properties of sulphadimidine are given in figure 10 and table VI. 
0
 N / с н э 
Fig. 10. Structure of sulphadimidine. 
Pharmacokinetic Properties 
Sulphadimidine is metabolized to N4-acetylsulphadimidine. This acety-
lation is polymorphic in human populations as already described in 1964 by 
Evans and White [25]. Sulphadimidine shows similar differences in metabolic 
rate between 'fast' and 'slow' acetylators as sulphapyridine. The plasma 
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Table VI. General properties of sulphadimidine and its metabolite N4-acetylsulphadimidine 
Compound Molecular 
weight 
Sulphadimidine 278.32 
N4-Acetylsulphadimidine 321.34 
PK. 
7.40 
7.10 
Data according to Avery [4], Reeves and Wilkinson [62], 
Protein 
binding, % 
90 
95 
Vree et al. [85, 87]. 
Vd,l/lcg 
0.61 
0.29 
concentration of N4-acetylsulphadimidine is 100 and 60% of the total plasma 
concentration of the sulphonamides, in 'fast' and 'slow' acetylators, re­
spectively, while the corresponding figures for sulphapyridine are 60 and 
32% [87]. This means that the acetylation of sulphadimidine is almost com­
plete, while with sulphapyridine there also exists the possibility of hydroxy-
lation of the pyridine ring. 
Classification 
Based on the Τ'Λ of elimination (T'/i of 1.5-5.5 h) [11, 47, 86], sulpha­
dimidine can be classified as an ultrashort- to short-acting sulphonamide. 
The Τ Vi of elimination depends on the differences in the rate of acetylation 
between 'slow' and 'fast' acetylators. 
pH Effects 
pH and Solubility. The solubility of sulphadimidine at pH values 5.5 
and 7 is given in table VII. The concentrations are given in mg/1 at 250C 
(room temperature). 
Table VII. Influence of the pH on the solubility of sulphadimidine and Nf-acetylsulpha-
d imi dine 
Compound Solubility in mg/1 at 25°C 
pH 5.5 pH 7.0 
Sulphadimidine 438 7,000 
Ni-Acetylsulphadimidine 752 1,340 
Data according to Hekster et al. [37] and Vree et al. [82]. 
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Fig. II. Plasma concentration-time profile (a) and renal excretion rate-time profile 
(b) of sulphadimidine (SD) and its metabolite ^-acetylsulphadimidme (N4-SD) in a 
'fast' acetylator under extreme acidic and alkaline urinary conditions. The urine pH has 
no direct influence on the Τ 'Λ of elimination as the main pathways of elimination (deacety-
lation and renal excretion) of the metabolite are independent of the urinary pH ; i.e. tubular 
reabsorption [from ref. 87]. 
pH and Absorption, Metabolism and Renal Excretion. Figure 11 shows 
the plasma concentration-time profile and the renal excretion rate-time pro­
file of sulphadimidine and its metabolite N4-acetyIsulphadimidine in a 'fast' 
acetylator under extreme acidic and alkaline urine conditions. It is clear 
that urinary pH has no influence on the T'/i of plasma elimination (1.5 h) 
of sulphadimidine. Also the Τ Vi of elimination of N4-acetylsulphadimidine 
is unchanged (5.0 h). Sulphadimidine is acetylated extremely fast and al­
most completely. Under acidic urine conditions only 1.9% of the dose 
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is excreted unchanged and almost 100% is excreted as N4-acetylsulpha-
dimidine. Under alkaline urine conditions these data are 0.9% for sulpha-
dimidine and 80.1% for N4-acetylsulphadimidine, respectively. The T'/i of 
both compounds, determined by their renal excretion rates, are the same as 
that determined from the plasma concentration-time curves. 
Influence of Acetylator Type on Τ Уі of Elimination 
As already has been reported by van Oudtshoorn and Potgieter [57] and 
du Souich et al. [73], 'fast' and 'slow' acetylators show different pharmaco­
kinetic properties; this is also shown in figure 12 [87]. In this figure the dif­
ferences in kinetic behaviour of sulphadimidine between 'fast' and 'slow' 
acetylators is clearly demonstrated. In a 'fast' acetylator sulphadimidine is 
eliminated with a TVi of 1.5 h. In a 'slow' acetylator the Τ'Λ of elimination 
of sulphadimidine is increased to about 5.5 h. The Τ'Λ of elimination of the 
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Fig. ¡2. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
dimidine and its metabolite N4-acetylsulphadimidine (N4-SD) in a typical 'fast' (a) and 
'slow' (b) acetylator. The difference in kinetic behaviour of this drug in 'fast' and 'slow' 
acetylators is much more pronounced than with sulphadiazine. The most characteristic 
feature is the large difference in T'/i of elimination of sulphadimidine between 'fast' 
(TVi = 1.5h) and 'slow* (T54 = 5.5h) acetylators [from ref. 87]. 
metabolite N-i-acetylsulphadimidine is 5.0 h in a 'fast' acetylator and 7 h 
in a 'slow' acetylator. In a 'fast' acetylator, N4-acetylsulphadimidine is 
formed so quickly that it may be considered to be a single component, which 
shows its intrinsic Τ'Λ of elimination (5 h). In a 'slow' acetylator, the forma­
tion of N4-acetylsulphadimidine still occurs and increases the Τ 'Λ of elimi­
nation of N4-acetylsulphadimidine to 7 h. Table VIII summarizes some 
pharmacokinetic parameters of sulphadimidine obtained from a group of 
volunteers. 
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Table VIII. Influence of urinary pH and acetylation phenotype on Т'Л and renal excretion 
of sulphadimidine and N4-acetylsu]phadimidine. Data according to Vree et al. [87] 
Subjects Acetylation Urine pH Τ Vi S, h 
type 
Τ·/,Ν4, h %S % N 4 
n=3 'fast* 5.64 ± 0.21 2.17 ± 1.15 4.67 ± 0.29 3.97 ± 2.91 82.7 ± 22.0 
n-1 'fast· 7.67 2.0 5.0 0.9 80.1 
n - 3 'slow' 5.28 ± 0.23 6.51 ± 3.10 8.67 ± 3.05 13.13 ±1.63 59.46 ± 19.22 
n = l 'slow' 7.45 6.0 8.0 6.3 69.0 
S=Sulphadimidine; N4=N4-acetylsulphadimidme; % = percentage of the dose excreted. 
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Fig. 13. Percentage N4-acetylsulphadinudme-time profiles in plasma in a group of 
'fast' (η=4) and 'slow' (η=4) acetylators. The 2 groups are well separated and blood 
samples taken at any time after administration and when absorption is completed would 
permit phenotyping. Note the difference in the Τ'Λ of the residual curves, representing 
the rate of acetylation of the parent compound. 
Renal Clearance of Sulphadimidine and N4-Acetylsulphadimidine in 
'Slow' and 'Fast' Acetylators 
The average renal clearance of sulphadimidine was 2.79 ± 2.40 ml/min 
(n = 3) for 'fast' acetylators and 4.30 ± 2.04 ml/min (n = 3) in 'slow' acetyl­
ators under acidic urine pH conditions. For N4-acetylsulphadimidine these 
data were 26.80 ± 9.13 ml/min (n = 3) in 'fast' acetylators and 33.72 ± 7.23 
ml/min (n = 3) in 'slow' acetylators, under these acidic urine pH conditions. 
The high clearance of the metabolite and the rapid acetylation of sulpha­
dimidine explains the low percentage of parent compound that is excreted 
unchanged in the urine (1-13%). The renal clearance of sulphadimidine is 
dependent on the urinary pH, while the renal clearance of the metabolite 
is independent of the urine pH. 
Metabolism 
Sulphadimidine is almost completely metabolized in the liver to N4-
acetylsulphadimidine. Figure 13 shows N4-acetylsulphadimidine as the per­
centage of total sulphonamide concentration-time profile in both 'fast' and 
'slow' acetylators. In the final elimination process 'fast' acetylators exhibit 
a percentage of N4-acetylsulphadimidine of 100 ± 3%, while 'slow' acetyl-
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ators give a value of 60 ± 14%. The Τ'Λ of the residual curve is 2 h in 'fast' 
acetylators and 5.5 h in 'slow' acetylators. These Τ Ά values are identical 
with those illustrated in figure 11 and 12 and represent the differences in the 
rate of acetylation of sulphadimidine between 'fast' and 'slow' acetylators. 
Sulphadimidine and Kidney Impairment 
Williams et al. [92] have studied the renal clearance of sulphadimidine 
in 10 patients with normal kidney function and in 10 patients with kidney 
failure. This study has been carried out under acidic urine pH conditions; 
pH 5.83 ± 0.44 for patients with kidney failure compared to pH 5.88 ± 0.49 
in patients with normal kidney function. No correlation could be shown 
between glomerular filtration rate (determined using 51Cr-labelled ethylene-
diamine-tetra-acetic acid), 51Cr-EDTA and sulphadimidine clearance. The 
authors found a significant difference between the renal clearance of sulpha· 
dimidine in the uraemic subjects (11.4 ml/min) compared with 6.3 ml/min 
in the controls. In the group of uraemic patients the serum sulphadimidine 
concentrations was significantly lower (average 22.3 //g/ml) than that of the 
controls (average 39.8/¿g/ml). 
In their experiments the authors [92] have only measured the free sul-
phadimidine levels. The explanation for these lower serum concentrations 
of sulphadimidine might be that in uraemic patients sulphadimidine re-
mains acetylated, resulting in lower serum concentrations and virtually 
higher renal clearance characteristics than in volunteers. The main criterion 
of objection against this research is that plasma concentrations, excretion 
rates and renal values of the metabolite have not been measured. Further-
more, no distinction is made between 'fast' and 'slow' acetylators among 
their population of patients with kidney impairment. The phenomenon of 
'fast' and 'slow' acetylation must hold true in a group of patients with im-
paired kidney function who are metabolizing sulphadimidine as it has been 
shown previously that acetylation is independent of kidney function. 
Talseth and Landmark [76], in their study of polymorphic acetylation of 
sulphadimidine in normal and uraemic man, separated their patients into 
'fast' and 'slow' acetylators, but neglected the influence of the urinary pH on 
the renal excretion of sulphadimidine and the percentage N4-acetylsulpha-
dimidine in urine. It has been shown for sulphamethoxazole that the same 
patient could be regarded as 'fast' or 'slow' acetylator on the basis of percent 
N4-acetylsulphamethoxazole in the urine by a simple shift in urinary pH, al-
though no real 'fast-slow' polymorphism exists for sulphamethoxazole [87]. 
For the separation of the patients into 'fast' and 'slow' acetylators, 
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Fig. 14. Plasma concentration-time and renal excretion rate-time profile of 773 mg 
sulphadimidine (S) and its metabolite Ni-acetylsulphadimidine (N4) in a 'slow' acety-
lator. In each plasma sample until 35 h, protein binding of sulphadimidine and of the 
metabolite was measured (S, N4 unbound). Protein binding of sulphadimidine is 89.7 ± 
1.40% and of N4-acetylsulphadimidine 94.7 ± 1.08%. 
plasma samples are adequate because of the big differences in rates of 
acetylation and because urine samples slightly disturb this good separation 
due to pH differences. In patients with kidney impairment, the effect of 
kidney failure is higher on the renal clearance of N4-acetylsulphadimidine 
(i.e. active tubular secretion of 50 ml/min) than on the renal clearance of 
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sulphadimidine (glomerular filtration-tubular reabsorption of 5-10 ml/min). 
With an unaltered rate of acetylation and decreased rate of excretion, the 
correlation between percentage of N4-acetylsulphadimidine in plasma and 
percentage N4 in urine will be lost in patients with kidney impairment. 
Sulphadimidine and Protein Binding 
In the experiment shown in figure 14, sulphadimidine (773 mg) was 
taken by a volunteer and subsequently 'slowly' acetylated and excreted. 
The Τ Vi of elimination of sulphadimidine is 8 h and the Τ 'Λ of the me­
tabolite N4-acetylsulphadimidine is similar to the parent compound. From 
the dose ingested, 25.6% was excreted in the urine unchanged and 65.0% 
as metabolite N4-acetylsulphadimidine. The volunteer abstained during the 
3 days of experiment of caffeine and nicotine. Therefore, the limit of detec­
tion of the HPLC analysis could be lowered to 80 ng/ml for both parent 
compound and metabolite. 
Blood samples of 2 ml were collected by the fingertip puncture method. 
100/il plasma were used for HPLC analysis and in 400/¿1 plasma the pro-
tein binding of sulphadimidine and N4-acetylsulphadimidine was established 
by means of Ultrafree® drug filters. The free plasma concentration of sul-
phadimidine started at 12.6% 1.5 h after the ingestion and decreased to 
8.5% at 16 h, the mean 10.3% ± SD 1.4. The free plasma concentration 
of the metabolite started at 7.9% of the total plasma concentration at 1.5 h 
after administration and ended at 4.6% at 20 h, the mean 5.35% ± SD 1.08. 
The renal clearance values were calculated on basis of total and free plasma 
concentrations and shown in table IX. 
Sulphadimidine as Essential Drug? 
In the second report of the WHO Expert Committee on the selection 
of essential drugs [91] sulphadiazine was deleted from the list of comple-
mentary antibacterial drugs, since it has no clear advantage over sulpha-
dimidine. So, sulphadimidine was added to the list. From the data, as de-
scribed in the chapters on sulphadiazine and on sulphadimidine, it is possible 
to compare these two drugs. As listed, both drugs show the 'slow-fast' 
acetylation phenomenon, but their pharmacokinetic behaviour differs widely. 
1. Metabolism. As shown in table IV and VIII, only 1-13% of the dose 
of sulphadimidine is excreted unchanged in the urine of respectively 'fast' 
and 'slow' acetylators. From sulphadiazine, however, 30-70% of the dose 
is excreted unchanged in the urine, in respectively 'fast' and 'slow' acetylators. 
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Table IX. Renal clearance values of 'total' and 'free' sulphadimidine and its metabolite 
N4-acetylsulphadimidme in 1 volunteer 
К, S'total' K
r
S'free· K
r
 N4 'total' K,. N4'free' Urine flow Urine pH 
ml/min ml/min ml/min ml/min ml/min 
4.86 ±1.53 46.28 ±14.42 34.71 ± 7.96 737.4 ± 230.3 2.62 ± 0.98 7.32 ±0.19 
4.46 ±1.08 41.46 ±10.16 30.77 ± 4.91 512.8 ± 204.1 2.48 ± 1.71 6.62 ± 0.33 
— — 28.85 ±5.28 — 3.93 ± 2.50 5.56 ±0.26 
S = Sulphadimidine; N4=N4-acetylsulphadimidine; K
r
=renal clearance ± SD. 
2. Phenotyped Acetylation. Fast acetylators do metabolize sulphadimi­
dine to an extent of even 80%, whereas sulphadiazine is metabolized by 'fast' 
acetylators to an extent of about 30% (table IV and VIII). 
Sjöqvist et al. [72] mention that in most European groups about 40% 
and in the USA 45% of the population are 'fast' acetylators, but 80-90% of 
Asian populations and nearly 100% of Canadian Eskimos are 'fast' ace-
tylators. For the Asian population it is doubtful whether the choice in favour 
of sulphadimidine is justified, based on the data mentioned before, because 
in the majority of the people sulphadimidine may be regarded as a prodrug 
of its non-effective metabolite N4-acetylsulphadimidine. Therefore, a re-
appraisal of the choice seems necessary. In general, sulphonamides with a 
high effectivity, high water solubility, low protein binding, low rate of 
acetylation and unimodal acetylator type should be recommended. 
N4-Acetylsulphadimidine 
N4-Acetylsulphadimidine is the acetylated metabolite of sulphadimidine 
(fig. 15). The compound is formed at different rates and yields in 'slow' and 
'fast' acetylators. General properties, such as molecular weight, protein 
binding and volume of distribution, are given in table VI. 
cru 
0 0
 N _ / 3 
CH3 
Fig. 15. Structure of N4-acetyIsulphadimidine. 
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Fig. 16. Plasma concentration-time and renal excretion rate-time profile of 523 mg 
N4-acetylsulphadimidine (N4) and its metabolite sulphadimidine (S) in a 'fast' acetylator. 
The T'/i of elimination of N4-acetylsulphadimidme is biphasic (4-7.5 h) due to the acety-
lation of the metabolite sulphadimidine. The main process of elimination of N4-acetyl-
sulphadimidine is renal excretion (93.9%). 
Pharmacokinetic Properties 
Classification 
Based on the TVi of elimination (T'/i 5 h), N4-acetylsulphadimidine is 
a short-existing and fast-excreted sulphonamide. 
pH and Solubility 
The solubility of Nvacetylsulphadimidine at pH 5.5 and pH 7.0 is 
given in table VII. 
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Absorption, Metabolism and Renal Excretion 
N4-Acetylsulphadimidine, when administered to a volunteer, is rapidly 
absorbed. The absorption is total, as 93% of the dose of N4-acetylsulpha-
dimidine is excreted in the urine and 5.8% as the metabolite sulphadimidine 
as shown in figure 16. The maximum plasma concentration of N4-acetyl-
sulphadimidine has been reached 2 h after the administration. The Τ'Λ of 
elimination is 5 h initially but gradually changes to 8.5 h. N4-Acetylsulpha-
dimidine is deacetylated to sulphadimidine, which in turn becomes ace-
tylated again. Sulphadimidine is measurable for 20 h. It was already no­
ticed by Krebs et al. [42] that N4-acetylsulphadimidine was deacetylated. 
It was however at that time impossible to detect sulphadimidine in plasma 
of man. The volunteer who deacetylated in their study [42] N4-acetylsulpha-
dimidine was a 'slow' acetylator, while the volunteer shown in figure 16 is 
a 'fast' acetylator of sulphadimidine. 
Sulphadoxine 
Introduction 
Sulphadoxine is no longer used as a single compound but, in combi­
nation with pyrimethamine, it is used against malaria in tropical areas. 
The combination is listed in the selection of essential drugs [91]. The struc­
ture and general properties are given in table X and figure 17. 
Table X. General properties of sulphadoxine and its metabolite N4-acetylsulphadoxme 
Compound Molecular pK
a
 Protein Vd, 1/kg 
weight binding, % 
Sulphadoxine 310.34 6.30 86 0.14 
N4-Acetylsulphadoxine 352.36 - - 0.10 
Data according to Otten and Plempel [56], Vree et al. [unpublished data]. 
OCH3 ОСНэ 
Fig. 17. Structure of sulphadoxine. 
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Pharmacokinetic Properties 
Classification 
The extremely long Τ Ά of elimination makes the compound useful for 
long-term prophylactic use by ingestion of 500 mg only once a week. The 
T'A of elimination of sulphadoxine is about 100 h [56] as is the T'/i of the 
metabolite N4-acetylsulphadoxine. Therefore, sulphadoxine is classified as 
an extremely long-acting sulphonamide. 
pH and Solubility. The solubility of sulphadoxine and its metabolite 
N4-acetylsulphadoxine at pH values 5.5 and 7 is given in table XI. 
Table XL Influence of the pH on the solubility of sulphadoxine and N -^acetylsulphadoxine 
Compound 
Sulphadoxine 
K4-Acetylsulphadoxine 
Solubility 
pH5.5 
186 
221 
in mg/1 at 250C 
pH7.0 
2,387 
3,420 
Data according to Vree et al. [unpublished data]. 
pH and Metabolism. Sulphadoxine is only slightly acetylated. When a 
dose of 500 mg is ingested, 60 h later 13.2% of the dose has been excreted 
Table XII. Urine pH and renal clearance values of sulphadoxine and N4-acetylsulphadoxine 
in 2 subjects [Vree et al., unpublished data] 
Urine flow 
ml/min 
2.49 ±1.75 
3.57 ± 3.54 
2.47 ±1.60 
3.15 ± 0.74 
3.53 ± 4.22 
2.91 ± 2.99 
Urine pH 
5.46 ± 0.24 
6.45 ± 0.42 
7.50 ± 0.51 
5.68 ±0.15 
6.38 ± 0.26 
7.33 ±0.24 
K
r
S 
ml/min 
0.230 ±0.171 
0.338 ± 0.254 
0.544 ± 0.191 
— 
— 
— 
K
r
N4 
ml/min 
2.87 ± 1.06 
3.27 ± 1.09 
4.40 ± 0.73 
3.82 ± 1.76 
4.35 ± 1.79 
6.02 ± 2.72 
η 
28 
5 
7 
5 
26 
18 
S=Sulphadoxine; N4=N4-acety(sulphadoxine; K
r
=renal clearance ± SD; η=number 
of urine samples. 
1. 
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Fig. 18. Plasma concentration-time curves of sulphadoxine (SD) and its metabolite 
N4-acetylsulphadoxine (N4SD) during steady state and of the co-medicated drug sulpha-
methoxazole (S; 504 mg) and its metabolite Ni-acetylsulphamethoxazole (N4) in a vol-
unteer ('fast' acetylator). The plasma concentration of N4-acetylsulphadoxme (N4SD) is 
influenced more by the co-medication than that of sulphadoxine. Sulphamethoxazole, by 
influencing the protein binding, increases the renal clearance of sulphadoxine and of 
N4-acetylsuIphadoxine. 
unchanged and 3.3% as N4-acetylsulphadoxine. The low degree of acetyla-
tion, the long T'/i and the impracticability to maintain acidic or alkaline 
conditions over such long time periods makes it impossible to investigate 
the effect of the urinary pH on the metabolism. 
pH and Renal Excretion. Like all the sulphonamides the renal clearance 
of sulphadoxine is dependent on the urinary pH as is shown in table XII. 
Drug Interaction with Sulphadoxine 
Compounds which remain in the body for weeks or months always 
give rise to the possibility of interaction with concomitant drugs. Sulpha-
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Table XIII. Interaction between sulphadoxine, Né-acetylsulphadiazine and sulphamethoxazole [Vree et al., unpublished data] 
Subject Compound Dose Urine flow Urine pH KrS KrN4 
mg ml/min ml/min ml/min 
Remarks 
A.M.B. N4-acetyl- 507 
sulphadiazine 
A.M.B. N4-acetyl- 977.6 
sulphadiazine 
A.M.B, sulphametho- 400 
xazole 
A.M.B. sulphametho- 504.4 
xazole 
A.M.B, sulphadoxine 500 
A.M.B. sulphadoxine 500 
sulphadoxine 500 
1.65 ± 1.03 5.85 ± 1.00 — 
3.43 ± 2.60 5.07 ± 0.28 — 
2.27 ± 1.68 5.36 ± 0.46 0.92 ± 0.59 
111.11 ±34.38 
93.86 ± 15.27 
ρ < 0.20 
43.16 ± 10.39 
2.13 ±1.87 5.30 ±0.51 0.73 ±0.43 58.26 ± 19.27 
0.15<p<0.20 0.125<p<0.025* 
2.49 ± 1.75 5.46 ± 0.24 0.23 ± 0.17 2.94 ± 1.01 
2.13 ±1.87 5.30 ±0.51 0.84 ± 0.030 4.05 ± 2.02 
p< 0.0005* 0.0125<p<0.025· 
3.43 ±2.60 5.07 ±0.28 5.22 ± 2.87 6.32 ± 3.27 
p< 0.0005* p < 0.0005* 
under sulphadoxine steady state 
under sulphadoxine steady state 
sulphamethoxazole 504 mg 
Ni-acetylsulphadiazine 977 mg 
S=Parent compound administered ; Ν« =· Ni-acetylsulphonamide derivative formed or administered ; K
r
=renal clearance ± SD ; ρ = ρ value 
of a two-sample t-test between value and 'blank' or reference values. 
* Statistically significant. 
Table XIV. Some pharmacokinetic parameters of Nt-acetylsulphadoxine and its metabolite sulphadoxine in man. Data according to Vree 
et al. [85] 
Subject 
M.O. 
Dose 
mg 
287 
T'/iS 
h 
110 
Τ'ΛΝ* % S 
h 
22.5 
β/.Ν4 
87.5 
K
r
S 
ml/min 
-
K
r
N4 
mi/min 
4.85 ± 2.27 
Urine pH 
6.66 ± 0.61 
Urine flow 
ml/min 
2.99 ± 3.56 
Creatinine clearance 
ml/min 
175.8 ± 53.3 
S=Sulphadoxine: N4=N4-acetylsulphadoxme. 
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doxine is capable of interacting with two other sulphonamides as was experi­
enced in this laboratory when one volunteer, during sulphadoxine steady 
state, took, for investigational purposes, N4-acetylsulphadiazine and sulpha-
methoxazole. The interaction between sulphadoxine and sulphamethoxazole 
is shown in figure 18. Both compounds had been taken on previous occa­
sions by the volunteer as reference compounds. Figure 18 shows a decrease 
in the plasma concentration of sulphadoxine as well as that of the metabolite 
N4-acetylsulphadoxine at the time sulphamethoxazole is taken orally. The 
renal excretion rates of the 4 compounds have been omitted from the figure 
for reasons of clarity. The renal clearance data show an increase for sulpha­
doxine, N4-acetylsulphadoxine, sulphamethoxazole and N4-acetylsulpha-
methoxazole. The influence of sulphadoxine on the renal clearance of N4-
acetylsulphadiazine is not significant. The data are summarized in table XIII. 
N4-Acetylsulphadoxine 
N4-Acetylsulphadoxine is present in the body as a metabolite of sulpha­
doxine but only in small amounts. The structure is given in figure 19. The 
compound has comparable water solubility and protein-binding properties 
to the parent compound as shown in table X and XI. 
C H , - C - N - { 0 ) - S - N ^ 0 N 
OCH3 OCH3 
Fig. 19. Structure of N4-acetylsulphadoxine. 
N4-Acetylsulphadoxine has a much shorter intrinsic Τ'Л of elimina­
tion and in this respect behaves in a similar way as all other N4-acetyl-
sulphonamides. The Τ Vi of N4-acetyIsulphadoxine is 22 h while the me­
tabolite sulphadoxine, the result of deacetylation, shows a Τ Vi of 110 h 
(fig. 21). This Τ'Λ is comparable to that derived from sulphadoxine as parent 
compound. In 160 h of experimental time 87.7% of the dose is excreted 
unchanged. No renal excretion of metabolite can be measured. The lack of 
renal excretion of sulphadoxine is probably due to the extremely low plasma 
concentration, the low free plasma concentration and the low renal clear­
ance of about 0.2 ml/min. The pharmacokinetic parameters of N4-acetyl-
sulphadoxine from this experiment are summarized in table XIV. 
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Fig. 20. Plasma concentration-time and renal excretion rate-time profiles of 287 mg 
Ní-acetylsulphadoxine (N4) and its metabolite sulphadoxine (S) in a volunteer ('fast' 
acetylator). The intrinsic Τ'Λ of N4-acetylsulphadoxine is 22 h. N4-Acetylsulphadoxme 
is deacetylated and the metabolite sulphadoxine shows its known Τ'Λ of 110 h. Duration 
of this time course of the experiment was 200 h where in 87.7% of the dose is excreted 
unchanged. 
The final stage of the plasma concentration-time curve shows an inter­
esting phenomenon. It was often observed that the plasma concentration 
of the parent drug is levelled off at the very end of the curve (fig. 20, 21). 
Unfortunately this levelling off always occurs at plasma concentrations 
which are just above the detection limit (fig. 20). 
In this figure and situation, sulphadoxine has been generated due to 
deacetylation of N^acetylsulphadoxine. Thus, sulphadoxine is in turn slowly 
and to a small extent acetylated. Thus, the compound with the smallest in­
trinsic Τ'Λ of elimination must be governed by the compound with the 
longest Τ'Λ of elimination, a situation which is always present when the 
aprent or active compounds are ingested. When more plasma samples are 
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Fig. 21. Plasma concentration-time profile of 287 mg N^acetylsulphadoxine (N4) 
and its metabolite sulphadoxine (S) in a volunteer ('fast' acetylator of figure 20). The TVi 
of N4-acetyIsuIphadoxine is 22 h in the first 160 h of the time course of elimination, but 
is increased to 110 h in the final stage (160-340 h). The deacetylated metabolite sulpha­
doxine is excreted with its normal T'/i of 110 h. The différence in the slope of the curve 
is the result of the equilibrium between acetylation and deacetylation that has been reached 
after about 160 h. In the final stage of the elimination the Τ Vi of the fast parent compound 
is governed by the slow metabolite. 
taken over a time period of 340 h, the kinetic profile appears as in figure 20. 
Sulphadoxine elicits the long Τ'Λ of 110 h, and N4-acetylsulphadoxme shows 
the same behaviour, as far as it can be measured. This situation can be 
observed with extremely low renal clearance values of both compounds. 
It is possible to observe the same effects with sulphamethoxazole and N4-
acetylsulphamethoxazole in patients with severely impaired kidney function 
who are treated with a high dose of sulphamethoxazole. In this case, the 
amount of sulphamethoxazole derived from deacetylation contributes sig­
nificantly and visibly to the original ingested sulphamethoxazole [83]. 
126 
Hekster/Vree 56 
Sulphaethidole 
Introduction 
Sulphaethidole (fig. 22) was introduced in 1940 by Vonkennel et al. [79] 
and was studied and prescribed until 1960. At the moment there is available 
a combination of sulphaethidole with sulphamethizole as a specific drug 
combination for urinary tract infections. General properties of sulpha­
ethidole, such as protein binding and molecular weight are given in table XV. 
Fig. 22. Structure of sulphaethidole. 
Pharmacokinetic Properties 
The Τ г of elimination of sulphaethidole measured in different studies 
shows considerable variation ranging from 4.2 h [41, 78] to 11.0 h [41]. 
Kostenbauder et al. [41] showed that the Τ'Λ of elimination is dependent on 
the urinary pH. With alkaline urine the tubular reabsorption is minimal, 
resulting in the short Τ Vi of 4.2 h. 
Table XV. General properties of sulphaethidole and its metabolite N4-acetylsu]phaethidole 
Compound 
Sulphaethidole 
N4-AcetyIsulphaethidole 
Data according to Struller [74], 
Table XVI. Influence of the pH 
ethidole 
Compound 
Sulphaethidole 
N<-Acetylsulphaethidole 
Molecular 
weight 
284.36 
326.38 
pK
a
 Protein Vd, 1/kg 
binding, % 
5.60 96-99 0.08 
0.14 
Vree et al. [unpublished data]. 
on the solubility of sulphaethidole and N^-acetylsulpha-
Solubility in mg/1 at 25°C 
pH 5.5 pH 7.0 
489 7,110 
392 7,850 
[Vree et al., unpublished data]. 
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Fig. 23. Plasma concentration-time and renal excretion rate-time profile of 430 mg 
sulphaethidole. Under acidic urine conditions, sulphaethidole is excreted with a T'/i of 
12 h. About 72% of the dose is excreted unchanged. Note that sulphaethidole is not 
metabolized into N4-acetylsulphaethidole. 
Classification 
Based on the Τ'Л of elimination as determined [41, 78], sulphaethidole 
can be classified as a short-acting to medium long-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubilities of sulphaethidole and its metabolite 
N4-acetylsulphaethidole at pH values 5.5 and 7.0 are given in table XVI. 
pH and Metabolism and Renal Excretion. From the studies of Viek et al. 
[78] and Kostenbauder et al. [41] it is clear that sulphaethidole is only acetyl-
ated to a minor extent (3%). Figure 23 shows the pharmacokinetic profile 
128 
Hekster/Vree 58 
-
ios 
ia 
1 
с 
plasma cone,pg/rnl 
renal ексг rate.pg/mm 
T-ri 
' 
^ s 
10 20 
X, 
»». 
urine pH 7341076 
' 1 • 
30 
1 • 
( 0 
78 ¿0% 
L Г 1—1 
\ T k 10h 
1 « 1 
50 6C 
Fig. 24. Plasma concentration-time and renal excretion rate-time profile of 683.S mg 
sulphaethidole. Under alkaline urine conditions, sulphaethidole is excreted with a Τ'Л 
of 10 h. About 78% of the dose is excreted unchanged. Note that sulphaethidole is not 
metabolized into N4-acetylsulphaethidole. 
of sulphaethidole in a volunteer whose urine was kept strictly alkaline, thus 
according to Kostenbauder et al. [41] a short Τ Vi of 4 h could be anticipated. 
However, the kinetic profile actually elicits a long Τ'Λ of 10 h, and 78.4% 
of the dose is excreted unchanged in the urine. The conclusion that sulpha­
ethidole had a short Τ'Λ time of elimination was based on urinary excretion 
rate data during a short sampling period of 20 h [41]. 
When the plasma concentration-time curve is extended to 60 h, the 
true 'beta' or longer T'/i of 10 h is revealed. In a volunteer with strictly 
acidic urine (fig. 24) the T'/i of elimination is extended to 12 h, while 71.6% 
of the dose is excreted unchanged in the urine. Under both urine pH con­
ditions the amount (if any) of the metabolite N4-acetylsulphaethidole is 
not detectable. 
Renal Excretion 
Sulphaethidole, despite its low renal clearance values, is still excreted 
via active tubular secretion. This mechanism can be demonstrated by the 
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Fig. 25. Plasma concentration-time and renal excretion rate-time profiles of 707 mg 
sulphaethidole (S) and probenecid (*), when probenecid is administered as co-medication 
to sulphaethidole in a volunteer ('slow' acetylator). Also the renal clearance (Kr) of 
sulphaethidole (Kr S) and probenecid are shown. Under probenecid co-medication, the 
T'/i of elimination of sulphaethidole is increased to 19 h, when the probenecid concentra-
tion is above 20 /ig/ml. In the final phase of the elimination process, sulphaethidole shows 
its normal TV» of about 9 h. 75% of the dose is excreted unchanged, while no metabolite 
N4-acetylsulphaethidole could be detected. The renal clearance of sulphaethidole (Kr S) 
is reduced under co-medication of probenecid in the first phase (0-25 h) but reaches its 
normal value when probenecid concentration is below 20/xg/ml. Probenecid itself shows a 
capacity limited elimination. When its concentration is high, the Τ'Λ is 7 h. After 25 h, 
when the concentration is below 20/ig/ml, the T'A is decreased to 4.3 h. 
competitive inhibition which is achieved by co-medication with probenecid 
[85]. Figure 25 shows the pharmacokinetic profile of sulphaethidole under 
probenecid co-medication. 1 h after the oral administration of sulphaethi­
dole, probenecid is taken orally in the following sequence, 1 g followed 
by 0.5 g 4 times at 0.5-h intervals. Under these conditions the Τ'Λ of sulpha-
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Table XVII. Some pharmacokinetic parameters of sulphaethidole and its metabolite NU-acetylsulphaethidole in man. Data obtained from 
Vree et al. [85] 
Subject 
T.J. 
Y.A.H. 
T.B.V. 
+ Probenecid 
Dose 
mg 
430 
684 
707 
TViS 
h 
12 
10 
9.0 
19.0 
ТУ, N4 
h 
-
-
-
% S 
71.6 
78.4 
75.2 
%N4 
-
-
-
-
K
r
S 
ml/min 
4.85 ± 0.97 
9.22 ± 1.85 
7.87 ± 2.04 
10.75 ± 1.78 
2.96 ± 0.69 
K
r 
N4 
ml/min 
-
-
-
-
Urine pH 
5.20 ±0.18 
5.73 ± 0.46 
7.34 ± 0.76 
7.13 ± 0.44 
7.41 ± 0.70 
Urine flow 
ml/min 
1.93 ± 1.65 
5.45 ± 4.55 
0.74 ± 0.40 
2.39 ± 1.46 
4.25 ± 3.87 
Creatinine clearance 
ml/min 
131.3 ± 26.3 
130.5 ±25.6 
154.6 ± 21.9 
163.6 ± 19.4 
140.2 ± 16.2 
Ì 
S=Sulphaethidole; N4=N4-acetyIsuIphaethidole; -=not present; Kr= 
benecid (fig. 25). 
renal clearance ± SD; + probenecid=under co-medication of pro-
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ethidole is increased from 10-12 to 19 h, during the time course (0-25 h) in 
which probenecid itself is eliminated with a Τ 'Λ of 7 h. During that time 
course the elimination rate of probenecid is inhibited probably by its own 
presence at the active tubular transport mechanism or by competitive in­
hibition of one of its metabolites. As soon as the probenecid auto-inhibition 
has ceased, and probenecid is eliminated by first order elimination with a 
Τ Vi of 4.3 h, sulphaethidole is excreted in a normal way, resulting in the 
normal Τ г of elimination of 9 h (alkaline urine). In the time course of 80 h 
75.2% of the dose is excreted unchanged in the urine, which is comparable 
to the data shown in figure 23 and 24. During the probenecid-inhibition 
period the renal excretion rate of sulphaethidole is almost constant. 
In figure 25 the renal clearance of sulphaethidole (solid line K
r
S) is 
shown. It appears that the renal clearance of sulphaethidole is lower (2.96 ± 
0.69 ml/min) during the probenecid inhibition period (0-25 h) than after 
when it is normal again (10.75 ± 1.78 ml/min). In the same period (0-25) 
the auto-inhibition of probenecid is shown. The renal clearance of pro­
benecid declines rapidly, increasing during the evening by stimulation of 
the urine production due to the intake of ethanol in a social drink, declining 
again overnight, and returning to normal values of about 10 ml/min dur­
ing the final time course of the experiment. The data are summarized in 
table XVII. 
Metabolism 
Sulphaethidole is not acetylated. The lack of acetylation is not due to the 
fast renal clearance (as with sulphamethizole). A possible explanation for 
the low rate of acetylation may be the higher protein binding (96-99%), 
and the corresponding low free plasma concentration, in addition to the 
non-sensibility of the molecule to the enzymes. Thus, the degree of acetyl­
ation might be compared with that of sulphamethizole with the extra hin­
drance of the higher degree of protein binding of sulphaethidole. There 
might be an extra complicating factor, i.e. the possible high rate of deacetyl-
ation of the formed metabolite, which will be explained below. 
Ni-Acetylsulphaethidole 
N4-Acetylsulphaethidole might be the metabolite of sulphaethidole. The 
structure is given in figure 26. N4-Acetylsulphaethidole has similar solubility 
and protein-binding characteristics to sulphaethidole. N4-Acetylsulpha-
ethidole does not exist in the human body as a metabolite of sulphaethidole. 
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Fig. 26. Structure of Na-acetylsulphaethidole. 
A possible reason for this observation may be given in figure 27. When the 
compound is taken orally, as done in figure 27, it is relatively well absorbed, 
and consequently eliminated with a Τ 'Λ of 9 h. The compound is rapidly 
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Fig. 27. Plasma concentration-time and renal excretion rate-time profiles of 285.4 mg 
Ni-acetylsulphaethidole (N4) and its metabolite sulphaethidole (S) in a volunteer ('slow' 
acetylator). N4-Acetylsulphaethidole is eliminated with a T'/i of 6 h in the first stage of 
the experiment, which is increased to about 9 h in the final stage. About 46% of the dose 
is excreted unchanged. N^-Acetylsulphaethidole is deacetylated to sulphaethidole that 
can be detected in plasma and urine. The Τ'Λ of sulphaethidole as metabolite is 13 h. 
About 3.5% of the dose is excreted as sulphaethidole. It is likely that there exists an 
acetylation-deacetylation equilibrium, resulting in an increase of T'/j of Ni-acetylsulpha-
ethidole from 6 to 9 h. The rate of deacetylation must be higher than the rate of acetylation. 
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deacetylated into sulphaethidole, which can be easily measured in plasma 
as well as in urine. 
Although deacetylation is a rapid process, the amount of metabolite 
(sulphaethidole) formed and excreted in urine is only 3.5%. Even when it 
is assumed that no other metabolites of the drug exist and the bioavail­
ability factor is 0.5, only 7% of the dose is deacetylated and excreted as 
such. The Τ'Λ of elimination of the metabolite sulphaethidole is 13 h, which 
is higher than under alkaline conditions, in the same volunteer (9 h in 
fig. 23). This increased TVi can be explained by the continuous deacetylation 
of N4-acetylsulphaethidole contributing to the plasma concentration of sul­
phaethidole. 
Sulphafurazole (Sulphisoxazole) 
Introduction 
Sulphafurazole (fig. 28) was introduced in the period 1946-1949 as a 
single compound. An article on its clinical evaluation was published in 1949 
by Rhoads et al. [65]. General properties of sulphafurazole such as protein 
binding and molecular weight are given in table XVIII. 
о 
CHj CHj 
Fig. 28. Structure of sulphafurazole. 
Table XVIII. General properties of sulphafurazole and its metabolite Nj-acetylsulpha-
furazole 
Compound 
Sulphafurazole 
Ni-Acetylsulphafurazole 
Data according to Avery [4], 
Molecular 
weight 
267.30 
319.32 
PK. 
4.90 
7.90 
Reeves et al. [61] and Vree et al. 
Protein 
binding, % 
84-90 
84-90 
[84]. 
Vd, I/kg 
0.16 
0.16 
1 3 4 
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Pharmacokinetic Properties 
Classification 
Based on the Τ Ά of elimination of 4-6 h [33] sulphafurazole can be 
classified as a short-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubility of sulphafurazole at pH values of 5.5 
and 7.0 is given in table XIX. The concentrations are given in mg/1 at 
250C (room temperature). 
Table XIX. Influence of the pH on the solubility of sulphafurazole and derivatives 
Compound Solubility 
pH5.5 
Sulphafurazole 1,533 
N4-AcetylsuIphafurazole 250 
Ni-Acetyl-N4-acetylsulphafurazole 12.3 
in mg/l at 250C 
pH7.0 
4.724 
6.893 
5.2 
Data according to Hekster et al. [37] and Vree et al. [82]. 
pH and Absorption, Metabolism and Renal Excretion. Figure 29 shows 
the plasma concentration-time curve and renal excretion rate-time profile 
of sulphafurazole in a volunteer ('fast' acetylator) after an oral dose of 572 mg 
of sulphafurazole, under alkaline urine conditions. Under these conditions 
the T'/ì of elimination is 6 h in the first period (0-35), thereafter the TVi 
is increased to 8.5 h. The Τ'/2 of elimination of the metabolite N4-acetyl-
sulphafurazole is much longer than the parent compound (about 18 h). The 
increase of Τ г of sulphafurazole after 35 h can be explained by an equi­
librium between acetylation and deacetylation, in which the deacetylation 
of N4-acetyIsulphafurazole contributes to the increase of Τ'Λ of sulpha­
furazole. The percentage of the dose excreted as metabolite is about 33%, 
and is comparable to the data of Goossens and van Oudtshoom [33] and 
Dettli and Spring [17]. About 67% of the dose is excreted unchanged in 
the urine. 
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Fig. 29. Plasma concentration-time and renal excretion rate-time profiles of 572 mg 
sulphafurazole (S) and its metabolite N4-acetylsulphafurazole (N4) in a volunteer ('fast' 
acetylator) under alkaline urine conditions. The Τ'Λ of sulphafurazole is 6 h in the first 
time course of the experiment (0-40 h). In the second stage, the T'A is increased to 8.5 h. 
About 67% of the dose is excreted unchanged and 33% as metabolite. The T'/i of the 
metabolite is 18 h. 
Figure 30 shows the effect of co-medication of probenecid in the same 
volunteer. Probenecid (1 g) was given 1 h after the oral intake of 632.7 mg 
of sulphafurazole and thereafter 0.5 g four times at 0.5-h intervals. Under 
these conditions the T'A of elimination of sulphafurazole is increased to 
12 h, the Τ/2 of N4-acetylsulphafurazole could not be determined accurately 
as shown in figure 30. Probenecid co-medication influences the ratio of the 
sulphafurazole and N4-acetylsulphafurazoIe excreted in the urine. 
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Fig. 30. Plasma concentration-time and renal excretion rate-time profiles of 632.7 mg 
sulphafurazole (S), its metabolite Nj-acetylsulphafurazole (N4) and the co-medicated 
drug probenecid, in a volunteer ('fast* acetylator of fig. 29). Under influence of co-medi­
cation of probenecid, the T'/i of sulphafurazole is increased to 12 h and only 46% of the 
dose is excreted unchanged. Under these circumstances more N4-acetylsulphafurazole is 
formed and about 50% of the dose is finally excreted in the urine. Probenecid shows its 
capacity limited elimination, as in figure 25. 
The percentage excreted as N4-acetylsulphafurazoIe is about 50% under 
probenecid conditions and 33% under normal (alkaline) conditions. Prob­
enecid co-medication favours the acetylation equilibrium and inhibits the 
renal excretion of sulphafurazole. With reduced renal excretion, the rate 
constant of the acetylation-deacetylation equilibrium reaches its closest ap­
proximation. 
Goossens and van Oudtshoorn [33] showed the influence of alkaline urine 
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conditions on the pharmacokinetics of sulphafurazole. Under normal con­
ditions the Т г of elimination was determined as 6.31 ± 0 . 1 4 h (n = 3), 
whereas under alkaline conditions the T'/i was 4.40 ± 0.19 h (n = 3). These 
data are comparable to the data found by Dettli and Spring [16]. The per­
centage of the drug excreted unchanged in the urine increased from 82.7 to 
89.9% under alkaline conditions, whereas the percentage of the drug ex­
creted as NVacetylsulphafurazole in the urine decreased from 28.9 to 23.3% 
under alkaline conditions. No data were found about these experiments 
under strictly acidic conditions. 
Metabolism 
Sulphafurazole is metabolized in the liver to NVacetylsulphafurazole. 
The percentage of NVacetylsulphafurazole based on the total amount of 
drug ingested varies from 14 to 28% as shown by Nelson and O'Reilly [53] 
in 1960. 
These authors were not aware of differences between 'fast' and 'slow' 
acetylators, which would probably explain the differences found. Goossens 
and van Oudtshoorn [33] showed that the percentage of acetylation, based 
on the total amount of drug excreted, is influenced by urinary pH. Under 
alkaline urine conditions this percentage was 26.2 and under normal urine 
conditions the percentage was 34.9. 
Sulphafurazole in Various Clinical States 
Reidenberg et al. [63] studied the metabolism of sulphafurazole in 6 
patients, who were hospitalized for starvation for weight reduction. They 
compared the rates of excretion and metabolism prior to starvation and 
during their starvation period. These patients showed unaltered mean me­
tabolic rates, but their excretion rates were decreased, at least partly due to 
a fall in urine pH, as these patients developed a mild metabolic ketoacidosis. 
In 4 azotemia patients both the excretion rate and the metabolic rate were 
significantly (about 50%) lower than that of the healthy (obese) subjects. 
A possible explanation may be that NVacetylsulphafurazole is rapidly 
and continuously deacetylated into sulphafurazole, with both compounds 
showing reduced renal clearance characteristics. Otherwise, an increase in 
the rate of metabolism and the achievement of the 'true' equilibrium could 
be expected when sulphafurazole is continuously and more completely acetyl-
ated in patients with kidney impairment, with an altered excretion rate of 
the parent compound. In healthy volunteers, however, deacetylation is a 
minor pathway [85]. 
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N4-Acetylsulphafurazole 
Introduction 
N4-Acetylsulphafurazole (fig. 31) is the acetylated metabolite of sulpha-
furazole. General properties of the compound are given in table XVIII. 
сНз-ё-мН^-з-мЛ 
¿KL си- Fig. 31. Structure of N4-acetylsulphafurazole. 
Pharmacokinetic Properties 
Classification 
Based on the Т'Л of elimination (Т'Л 19 h), N4-acetylsulphafurazole 
is a long-existing and slowly excreted sulphonamide derivative. 
pH Effects 
pH and Solubility. The solubility of N4-acetylsulphafurazole at pH 5.5 
and 7 is given in table XIX. 
Absorption, Metabolism and Renal Excretion 
Figure 32 shows the plasma concentration-time curves of N4-acetyl-
sulphafurazole and its metabolite sulphafurazole and the renal excretion 
rate-time curve of the parent compound. The Τ г of N4-acetylsulphafurazole 
is 19 h, and the T'/i of sulphafurazole, with its intrinsic T'/i of 6 h, is now 
similar to the parent compound, i.e. 19 h. In the experimental period of 
60 h (3 x Τ '/ι), only 42.3% of the dose is excreted unchanged. Deacetylation 
is rapid, 4 h after ingestion of the drug, the metabolite reaches its maximal 
plasma concentration. The plasma concentration of the metabolite is low, the 
renal clearance is less than 10 ml/min and the protein binding may be expected 
at 90%. These factors may explain why the renal excretion of sulphafurazole 
is below or at the detection limit. The compound Ni-acetyl, N4-acetylsulpha-
furazole elicits the same pharmacokinetic behaviour of N4-acetylsulpha-
furazole, indicating that the deacetylation at Ni is extremely fast and com­
plete. Ni-Acetylsulphafurazole is accordingly fast deacetylated to sulpha­
furazole which in turn is acetylated at the N4 position. 
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Fig. 32. Plasma concentration-time and renal excretion rate-time profiles of 313.2 mg 
N4-acetylsulphafurazole and its metabolite sulphafurazole (dotted line) in a volunteer 
('fast' acetylator). The T'A of N4-acetylsulphafurazole is 19 h (cf. fig. 29). About 42% of 
the dose is excreted unchanged. Na-Acetylsulphafurazole is deacetylated and sulpha-
furazole can be detected in plasma but not in urine. The Τ'Л of sulphafurazole as metabo­
lite is now 19 h. Its intrinsic Т'Л is 6 h, so the kinetics of the parent compound with its 
long T'/i (19 h) governs the elimination of sulphafurazole as its metabolite. 
Sulphamethizole 
Introduction 
Sulphamethizole (fig. 33) was introduced in 1940 and marketed as a 
single compound. General properties of sulphamethizole such as protein 
binding and molecular weight are given in table XX. 
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Fig. 33. Structure of sulphamethizole. 
Table XX. General properties of sulphamethizole and its metabolite N4-acetylsulpha-
methizole 
Compound 
Sulphamethizole 
N4-Acetylsulphamethizole 
Data according to Avery [4], 
Molecular 
weight 
270.33 
312.35 
pK
a 
5.40 
5.10 
Protein 
binding, % 
85 
98 
Vd,l/kg 
0.35 
0.10 
Reeves et al. [61] and Vree et al. [unpublished data]. 
Pharmacokinetic Properties 
Classification 
Based on the Τ 'Λ of elimination (T г of about 2 h) sulphamethizole 
can be classified as an ultrashort-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubility of sulphamethizole at pH values 5.5 
and 7 given in table XXI. 
Table XXI. Influence of the pH on the solubility of sulphamethizole and Nj-acetylsulpha-
methizole 
Compound Solubility 
pH5.5 
Sulphamethizole 1,555 
N4-AcetyIsulphamethizole 200 
in mg/l at 250C 
pH7.0 
5,022 
3,000 
Data according to Hekster et al. [37] and Vree et al. [82]. 
141 
Clinical Pharmacokinetics of Sulphonamides and Their N4-Acetyl Derivatives 71 
.plasma conc.pg/ml 
renal excr rale, gg/min 
S (prob) 74.1% 
S Bl.1% 
S(prob)Ti5.0h 
N4 (prob) Τι 13.0h 
20 25h 
Fig. 34. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
methizole (S; 496 mg), N4-acetyIsulphamethizole (N4) and sulphamethizole (Sprob; 
476 mg) and Nj-acetylsulphamethizole (N4-prob) under influence of co-medication of 
probenecid in a volunteer. Sulphamethizole (S) is rapidly excreted from the body with a 
Τ'Λ of 1.25 h. The compound is metabolized to a minor extent (1-2%) and the metabolite 
(N4) shows a Τ'/a of 3 h. About 81% of the dose is excreted unchanged. Under probenecid 
co-medication the Τ'Λ of sulphamethizole (Sprob) is increased to 5.0 h, and of Ni-acetyl-
sulphamethizole (N4prob) to 13.0 h. In the same time course of the experiment, less 
sulphamethizole is excreted (74.1%) as a result of the decrease in renal clearance of sulpha­
methizole. 
pH, Absorption, Metabolism and Renal Excretion. Figure 34 shows the 
plasma concentration-time curve and renal excretion rate time-profile of 
sulphamethizole and N-j-acetylsulphamethizole in a volunteer after an oral 
dose of 496 mg of sulphamethizole and the same curves after an oral dose of 
476 mg of sulphamethizole under co-medication of probenecid. Sulpha-
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Table XXII. Some pharmacokinetic variables of sulphamethizole and its metabolite N4-acetylsulphamethizole, 
Data according to Vree et al. [85] 
Subject 
C.K.L. 
H.T.H. 
L.M. 
м.о. 
м.о. 
A.M.B. 
W.T.F.» 
A.S.i 
Dose 
mg 
496 
468 
463 
488 
490 
546 
476 
496 
Τ'Л S Τ г N4 
h 
1.3 
1.3 
1.5 
1.6 
1.5 
1.5 
4.6 
4.4 
h 
3.0 
2.5 
2.5 
3.0 
3.0 
3.0 
13.0 
12.5 
ι % S 
81.1 
77.8 
86.2 
74.1 
82.8 
89.0 
74.1 
90.3 
%N4 K
r
S 
2.9 
1.2 
1.0 
1.7 
3.0 
1.3 
1.4 
3.0 
ml/min 
93.54 ±21.99 
108.99 ± 20.38 
115.86 ±26.20 
76.29 ± 52.02 
99.00 ± 43.90 
165.00 ±44.14 
31.01 ± 5.30 
28.60 ± 2.77 
K
r
N4 
ml/min 
60.97 ± 24.83 
30.16 ± 3.93 
55.48 ± 5.68 
48.95 ±10.11 
40.95 ± 25.40 
73.23 ± 13.29 
5.51 ± 0.68 
9.01 ± 6 . 1 2 
Urine pH 
6.51 ± 0.80 
7.21 ± 0.43 
5.85 ± 0.62 
5.38 ± 0.84 
7.55 ± 0.42 
5.60 ± 0.83 
6.82 ± 0.74 
6.80 ± 0.85 
Urine flow 
ml/min 
2.98 ± 1.58 
1.46 ±0.60 
2.94 ± 2.24 
3.05 ± 3.84 
2.06 ± 2.59 
2.19 ± 1.53 
1.42 ±0.33 
2.59 ±2.15 
S = Sulphamethizole ; N4=N4-acetylsulphamethizole ; % = percentage of the dose excreted ; K
r
=renal clear­
ance ± SD. 
1
 Under probenecid co-medication. 
methizole is rapidly absorbed and is eliminated from the body with a Τ'Λ 
of elimination of about 1.5 h. The drug is acetylated to the maximum 
extent of 3% under both alkaline and acidic urine conditions [86]. About 
80% of the dose given is found in the urine unchanged, independent of the 
pH of the urine. The different pharmacokinetic parameters of sulpha­
methizole obtained from a group of volunteers are summarized in table XXII. 
Table XXIII compares the influence of urinary pH on the Τ Vi and renal 
excretion of sulphamethizole and N4-acetylsulphamethizole. 
pH and Renal Clearance. As shown in table XXIV the renal clearance 
of sulphamethizole accounts for about 100 ml/min [48, 50] under acidic as 
well as alkaline urine conditions. The renal clearance was determined as 
described in the introduction. 
Table XXIII. Influence of urinary pH on the Τ'Λ and renal excretion of sulphamethizole 
and N4-acetylsulphamethizole. Data according to Vree et al. [85] 
Subjects 
n= 
n = 
S = 
= 3 
 3 
Urine pH 
7.09 ± 0.53 
5.61 ± 0.24 
Sulphamethizole ; N«=N4 
T'AS, h 
1.37 ±0.12 
1.53 ±0.06 
T,/,N4,h 
2.83 ± 0.29 
2.83 ± 0.29 
% S 
80.6 ± 2.54 
83.1 ± 7.92 
% N 4 
2.37 ± 1.01 
1.33 ±0.35 
-acetylsulphamethizole ; % = percentage of the dose excreted. 
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Table XXIУ. Influence of the urinary pH on the renal clearance of sulphamethizole and 
N4-acetylsulphamethizole. Data according to Vree et al. [85] 
Subjects 
n = 3 
n = 3 
n = 6 
Compound 
sulphamethizole 
sulphamethizole 
N4-acetylsulphamethizole 
Urine pH 
5.61 ± 0.24 
7.09 ± 0.53 
6.08 ± 0.27 
Renal clearance 
mi/min ± SD 
119.0 ±44.4 
100.5 ± 7.8 
51.6 ±15.2 
Metabolism 
Sulphamethizole is only slightly metabolized in the liver to N4-acetyl-
sulphamethizole (about 3%). Acetylation of sulphamethizole is not the main 
pathway in the elimination process of sulphamethizole. Under co-medica­
tion of probenecid, the percentage of excretion of N4-acetyIsulphamethizole 
is hardly increased, as shown in figure 33. Under the influence of probenecid 
co-medication, inhibiting the active tubular secretion, the Τ'Λ of elimination 
of sulphamethizole is increased to 5.0 h. The Τ Vi of elimination of N4-
acetylsulphamethizole is increased from 3.0 to 13.0 h. The percentage of 
the drug excreted as N4-acetylsulphamethizole is virtually not influenced (2.2% 
under probenecid co-medication). The renal clearance of sulphamethizole is 
reduced to 30 ml/min and of N4-acetylsulphamethizole to 7.5 ml/min [85]. 
Probenecid only affects the renal excretion but not the metabolic pathway 
of sulphamethizole. p-Iodo-hippurate is able to reduce the renal clearance 
of sulphamethizole from 100 to 60 ml/min [50]. 
Sulphamethizole and Impaired Kidney Function 
Sulphamethizole is excreted virtually unchanged in the urine of pa­
tients with reduced kidney function in amounts and concentrations equiva­
lent to that of individuals with normal kidney function [32]. However, sig­
nificant accumulation of the compound occurred, with resultant elevation 
of the serum level of the free drug. The biotransformed serum fraction of 
sulphamethizole was not measured in this investigation [32]. The Τ'Λ of 
elimination of sulphamethizole in anurie patients was increased to 58 h on 
the average [49]. 
Sullivan et al. [75] have studied the urinary concentration of sulpha­
methizole in patients with chronic pyelonephritis with involvement of a 
kidney to a greater extent than the contralateral kidney. Surprisingly, the 
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Table XXV. Relationship between the renal clearance of sulphamethizole and the creatinine 
clearance in different kind of kidney disease states. Data according to Lindahl and 
Josephson [48] 
Disease state К, sulphamethizole-K
r
 creatinine Number of patients 
Hypertrophia prostata г = 0.878 12 
у = 0.83 χ -2.94 
Nephrolithiasis г = 0.841 8 
у = 0.466 x+87.81 
Nephritis chronica г = 0.839 14 
у = 1.03 χ+7.61 
peak urinary concentration of the poorly functioning kidney in comparison 
to the better kidney was greater than its percentage relative blood flow or 
creatinine clearance. 
Lindahl and Josephson [48] analysed the renal clearance of sulpha­
methizole and the corresponding creatinine clearance for a series of kidney 
diseases. From their data, it is possible to discover that for different disease 
states, the relationship between the two clearance values holds true, as can 
be read from table XXV. 
N4-Acetylsulphamethizole 
N4-Acetylsulphamethizole is the acetylated metabolite of sulphamethi­
zole. The compound is extremely slowly formed from the parent compound 
and the total yield never exceeds 5% of the dose of the parent compound. 
General properties of N^acetylsulphamethizole are given in table XX and 
its structure in figure 35. 
^ ^ 0HN—N Fig. 35. Structure of N4-acetylsulphamethizole. 
Pharmacokinetic Properties 
Classification 
Based on the T'/i of elimination (Τ '/i about 5 h) N4-acetylsulphamethi-
zole can be classified as a short-existing sulphonamide derivative. 
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Table XXVI. Pharmacokinetic parameters of N4-acetylsulphamethizole in man. Data 
according to Vree et al. [85] 
Subjects 
n = 3 
n = 3 
TVi, h 
5.1 ±1.4 
4.3 ± 0.65 
%N4 
28.1 ± 18.2 
49.1 ± 4.5 
% N4=Percentage of the dose excreted as 
ance value. ± =SEM. 
Kr N4 Urine pH 
ml/min 
25.57 ± 12.43 5.91 ± 0.092 
27.44 ± 6.60 6.24 ±0.29 
Ni-acetylsulphamethizole; Kr= 
Urine flow 
ml/min 
2.31 ± 0.55 
1.89 ± 1.45 
= renal clear-
pH Effects 
pH and Solubility. The solubility of sulphamethizole at pH values 5.5 
and 7.0 is given in table XXI. 
pH, Absorption, Metabolism and Renal Excretion. N4-Acetylsulpha-
methizole is absorbed irregular from the gastro-intestinal tract because of 
the low water solubility. The T'A is about 5 h and the renal clearance value 
is not dependent on urine parameters, urine pH and urine flow. Deacetyl-
ation must be possible but could not yet be detected. The results are sum-
marized in table XXVI. 
Sulphamethoxazole 
Introduction 
Sulphamethoxazole (fig. 36) was introduced in 1962 as a single com-
pound. Since 1969 the drug has been mainly used in combination with 
trimethoprim at a fixed ratio of 5:1. This combination is known under its 
generic name co-trimoxazole. The combination is listed in the selection of 
essential drugs [91]. General properties of sulphamethoxazole such as pro-
tein binding and molecular weight are given in table XXVII. 
Fig. 36. Structure of sulphamethoxazole. 
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Table XXVII. General properties of sulphamethoxazole, its metabolite N4-acetylsulpha-
methoxazole and its pro-drug Ni-acetylsulphamethoxazole 
Compound 
Sulphamethoxazole 
N4-Acetylsulphamethoxazole 
Ni-Acetylsulphamethoxazole 
Molecular 
weight 
253.31 
295.33 
295.33 
PK. 
5.70 
5.00 
10.80 
Protein 
binding, % 
65 
75 
Vd, 1/kg 
0.17 
0.17 
Data according to Avery [4], Reeves and Wilkinson [62] and Vree et al. [84]. 
Pharmacokinetic Properties 
Classification 
Based on the T'/Î of elimination (T'/i of 10-12 h), sulphamethoxazole 
can be classified as a medium long-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubility of sulphamethoxazole at pH values S.S 
and 7 is given in table XXVIII. 
Table XXVIII. Influence of the pH on the solubility of sulphamethoxazole and derivatives 
Compound 
Sulphamethoxazole 
N4-AcetyIsuIphamethoxazoIe 
Ni-Acetylsulphamethoxazole 
Solubility 
pH 5.5 
300 
115 
66 
in mg/1 at 250C 
pH 7.0 
1,900 
1,000 
66 
Data according to Hekster et al. [3η and Vree et al. [82]. 
pH and Absorption, Metabolism and Renal Excretion. Figure 37 shows 
the plasma concentration-time curve and renal excretion rate time profiles 
of sulphamethoxazole and of N4-acetylsulphamethoxazole in a volunteer 
after an oral dose of 800 mg of sulphamethoxazole, under acidic (pH 5.5-6.0) 
and alkaline (pH 7.5-8.0) urine conditions. 
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Fig. 37. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
methoxazole (S) and its metabolite N4-acetylsulphamethoxazole (NAcS) under conditions 
of acidic fa) and alkaline (b) in the same volunteer ('fast' acetylator) who took 800 mg of 
sulphamethoxazole orally. Note that with acidic urine only 9.5% sulphamethoxazole 
was excreted unchanged while this amount increased to 36% with alkaline urine. The 
elimination T'/i of sulphamethoxazole with acidic urine is slightly higher (11 h) than with 
alkaline urine (9 h) [from ref. 81]. 
Under acidic conditions the Τ'Λ of elimination is slightly longer (11 h) 
than under alkaline conditions (9 h). The two extremes of the urinary pH 
also have some influence on the absorption rate of sulphamethoxazole. 
Under alkaline conditions sulphamethoxazole is absorbed faster, the maxi­
mum plasma concentration is reached after 3 h. As a result the maximum 
plasma concentration of the metabolite is reached earlier under alkaline 
than under acidic conditions. The areas under the curve of sulphametho­
xazole and its metabolite do not differ greatly under the two pH extremes. 
The net percentage of the compound excreted is clearly influenced by the 
pH conditions. Under acidic conditions 9.5% of the dose is excreted as 
parent compound, whereas under alkaline conditions the percentage excreted 
is increased to 36%. The percentage of the dose excreted as metabolite 
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Table XXIX. Influence of urinary pH on Τ'Λ and renal excretion of sulphamethoxazole 
and Nt-acetylsulphamethoxazole. Data according to Vree et al. [80, 81, 84] 
Subjects Urine pH 
η=Π 7.28 ±0.21 
n= 7 5.90 ±0.38 
S = Sulphamethoxazole; N4= 
excreted. ±=SEM. 
T'/» S 
9-12 
9-12 
,h TViN^h 
9-12 
9-12 
= N4-acetylsulphamethoxazole 
% S % N4 
32.6 ± 6.2 51.1 ± 13.3 
16.7 ±10.4 37.7 ± 8.3 
; % = percentage of the dose 
Table XXX. The influence of the urinary pH on the renal clearance of sulphamethoxazole 
and N4-acetylsulphamethoxazole. Data according to Vree et al. [80, 81] 
Compound 
Sulphamethoxazole 
N4-Acetylsu!phamethoxazole 
Urine pH 
5 
7 
5-7 
Renal clearance, ml/min 
0.5-2.5 
5-25 
40-60 
Table XXXI. Correlation of the relationship between the renal clearance of sulphamethox­
azole and some urine variables. Data according to Vree et al. [81] 
Compound 
Sulphamethoxazole 
S = Sulphamethoxazole; K
r
= 
К,' 
г = 
/s pH K
r
 vs urine flow K
r
 S-K
r
 creatinine 
0.84 r = 0.82 
renal clearance. 
r = 0.30 
seems independent of the pH of the urine, as 50-70% of the dose is excreted 
as N4-acetylsulphamethoxazole in a group of volunteers. This percentage 
seems to depend on the person-to-person variation and not on the urine 
conditions. The renal excretion rate of sulphamethoxazole after a dose of 
800 mg is much higher under alkaline urine conditions (about 300/ig/min) 
than under acidic conditions (about 80/(g/min). These differences are not 
seen with the metabolite. The different pharmacokinetic parameters of sul­
phamethoxazole obtained from a group of volunteers are summarized in 
table XXIX. 
pH and Renal Clearance. As shown in table XXX the renal clearance 
of sulphamethoxazole is markedly influenced by the urine pH. The rela-
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Fig. 38. Structure of Ni-acetylsulphamethoxazole. 
tionship between the renal clearance of sulphamethoxazole and of each of 
the urine variables, pH, urine flow and the renal clearance of creatinine, is 
shown in table XXXI. The correlation coefficient of the relationships were 
determined for the flow and the renal clearance of creatinine at constant 
urinary pH. 
Metabolism 
Sulphamethoxazole is metabolized in the liver mainly to N-i-acetyl-
sulphamethoxazole. When the plasma concentration of N4-acetylsulpha-
methoxazole is expressed as percent of the total sulphonamide concentra­
tion, the percentage of the metabolite reaches a value of 20% in the final 
elimination phase after a single oral dose. In figure 3 the development of 
the percentage N4-acetylsulphamethoxazole in plasma of 'fast' and 'slow' 
acetylators of sulphamethoxazole is shown. It is clear that sulphametho­
xazole is acetylated unimodally. From the curve it also can be seen that 
the Τ Vi of the residual curve, being the complex function of the rate con­
stants of formation and elimination, is 7 h in both 'fast' and 'slow' acetylators. 
Acetylation of sulphamethoxazole is the predominant process in its 
elimination. The overwhelming presence of acetyl-coenzyme-A and N-
transferase activity throughout the body makes acetylation virtually inde­
pendent of disease states of the patients. Patients with extremely poor kidney 
function and terminal patients show the same T'/i of elimination of sulpha­
methoxazole as healthy volunteers [5, 67, 83], namely ± 11.5 h. 
Ni-Acetylsulphamethoxazole 
Introduction 
Ni-Acetylsulphamethoxazole (fig. 38) is the on the Ni position acetylated 
form of sulphamethoxazole. General properties of Ni-acetylsulphametho-
xazole such as pK, and molecular weight are summarized in table XXVII. 
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Fig. 39. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
methoxazole (SMZ) and N4-acetylsulphamethoxazole (Kj-AC-SMZ) in a volunteer ('slow' 
acetylator) after an oral dose of 150 mg 1^-acetylsulphamethoxazolc [from ref. 84]. 
Pharmacokinetic Properties 
Determination of Ni-Acetylsulphamethoxazole 
After oral intake of Ni-acetylsulphamethoxazole this compound could 
not be detected in plasma and urine [84]. 
Absorption, Metabolism and Renal Excretion 
After oral intake of Ni-acetylsulphamethoxazole, the compound is rap-
idly deacetylated and thereafter acetylated again at the N4 position. Figure 39 
shows the plasma concentration-time curve and renal excretion rate of sul-
phamethoxazole and N-i-acetylsulphamethoxazole as the metabolites of N1-
acetylsulphamethoxazole. The different pharmacokinetic parameters ob-
tained from a group of volunteers are summarized in table XXXII. 
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Table XXXII. Influence of the urine pH on Τ'Λ and renal excretion of the metabolites of 
N^acetylsulphamethoxazole. Data according to Vree et al. [81] 
Subjects 
n = 2 
n = 3 
Urine pH 
5.25 
7.60 ± 0.09 
S=SuIphamethoxazole; N4= 
excreted. ±=SEM. 
T'/iS.h 
8.5 
8.0 ± 2.0 
T'/iN4,h 
8.5 
8.0 ± 2.0 
= N4-acety Isulphamethoxazole ; 
% S % N4 
24.2 42.7 
23.0 ± 5.95 22.4 ± 3.48 
% = percentage of the dose 
0
 ^
 0 
11 / 7 Λ 11 IHj-C-N-fOV-S-N-r , 
3
 H \ £ У η н " 1 
Fig. 40. Structure of N4-acetylsulphamethoxazole. 
Ni-Acetylsulphamethoxazole 
Introduction 
N4-AcetyIsulphamethoxazole (fig. 40) is the acetylated metabolite of 
sulphamethoxazole. General properties of N4-acetyIsulphamethoxazole, such 
as pK
a
 and molecular weight are summarized in table XXVII. 
Pharmacokinetic Properties 
Classification 
The intrinsic Τ'Λ of elimination of N4-acetyIsulphamethoxazole is 
about 3 h in healthy volunteers [84]. 
pH Effects 
pH and Solubility. The solubility of N4-acetylsulphamethoxazole at pH 
values 5.5 and 7 are given in table XXVIII. 
pH and Absorption, Metabolism and Renal Excretion. Figure 41 shows 
the plasma concentration-time curve and renal excretion rate-time profile 
of N4-acetylsulphamethoxazole in a volunteer after an oral dose of 300 mg 
of N4-acetylsulphamethoxazole under acidic (pH 5.43 ±0.21) and alkaline 
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Fig. 4L Plasma concentration-time and renal excretion rate-time profiles of N«-
acetylsulphamethoxazole in a volunteer ('fast' acetylator) after an oral dose of 300 mg 
N4-acetylsulphamethoxazole. The experiment was conducted under the two pH extremes 
of the urine (solid line pH 5.43 ± 0.21, and dotted line pH 7.20 ± 0.35) [from ref. 84]. 
(pH 7.20 ± 0.35) urine conditions. It can be seen that the pH has hardly 
any effect on the absorption and elimination of N4-acetylsulphamethoxazole. 
The main process of elimination is the dose of renal excretion, with about 
50-70% of N4-acetylsulphamethoxazole excreted in the urine. The different 
pharmacokinetic parameters of N4-acetylsulphamethoxazole obtained from 
a group of volunteers are summarized in table ΧΧΧΙΠ. 
Deacetylation 
In healthy volunteers there is no possibility to detect deacetylation of 
Ni-acetylsulphamethoxazole into sulphamethoxazole [84]. 
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Table XXXIII. Influence of the urinary pH on TVi and renal excretion of N4-acetyl 
sulphamethoxazole. Data according to Vree et al [81] 
Subjects 
η = 3 
η = 4 
Urine pH 
5.28 ±0.17 
7.29 ± 0.42 
Τ'Λ, h 
3.4 ± 0.1 
2.5 ± 0.4 
Percentage of the dose excreted 
68.9 ± 13.9 
74.3 ± 19.5 
i SEM. 
N-i-Acetylsulphamethoxazole and Renal Impairment 
As shown in the data of the parent sulphonamides, the overwhelming 
presence of acetylcoenzyme A makes acetylation virtually independent of 
disease states of the patients. As the elimination of the N4-acetylsulpha-
methoxazole is mainly by renal excretion, blocking this pathway will lead to 
accumulation of the N4-acetylsulphamethoxazole metabolite in plasma [62] 
and makes the deacetylation visible [83]. 
Inhibition of the Renal Clearance of N4-Acetylsulphamethoxazole by 
Probenecid 
In figure 43 probenecid is used as co-medication in the experiments 
with N4-acetylsulphamethoxazole. As a result, the average renal clearance 
of N4-acetylsulphamethoxazole is reduced from 60 to 15ml/min [83, 86]. 
The Τ Уг of elimination of N4-acetylsulphamethoxazole under comedication 
of probenecid is increased from the reference value of 3-7 h. 
Sulphametrole 
Introduction 
Sulphametrole (fig. 42) was introduced in 1975. The drug is used in 
combination with trimethoprim in a fixed ratio of 5:1. General properties 
of sulphametrole such as protein binding and molecular weight are sum­
marized in table XXXIV. 
о 
^N^gbl-N-Ç-C-OCH, 
О Мч ^ N 
Fig. 42. Structure of sulphametrole. 
154 
Hekster/Vree 
plasirraconc,pg/ml -
84 
renal excr. rale, μς/ιτιιη 
! · ! • 
Fig. 43. Plasma concentration-time and renal excretion rate-time profiles of 300 mg 
N4-acetylsulphamethoxazole under control conditions (dashed line) and under the co-
medication of probenecid. The Τ'Λ of N4-acetyIsulphamethoxazole increases from 3.S 
to 7.0 h due to co-medication of probenecid and a reduced renal clearance. The percentage 
of the dose excreted in the urine is decreased from 82.7% under control conditions to 
54.4% under probenecid co-medication. 
Pharmacokinetic Properties 
Classification 
Based on the Τ'Λ of elimination (ТУ* of 9-12 h), sulphametrole can 
be classified as a medium long-acting sulphonamide. 
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Table XXXIУ. General properties of sulphametrole and its metabolite N4-acetylsulpha-
metrole 
Compound Molecular pK
a
 Protein Vd, 1/kg 
weight binding, % 
Subhametrole 286.33 4.70 78 0.12 
N4-AcetyIsulphametrole 328.35 - - 0.15 
Data according to Chemie Linz [12] and Hekster et al. [37]. 
pH Effects 
pH and Solubility. The solubility of sulphametrole at pH values 5.5 and 
7 is given in table XXXV. 
Table XXXV. Influence of the pH on the solubility of sulphametrole and N4-acetylsulpha-
metrole 
Compound 
Sulphametrole 
N4-AcetylsuIphametrole 
Ni-Acetylsulphametrole 
Solubility 
pH 5.5 
460 
1,100 
34 
in mg/l at 250C 
pH 7.0 
1,700 
6,000 
24 
Data according to Hekster et al. [37] and Vree et al. [82]. 
pH and Absorption, Metabolism and Renal Excretion. Figure 44 shows 
the plasma concentration-time curve and renal excretion rate time-profile 
of sulphametrole and of N4-acetylsulphametrole in a volunteer after an oral 
dose of 595 mg of sulphametrole under acidic (pH 5.35 ± 0.40) and after 
an oral dose of 800 mg under alkaline (pH 7.36 ± 0.46) urine conditions. 
Under acidic conditions the Τ'Λ of elimination is slightly longer 
(10 h) than under alkaline conditions (7.5 h). The two extremes of the urinary 
pH also have some influence on the absorption rate of sulphametrole. Under 
alkaline conditions sulphametrole is absorbed faster, the maximum plasma 
concentration is reached after 1 h. Under acidic conditions the maximum 
plasma concentration is reached after 5 h. As a result of the faster absorp­
tion, the maximum plasma concentration of the metabolite is reached earlier 
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Fig. 44. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
metrole (S) and Na-acetylsulphametrole (N4) in a volunteer ('fast' acetylator) under acidic 
(595 mg) (a) and alkaline (800 mg) (b) urine pH conditions. Sulphametrole is excreted 
unchanged to a higher percentage (21.4%) under alkaline urine conditions than under 
acidic conditions (2.5%). The percentage of the dose excreted as metabolite N4-acetyl-
sulphametrole is virtually identical in both situations (about 50%). The Τ'Λ of sulpha­
metrole and N4-acetylsulphametrole is 7.5 h under alkaline urine conditions and 10 h 
under acidic conditions. 
under alkaline than under acidic conditions. The areas under the curve of 
sulphametrole and its metabolite do not differ greatly under the two pH 
extremes. The net percentage of the compound excreted is clearly influenced 
by the pH conditions. Under acidic conditions 2.5% of the dose is excreted 
as parent compound, whereas under alkaline conditions the percentage is 
increased to 21.4%. The percentage of the dose excreted as metabolite seems 
independent of the pH of the urine, as 50-70% of the dose is excreted as 
N4-acetylsulphametrole in a group of volunteers. This percentage seems to 
depend on the person to person variation and not on the urine conditions. 
The renal excretion rate of sulphametrole after an oral dose is much higher 
under alkaline conditions (about 500/ig/min) than under acidic conditions 
157 
Clinical Pharmacokinetics of Sulphonamides and Their Ni-Acetyl Derivatives 87 
Table XXXVI. Influence of the urinary pH on Τ'Λ and renal excretion of sulphametrole 
and N4-acetylsulphametroIe. Data according to Hekster et al. [37] 
Subjects Urine pH Τ'Λ S, h T'A N4, h % S % N4 
n = 5 5.37 ±0.23 9-11 9-11 3.88 ± 1.50 73.6 ± 17.6 
n = 4 7.72 ±0.42 9-11 9-11 24.4 ±13.5 53.5 ± 4.4 
S = Sulphametrole; N4=N4-acetylsuIphametrole; % = percentage of the dose excreted; 
±SEM. 
Table XXXVII. Influence of the urinary pH on the renal clearance of sulphametrole and 
its metabolite N4-acetylsulphametrole. Data from Hekster et al. [37] 
Subjects Urine pH K
r
 S К, N4 
ml/min ml/min 
n = 5 5.37 ±0.23 0.74 ±0.41 34.99 ± 9.25 
n = 3 7.51 ±0.13 7.92 ±3.69 34.90 ± 7.97 
S = Sulphametrole; N4=N4-acetylsulphametrole; K
r
=renal clearance value. ± = SEM. 
Table XXXVIII. Correlation of the relationship between the renal clearance of sulpha­
metrole and some urine variables. Data from Hekster et al. [37] 
Compound 
Sulphametrole 
K
r
 vs pH 
г = 0.89 
K
r
 vs urine flow 
r = 0.49 
K
r
 vs K
r
 creatinine 
r = 0.23 
К
 r
=Renal clearance. 
(60 ¿tg/min). These differences are not seen with the metabolite. The differ-
ent pharmacokinetic parameters of sulphametrole obtained from a group 
of volunteers are summarized in table XXXVI. 
pH and the Renal Clearance. As shown in table XXXVII the renal 
clearance of sulphametrole is markedly influenced by the urine pH. The 
renal clearance was determined as described in the introduction. The re-
lationship between the renal clearance of sulphametrole and each of the 
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Fig. 45. N4-Acetylsulphametrole in plasma plotted as percentage of the total sul-
phonamide concentration (parent drug+metabolite) versus the time course of the experi­
ment. No difference could be observed in the percentage Ni-acetylsulphametrole-time 
course in a group of 7 volunteers consisting of 3 'fast' and 4 'slow' acetylators. 
urine variables, pH, urine flow and the renal clearance of creatinine, is 
shown in table XXXVIII. The correlation of the relationship for the flow 
and the renal clearance of creatinine were determined at constant urinary pH. 
Metabolism 
Sulphametrole is metabolized in the liver mainly to N-j-acetylsulpha-
metrole. When the plasma concentration of Nracetylsulphametrole is ex­
pressed as percent of the total sulphonamide concentration, the percentage 
of the metabolite reaches a value of 40% in the final elimination phase after 
a single oral dose. In figure 45 the development of the percentage of N4-
acetylsulphametrole in plasma of 'fast' and 'slow' acetylators (of sulpha-
dimidine) is shown. It is clear that sulphametrole is acetylated unimodally. 
From the curve it can also be determined that the Τ Vi of the residual curve, 
being the complex function of the rate constants of formation and elimi­
nation is about 7 h in both 'fast' and 'slow' acetylators. 
Acetylation of sulphametrole is the predominant process in its elimi­
nation. The overwhelming presence of acetyl coenzyme-Α and 7V-acetyl-
transferase activity throughout the body makes acetylation virtually in­
dependent of disease states of the patient. Even in patients with impaired 
renal function the Τ Vi of elimination remains the same as in healthy volun­
teers, namely about 9-11 h [38]. 
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N4-Acetylsulphametrole 
Introduction 
Ni-Acetylsulphametrole (fig. 46) is the acetylated metabolite of sulpha-
metrole. General properties of N4-acetyIsulphametrole, such as pKa and 
molecular weight, are given in table XXXIV. 
cH3-í-íi4obb-s-f-ocH3 
0 O Ns ,N 
Fig. 46. Structure of Ki-acetylsulphametrole. 
Pharmacokinetic Properties 
Classification 
The intrinsic Τ'Λ of elimination of N4-acetylsulphametrole is about 
3 h in healthy volunteers. 
pH Effects 
pH and Solubility. The solubility of N4-acetylsulphametrole at pH val­
ues 5.5 and 7 are given in table XXXV. The concentrations are given in 
mg/1 at 250C (room temperature). 
Absorption and Renal Excretion 
Figure 47 shows the plasma concetration-time curve and renal ex­
cretion rate-time profile of N4-acetylsulphametrole under acidic conditions. 
The main process of elimination is renal excretion, with about 50-90% of 
N4-acetylsulphametrole excreted in the urine. The different pharmacokinetic 
parameters of N4-acetylsulphametrole obtained from a group of volunteers 
are summarized in table XXXIX. 
Deacetylation 
In healthy volunteers there is no possibility to detect deacetylation of 
N4-acetylsulphametrole into sulphametrole. 
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Fig. 47. Plasma concentration-time and renal excretion rate-time profile of 402 mg 
Ní-acetylsulphametrole when 402 mg N4-acetylsulphametrole is ingested by a volunteer 
('slow' acetylator). The intrinsic Τ'Л of Ni-acetylsulphametrole is 3.2 h. About 88% of 
the dose is excreted unchanged. No deacetylation of N4-acetylsulphametrole into sulpha· 
metrole could be observed. 
Table XXXIX. Pharmacokinetic parameters such as Τ'Л, renal excretion and the renal 
clearance of N4-acetylsulphametrole. Data from Hekster et al. [37] 
Subjects 
n = 3 
Urine pH 
5.87 ± 0.75 
TVi.h 
3.53 ± 0.35 
% of dose 
excreted 
77.7 ± 21.5 
Renal clearance 
ml/min 
36.51 ± 6.23 
±SEM. 
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N4-Acetylsulphametrole and Renal Impairment 
As shown in the data of the parent sulphonamides, the overwhelming 
presence of acetyl coenzyme-Α makes acetylation virtually independent of 
disease states of the patients. As the elimination of the N4-acetylsulpha-
metrole is mainly by renal excretion, blocking this pathway will lead, to 
accumulation of the N4-acetylsulphametrole in plasma [38]. 
Sulphapyridine 
Introduction 
Sulphapyridine was introduced in 1938 by Whitby [90]. Sulphapyridine 
(fig. 48) is a biologically active moiety of salazosulphapyridine. This combi­
nation is known under its generic name of sulfasalazine. This combination 
is listed in the selection of essential drugs [91]. This drug consists of 5-amino-
salicylic acid and sulphapyridine, which are linked by an azo bond. General 
properties of sulphapyridine such as protein binding and molecular weight 
are given in table XL. 
о 
Fig. 48. Structure of sulphapyridine. 
Table XL. General properties of sulphapyridine and its metabolite N4-acetylsulpha-
pyridine 
Compound Molecular pK
a
 Protein Vd, 1/kg 
weight binding, % 
Sulphapyridine 249.29 8.40 61 0.43 
N4-Acetylsulphapyridine 291.31 8.30 86 0.20 
Data according to Bates et al. [7], Fischer and Klotz [28], Hawking [35], Reinhold ti al. [64]. 
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Pharmacokinetic Properlies 
Classification 
Based on the Τ'/ί of elimination of 5-13 h, sulphapyridine can be 
classified as a short-acting to medium long-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubility of sulphapyridine at pH values 5.5 
and 7.0 is given in table XLI. The concentrations are given in mg/1 at 
250C (room temperature). 
Table XLI. Influence of the pH on the solubility of sulphapyridine and N4-acetylsulpha-
pyridine 
Compound Solubility 
pH5.5 
Sulphapyridine 120 
N4-Acetylsulphapyridine 313 
in mg/1 at 25°C 
pH7.0 
200 
440 
Data according to Hekster et al. [3η and Vree et al. [82]. 
pH and Absorption, Metabolism and Renal Excretion. Many studies have 
been carried out concerning the pharmacokinetic characterization of sulpha­
pyridine. It is clear that the effects of the differences between 'fast' and 'slow' 
acetylators are apparent [7, 28, 71]. The acetylator phenotype strongly in­
fluences the concentration of N4-acetylsulphapyridine in serum and urine. 
In both 'fast' and 'slow' acetylators absorption is a rapid process. The 
mean values of the maximum concentration of sulphapyridine after an oral 
dose of 1.25 g in 7 'slow' and 4 'fast' acetylators varied from 21.6 mg/1 in 
'slow' acetylators to 16.7 mg/1 in 'fast' acetylators [28]. There seems to be 
an association between side-effects and acetylator phenotype. Reported side-
effects are associated with high plasma levels and mainly experienced in 
'slow' acetylators [14]. 
Figure 49 shows the plasma concentration-time profile and renal ex­
cretion rate-time profile of sulphapyridine and its metabolite N4-acetylsulpha-
pyridine in a typical 'fast' and'slow'acetylator. As can be seen from figure 49, 
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Fig. 49. Plasma concentration-time and renal excretion rate-time profiles of sulpha-
pyridine and its metabolite N4-acetylsuIphapyridine in a typical 'fast' (a) and 'slow' (b) 
acetylator. Note that in the 'fast' acetylator N4-acetylsulphapyridine reaches a higher 
maximum plasma concentration than in the 'slow' acetylator. Also the percentage of the 
drug excreted as metabolite in the 'fast' acetylator is higher than in the 'slow' acetylator 
[from ref. 87]. 
in the 'fast' acetylator, the maximum plasma concentration of N4-acetyl-
sulphapyridine is much higher (about 6 /¿g/ml) than in the 'slow' acetylator 
(about 3 /ig/ml). The amount of sulphapyridine excreted in the urine of the 
'fast' acetylator is 6.6% of the dose, whereas in the'slow'acetylator 17.6% 
of the dose is excreted in the urine as sulphapyridine. The amount excreted 
as N4-acetylsulphapyridine in the urine is about 42% in the 'fast' acetylator, 
and in the urine of the 'slow' acetylator about 16%. The Τ'Λ of elimi­
nation did not show any difference in these volunteers. In table XLII some 
pharmacokinetic parameters of sulphapyridine obtained from a group of 
volunteers are summarized. 
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Table XLIl. Influence of the urinary pH and acetylator phenotype on Τ'Λ and renal 
excretion of sulphapyridine and NU-acetylsulphapyridine. Data according to Vree et al. [87] 
Subjects Acetylator Urine pH Τ Vi S, h Τ'/a N4, h % S % N4 
phenotype 
n = 4 'fast' 5.32 ±0.36 5.75 ±1.85 6.50 ±1.78 6.88 ± 2.46 26.38 ± 10.98 
n = 3 'slow' 5.30 ±0.31 11.70 ±2.82 12.67 ±4.04 18.43 ±1.62 18.33 ± 2.38 
n = 2 'slow* 7.19 9.0 9.8 17.05 17.35 
S=Sulphapy ridine; N4 = N4-acetylsulphapyridine; % = percentage of the dose excreted. 
Table XLIII. Renal clearance values of sulphapyridine and N4-acetylsulphapyridme in 
'slow' and 'fast' acetylators. Data according to Vree et al. [87] 
Subjects Acetylator K
r
S K
r
 N4 
phenotype ml/min ml/min 
n=4 'fast' 7.79 ±2.80 25.56 ± 5.66 
n = 5 'slow' 10.99 ±2.42 29.54 ± 3.07 
S=Sulphapyridine; N4=N4-acetylsulphapyridme; K
r
=renal clearance ± SEM. 
Renal Clearance 
The renal clearance values of sulphapyridine and N4-acetylsulphapyri-
dine in a group of volunteers of 4 'fast' and 5 'slow' acetylators are given 
in table XLIII. 
Metabolism 
Sulphapyridine is metabolized in the liver to N-j-acetylsulphapyridine. 
Also the 5-hydroxyl derivative, its glucuronides [27] and some other me­
tabolites have been identified [27] as summarized by Das and Dubin [14]. 
The rate at which sulphapyridine is acetylated is genetically determined. 
The acetylation type can be determined even with one urine specimen [70], 
but it is always better to rely on plasma samples as renal excretion variables 
may disturb the acetylator phenotyping measurements. Figure 50 shows 
the percentage N4-acetylsulphapyridine-time profile in plasma in both 'fast' 
and 'slow' acetylators. In the final elimination phase 'fast' acetylators exhibit 
a percentage of N4-acetylsulphapyridine of 60 ± 4%, while 'slow' acetyl­
ators give a value of 32 ± 6%. 
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Fig. SO. Percentage N4-acetyIsulphapyridine-time profile in plasma in a group of 
'fast' (n=4) and 'slow' (n=4) acetylators. The difference in percentage metabolite in 
plasma between the two groups is greater than observed with sulphadiazine [from ref. 87]. 
The Τ Vi of the residual curve for both 'fast' and 'slow' acetylators is 
of the same order (T Vi 2.0 and 2.5 h). Das and Dubin [14] determined in 
serum the percentage of acetylation of sulphapyridine during steady state 
in patients with ulcerative colitis. They measured 25.2 ± 9.6% in 'slow' 
acetylators (n= 10) and 62.9 ± 8.5% in 'fast' acetylators (n = 6). These data 
are comparable with the data found after one oral dose of sulphapyridine 
by Vree et al. [87]. 
N4-Acetylsulphapyridine 
Introduction 
N4-Acetylsulphapyridine (fig. 51) is the acetylated metabolite of sulpha­
pyridine. General properties of Ni-acetylsulphapyridine such as pK
a
 and 
molecular weight are summarized in table XL. 
C H3-C-N<ÖH-H^O> Ö 
Fig. 51. Structure of Ni-acetylsulphapyridine. 
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Pharmacokinetic Properties 
Classification 
The intrinsic T'/J of elimination of N4-acetylsulphapyridine is about 
5 h in healthy volunteers. 
pH Effects 
pH and Solubility. The solubility of N4-acetylsulphapyridine at pH 
values 5.5 and 7 is given in table XLI. The concentrations are given in mg/1 
at 25°C (room temperature). 
Absorption, Deacetylation and Renal Excretion 
Figure 52 shows the plasma concentration-time curve and renal excre­
tion rate-time profile of N4-acetylsulphapyridine in a volunteer after an 
oral dose of 526 mg of N4-acetylsulphapyridine under alkaline urine condi­
tion. The Τ Vi of elimination of N4-acetylsulphapyridine is 5.0 h. 
N4-Acetylsulphapyridine is deacetylated to a small extent, and in serum 
the 'metabolite' sulphapyridine could be detected. Its Τ 'Λ of elimination 
is 8.5 h. It was not possible to detect sulphapyridine in the urine after an 
oral dose of N4-acetylsulphapyridine. About 35% of the dose is excreted 
in the urine as N4-acetylsulphapyridine. In table XLIV the different phar­
macokinetic parameters of N4-acetylsulphapyridine obtained from a group 
of volunteers are summarized. 
Table XLIV. Pharmacokinetic parameters of Nt-acetylsulphapyridine. Data according to 
Vree et al. [85] 
Subjects T'/i, h % excreted 
η = 3 3.67 ± 0.31 35.47 ± 20.29 
K
r
 N«, ral/min 
33.35 ± 7.76 
K
r
=Renal clearance; % = percentage of the dose excreted; ± SEM. 
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Fig. 52. Plasma concentration-time and renal excretion rate-time profile of 526 mg 
N4-acetyIsulphapyridme (N4) and its metabolite sulphapyridine (S) in a 'slow' acetylator. 
TVi of elimination of N4-acetylsulphapyridine is 5.0h. The elimination is due to renal 
excretion and deacetylation into sulphapyridine. Sulphapyridine shows its normal Τ'Λ of 
8.5 h (fig. 49). No sulphapyridine could be detected in the urine. 
Sulfisomidine 
Introduction 
Sulfisomidine was synthesized and introduced in 1939/1940 (fig. 53). 
General properties of sulfisomidine such as protein binding and molecular 
weight are given in table XLV. 
9 м ^ " 3 /—4 " / — \ 
CH, Fig. 53. Structure of sulfisomidine. 
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Pharmacokinetic Properties 
Classification 
Based on the Τ'/2 of elimination of 6-7 h sulfisomidine can be classified 
as a short-acting sulphonamide. 
Table XL V. General properties of sulfisomidine and its metabolite Na-acetylsulfisomidine 
Compound Molecular 
weight 
Sulfisomidine 278.34 
N4-Acetylsulfisomidine 320.36 
PK. 
7.4 
Data according to Offen and Plempel [56], Portwich et al. 
lished data]. 
160], 
Protein 
binding 
87 
97 
and Vree et al 
Vd, l/kg 
0.13 
0.08 
. [unpub-
pH and Solubility. The solubility of sulfisomidine at pH values of S.5 
and 7.0 is given in table XLYI. The concentrations are given in mg/1 at 
250C (room temperature). 
Table XL VI. Influence of the pH on the solubility of sulfisomidine and N4-acetylsulfi-
somidine 
Compound Solubility 
pH5.5 
Sulfisomidine 1,580 
N4-Acetylsulfisomidine 53 
in mg/l at 250C 
pH7.0 
2,480 
128 
Data according to Hekster et al. [37] and Vree et al. [82]. 
pH, Absorption, Metabolism and Renal Excretion. Sulfisomidine is less 
metabolized than sulphadimidine. A volunteer who took 363 mg of sulfi­
somidine excreted 87% of the dose unchanged and 6% as N-j-acetylsulfi-
somidine. The Τ'Λ of elimination was 8 h and the T'/i of the metabolite 
10 h as is shown in figure 54. The renal clearance value of sulfisomidine is 
about IS ml/min while that of the metabolite is lower, 7 ml/min. The data 
are summarized in table XLVII. 
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Riplasma conc^pg/ml 
Fig. 54. Plasma concentration-time and renal excretion rate-time profiles of sulfi-
somidine (S; 363 mg) and its metabolite N4-acetylsulfisomidme (N4) in a 'slow' acetylator. 
Sulfisomidine is eliminated (T'/i 8 h) mainly via renal excretion (87.1%) and to a minor 
extent via acetylation (6.2%). The T'/i of N4-acetylsulfisomidine is longer (IS h) than 
that of the parent compound. 
Table XLVH. Some pharmacokinetic parameters of sulfisomidine. Data according to 
Vree et al. [85] 
Subject Dose 
mg 
n = 
S = 
= 1 363 
T'/iS 
h 
8.0 
Τ'Λ N4 
h 
10 
% S 
87.1 
% N 4 
6.2 
^Sulfisomidine; N4=N4-acetyIsulfisomidme; 
=renal clearance value. 
K
r
S 
ml/min 
K
r
N4 
ml/min 
14.98 ± 9.05 7.37 ± 0.59 
Urine pH 
6.60 ± 0.34 
% = percentage of the dose excreted; 
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Fig. 55. Nj-Acetylsulfisomidine and N4-acetylsulphadimidine as percentage of the 
total concentration (parent compound + metabolite) plotted versus time after adminis­
tration in a 'slow' acetylator. Both parent compounds are acetylated and show in the 
final stage of the elimination the same percentage of N4-acetyl derivative in plasma (51 %). 
Sulphadimidine is in this 'slow' acetylator much faster acetylated than sulfisomidine. 
Table XL Ш. Comparison between the renal clearance values of sulphadimidine and 
sulfisomidine in a 'slow' acetylator [Vree et al., unpublished results] 
Subject 
T.J. 
T.J. 
Compound 
sulfisomidine 
sulphadimidine 
Dose 
mg 
363 
773 
К, sulphonamide 
ml/min 
14.78 ± 9.05 
4.86 ± 1.53 
K
r
N4-acetyI-
sulfonamide 
ml/min 
7.37 ± 0.59 
34.71 ± 7.96 
K
r
=Renal clearance ± SD. 
The low percentage of acetylation reduces the possibility of the exist­
ence of 'slow' and 'fast' phenotypes in the acetylation. The proband in 
table XLVII is a 'slow' acetylator of sulphadimidine. The position of the 
nitrogen atoms in the Ni substituted heterocyclic ring system has no in­
fluence on the pK
a
 value as sulphadimidine and sulfisomidine have similar 
pK
a
 values (7.4). Also in NMR studies, the protons at N4 are in the same 
magnetic field: H proton N4-sulfisomidine¿ = 10.10; H proton N4-sulpha-
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dimidine(5= 10.13. Nevertheless these similarities, the metabolic behaviour 
of these 2 compounds is totally different. 
Figure 55 shows the increase of the plasma concentration of N^acetyl-
sulfisomidine expressed as percentage of the total concentration of parent 
compound and metabolite, as a function of time. The percentage of N4-
acetylsulfisomidine in plasma-time curve is compared with that of N4-
acetylsulphadimidine. Both compounds reach after 60 h ( 7 * Τ'Λ of the 
parent compound) a final percentage of 51%. The rate of acetylation of 
sulphadimidine is much faster than that of sulfisomidine. The rate of acetyl­
ation of sulphadimidine as shown in figure 55, is the net result of acetylation 
and renal excretion. The renal clearance of N4-acetylsulfisomidine in this 
subject ('slow' acetylator) is even smaller than of N4-acetylsulphadimidine 
as shown in table XLVIII. 
N4-Acetylsu]fisomidine 
Introduction 
N4-acetylsulfisomidine is the metabolite of sulfisomidine. General prop­
erties and structure are given in table XLV and in figure 56. 
Fig. 56. Structure of Ni-acetylsulfisomidme. 
Pharmacokinetic Properties 
Classification 
Based on the Τ Vi of elimination of 14 h, N4-acetylsulfisomidine can be 
classified as a medium long-existent sulphonamide derivative. 
pH and Solubility. N4-Acetylsulfisomidine is poorly soluble as is already 
shown in table XLVI of the section sulfisomidine. In urine of 37°C the 
solubility is a factor higher (3,600 mg/1 at pH 5.5 and 11 g/1 at pH 7). 
pH, Absorption, Metabolism and Renal Excretion. Figure 57 shows the 
pharmacokinetic behaviour of N4-acetylsulfisomidine in a volunteer after 
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Fig. 57. Plasma concentration-time and renal excretion rate-time profiles of 337.4 mg 
Nt-acetylsulfisomidine in a 'slow' acetylator. The Τ'Λ of elimination is 14 h, which is 
identical with the Τ '/> of N-i-acetylsul&omidine as metabolite, as shown in figure 54. 
From the administered dose only a small percentage is excreted unchanged in the urine 
(16.1%) and no deacetylation could be detected. These observations lead to the con­
clusion that a small fraction of the dose is absorbed. 
ingestion of 337.4 mg orally. The compound elicits at T'/i of 14 h, and only 
16% of the dose ingested is excreted unchanged. The renal clearance value 
is 6ml/min. The low renal clearance accounts for the long Τ Vi of 14 h. 
Continuous resorption from the gastro-intestinal tract, due to the poor 
solubility of N4-acetylsulfisomidine is less likely; moreover, the total amount 
excreted was only 16% and plasma concentrations are low. 
Sulphathiazole 
Introduction 
Sulphathiazole was introduced in 1941. The drug is hardly used alone, 
but frequently in combination with other sulphonamides. General properties 
and structure of sulphathiazole are given in table XLIX and figure 58. 
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Fig. 58. Stracture of sulphathiazole. 
Table XLIX. General properties of sulphathiazole and its metabolite Nt-acetylsulpha-
thiazole 
Compound Molecular pK
a
 Protein Vd, l/kg 
weight binding, % 
Sulphathiazole 255.32 7.2 82 0.18 
N4-Acetylsulphathiazole 297.34 5.40 93 0.15 
Data according to Avery [4], Reeves et al. [61] and Vree et al. [unpublished data]. 
Pharmacokinetic Properties 
Classification 
Based on the Τ Vi of elimination of about 4 h, sulphathiazole can be 
classified as an ultrashort- to short-acting sulphonamide. 
pH Effects 
pH and Solubility. The solubility of sulphathiazole and N-i-acetylsulpha-
thiazole at pH values 5.5 and 7 is given in table L. The concentrations are 
given in mg/1 at 250C (room temperature). 
Table L. Influence of the pH on the solubility of sulphathiazole and N4-acetylsulpha-
thiazole 
Compound Solubility 
pHS.5 
Sulphathiazole 4,565 
N4-Acetylsulphathiazole 54 
in mg/I at 250C 
pH7.0 
130,868 
233 
Data according to Hekster et al. [37] and Vree et al. [82]. 
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Fig. 59. Plasma concentration-time and renal excretion rate-time profiles of 380 mg 
sulphathiazole (S) and its metabolite Nd-acetylsulphathiazole (N4) in a 'slow' acetylator. 
T'/i of both parent compound and metabolite are identical (4.5 h) in a 'slow' acetylator, 
while in a 'fast' acetylator the Τ'Λ of the metabolite is 6h. For sulphathiazole there 
exists polymorphic acetylation. 
Fig, 60. Plasma concentration-time and renal excretion rate-time profiles of 335 mg 
sulphathiazole (S), its metabolite Ni-acetylsulphathiazole (N4) and 2.5 g probenecid in a 
'slow' acetylator with co-medication of probenecid. Probenecid was administered 1 h 
after the administration of sulphathiazole to allow complete and fast absorption of 
sulphathiazole. Three phases in the elimination of sulphathiazole can be distinguished, 
characterized by the corresponding Τ'Λ of 4,5-14, and 7h. In the time course charac­
terized by the T'/i of 14 h, there is equilibrium between acetylation and deacetylation, 
while the inhibition of renal clearance of the sulphonamides by probenecid is maximal. 
Probenecid favours the metabolic equilibrium and allows detection of the final slow elimi­
nation phase of both parent compound and metabolite (T'/J 7 h). 
pH and Absorption, Metabolism and Renal Excretion. Figure 59 shows the 
plasma concentration-time curve and renal excretion rate-time profile of 
sulphathiazole and N4-acetylsulphathiazole after an oral intake of 380 mg 
of sulphathiazole by a volunteer. Sulphathiazole shows a short Τ'Λ of 
elimination of about 4.5 h. The elimination of its metabolite N4-acetylsuIpha-
175 
Clinical Pharmacokinetics of Sulphonamides and Their Na-Acetyl Derivatives 105 
Table LI. Some pharmacokinetic parameters of sulphathiazole and its metabolite N4-
acetylsulphathiazole. Data according to Vree et al. [85] 
Subjects 
n=2 
n=l+probenecid 
TViS.h 
2.5; 7 
4; 14;7 
S = Sulphathiazole ; N4 = N4-acetylsulphathiazole 
T,/i = consecutive T'/i values observed. 
TV, N4, h 
4; 7 
4; 14;7 
% S 
75 
46 
% N 4 
20.5 
8.3 
; % = percentage excreted of the dose; 
Table LU. Renal clearance values of sulphathiazole and its metabolite N4-acetylsulpha-
thiazole. Data according to Hawking [35] and Vree et al. [85] 
Subjects 
η=unknown (35) 
π =2 (85) 
n = l (+probenecid (85) 
К, sulphathiazole 
ml/min 
43 
49 
21 
K
r
 N4-acetylsulphathiazole 
ml/min 
55 
60 
12 
K
r
=Renal clearance. 
thiazole is of the same order, so its intrinsic Τ'Л of elimination should 
be much shorter, as already was discussed by sulphamethoxazole and N4-
acetylsulphamethoxazole [81]. 
About 70% of the drug is excreted unchanged in the urine. About 17% 
of the drug is acetylated and excreted as N4-acetylsulphathiazole. Under 
co-medication of probenecid (fig. 60) sulphathiazole and N4-acetylsulpha-
thiazole are inhibited in their renal excretion. Only about 50% of the dose 
of sulphathiazole is excreted unchanged in the urine and less than 10% 
as N4-acetylsulphathiazole. The Τ Vi of elimination of sulphathiazole in 
plasma shows a peculiar behaviour. Before probenecid reaches its inhibitory 
concentration to block the active tubular secretion of sulphathiazole, the 
drug is excreted with its normal Τ'Λ of elimination (4.5 h). Due to the 
decreased renal clearance under probenecid co-medication, the Τ'Л is in­
creased to 14 h. In the final elimination phase, sulphathiazole is eliminated 
with a Τ г of elimination of 7 h. This is a result of the lower concentration 
of probenecid at which no further inhibition takes place, as shown in figure 
60. The different pharmacokinetic parameters of sulphathiazole obtained 
from 2 volunteers are given in table LI. 
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Renal Clearance of Sulphathiazole 
The renal clearance of sulphathiazole and N4-acetylsulphathiazole is 
given in table LH. 
Sulphathiazole and Kidney Impairment 
Sulphathiazole has proven to be an 'older' sulphonamide drug that 
caused renal injury by crystalluria [43]. In the presence of renal insufficiency, 
persistently high blood concentrations may be obtained from relatively small 
doses of sulphathiazole [29] having a striking therapeutic effect. Nelson [52] 
studied the kinetics of acetylation and excretion of sulphathiazole compared 
to other sulphonamides. From his study, it was concluded that the first 
order processes for acetylation and for excretion for some sulphonamides 
did not hold through for a dose of 1 g of sulphathiazole, but the model 
could be described for 0.5 g of sulphathiazole. He concluded that it was 
apparent that crystalluria must have occurred during the 1-gram dose. It is 
possible that the low solubility of N4-acetylsulphathiazole contributes to 
the formation of crystalline concretions [6]. 
N-j-Acetylsulphathiazole 
N4-Acetylsulphathiazole is the acetylated form of sulphathiazole. Gen­
eral properties such as pKa value, structure and molecular weight are given 
in table XLIX and figure 61. 
о 
II 
CH3-C-r®-foû Fig, 61. Structure of N^-acetylsulphathiazole. 
Pharmacokinetic Properties 
Classification 
The intrinsic Τ'Λ of elimination of N4-acetylsulphathiazole is about 
2 h in healthy volunteers. 
pH Effects 
pH and Solubility. The solubility of N4-acetylsulphathiazole at pH 
values 5.5 and 7.0 is given in table L of sulphathiazole. 
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Fig. 62. Plasma concentration-time and renal excretion rate-time profiles of 338 mg 
N4-acetylsulphathiazole (N4) and its metabolite sulphathiazole (S) in a 'slow' acetylator. 
N4-Acetylsulphathiazole shows an extremely short T'A of 2h and only 23.5% of the dose 
is excreted in the urine unchanged. Deacetylation and high renal clearance of the metabo­
lite accounts for the relatively high percentage of the dose excreted as metabolite (6.3%). 
pH, Absorption, Metabolism and Renal Excretion. Figure 62 shows the 
plasma concentration time profile and renal excretion rate-time profile of 
N4-acetylsulphathiazole and its metabolite sulphathiazole after an oral dose 
of 358 mg of this compound by a volunteer. It can be seen that N4-acetyl-
sulphathiazole is rapidly excreted with the Τ'Λ time of elimination of 2 h. 
Although excretion is a rapid process, N4-acetylsulphathiazole is deacetyl-
ated to form sulphathiazole, being detected in urine and plasma of this 
volunteer. About 23.5% of the dose is excreted unchanged and about 6% 
is deacetylated and excreted in the urine as sulphathiazole. As shown with 
many other N4-acetylsulphonamide derivatives, the absorption of these 
compounds is limited. 
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Miscellaneous Sulphonamides 
The pharmacokinetic behaviour of N4-acety1sulphamerazine and N4-
acetylsulphamethoxydiazine will be discussed in this paragraph to illustrate 
once more the existence of the acetylation-deacetylation equilibrium and the 
observation that the compound with the longest Τ'Λ of elimination governs 
the T'/i of the metabolite with a shorter intrinsic Τ'Λ [69]. This behaviour 
was illustrated already for N4-acetylsuIphadoxine in figure 21. 
Ni-A cetylsulphamerazine 
N4-Acetylsulphamerazine is the acetyl metabolite of sulphamerazine 
(fig. 63). Sulphamerazine has a long T'/i of 23 h, and can be classified 
as a long-existing sulphonamide. Sulphamerazine is metabolized into N4-
acetylsulphamerazine for about 45% [77]. From the foregoing sulphon­
amides it may be anticipated that the Τ Vi of elimination of N4-acetylsulpha-
merazine as metabolite will be similar to the Τ 'Λ of the parent compound, 
i.e. 23 h. The long Τ Vi of sulphamerazine is not caused by extremely high 
protein-binding characteristics. According to Earle [22], the protein binding 
of sulphamerazine is 63%, as is the metabolite N4-acetylsulphamerazine. 
Earle [22] measured a renal clearance value of 3.9 ml/min for sulphamerazine 
and 52.4 ml/min for the metabolite N4-acetylsulphamerazine. The metabolite 
was administered to volunteers. 
CH3-C-NH^0)-g-N4N0) 
Fig. 63. Structure of N4-acetylsuIphamerazme. 
A renal clearance value of 50 ml/min, calculated on basis of free sul­
phonamide concentration, makes the compound comparable to N4-acetyl-
sulphadiazine, N4-acetylsulphamethoxazole and N4-acetylsulphametrole. 
Thus, the anticipated Τ Vi of N4-acetylsulphamerazine must be 5 h in man. 
Figure 64 shows the pharmacokinetic profile of N4-acetylsulphamerazine 
and its metabolite sulphamerazine in a volunteer after oral intake of 468 mg 
of N4-acetylsulphamerazine. The T'/i of elimination of N4-acetylsulphamera-
zine initially is 5 h for about 25 h, but increases in the final part of the elimi­
nation process to 23 h. Sulphamerazine is formed by deacetylation of N4-
acetylsulphamerazine and shows its normal and long Τ Vi of 23 h. 
179 
Clinical Pharmacokinetics of Sulphonamides and Their N^-Acetyl Derivatives 109 
plasma cone ,pg/ml — 
renal txer raleryg/min 
1 — ι — " — ι — ι — ι — ι — ι — · — ι — ι — I -
0 10 20 30 «0 SO 60 h 
Fig. 64. Plasma concentration-time and renal excretion rate-time profiles of 468 mg 
N4-acetylsulphamerazine (N4) and its metabolite sulphamerazine (S) in a 'slow' acetylator. 
The elimination of N4-acetyIsulphamerazine shows a biphasic character with Τ'Λ values 
of 5.0 and 23 h. The metabolite sulphamerazine shows its normal Τ г of 23 h. In the final 
stage of the elimination, acetylation of the metabolite governs the elimination of the 
'parent' compound N4-acetylsulphamerazine. The main pathway of elimination of N4-
acetylsulphamerazine is renal excretion (97.3%). 
The volume of distribution of N4-acetyIsulphamerazine is 0.181/kg. 
From the dose ingested, 97.3% is excreted unchanged in the urine and 2.7% 
as metabolite sulphamerazine. The pH of the urine was kept predominantly 
acidic. It was possible to show that the renal clearance of N4-acetylsulpha-
merazine is dependent on the urinary flow. The results are summarized in 
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Table LUI. Renal clearance values of N4-acetylsulphamerazine and its metabolite sulpha-
merazine. Data according to Vree et al. [85] 
Subject 
n=l 
Urine pH 
5.61 ± 0.24 
6.40 ± 0.30 
7.36 ± 0.45 
S=Sulphamerazine; N4=N4-
Urine flow 
ml/min 
1.38 ±1.11 
3.88 ± 6.00 
1.42 ±0.51 
acetylsulphamerazine ; 
K
r
N4 
ml/min 
32.86 ± 4.60 
54.68 ± 26.54 
37.83 ± 3.89 
K
r
S 
ml/min 
4.47 ± 1.66 
4.36 ± 2.20 
4.75 ±1.18 
K
r
=renal clearance ± SD. 
table LIII. From the observation made by Earle[22], Traeger and Stein [77] 
and Vree et al. [85] it may be concluded that N4-acetylsulphamerazine be­
haves exactly like N4-acetylsulphadiazine (fig. 9) and the kinetics of sulpha-
merazine are comparable to those of sulphadiazine. It is not certain whether 
there exists a 'slow-fast' acetylator phenotype. 
Nt-Acetylsulphamethoxydiazine 
Ni-Acetylsulphamethoxydiazine is the acetyl metabolite of sulphametho-
xydiazine, the structure is given in figure 65. Sulphamethoxydiazine is a 
long-existing sulphonamide (TVi 26 h) with a volume of distribution of 
0.23-0.70 ml/kg [39] and 0.13 1/kg in the volunteer in figure 66. Sulpha­
methoxydiazine is acetylated to a small extent. In analogy to all other 
sulphonamides, the Τ'Л of elimination of the metabolite, when administered, 
must be shorter than that of the parent drug (26 h). In figure 66 the pharmaco­
kinetic profile of N-j-acetylsulphamethoxydiazine and its metabolite sulpha­
methoxydiazine is shown in a volunteer who took 504 mg of N4-acetyl-
sulphamethoxydiazine orally. 
с н г С - { ] - ( о > - ^ о ) - о с н , 
Fig. 65. Structure of N4-acetylsulphamethoxydiazine. 
N4-Acetylsulphamethoxydiazine elicits a Τ г of elimination of 9.5 h 
during 45 h, but thereafter the Τ'Λ increases to 29 h. During the whole 
time period of the experiment of 75 h, N4-acetylsulphamethoxydiazine is 
deacetylated to sulphamethoxydiazine, as is indicated by the continuously 
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Fig. 66. Plasma concentration-time and renal excretion rate-time profiles of 504 mg 
N4-acetylsulphamethoxydiazme (N4) and its metabolite sulphamethoxydiazine (S) in a 
'slow' acetylator. N4-Acetylsulphamethoxydiazme elicits а Τ'Λ of 9.5 h in the first stage 
of the elimination but this Τ'Λ increases to 36 h in the final stage, due to acetylation of 
the metabolite sulphamethoxydiazine. 
Table LIV. Renal clearance values of sulphamethoxydiazine and Ni-acetylsulphametho-
xydiazine. Data according to Vree et al. [85] 
Subject 
n = l 
Urine pH 
5.55 ± 0.26 
6.40 ± 0.27 
7.20 ± 0.01 
S=Sulphamethoxydiazine ; 
± S D . 
N4 = 
Urine flow 
ml/min 
1.10 ±0.90 
1.16 ±0.33 
1.78 ±1.16 
K
r
N4 
ml/min 
11.01 ±4.87 
13.94 ± 3.46 
20.03 ± 9.86 
= N«-acetylsulphamethoxydiazme; K
r
< 
K
r
S 
ml/min 
2.86 ±1.30 
5.53 ± 2.16 
4.24 ± 2.03 
=renal clearance 
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increasing plasma concentration. 45 h after administration, acetylation of 
the formed metabolite contributes substantially to the plasma concentration 
of N4-acetylsulphamethoxydiazine and increases the Τ 'Λ from 9.5 to 29 h. 
The renal clearance of N4-acetylsulphamethoxydiazine and its metabolite 
is dependent on the variables of tubular reabsorption, i.e. urine flow and 
urine pH as shown in table LIV. 
Appendix 
Side-Effects as Experienced by Volunteers 
The side-effects experienced are personal feelings which hold through the group of 
volunteers but escape statistics. For instance, some sulphonamides decrease urine flow 
and the urge for micturition. At the end of the experimental time, urine flow and mic­
turition frequency increase suddenly for a period of about 12 h, like after the intake of 
furosemide. 
It is hardly possible to recognize this effect in rational data on urine flow, as this is 
influenced by the normal rhythm of social coffee and alcohol intake. Just personal feel­
ings about altered urine production and micturition frequency remain, which invariably 
is realized at the end of the experiments. Among the sulphonamides which provoke these 
effects are sulphametrole, Ni-acetylsulphadiazine, sulphadoxine, Ni-acetylsulphadoxine 
and sulphafurazole. 
N4-AcetylsuIphonamide derivatives in a dose of 500-1,000 mg give a feeling of 
tiredness, trembling, feather headed and lack of any activity. The feeling is almost the 
same as experienced after a dose of 2-3 g of probenecid. Probenecid and N4-acetyl sul-
phonamide derivatives are both excreted by active tubular secretion and may be processed 
by active transport mechanisms throughout the body in a similar way, influencing mood 
and feelings. The compound which is responsible for the probenecid-like effect is for 
instance N4-acetylsulphadiazine (1 g) because 1 g of sulphadiazine itself does not result 
in these effects. 
Acknowledgements 
This compilation of 'old' and 'new' data on sulphonamides is the result of the 
efforts of the Clinical Pharmacokinetics Group, from which each of its members con­
tributed to specific items. Sincere thanks are expressed to: Margriet Bookman, Ita Baars, 
Theo Campschreur, Roelof van Dalen, Joke Damsma, Rita Dirks, Bill Friesen, Jan Hafken-
scheid, Francis Hurkmans, Tom Jansen, Wim Janssen, Eppo van der Kleijn, Mari/n Ooster-
baan. Joke Reekers, Marijcke Schools van de Siepkamp, Emiel Termond, Marian Tijhuis, 
Ineke van Velzen and Rene Waas for analysing, volunteering, synthesizing, calculating, 
literature search, secretarial aid and general support and enthusiasm. 
Authors and publishers gave permission to reproduce the following figures: 6, 7,11, 
12. 37, 39, 41, 49, 50. 
183 
Clinical Pharmacokinetics of Sulphonamides and Their N4-Acetyl Derivatives 113 
References 
1 Anand, N.: Sulfonamides and sulfones; in Wolff, Burger's medicinal chemistry, 
4th ed., part II, pp. 1-40 (Wiley & Sons, Chichester 1979). 
2 Andreasen, F.: Protein binding in plasma from patients with acute renal failure. 
Acta pharmac. tox. 32: 417-429 (1973). 
3 Angier, R.B.; Boothe, J.H.; Hutchings, B.L.; Mowat, J.H.; Semb, J.; Stockstad, 
E.L.R.; Subba, R.Y.; Waller, C.W.; Cosulich, D.B.; Fahrenbach, M.J.; Multquist, 
M.E.; Kuh, E.; Northey, E.H.; Seeger, D.R.; Sickless, J.P.; Smith, J.M.: Structure 
and synthesis of liver L. casei factor. Science 103: 667-669 (1946). 
4 Avery, G.S.: Drug data information. Drug treatment; 2nd ed., appendix A (Adis 
Press, Sydney/Churchill-Livingstone, London 1980). 
5 Baethke, R.; Golde, G.; Gahl, G.: Sulfamethoxazole/Trimethoprim: Pharmaco-
kinetic studies in patients with chronic renal failure. Eur. J. din. Pharmacol.^: 223-
240 (1972). 
6 Barnes, R.W.; Kawaichi, G.K.: Factors influencing the formation of sulfonamide 
urinary concretions. J. Urol. 49: 324-330 (1943). 
7 Bates, T.R.; Blumenthal, H.P.; Pieniaszek, H.J.: Salivary excretion and pharmaco-
kinetics of sulfapyridine after sulfasalazine. Clin. Pharmacol. Ther. 22: 917-927 
(1977). 
8 Bergan, T.; Brodwall, E.K.; Vik-Mo, H.; Anstad, U. : Pharmacokinetics of sulpha· 
diazine, sulphamethoxazole and trimethoprim in patients with varying renal function. 
Infection 4: suppl.» 382-386 (1979). 
9 Bratton, A.C.; Marshall, E.K.: New coupling component for sulfanilamide deter-
mination. J. biol. Chem. 128: 537-550 (1939). 
10 Bräunlich, H. ; Splinter, F.К. : Renale Ausscheidung von Langzeitsulphonamiden bei 
Flüssigkeitsbelastung und Änderung des pH Wertes des Hams. Acta biol. med. 
germ. 35: 793-798 (1976). 
11 Chapron, D.J.; Blum, M.R.: Relationship of sulphamethazine disposition kinetics 
to acetylator phenotype in man. A preliminary study. J. clin. Pharm. 16: 338-344 
(1976). 
12 Chemie Linz: Product information on Lidatrim 1977. 
13 Colebrook, L.; Kenny, M.: Treatment of human puerperal infections and experi-
mental infections in mice with Prontosil. Lancet 1; 1279-1286 (1936). 
14 Das, K.M. ; Dubin, R. : Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacol. 
1: 40^425 (1976). 
15 Despopoulos, A. : A definition of substrate specificity in renal transport of organic 
anions. J. theor. Biol. 8: 163-192 (1965). 
16 Dettli, L.; Spring, P.: Diurnal variations in the elimination rate of a sulfonamide 
in man. Helv. med. Acta 33: 291-306 (1966). 
17 Dettli, L.; Spring, P.: Pharmacokinetics as a basic medical problem; in Aliens, 
Physico-chemical aspects of drug action, pp. 5-32, vol. 7 (Pergamon Press, Oxford 
1966). 
18 Dettli, L.; Spring, P.; Raeber, I.: The influence of alkali administration on the 
biological half-life of two sulfonamides in human blood serum. Int. J. clin. Pharmacol. 
2: 130-134 (1967). 
184 
Hekster/Vree 114 
19 Doerge, R.F. : Sulfonamides and sulfones with antibacterial action; in Wilson, Gis-
vold and Doerge, Textbook of organic medicinal and pharmaceutical chemistry; 
7th ed., pp. 203-221 (Lippincott, Philadelphia 1977). 
20 Domagk, G. : Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dt. med. 
Wschr. 61: 25&-25Э (1935). 
21 Domagk, G.: Eine neue Klasse von Desinfektionsmitteln. Dt. med. Wschr. 61: 
829-832 (1935). 
22 Earle, D.P.: Renal excretion of sulfamerazine. J. clin. Invest. 23: 914-920 (1944). 
23 Ekström, В.; Forsgren, U.; örtengren, В.; Bergan, T.: Development of sulphon-
amide-trimethoprim combinations for urinary tract infections. I. Comparison of 
the antibacterial effect of sulphonamides alone and in combination with trimetho­
prim. Infection 7: suppl. 4, pp. 359-366 (1979). 
24 Evans, D.A.P.: An improved and simplified method detecting the acetylator pheno-
type. J. med. Genet. 6: 405^07 (1969). 
25 Evans, D.A.P.; White, T.A.: Human acetylation polymorphism. J. Lab. din. Med. 
63: 394-^03 (1964). 
26 Fildes, P.: A rational approach to research in chemotherapy. Lancet i.' 955-957 
(1940). 
27 Fischer, C; Klotz, U.: Determination of sulfapyridine and its major metabolites 
in plasma by high pressure liquid chromatography. J. Chromatogr., biomed. Appi. 
146: 157-162(1978). 
28 Fischer, C; Klotz, U.: High performance liquid chromatography determination of 
aminosalicylate, sulphapyridine and their metabolites. Its application for pharmaco­
kinetic studies with salicylazosulfapyridine in man. J. Chromatogr., biomed. Appi. 
162: 237-243 (1979). 
29 Fishberg, A.M.: The use of sulfonamides in renal insufficiency. J. Mt Sinai Hosp. 
S: 509-513 (1942). 
30 Frisk, A.R.: Sulfanilamide derivatives. Chemotherapeutic evaluation of Ni-sub-
stituted sulfanilamides. Acta med. scand. 142: suppl. CXLII, pp. 1-199 (1943). 
31 Fuller, A.T. : Is p-aminobenzenesulphonamide the active agent in prontosil therapy ? 
Lancet i: 194-198 (1937). 
32 Goff, J.B. ; Schlegel, J.U. ; O'Dell, R.M. : Urinary excretion of nalidixic acid, sulpha-
methizole and nitrofurantoin in patients with reduced renal function. J. Urol. 99: 
371-375 (1968). 
33 Goossens, A.P.; Oudtshoorn, M.C.B. van: Determination of pharmacokinetic para­
meters for urinary excretion of sulphafurazole under normal and controlled alkaline 
urine conditions. J. Pharm. Pharmac. 22: 224-226 (1970). 
34 Hall, P.W. : Renal secretory Tm for sulphonamide. Clin. Res. 9: 248 (1961). 
35 Hawking, F. : Recent work on the pharmacology of sulphonamides. Br. med. J. i: 
505-509 (1945). 
36 Hearse, D.J.; Weber, W.W.: Multiple N-acetyl transferases and drug metabolism. 
Tissue distribution, characterization and significance of mammalian N-acetyl trans­
ferase. Biochem. J. 132: 519-526 (1973). 
37 Hekster, Υ.Α.; Vree, T.B.; Damsma, J.E.; Friesen, W.T.: Pharmacokinetics of 
sulphametrole and its metabolite N4-acetylsulphametrole in man. J. antimicrob. 
Chemother. 8:133-144 (1981). 
185 
C'inical Pharmacokinetics of Sulphonamides and Their N4-Acetyl Derivatives 115 
38 Hitzenberger, G.; Korn, Α.; Pichler, H.; Bonelli, J.; Magometschnigg, D.: Phar­
macokinetics of lidaprim in cases of impaired renal function. Int. J. clin. Pharmacol. 
15: 310-314 (1977). 
39 Kaumeier, S. ; Kisslinger, E. ; Neiss, A. : The effect of gastro-intestinal filling on the 
absorption of sulphamethoxydiazine. Int. J. clin. Pharmacol. Biopharm. 17: 412-415 
(1979). 
40 Korger, G.; Wagner, W.H.: Sulfonamide; in Ehrhart, Ruschig, Arzneimittel, Ent­
wicklung, Wirkung, Darstellung. Band 2: pp. 1431-1481 (Verlag Chemie, Wein-
heim 1968). 
41 Kostenbauder, H.B.; Portnoff, J.B.; Swintosky, J.V.: Control of urine pH and its 
effects of sulfaethidole excretion in humans. J. pharm. Sci. 51: 1084-1089 (1962). 
42 Krebs, H.A.; Sykes, W.O.; Bartley, W.C: Acetylation and deacetylation of the 
/»-amino group of sulphonamide drugs in animal tissues. Biochem. J. 41: 622-630 
(1947). 
43 Krüger-Thiemer, E. ; Bünger, P. : Evaluation of the risk of crystalluria with sulpha 
drugs. Proc. Eur. Soc. Study Drug Tox. 6: 185-207 (1965). 
44 Kucers, A. ; McK Bennett, N. : The use of antibiotics. A comprehensive review with 
clinical emphasis; 3rd ed. (Heinemann, London 1979). 
45 Lehr, D. : Prevention of renal damage by use of mixtures of sulphonamides. Br. med. 
J. ü: 934-946 (1947). 
46 Lehr, D.: Clinical toxicity of sulfonamides. Ann. N.Y. Acad. Sci. 69:417-447 (1957). 
47 Lima, J.J.; Jusko, W.J.: Determination of procainamide acetylator status. Clin. 
Pharmacol. Ther. 23: 25-29 (1978). 
48 Lindahl, O.; Josephson, В.: The kidney function and the renal clearances of some 
sulfanilamide derivatives. Acta med. scand. 120: 195-226 (1945). 
49 Lowentritt, L.L. ; Schlegel, J.U. : Treatment of bacteriuria in patients with impaired 
renal function. J. Urol. 102: 473-478 (1969). 
50 Lundquist, F. : Renal tubular secretion of sulphonamides and /»-aminobenzoic acid. 
Acta Pharmacol. 1: 307-324 (1945). 
51 Martindale: in Wade, The extra pharmacopoeia, sulphonamides; 27th ed., pp. 1465-
1497 (Pharmaceutical Press, London 1977). 
52 Nelson, E. : Relationship between the kinetics of acetylation and excretion of sulpha-
thiazole or other sulfonamides and the occurrence of crystalluria. J. pharm. Sci. 
JO; 912-915 (1961). 
53 Nelson, E. ; O'Reilly, I. : Kinetics of sulfisoxazole acetylation and excretion in humans. 
J. Pharmac. exp. Ther. 129: 368-372 (1960). 
54 Ohnhaus, E.E. ; Spring, P. : Elimination kinetics of sulphadiazine in patients with 
normal and impaired renal function. J. Pharmacokinet. Biopharm. 3:171-179 (1975). 
55 örtengren, В.; Magni, L.; Bergan, T.: Development of sulphonamide-trimethoprim 
combinations for urinary tract infections. Infection 7: suppl. 4, pp. 371-381 (1979). 
56 Otten, H.; Plempel, M.: Synthetische Chemotherapeutica mit breitem Wirkungs­
bereich; in Otten, Plempel, Siegenthaler, Antibiotika-Fibel, pp. 109-148 (Thieme, 
Stuttgart 1975). 
57 Oudtshoom, M.C.B. van; Potgieter, F.J.: Determination of pharmacokinetic para­
meters for rapid and slow acetylators of sulphadimidine. J. Pharm. Pharmacol. 24: 
357-360 (1972). 
186 
Hekster/Vree 116 
58 Perry, D.C.: Sulfonamides; in Sadee, Beelen, Drug level monitoring. Analytical 
techniques, metabolism and pharmacokinetics, pp. 431-441 (Wiley & Sons, New 
York 1980). 
59 Peterson, O.L.; Finland, M.: The effect of food and alkali on the absorption and 
excretion of sulfonamides drugs after oral and duodenal administration. Am. J. 
med. Sci. 204: 581-588 (1942). 
60 Portwich, F. ; Büttner, H. ; Engelhardt, К. : Nierenausscheidung und Eiweissbindung 
von Sulfonamiden. Klin. Wschr. 41: 447-451 (1963). 
61 Reeves, D.S.; Bint, A.J.; Bullock, D.W.: Today's treatment use of antibiotics. 
Sulphonamides, co-trimoxazole and tetracyclines. Br. med. J. ii: 410-413 (1978). 
62 Reeves, D.S. ; Wilkinson, P.J. : The pharmacokinetics of trimethoprim and trimetho-
prim/sulphonamide combinations, including penetration into body tissues. Infection 
7: suppl. 4, pp. 330-341 (1979). 
63 Reidenberg, M.M.; Kostenbauder, H.; Adams, W.P.: Rate of drug metabolism in 
obese volunteers before and during starvation and in azotemic patients. Metabolism 
18: 209-214 (1969). 
64 Reinhold, J.R. ; Flippin, H.F. ; Domm, A.H. ; Zimmerman, J.J. ; Schwartz, L. : Renal 
clearance of sulphamerazine, sulphadiazine, sulphathiazole and sulphapyridine in 
man. J. Pharmac. exp. Ther. 83: 279-287 (1945). 
65 Rhoads, P.S.; Svee, F.A.; Rohr, J.H.: Clinical evaluation of a new sulfonamide -
Gantrisin. Quart. Bull. Northwestern Univ. med. School 23: 104-111 (1949). 
66 Rieder, J.: Quantitative determination of the bacteriostatically active fraction of 
sulfonamides and the sum of their inactive metabolites in the body fluids. Chemo­
therapy 17: 1-21 (1972). 
67 Rieder, J.; Schwarz, D.E.; Femex, M.; Bergan, T.; Brodwall, Ε.К.; Blumberg, Α.; 
Cottier, P.; Scheitlin, W. : Pharmacokinetics of the antibacterial combination sulfa­
methoxazole-trimethoprim in patients with normal or impaired kidney function. 
Antibiotics Chemother. 18: 148-198 (1974). 
68 Ritschel, W.A.: Biological half-lives of drugs. Drug Intell. clin. Pharm. 4: 332-347 
(1970). 
69 Rossum, J.M. van; Ginneken, C.A.M, van; Henderson, P.T.; Ketelaars, H.C.J.; 
Vree, T.B.: Pharmacokinetics of biotransformation; in van Rossum, Kinetics of 
drug action, chap. 3, pp. 125-167 (Springer, Berlin 1977). 
70 Schröder, Η. : Simplified method for determining acetylator phenotype. Br. med. J. 
IH: 506-507 (1972). 
71 Schröder, Η.; Evans, D.A.P.: The polymorphic acetylation of sulphapyridine in 
man. J. med. Genet. 9: 168-171 (1972). 
72 Sjöqvist, F.; Borga, О.; L'È. Orme, M.: Fundamentals of clinical pharmacology; 
in Avery, Drug treatment. Principles and practice of clinical pharmacology and 
therapeutics; 2nd ed., pp. 1-61 (Adis Press, Sydney 1980). 
73 Souich, P. du; McLean, A.J.; Stoeckel, K.; Ohlendorf, D.; Gibaldi, M.: Screening 
methods using sulphamethazine for determining acetylator phenotype. Clin. Pharma-
col. Ther. 26: 757-765 (1979). 
74 Struller, Th. : Progress in sulfonamide research; in Jucker, Progress in drug research, 
pp. 390-457 (Birkhäuser, Basel 1980). 
75 Sullivan, J.W. ; Bueschen, A.J. ; Schlegel, J.U. : Nitrofurantoin, sulphamethizole and 
187 
Clinical Pharmacokinetics of Sulphonamides and Their N4-Acetyl Derivatives 117 
cephalexin urinary concentration in unequally functioning pyelonephritic kidneys. 
J. Urol. 114: 343-347 (1975). 
76 Talseth, T. ; Landmark, K.H. : Polymorphic acetylation of sulphadimidine in normal 
and uraemic man. Eur. J. din. Pharmacol. 11: 33-36 (1977). 
77 Traeger, Α.; Stein, G.: Pharmacokinetics of sulfamerazine and sulfaclomide in 
patients with impaired renal function after first and after repeated application. Int. 
J. clin. Pharmacol. 15: 315-320 (1977). 
78 Viek, N. ; Campbell, E.G. ; Gislason, G.J. ; Bondi, A. : Sulfaethylthiadiazole (SETD) 
therapy for simple and complicated urinary tract infections. J. Urol. 77: 777-781 
(1957). 
79 Vonkennel, J.; Kimmig, J.; Korth, В.: Experiments and investigations with new 
sulphonamides. Z. klin. Med. 138: 695-743 (1940). 
80 Vree, T.B. ; Hekster, Υ. Α. ; Baars, A. M. ; Damsma, J.E. ; Kleijn, E. van der : Determi­
nation of trimethoprim and sulphamethoxazole (co-trimoxazole) in body fluids of 
man by means of high-performance liquid chromatography. J. Chromatogr., biomed. 
Appi. 146: 103-112(1978). 
81 Vree, T.B.; Hekster, У.Α.; Baars, A.M.; Damsma, J.E.; Kleijn, E. van der: Phar­
macokinetics of sulphamethoxazole in man. Clin. Pharmacokinet. 3: 319-329 (1978). 
82 Vree, T.B.; Hekster, Y.A.; Dalen, R. van: Het meten van de concentratie van Sul­
fonamiden in bloed en urine van patiënten met gestoorde nierfunktie. Folia Chemo-
therapeutica (Roche) 1981: 1-30. 
83 Vree, T.B.; Hekster, Y.A.; Damsma, J.E.; Dalen, R. van; Haf kenscheid, J.C.M.; 
Friesen, W.T. : Renal excretion of sulphamethoxazole and its metabolite N4-acetyl-
sulphamethoxazole in patients with impaired kidney function. Therap. Drug. Monit. 
3: 129-135 (1981). 
84 Vree, T.B.; Hekster, Υ.Α.; Damsma, J.E.; Kleijn, E. van der; O'Reilly, W.J.: 
Pharmacokinetics of Ni-acetyl, and N4-acetylsulphamethoxazole in man. Clin. Phar­
macokinet. 4: 310-319 (1979). 
85 Vree, T.B.; Hekster, Y.A.; Damsma, J.E.; Tijhuis, M.; Friesen, W.T.: Pharmaco­
kinetics and mechanism of renal excretion of short acting sulphonamides and N4-
acetylsulphonamide derivatives in man. Structural requirements of sulphonamides 
for active tubular secretion. Eur. J. clin. Pharmacol. 20: 283-292 (1981). 
86 Vree, T.B. ; Hekster, Υ. Α. ; Kleijn, E. van der : Clinical Pharmacokinetics of sulphon­
amides; in Merkus, The serum concentration of drugs. Clinical relevance, theory and 
practice, pp. 205-214 (Excerpta Medica, Amsterdam 1980). 
87 Vree, T.B.; O'Reilly, W.J.; Hekster, Y.A.; Damsma, J.E.; Kleijn, E. van der: 
Determination of the acetylator phenotype and pharmacokinetics of some sulphon­
amides in man. Clin. Pharmacokinet. 5: 274-294 (1980). 
88 Weber, W.W.: Acetylation, deacetylation and amino acid conjugating enzymes; in 
Brodie, Gillette, Ackerman, Handbook of experimental pharmacology. XXVIII, 
pp. 564-583 (Springer, Berlin 1971). 
89 Weinstein, L.: Sulfonamides and trimethoprim-sulphamethoxazole; in Goodman, 
Gilman, The pharmacological basis of therapeutics; 5th ed., pp. 1113-1129 (Mac 
Millan, New York 1975). 
90 Whitby, L.E.H.: Chemotherapy of pneumococcal and other infections with 2-(p-
aminobenzene sulphonamide)pyridine. Lancet i: 1210-1213 (1938). 
186 
Hekster/Vree 118 
91 WHO: The selection of essential drugs. Second report. Tech. Rep. Ser. Wld Hlth 
Org. 1979: 641. 
92 Williams, D.H.; Wimpenny, J.; Asscher, A.W.: Renal clearance of sodium sulpha-
dimidine in normal and uraemic subjects. Lancet /i: 1058-1060 (1968). 
93 Woods, D.D. : Relation of p-aminobenzoic acid to mechanism of action of sulphanil-
amide. Br. J. exp. Path. 21: 74-90 (1940). 
Y.A. Hekster, Department of Clinical Pharmacy, St. Radboud Hospital, 
Catholic University of Nijmegen, Geert Grooteplein Zuid 10, 
6S2S GA Nijmegen (The Netherlands) 
189 

Journal of Antimicrobial Chemotherapy (\9il)S, 133-144 Appendix I 2 
Pharmacokinetics of sulphametrole and its metabolite 
N4-acetylsulphametrole in man 
Y. A Hekster*, Т. В Vree*, J. E. Damsma* and W. T. Friesen*t 
*Department of Clinical Pharmacy Sint Radboud Hospital, University of Nijmegen, 
Nijmegen, The Netherlands* and School of Pharmacy, University of Tasmania, Hobart, 
Australiat 
Sulphametrole is metabolized into N4-acetylsulphametrole and both compounds 
are eliminated from the body with a similar 7Ί/2 of about 10 h. 
Sulphametrole is acetylated in an unimodal way and there exists no acetylator 
phenotype. 
The renal clearance of sulphametrole is dependent on the urine flow and urine 
pH, while the renal clearance of the metabolite N4-acetylsulphametrole is not 
dependent on these variables of tubular reabsorption. 
No tubular secretion is involved in the renal excretion of sulphametrole while 
the metabolite N4-acetylsulphametrole is excreted predominantly by active 
tubular secretion. Probenecid co-medication decreases the rate of absorption of 
sulphametrole and the tubular secretion of the metabolite Ν,-acetylsulphametrole.' 
Introduction 
The introduction of sulphametrole represents a new development in the wide range 
of sulphonamide derivatives which have been available for three decades 
(Brandesky &. Takacs 1975). The combination of sulphametrole and trimethoprim, 
known as LidatrimR or Lidaprim", has been developed as an alternative preparation 
to co-trimoxazole. The sulphametrole-trimethoprim combination claims larger 
safety limits concerning the incidence of crystalluria, based on the high water 
solubility of sulphametrole and its metabolite in comparison to sulphamethoxazole. 
Another recent combination of antimicrobial drugs is sulphadiazine and tri­
methoprim (SepturylR). Both of these combinations are intended as additional 
preparations to the well known combination of sulphamethoxazole-trimethoprim 
(co-trimoxazole, Bactrim11, Eusaprim11). The pharmacokinetics of sulphadiazine 
and sulphamethoxazole have been well described (Bergan, Vik-Mo & Anstad 1977; 
Örtengren, Magni & Bergan 1979; Reeves & Wilkinson 1979; Baethke, Golde & 
Gahl, 1972; Vree et al, 1978, 1980), while reports on the pharmacokinetics of 
sulphametrole are still scarce (Hitzenberger et al, 1977)'. 
It can be anticipated that the kinetic behaviour of sulphametrole can be compared 
with the well-studied drug, sulphamethoxazole. The combination of the drug with 
trimethoprim requires that the halflife of sulphametrole must be of the same 
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magnitude as that of trimethoprim (Π/2 = 10 h). The elimination of sulphametrole 
will proceed by metabolism (acetylation) and by renal excretion. The renal excretion 
of sulphametrole may depend on the pH of the urine and the urine flow in analogy to 
the behaviour of sulphamethoxazole (Vree et al., 1978). The aims of this pharmaco­
kinetic study in man are to investigate: 
(a) pharmacokinetic parameters of sulphametrole and its metabolite N4-acetyl-
sulphametrole; 
(b) the existence of a difference in the rate and extent of acetylation of sulpha­
metrole (slow and fast acetylators); 
(c) the mechanism of renal excretion of sulphametrole and its metabolite 
N4-acetylsulphametrole. 
Materials and methods 
Equipment 
A Spectra Physics 3500B high performance liquid Chromatograph (HPLC), 
equipped with a column oven (Model 748) and a Pye Unicam LC-U V spectrophoto-
metric detector was used. The detector was connected to a 1 mV recorder (BD 7, 
Kipp and Sons, Delft, The Netherlands.) 
A stainless steel column, 10 cm long and 4 6 mm i.d. was packed with Lichrosorb 
RP8, 5 μιη, obtained from Chrompack (Middelburg, The Netherlands). An injection 
loop of 100 μΐ was used. The oven temperature was 40°C. Detection of the 
sulphonamides was performed at 260 nm, the detection limit being 0 5 mg/1. 
Solvents 
The solvent was a mixture of phosphate buffer and methanol at pH 6 7 (390 ml of 
0067 M KH 2 P0 4 was mixed with 10 ml of 0067 м Na 2 HP0 4 and 80 ml of 
methanol). The solvent flow rate was 1 6 ml/min at a pressure of 150 atm. 
Drugs 
Sulphametrole and N4-acetylsulphametrole were obtained from Warrick Nederland 
and Chemie Linz. Both compounds were 100% pure according to the HPLC 
chromatogram. Pure trimethoprim was obtained from Wellcome. 
Probenecid was obtained from the Hospital Pharmacy. Probenecid was measured 
in plasma and urine by means of a HPLC method as described by Guelen et al. 
(1980). Probenecid was administered as follows: initially 1 g 2 h before the start of 
the experiment, followed by 0 5 g every 6 h. 
Subjects 
Eight healthy Caucasian subjects, all employees of the Department of Clinical 
Pharmacy, volunteered for the study. Sulphametrole was administered in doses of 
800 mg powder (see Table II) in a gelatine capsule or as commercial tablet Lidatrim, 
consisting of 800 mg sulphametrole and 160 mg trimethoprim. 
The drug was taken orally 1 5 h after a standard breakfast. Blood samples of 0 2 ml 
were collected at scheduled time intervals by fingertip puncture (AMEFA 
Blutlanzetten, or AutoletR puncture). Spontaneously voided urine was collected for 
60 h. The urine was maintained alkaline (pH 7-8) by the regular intake of 10 g 
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Table 1. Solubility of a series of short acting 
sulphonamides and their N4-acetylderivatives (mg/1 at 
25'C) room temperature 
Compound 
Sulphametrole 
N4-acetylsulphametrole 
Sulphamethoxazole 
N4-acetylsulphamethoxazole 
Sulphapyndine 
N4-acetylsulphapyridine 
Sulphadimidine 
N
r
acetylsulphadimidine 
Sulphamethizole 
N4-acetylsulphamethizole 
Sulphadiazine 
N4-acetylsulphadiazine 
Sulphathiazole 
N4-acetylsulphathiazole 
ρΗ5·5 
460 
1100 
300 
115 
120 
313 
438 
752 
1555 
200 
265 
411 
4565 
54 
pH 7 5 
1700 
6000 
1900 
1000 
200 
440 
7000 
1340 
5022 
3000 
950 
1620 
130868 
233 
sodium bicarbonate per day. An acidic urine (pH 5-6) was achieved by the intake of 
8 g of ammonium chloride per day. Kidney function was recorded by measurement 
of the creatinine clearance. Determination of creatinine was carried out by using 
standard automated techniques (JaíTé method). 
Sample preparation 
Serum. The serum was diluted 1 in 10 with distilled water. 0 8 ml of perchloric acid 
(ОЗЗ N) was added to 0-2 ml of diluted serum. The solution was thoroughly mixed 
on a Vortex mixer and subsequently allowed to stand for 10 min. After 
centnfugation at 4000 rpm for 5 min, 100 μΐ of the supernatant was injected onto the 
column. A calibration curve was made by adding known concentrations of sulpha­
metrole and N4-acetylsulphametrole to the drug free serum. 
Urine 
0 5 ml of perchloric acid (033 N) was added to 10/Л of urine. The solution was 
mixed and 100 μΐ injected onto the column. 
Recovery 
Recovery of sulphametrole and N4-acetylsulphametrole added to human serum in 
the concentration range of 1-200//g/ml was 89%±4 (S.D.) and 91%±4 (S.D.), 
respectively. The recovery of sulphametrole and N4-acetylsulphametrole added to 
unne was 99% ± 2 (S.D.). 
Renal clearance 
The renal clearance was calculated as follows: the renal excretion rate (jig/min) is 
proportional to the plasma concentration (mg/1) by the proportionality constant, i.e. 
the renal clearance (ml/min). For the calculation of the renal clearance (K
r
), the 
average renal excretion rate was divided by the mean plasma concentration during 
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the measured time interval. The renal clearance constant was calculated from each 
urine and the corresponding plasma sample. 
Determination of the acetylator phenotype in subjects 
The subjects are initially phenotyped as 'fast' and 'slow' acetylators in this study by 
their ability to metabolize sulphadimidine (Vree et ai, 1980). 
Percentage ofN^acetylsulphametrole in plasma 
The percentage of N4-acetylsulphametrole in plasma was calculated as follows: 
(N^-acetylsulphametrole) 
(sulphametrole) + (N4-acetylsulphametrole) xl00% 
Solubility studies 
Saturated solutions of sulphonamides and N4-acetylsulphonamides were made in 
phosphate buffer of pH 55 and 75 at room temperature. The concentration of the 
sulphonamides was measured by means of HPLC (Table I). 
Statistics 
Regression lines and correlation coefficients were calculated according to standard 
statistical procedures with a HP 9810 calculator (Hewlett Packard). 
Plasmo Conen {ßg/m\)
 UQQ m g Sulphametrole 
Renal e»cr (¿ig/min)
 | 6 0 ^ χ,-,,,,β,^ ρ,,,,, 
Orally 
С real mine clearance 
126 ml/mm 
Sub| Τ В V 
β! 5 % N 4 
Time (h) 
Figure 1. Plasma concentration- and renal excretion rate-time profiles of trimethoprim (TMP), 
sulphametrole (S) and its metabolite N4-acetylsulphametrole (N4) in a volunteer after an oral dose of 800 mg sulphametrole and 160 mg trimethoprim. Trimethoprim is excreted almost unchanged (78-4%), 
while sulphametrole (62%) is mainly metabolized into N.-acetylsulphametrole which is then excreted 
(81-5%). 
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Results 
Figure 1 shows the plasma concentration- and renal excretion rate-time profiles of 
trimethoprim, sulphametrole and its metabolite N4-acetyIsuIphametroIe in a 
volunteer after an oral dose of 800 mg sulphametrole and 160 mg trimethoprim (1 
tablet LidatrimR). As can be seen from the figure sulphametrole and trimethoprim 
elicit similar half lives of elimination (10 h). The plasma concentration of sulpha­
metrole is approximately 50 times higher than the plasma concentration of 
trimethoprim. 
Effect of urinary pH on the percentage of renal excretion half life and absorption rate 
Figure 2 shows the effect of urinary pH on the renal excretion rate of sulphametrole 
and its metabolite N4-acetylsulphametrole in the same volunteer at acid (left) and 
alkaline (right) urine pH. Under acidic conditions (pH 535 ± 040) sulphametrole 
was reabsorbed strongly. The average renal clearance under these conditions was 
013 ± 007 ml/min. The net percentage of the compound excreted unchanged was 
25%, whilst 59-6% of the dose was excreted as N4-acetylsulphametrole. The renal 
excretion rate of the metabolite (2927 ± 8-65 ml/min) is much higher than that of 
the parent compound (0-13 ± 007 ml/min). 
When the urine is maintained alkaline (pH 7-36 ± 0-46), the reabsorption 
of sulphametrole is minimal, resulting in an average renal clearance of 
459 ± 235 ml/min and 214% of the dose is excreted unchanged. The percentage 
-JPIosmo conen tug/ml) 
100· 
10-
Renal euer, rate (/ifl/mm) sulphametrole 595 mg 
jPtosmo concn l/ig/ml) 
5 9 6 % N4 
ν-
IO h 
2 5 % S 
Urine pH 5 3 5 * 0 4 0 
Subj. YAH 
Ю 
20 30 
(a) 
4 0 50 
Figure 2. Plasma concentration- and renal excretion rate-time profiles of sulphametrole (S) and 
Ν,-acetylsulphametrole (N,) in a volunteer under acidic (a) and alkaline urine conditions (b). 
Sulphametrole is excreted unchanged to a higher percentage (214%) under alkaline urine conditions than 
under acidic urine conditions (2'5%). The percentage of the dose excreted as metabolite is virtually 
identical in both situations. 
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of the dose excreted as its metabolite N4-acetylsulphametrole (30-50%) is 
independent of the unnary pH. The percentage appears dependent on the person-to-
person variation and not on the unnary conditions. 
The half life of sulphametrole is affected by the unnary pH. The half life of 
sulphametrole is slightly longer under acidic conditions (10 h) than under alkaline 
conditions (7 5 h) The two extremes of the urinary pH also had some influence on 
the absorption rate of sulphametrole. Under alkaline conditions the compound was 
absorbed faster. The maximum plasma concentration of sulphametrole was reached 
1 h after oral intake under alkaline conditions, while the maximum concentration 
was reached after 5 h under acidic conditions (see Figure 2). As a result, the maxi­
mum plasma concentration of the metabolite is reached earlier under alkaline 
conditions (75 h) than under acidic conditions (11 h). The area under the curve 
(AUC) of sulphametrole and its metabolite N4-acetylsulphametrole do not differ 
significantly under the two unnary pH extremes (Table II). 
The renal excretion rate of sulphametrole is much higher under alkaline unne 
conditions (500 //g/min) than under acidic conditions (60 pg/min). These differences 
are not seen with the metabolite N4-acetylsulphametrole. The different parameters, 
7}, per cent excretion and renal clearance constants are shown in Table II. 
Renal clearance versus urinary pH 
From Table II it can be seen that the renal clearance of sulphametrole is strongly 
dependent on the urinary pH At acidic urinary pH (pH 50-5-5) the renal clearance 
ranges from 013-1 23 ml/mm. At alkaline unnary pH (pH 70-80) the renal 
clearance ranges from 4*59-11'88 ml/mm The renal clearance of the metabolite 
does not depend on the unnary pH. The range in renal clearance in the volunteers 
over the whole range of urinary pH's (5-8) is from 25-50 ml/min. 
Renal clearance versus urinary flow at constant urine pH 
When the unne is kept stnctly acidic or alkaline, a linear relationship between the 
Sulphametrole 1 
% N4 acetytsulphameirole in plasma 
41 00 t 8 04 % 
л < 7 pH 5 - 7 fast and slow acetylators 
1 1 1 1 1 
О 10 20 30 40 SO 60 
Time ( h ) 
Figure 3 N4-acetylsulphametrole in plasma plotted as percentage of the total sulphonamide concentra­
tion (parent drug + metabolite) versus the time course of the experiment No difference could be observed 
in the percentage Ν,-acetylsulphametrole-time curves in a group of 7 volunteers, consisting of 3 'fast' and 
4 'slow' acetylators 
100-
10-
: 
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urine flow and the renal clearance of sulphametrole could be observed in each case, 
with high correlation coefficients (r = 075-0-90). 
No relationship between the renal clearance and urine flow can be observed for 
the metabolite N4-acetylsulphametrole, with either acidic or alkaline urine. 
Acetylation of sulphametrole 
For the determination of the acetylator type, the percentage N4-acetylsulphametrole 
in each plasma sample was plotted against the time after administration. Figure 3 
shows the development of the percentage of N4-acetylsulphametrole in plasma as 
average values ± S.D. in a group of 7 volunteers consisting of 4 'slow' and 3 'fast' 
acetylators (of sulphadimidine). No difference in the rate and percentage of acetyl­
ation of sulphametrole can be observed when the compound is metabolized by 'slow' 
or 'fast' acetylators. 
Renal excretion of the metabolite NA-acetylsulphametrole 
Figure 4 shows the plasma concentration- and renal excretion rate-time profiles 
when 402 mg N4-acetylsulphametrole and 626 mg N4-acetylsulphamethoxazole 
were ingested simultaneously by a volunteer. The halflife of elimination of N4-
acetylsulphametrole was 3*2 h, while that of N4-acetylsulphamethoxazole was 2*8 h. 
883% of the dose of N4-acetylsulphametrole was excreted unchanged in the urine, 
while under the same excretion conditions 68*4% of N4-acetylsulphamethoxazole 
was excreted. 
юоо-
100 -. 
ю-
Plosma eoncn (де/піі) 
Renal excr rate (/ig/mm) 
N4 - acetylsulphamethoxazole 626 mg 
N4 - acelylsulphamelrole 4 0 2 mg 
Time (h) 
Figure 4. Plasma concentration- and renal excretion rate-time profiles of N4-acetylsulphametrole and N4-acetylsulphamethoxazole when 402 mg N4-acetylsulphametrole and 626 mg of N4-acetylsulpha-
methoxazole are simultaneously ingested orally by a volunteer. N4-acetylsulphametrole is absorbed 
slightly faster and to a higher extent than N4-acetylsulphamethoxazole. 
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N4-acetylsulphametrole was absorbed slightly faster than N4-acetylsulpha-
methoxazole. The maximum plasma concentration of N4-acetylsulphametrole was 
reached 3 h after ingestion of the compound, while N4-acetylsulphamethoxazole 
reached its maximum 5 h after ingestion. The renal clearance of N4-acetylsulpha-
metrole in this volunteer is 4370 ± 14-60 ml/min at an average urine 
pH6-74 ± 046 and an average urine flow of 207 ± 1-16 ml/min and the renal 
clearance for N4-acetylsulphamethoxazole under the same conditions was 
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Figure 5. Renal clearance values (Kr) of N4-acetylsulphametrole plotted venus renal clearance values of 
N4-acetylsulphamethoxazole. The values are obtained from the experiment shown in Figure 4. The linear 
relationship between the renal clearance values of both compounds indicates that both compounds are 
excreted by the same renal mechanism. 
Plasma cone η 0/g/ml) 
Renal excr rate (/ig/min) 
100-
N 4 6 4 5 % 
ΓΙ/2 10 h 
800 mg Sulphametrole 7-1/2 7 5h 
Urine pH 5Б4±0-56 
Sub) W.T F. 
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Figure 6. Plasma concentration- and renal excretion rate-time profiles of sulphametrole (S) and its 
metabolite N4-acetylsulphameirole (N4) under control conditions (a) and under probenecid co-medication 
(b). I g of probenecid was administered to a volunteer 2 h before sulphametrole was ingested. Probenecid 
is administered throughout the experiment as indicated by the stars (each star = 0-5 g of probenecid). The 
halflife of N,-acetylsulphametrole is increased from 10-44 h under the influence of probenecid co-
medication as a result of decreased tubular secretion. The halflife of sulphametrole is increased from 
7 5-16 h under probenecid co-medication as a result of delayed absorption. 
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Table II. Pharmacokinetic parameters of sulphametrole 
1—* 
ю 
Subject 
T B V 
T B V 
YAH 
Y A H 
J E D 
PC 
AB 
WTF. 
W T F 
• p^robenecid 
Dose 
(mg) 
800 
800 
595 
800 
589 
800 
800 
800 
800 
n / 2 S n / 2 N 4 (h) (h) 
10 5 
8 5 
too 
7 5 
8 3 
8 0 
8 0 
8 0 
160 
10 5 
8 5 
100 
7 5 
100 
120 
100 
10 5 
440 
%s 
6 2 
35 8 
2 5 
214 
4 0 
33 9 
2 6 
41 
6 6 
/V.-acetylsulphametrole as parent compound 
T B V 
JH 
ET 
403 
234 
ИЗО 
3 2 
3 9 
3 5 
%N< 
81 5 
48 1 
59 6 
52 9 
58 7 
58 8 
94 7 
645 
54 4 
88 3 
53 0 
91 8 
K
r
S 
ml/min 
0 59 ± 0 20 
11 88 ± 7 37 
0 13 ± 0 0 7 
4 59 ± 2 35 
0 86 ± 1 03 
7 28 ± 5 25 
088 ± 0 9 9 
1 23 ± 1 35 
7 56 ± 2 11 
2 34 ± 1 30 
2 13 ± 1 16 
098 ± 0 58 
K
r
N 4 
ml/mm 
47 24 ± 8 96 
44 07 ± 18 30 
29 27 ± 8 65 
3093 ± 9 28 
24 9 2 ± 5 21 
29 69 ± 10 9 
4 I 8 6 ± 1121 
31 65 ± 7 83 
19 62 ± 5 46 
14 72 ± 6 47 
15 79 ± 8 85 
12 89 ± 3 61 
43 7 0 ± 14 60 
32 6 5 ± 15 05 
33 18 ± 4 30 
pH 
5 16 ± 0 26 
7 59 ± 0 85 
5 3 5 ± 0 4 0 
7 36 ± 0 4 6 
5 I 4 ± 0 2 1 
7 58 ± 0 59 
5 55 ± 0 20 
5 64 ± 0 56 
8 33 ± 0 20 
7 05 ± 0 14 
6 38 ± 0 25 
561 ± 0 4 0 
6 74 ± 0 4 6 
5 50 ± 0 75 
5 38 ± 0 57 
Urine 
now 
ml/min 
122 ± 0 4 9 
1 62 ± 0 94 
0 99 ± 1 14 
1 03 ± 0 52 
1 75 ± 1 70 
1 84 ± 1 43 
0 66 ± 0 19 
1 79 ± 1 60 
2 90 ± 1 46 
0 70 ± 0 45 
1 95 ± 1 74 
103 ± 0 31 
2 07± 1 16 
0 72 ± 0 26 
2 29 ± 1 68 
Creatinine 
ml/mm 
126 1 ± 15 8 
137 8 ± 2 0 5 
156 8 ± 2 7 6 
1380 ± 166 
129 2 ± 3 4 3 
123 6 ± 2 9 4 
100 8 ± 19 2 
87 7 ± 23 8 
82 3 ± 2 1 0 
161 6 ± 2 4 1 
1253 ± 154 
97 5 ± 9 16 
AUCs 
/ig/min h"1 
1181 
481 
665 
669 
895 
673 
698 
654 
569 
A U C N 4 
¿ig/min fr' 
302 
165 
282 
268 
256 
325 
382 
346 
1211 
132 
70 
526 
Phenotype 
slow 
slow 
fast 
fast 
slow 
fast 
slow 
slow 
slow 
7Ί/2 halflife of elimination of sulphametrole 
71/2 N, halflife of elimination of N4-acetylsulphametrole 
%S Per cent of the dose excreted as sulphametrole 
%N4 Percent of the dose excreted as metabolite N4-acetylsulphametrole 
KfS Renal clearance constant of sulphametrole ( ± s D ) 
K
r
N4 Renal clearance constant ( ± s D ) of N4-acetylsulphametrole 
Creatinine Renal clearance constant of creatinine ( ± s о ) 
AUCj Area under the plasma concentration-time curve of sulphametrole 
A U C N Area under the plasma concentration-time curve of N4-acetylsulphametrole 
Phenotype acetylator phenotype 
+Probenecid Sulphametrole + probenecid co-medication The renal clearance values of parent compound and metabolite are calculated for different pH values of the 
unne 
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567 ± 238 mi/min. No relationship between the renal clearance of N4-acetyl-
sulphametrole (as parent compound) with the urine flow, urine pH or creatinine 
clearance can be observed. 
In Figure 5 the renal clearance values obtained from the experiment described in 
Figure 4 of N4-acetylsulphametrole are plotted against the renal clearance values of 
N4-acetylsulphamethoxazole. The linear relationship between the clearances of the 
two compounds indicate that: (a) the mechanisms of excretion of both compounds 
are the same, or (b) each compound has his own (and constant) excretion 
mechanism. 
Sulphametrole with probenecid co-medication 
Figure 6 shows the pharmacokinetic behaviour of sulphametrole with probenecid 
co-medication (right) in comparison with sulphametrole alone in the same volunteer 
(left). The pharmacokinetic behaviour of sulphametrole under acidic urine 
conditions (pH 564 ± 056) in this volunteer is similar to those data shown in 
Figures 1 and 2 and summarized in Table II. The renal clearance values of 
sulphametrole and its metabolite under these conditions were 1-23 ± 135 ml/min 
and 31 65 ± 7-83 ml/min respectively. Under co-medication of probenecid (2 g/day 
and a plasma concentration of probenecid 50-60 /¿g/ml) the kinetic behaviour of 
sulphametrole and its metabolite changed drastically. From Figure 6 it can be seen 
that the halflife of the metabolite N4-acetylsulphametrole was increased from 
10-44 h. The renal excretion rate of N4-acetylsulphametrole decreased from 
400-500 /ig/min under control conditions to 150-200 /ig/min under probenecid 
co-medication, which remained constant for about 40 h. 
The renal clearance of the metabolite N4-acetylsulphametrole is reduced from 
31 "65 ± 7-83 ml/min under control conditions to 1289 ±3-61 ml/min under 
probenecid co-medication. This strong reduction in renal clearance did not favour 
metabolic conversion of the compound since 54-6% of the dose ingested sulpha-
metrole was excreted as metabolite after 60 h as compared to 64-5% conversion 
under control conditions. 
The urine pH in the experiment with probenecid was not kept constant, so it was 
possible to show the slight influence of the urine pH on the renal clearance of the 
metabolite under probenecid co-medication. When the pH increases from 
5*61-8*33, the renal clearance increases from 12*89 ±3*61 ml/min to 
19*62 ± 5*46 ml/min (see Table II). Sulphametrole itself, under co-medication of 
probenecid, showed no decrease in renal clearance. As can be seen from Table II, the 
renal clearance under probenecid co-medication was slightly higher than under 
control conditions, because the urine pH is more alkaline. 6*6% of the dose excreted 
was unchanged. 
The halflife of sulphametrole under probenecid co-medication was found to be 
16 h instead of 7*5 under control conditions. The maximal plasma concentration of 
sulphametrole under probenecid co-medication, reached 5 h after ingestion, was 
much lower (23 mg/l) than under control conditions (40-60 mg/1). Also the AUC of 
sulphametrole under probenecid co-medication is somewhat less than under 
control experiments. The probenecid medication was started with the ingestion 
of 1 g 2 h before sulphametrole was administered. The increase of the halflife of 
sulphametrole must thus be attributed to an inhibition of the absorption process of 
sulphametrole. 
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Discussion 
The pharmacokinetic behaviour of sulphametrole is very similar to that of sulpha-
methoxazole. Sulphonamides with a halflife of the same magnitude as that of 
trimethoprim are most suitable for a combination with trimethoprim when a 
synergistic action is required in the treatment of infections. 
From Figures 2 and 5, it can be deduced that the rate of acetylation of sulpha­
metrole must be similar to that of sulphamethoxazole. The metabolite Ν,-acetyl-
sulphametrole shows the same or slightly longer halflife than the parent compound, 
which means that the compound N4-acetyIsulphametrole itself, when administered 
as a parent compound must have a shorter halflife. 
The experimental results, shown in Figure 4 shows that the halflife of N4-acetyl-
sulphametrole as parent compound is the same as that of N4-acetylsulpha-
methoxazole (3 h) and that both compounds are almost entirely excreted unchanged. 
The renal clearance of sulphametrole is low due to extensive reabsorption, which is 
clearly demonstrated by the dependency of its renal clearance on the parameters of 
tubular reabsorption, urine flow and urine pH. 
Thus, the main route of elimination of sulphametrole is the metabolic route by 
acetylation and the metabolite N4-acetylsulphametrole is predominantly eliminated 
by renal excretion. The mechanism of renal excretion of N4-acetyIsulphametrole is 
mainly active tubular secretion. The following arguments support this conclusion: 
(a) the renal clearance of N4-acetylsulphametrole shows no correlation with the 
renal clearance of creatinine, which is a parameter of glomerular filtration; 
(b) the renal clearance of N4-acetylsulphametrole shows no correlation with 
urine flow and urine pH which are parameters of tubular reabsorption; 
(c) co-medication with probenecid reduces the renal clearance of N4-acetyl-
sulphametrole from about 40-12 ml/min. N4-acetylsulphamethoxazole, 
with probenecid co-medication, shows a reduction from about 
60-12 ml/min (Vree et αϊ, 1980). The renal clearance of sulphametrole (and 
sulphamethoxazole) remains unchanged under probenecid co-medication. 
benecid co-medication. 
(d) when N4-acetylsulphametrole and N4-acetylsulphamethoxazole are 
administered together and the renal clearance values are plotted against 
each other (Figure 5) a linear relationship is obtained. This means that two 
identical mechanisms are present. It has already been shown that N4-
acetylsulphamethoxazole is excreted by means of active tubular secretion 
(Vree et al., 1980). 
The renal excretion of N4-acetylsulphametrole is slightly less than that of N4-acetyl-
sulphamethoxazole (08 x). 
When the plasma concentration of N4-acetylsulphametrole is expressed as a 
percentage of the total sulphonamide concentration, the percentage of the 
metabolite reaches a value of 40% in the final elimination phase after a single oral 
administration (Figure 3). This value is 20% for sulphamethoxazole (Vree et al., 
1980). The presence of high concentrations of the sulphonamides may result in the 
occurrence of side effects as Lupus Erythematosus and even crystalluria (Vree et al., 
1981). The risk of crystalluria is always present in situations which are very 
unfavourable for the renal excretion of sulphonamides. These situations include: (a) 
a metabolic acidosis, resulting in an acidic urine pH; (b) low water solubility; (c) 
impaired kidney function. 
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From Table I it may be deduced that the water solubility of N4-acetylsulpha-
metrole is 1100 mg/1 at pH 5 5 The water solubility is 10 times higher than that of 
N4-acetylsulphamethoxazole The water solubilities of sulphametrole and sulpha-
methoxazole are almost identical 
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Pharmacokinetics and Mechanism of Renal Excretion of Short Acting 
Sulphonamides and N4-Acetylsulphonaimde Derivatives in Man 
Structural Requirements of Sulphonamides for Active Tubular Secretion 
T. B. Vree, Υ. Α. Hekster, J. E. Damsma, M. Tijhuis, and W. T. Friesen* 
Department of Clinical Pharmacy, Sint Radboud Hospital, University of Nijmegen, The Netherlands 
Summary. The pharmacokinetics of short acting sul­
phonamides and a series of N^acetylsulphonamide 
derivatives has been investigated. Sulphonamides 
with a sulphur atom two atomic bond distances from 
the N, atom are excreted by active tubular secretion, 
e.g. sulphamethizole, sulphaethidole and sul-
phathiazole. When the sulphur atom is replaced by 
an oxygen or nitrogen atom, active renal excretion no 
longer occurs. N4-acetylsulphonamides are excreted 
by active tubular secretion. The renal clearance val­
ues of the N4-acetylsulphonamides are not influenced 
by the substituent at the N, position. Two groups of 
N4-acetylsulphonamides can be distinguished. One 
has а Ту, of 4-6 h and a renal clearance value of 
20-60 ml/min and the second has a TVl of 10-20 h 
and a renal clearance of less than 10 ml/min. N4-
acetylsulphonamides are deacetylated to the extent 
of about 5%. 
Key words: sulphonamides, N4-acetylsulphonamide 
derivatives; pharmacokinetics, renal excretion, tubu­
lar secretion, structure-excretion relationship, 
deacetylation 
The renal excretion of drugs in most cases is the final 
process in the elimination of a drug from the body, 
and together with metabolism it comprises the major 
part of the total elimination process. Until recently, 
most attention to sulphonamides, including phar­
macokinetic studies, has been devoted to the parent 
compounds. The lack of interest in the metabolites 
has partly been due to the limitation imposed by the 
* Present address: School of Pharmacy, University of Tasmania, 
Hobart, Australia 
relatively non-specific hydrolysis of conjugates in the 
Bratton-Marshall analytical method (1939). 
With an HPLC technique (Vree et al. 1978), it 
has become possible to measure specifically the N4-
acetyl derivative, thus opening the way for study of 
the pharmacokinetics of these compounds. A second 
reason for the lack of attention to the pharmaco­
kinetics of the N4-acetyl derivatives is the finding that 
they do not possess antimicrobial activity. 
The role of renal excretion in the total elimina­
tion of sulphonamides becomes of major importance 
when this component of elimination has deteriorated, 
as in the case of impaired kidney function. Due to 
continuous acetylation of the sulphonamides, and the 
decreased renal clearance of N4-acetyIsulphon-
amides, the plasma concentration of N4-acetylsul-
phonamides will then accumulate to an unexpectedly 
high level (Vree et al., 1981). 
It has been observed that the T.¿ of most N4-
acetyl derivatives as metabolites is much the same as 
that of their parent compounds (Vree et al. 1978, 
1980), indicating that the intrinsic TiA of the metabo-
lites must be shorter (van Rossum et al. 1977). 
When N4-acetylsulphonamide derivatives are 
administered to volunteers as the primary com-
pounds, it is possible to determine their intrinsic T,,, 
and renal clearance, and to examine the possibility of 
deacetylation, as has already been done in a first 
attempt for N4-acetylsulphamethoxazole (Vree et al. 
1979). 
The results obtained in the present study of a 
series of N4-acetylsulphonamide derivatives show the 
interesting phenomenon that two groups of deriva-
tives can be distinghuished, each with a characteristic 
Т
й
. This observation affects the theory of 
Despopoulos (196S), concerning the mechanism of 
active tubular secretion of sulphonamides by the 
tubular anion transport mechanism. Short acting sul-
0031-6970/81/0020/0283/$02.00 
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phonamides (Τ,, 2-5 h) show a high renal clearance 
From the observed behaviour of N4-acetylsul-
phonamide derivatives and short acting sul-
phonamides, an attempt is made to elucidate the 
structure of the sulphonamide, which is required for 
active tubular secretion 
Materials and Methods 
Drug Analysis 
Sulphonamides in plasma and unne were measured 
by HPLC analysis as previously described (Vree et al 
1978, 1979, 1980) Small day-to-day modifications 
in the solvent system were used to achieve the 
required separation of the sulphonamide and its cor­
responding Nj-acetylsulphonamide from endoge-
neous body compounds and food constituents, such 
as caffeine and nicotine 
Subjects 
19 healthy Caucasian volunteers (14 males and S 
females, aged 20-40 years), from the Department of 
Clinical Pharmacy, volunteered for the study 
Drugs 
The sulphonamides were obtained from the following 
sources 
Sulphamethoxazole, N4-acetylsulphamethoxazole, 
sulphafurazole, N4-acetylsuIphafurazole, sulphado-
xin and N4-acetylsulphadoxin from Hoffmann 
LaRoche, Mijdrecht, The Netherlands 
Sulphametrole and N^acetylsulphametrole from 
Warrick, Amstelveen, The Netherlands 
Sulfisomidine and Ni-acetylsulfisomidine from Ciba-
Geigy, Amhem, The Netherlands 
Ni-acetylsulphadiazine from Astra, Rijswijk, The 
Netherlands 
Sulphaethidole from Boehnnger Ingelheim, Haar­
lem, The Netherlands, Sulphamoxole and sulpha-
merazine from Sigma, St Louis, U S A 
Sulphapyndine, Sulphadunidine, Sulphadiazine, Sul-
phathiazole were obtained from the OPG (Onder­
linge Pharmaceutische Groothandel, Utrecht, The 
Netherlands), 
Sulphamethizole and N4-acetylsulphamethizole were 
obtained from Lundbeck, Amsterdam, The Nether­
lands, 
Sulphamethoxydiazine and N^acetylsulphamethoxy-
diazine from Bayer, Mijdrecht, The Netherlands 
N4-acetylsulphapyndme, Nj-acetylsulphadimidine, 
Ni-acetylsulphathiazole, N4-acetylsulphaethidole, 
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N4-acetylsulphamerazme and N4-acetylsulphamox-
ole were synthesized according to Vree et al (1979) 
Probenecid (Benemid) was obtained from the hospi­
tal pharmacy, and had been manufactured by Merck, 
Sharp and Dohme Ammonium chloride was 
obtained from Sudmedica, München, and sodium 
bicarbonate from the hospital pharmacy 
Sampling Procedure 
Blood 0 2 ml blood samples were collected at regu-
lar time intervals by means of fingertip puncture with 
AMEFA Blutlancets, or by Monolet lancets (Mono-
ject, USA) 
Urine Unne was collected on spontaneous voiding 
The time penods of collecting the urine samples were 
kept as short as possible The total time of sample 
collection varied between 40 and 60 h, depending on 
the purpose of the expenment 
Urinary pH Unnary pH was measured immediately 
after collection from the volunteers Measurements 
were made with a Radiometer (Copenhagen PMH 
61) instrument Unnary pH in the volunteers was 
kept constant (acid or alkaline) by the ingestion of 
ammonium chlonde 8 g or sodium bicarbonate 10 g 
daily 
Renal Clearance Renal clearance (Kr) was calcu-
lated from the average renal excretion rate divided 
by the mean plasma concentration during the mea-
sured time interval The renal clearance (ml/mm) 
was calculated for each unne sample and its corre-
sponding plasma sample 
Creatinine Creatinine in the plasma and unne sam-
ples from each subject was measured by a standard 
procedure (automated Jaffe method) in the Labora-
tory of Clinical Chemistry, Department of Internal 
Medicine 
Statistics Regression lines and correlation coeffi-
cients were calculated according to standard statisti-
cal procedures with a HP 9810 calculator (Hewlett 
Packard) 
Results 
A Sulphonamides as Parent Compounds 
The parent compounds investigated all showed rela-
tively short half-lives of elimination Ύ,,, 1 3-1 5 h 
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Tifale 1. Renal Clearance of sulphonamide derivatives with a relatively short half-life of elimination 
Compound 
+ probenecid 
Sulphathiazolc 
Sulphametrole 
+ probenecid 
Sulplufunzole 
+ probenecid 
SuUisonudme 
Sulphaethidole 
+ probenecid 
Subject 
С К L 
H T H 
L M 
M О 
M О 
A M В 
W T F 
A S 
A M В 
Τ J 
Τ J 
Т В V 
Y A H 
Ρ С 
W T F 
W T F 
J ILK. 
J R.K 
Y A H 
Y A H 
Τ J 
Τ J 
Y A H 
Т В V 
Dose 
[mg] 
496 
468 
463 
488 
490 
546 
476 
496 
512 
380 
335 
800 
595 
eoo 
eoo 
eoo 
486 
485 
572 
633 
363 
430 
684 
707 
Τ * S 
[h] 
13 
13 
15 
16 
15 
15 
4 6 
4 4 
2 5 
4-7 
4-14-7 
10 5 
9 8 
6 0 
8 0 
16 0 
4 5 
6-13 
5-85 
12 
8 0 
12 
10 
9 0 
19 0 
T t t N 
[h] 
3 0 
2 5 
2 5 
3 0 
3 0 
3 0 
13 
12 5 
4 0 
4-7 
4-14-7 
10 5 
9 8 
14 0 
10 5 
440 
4 5 
13 
18 
25 
10 
-
_ 
-
-
% S 
81 1 
77 8 
862 
74 1 
82 8 
89 0 
74 1 
903 
79 9 
710 
462 
6 2 
2 5 
33 4 
4 1 
6 6 
364 
59 4 
67 2 
463 
87 1 
716 
78 4 
75 2 
% N 4 
2 9 
12 
10 
17 
3 0 
13 
14 
3 0 
23 6 
17 4 
8 3 
815 
59 6 
58 3 
645 
54 4 
16 2 
242 
33 4 
49 8 
6 2 
-
-
-
-
KrS 
[ml/min] 
93 54±21 99 
108 99+20 38 
115 86±26 20 
76 29+52 02 
99 0O±43 90 
165 00+44 14 
3101± 5 30 
28 60+ 2 77 
49 76±1188 
47 79±18 00 
2134± 5 49 
0 59±0 20 
0 13±0 07 
7 28±5 25 
1 23±1 35 
7 56±2 11 
2 34±130 
2 13±1 16 
0 98 ±0 54 
14 00±2 22 
8 37±170 
12 57±2 34 
17 64±0 81 
8 43±2 44 
2 24 ±0 79 
1124±6 41 
14 78±9 05 
4 85±0 97 
9 22±185 
7 87+2 04 
10 75±178 
2 96±0 69 
KrN 4 
[ml/mm) 
60 97±24 83 
3016± 3 93 
55 48± 5 68 
48 95±10 11 
40 95±25 40 
73 23±13 29 
551± 068 
9 01± 6 12 
72 90±17 78 
47 06±21 35 
1197± 3 25 
47 27± 8,% 
29 27± 8 65 
29 69+10 91 
3165± 7 83 
19 62± 5 46 
14 72± 6 47 
15 79± 8 85 
12 89± 3 62 
12 44±2 58 
7 99±129 
7 77±123 
7 13±156 
8 35±149 
3 28±0 74 
741±2 85 
7 37±0 59 
-
-
-
-
UnnepH 
651±0 80 
7 21 ± 0 4 3 
5 85±062 
S 38±0 84 
7 5510 42 
5 60±0 83 
6 82+0 74 
6 80±0 85 
5 12±0 47 
7 06±0 40 
6 78±0 84 
5 16±0 26 
5 35±0 40 
7 58+0 59 
5 64 ±0 56 
8 33±0 20 
7 15±0 14 
6 38±0 25 
561±0 40 
7 47±0 17 
6 50+0 40 
7 58±0 23 
8 19±0 13 
7 00±0 73 
5 33+0 26 
6 48 ±0 39 
6 60±0 34 
5 20±0 18 
5 73±0 46 
7 34+0 76 
7 13+0 44 
7 41 ±0 70 
Unnefkw 
[ml/min] 
2 98±158 
146±0 60 
2 94±2 24 
3 05±3 84 
2 06±2 59 
2 19±1 53 
1 42 ±0 33 
2 59±2 15 
2 15±106 
3 42±3 18 
2 89±2 60 
1 22±0 49 
0 99±1 14 
184±143 
179±160 
2 90±146 
0 90+0 45 
195±174 
103+0 31 
1 36±0 78 
0 64±0 20 
1 07±0 54 
1 88±0 55 
0 76±0 37 
115±152 
2 13±182 
1 82±0 59 
1 93±1 65 
5 45±4 55 
0 74±0 40 
2 39±146 
4 25±3 87 
Creatinine clearance 
[ml/nun] 
_ 
-
-
-
-
-
-
-
130 8± 19 9 
125 6±20 5 
122 6±29 7 
126 1 + 158 
156 8±27 6 
123 6±29 4 
87 7±23 8 
70 2± 6 7 
69 5±36 9 
76 4±30 2 
88 9+14 3 
115 2±122 
109 1± 4 0 
102 4± 19 8 
139 7±13 7 
138 0±15 8 
137 9±15 7 
135 8±13 4 
152 3±32 8 
1313±26 3 
130 5±25 6 
154 6±219 
163 6± 19 4 
140 2± 16 3 
Abbreviations 
dose mg of compound administered in a gelatine capsule 
Ту, S half life of elimination of parent compound 
Ту, N4 half life of elimination of the N4 acetyl metabolite 
% S percentage of the dose excreted as parent compound 
% N4 percentage of the dose excreted as N^acetyl metabolite 
Кг S renal clearance of the parent compound 
Кг N4 renal clearance of the N4 acetyl metabolite 
+ probenecid experiment under co-medication of probenecid 
The renal clearance values are given as mean ± SD of the calculated renal clearance values in each unne sample Different clearance values of the same compound m the same volunteer 
are given when one of the unne parameters, unne flow or unne pH, was different 
When different T^ values were observed in the plasma concentration tune elimination curve, they are given m the appropriate column 
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Fig. 1 a and b. Plasma concentration- and renal excretion rate-time profiles of sulphathlazole (S) and its metabolite N^acetylsulphathiazole 
(N4) under control conditions (left, Fig 1 a) and during co-medication with probenead (right, Fig 1 b) Probenead 2 5 g was administered 
orally 1 h after intake of sulphaethidole 335 mg Before probenecid reached its inhibitory concentration, sulphathlazole was eliminated 
with a Τ,,, of 4 5 h, which later increased to 14 h The final T^ of both parent compound and metabolite was 7 h As probenecid inhibits 
renal clearance of both the parent drug and its metabolite, the compounds are excreted more slowly than under control conditions 
Sulphamethizole Sulphamethizole had a T^ of 1.3 h 
and its renal clearance amounted to about 100 ml/ 
mm. The compound was very slightly acetylated 
(about 3%). Probenecid co-medication reduced the 
renal clearance from about lOOml/min to about 
ЗОтІ/тіп, and consequently increases the T,,,, of 
elimination from about 1.3 h to 4.5 h. The percent­
age of acetylation was not increased by co-medica­
tion with probenecid (Table 1). 
Sulphathlazole- Sulphathlazole showed the short Ту, 
of elimination of about 4 h. The elimination of sul­
phathlazole is depended on acetylation (about 20% 
metabolite) and renal clearance of about 50 ml/min 
(Fig. 1 a). Co-medication with probenecid, as shown 
in Fig. lb, decreased the renal clearance of the 
parent compound from about 50ml/min to 20 ml/ 
min, and the TVj of elimination increased from 4 to 
14 h; the renal clearance of the metabolite also 
decreased from about 50 ml/min to about 12 ml/min 
The final TVl of elimination both of sulphathlazole 
and its metabolite was 7 h. Reduction of the renal 
clearance of N4-acetylsulphathiazole decreased the 
total amount excreted in the 60 h sampling period, 
which could have led to the incorrect conclusion that 
acetylation had been influenced by probenecid. 
Sulphametrole. Sulphametrole showed a Ту, of elimi­
nation of 6-10.5 h. The elimination of sulphametrole 
was mainly by acetylation (60%) and by renal clear­
ance of the parent compound (0.1-7 ml/min). The 
renal clearance of sulphametrole was dependent on 
urine flow and urine pH. 
Probenecid co-medication had no influence on 
the rate of acetylation of sulphametrole, because the 
amount of sulphametrole excreted unchanged 
remained low (5%). The rate of absorption of sul­
phametrole was decreased when probenecid was 
taken 2 h before hand. 
Delayed absorption increased the Т,
л
 of sul­
phametrole from 10 to 16 h. The areas under the 
curve of sulphametrole and its metabolite under con­
trol conditions were 654 ug/ml/h and 346 ug/ml/h, 
respectively. These values during co-medication with 
probenecid were 581 ug/ml/h for sulphametrole, and 
1211 ug/ml/h for the metabolite. 
The renal clearance of the metabolite N4-acetyl-
sulphametrole was reduced from 31 to 15 ml/min. It 
was not dependent on urine flow or unne pH with 
normal kidney function. 
Under the influence of probenecid co-medica­
tion, when tubular secretion was blocked, reabsorp-
tion phenomena were apparent. Then, the renal 
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ч plasma cone ug/ml 
• rtflal »жег ral* ug/mn 
Hf. 2. Plasma concentration- and renal excretion rate-time 
profiles of sulphaethidole m a volunteer after an oral dose 
of 430 mg Sulphaethidole is not acetylated and its renal 
clearance is 5-10 ml/nun Both of these faeton account for 
the long Ту, of elimination 
clearance of N4-acetylsulphametrole was dependent 
on urine pH (r = 0.901) and urine flow (r = 0.933), 
as can be derived from Table 1. 
Sulphafurazole. Sulphafurazole had the short elimi­
nation Ту, of about 6h. Elimination proceeded 
mainly via renal excretion (30-60%), and to a lesser 
extent via acetylation (16-33%). The renal clearance 
of sulphafurazole was dependent on urine flow and 
urine pH. 
N4-acetylsulphafurazole had the low renal clear­
ance value of about 7 ml/min, which was not depend­
ent on the variables of tubular reabsorption, i. e urine 
flow and urine pH. 
Probenecid co-medication decreased the renal 
clearance of N4-acetylsulphafurazole only slightly, 
from 7 ml/min to 3 ml/min, and increased the Т,
л
 of 
elimination from 13-18 to 25 h. Plasma sul­
phafurazole concentrations were biphasic in charac­
ter, starting with a relatively short T
№
 of 4-6 h, fol­
lowed by a beta-phase with the longer TV] of 
8.5-13 h. Probenecid co-medication eliminated the 
short phase and immediately revealed the longer 
elimination phase of 12 h. 
Sulphaethidole. Sulphaethidole showed the longest 
Ту, of the series of parent compounds - 1 2 h. The low 
renal clearance of 5-9 ml/min, and the absence of 
acetylation, account for the long TV ! (Fig. 2). The 
renal clearance of sulphaethidole depended on urine 
flow (r = 0.73) and pH (r = 0.84). Probenecid co-
medication reduced the renal clearance of sul­
phaethidole from 10 ml/min to 3 ml/min, and 
increased the Ту, from 9 to 19 h (Table 1). 
The pharmacokinetic parameters of the sul­
phonamides are summarized in Table 1. 
B. N4-acetybulphonamute Derivatives as Parent 
Compounds 
The pharmacokinetic behaviour of N4-acetylsul-
phonamide derivatives can be devided into two 
groups according to the observed Т^ of elimination 
and corresponding renal clearance. One group of 
derivatives has a half-life of elimination of 3-6 h, and 
a renal clearance of 20-60 ml/min; this group 
includes: 
N4-acetylsulphamethizole, N4-acetylsuIphameth-
oxazole, N^acetylsulphametrole, N4-acetylsulpha-
pyridine, N4-acetylsulphathiazole, N4-acetylsulpha-
diazine, N4-acetylsuIphamerazme and N4-acetylsul-
phamoxole. 
The half lives, renal clearances etc. are sum­
marized in Table 2. The renal clearance of the 
derivatives of this group can be decreased by co-
medication with probenecid. 
The plasma concentration and renal excretion 
rate versus time curves of N4-acetylsulphamethox-
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M 
О 
Compound 
N4-acetylsiilpha-
methizole 
N4-acetylsulpha-
dimidme 
Subject Dose TM S 
[mg] [h] 
TV,N4 
[h] 
% S % N 4 Кг S 
[ml/min] 
Kr N4 
[ml/mm] 
Urine pH Unne flow 
[ml/nun] 
Creatinine clearance 
[ml/min] 
IvdW 
CvdM 
Ρ С 
Ρ С 
M О 
Τ В V 
524 
495 
500 
85 
138 
403 
6 6 
48 
50 
43 
37 
39 
15 7 
19 5 
445 
52 5 
52 0 
49 0 
1177± 4 12 
29 04± 9 78 
23 63± 4 89 
23 62± 5 60 
35 06± 7 37 
35 89±12 14 
5 96±0 96 
5 96±169 
6 58±0 83 
6 06±0 57 
6 09+0 40 
5 80±0 60 
2 63 + 144 
2 62±169 
0 77±0 22 
1 36+1 37 
3 53+4 63 
168±1 29 
121 5±29 5 
133 1±38 0 
154 1±25 7 
145 9±18 5 
203 7±27 5 
153 2±25 6 
N4-acetylsulpha-
methoxazole 
+ probenecid 
N4-acetylsulpha-
metrole 
N4-aoetylsulpha-
pyndme 
N4-acety]sulpha-
thiazole 
moxole 
Τ В V 
J Η 
Т В V 
Τ В V 
J Η 
E T 
G H 
D F 
Τ J 
Τ В V 
Τ J 
Y A 
626 
356 
332 
403 
234 
ИЗО 
437 
471 
526 
359 
414 
367 5 0 
3 5 
3 0 
7 0 
3 3 
3 9 
35 
3 4 
3 6 
4 0 
68 4 
43 7 
544 
883 
53 0 
918 
19 5 
28 6 
58 3 
2 5 6 3 23 S 
3 0 3 4 13 4 
5 0 20 6 
44 74+ 
44 28± 
3 72 
9 45 
56 70±23 80 
32 68+1191 
15 98± 3 99 
43 70±14 60 
32 65 ±15 05 
33 18± 4 30 
4196± 8 20 
26 91± 4 62 
31 18± 6 54 
43 23±15 52 
38 36+1176 
44 92±17 95 
6 74+0 46 
5 50±0 75 
5 67±0 31 
6 74±0 46 
5 50±0 75 
5 38±0 57 
5 67±0 45 
6 96±0 73 
6 94±0 44 
5 89±0 53 
6 96+0 51 
6 66+0 81 
2 07±1 16 
0 72±0 26 
167±136 
2 07±0 46 
0 72±0 26 
2 29±168 
4 29±2 76 
1 77±1 01 
3 04±2 66 
1 12±0 41 
3 13±2 37 
0 57±0 27 
161 6±24 1 
115 2±156 
124 9±60 0 
1616±24 1 
115 2±156 
97 5± 9 2 
115 9±25 3 
114 5±103 
1317±12 2 
154 0±35 6 
134 9±189 
169 4 ±23 6 
Nj-acetylsulpha- A M В 
Т В V 
507 
778 14 
2 5-5 0 
5 0-14 12 
400 
403 32 53±21 77 
30 57±17 92 
5165±1195 
1117 ±34 76 
1912± 4 91 
52 38±1112 
5 85±100 
6 83+0 44 
5 43±0 33 
5 47±0 33 
165±103 
2 03±148 
1 39±0 81 
1 46±0 59 
79 2+ 3 9 
72 6±24 5 
152 2±114 
1714±20 6 
M о 523 5 0 5 0 5 8 93 9 30 37± 9 13 38 24±12 87 6 66+0 61 2 99+3 56 175 8±53 5 
H 
m 
I 
N4-acetylsulpha-
merazuie 
Τ В V 468 20 5 0-20 2 7 97 3 4 47± 166 
4 36± 2 20 
4 75± 1 18 
32 86± 4 60 
54 68±26 54 
37 83± 3 89 
5 61 ±0 24 
6 40±0 30 
7 3 6 ± 0 45 
1 38±1 11 
3 88±6 00 
142±0 51 
153 2±15 6 
145 6±18 7 
159 7±14 6 
Abbreviations 
dose mg of compound administered m a gelatine capsule 
Ту, S half life of elimination of the metabolite 
Ту, N4 half life of elimination of the parent compound 
% S percentage of the dose excreted as metabolite 
% N4 percentage of the dose excreted as parent drug 
Kr S renal clearance of the metabolite 
Kr N4 renal clearance of the parent drug 
+ probenecid experiment during co-medication with probenecid 
The renal clearance values are given as mean ± SD of the calculated renal clearance for each unne sample 
Different clearance values of the same compound in the same volunteer are given when one of the unne parameters, unne flow or unne pH, was different 
When different T^ values were observed m the plasma concentration-tune elimination curve, they are shown in the appropnate column 
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Flg. Э. Plasma concentration- and renal excretion rate-time pro­
files of N4-acetylsulphamethoxazole under control conditions (dashed line) and during co-administration of probenead (solid 
Ime) Probenecid 1 S g initially followed by two doses of 0 S g, 
(indicated by a * in the figure) decreased the renal clearance of N4-
acetylsulphamethoxazole from 56 ml/mm to 15ml/min, and 
increased the Ίγ. from 3 5 h to 7 h 
2β5»maN4 acetylsulphaethldole 
ito %NÍ 
Flg. 4. Plasma concentration- and renal excretion rate-time pro-
files of N4-acetylsulphaethidole (N4) and its metabolite sul-
phaethidole (S) in a volunteer after an oral dose of 28S 4 mg N4-
acetylsulphaethidole N4-acelylsulphaethKlole is deacetylated fas-
ter in the human body than it is acetylated (cf Fig 2) 
azole with and without probenecid co-medication are 
shown in Fig. 3. Probenecid reduced the renal clear-
ance of N4-acetylsulphamethoxazole from 56 ml/min 
to IS ml/min, and increases the TV| from 3.5 to 7 h. A 
similar decrease was found in the renal clearance of 
N4-acetylsulphamethizole, N4-acetylsulphathiazole 
and N4-acetylsulphametrole. (Table 1). Ni-acetylsul-
phonamide derivatives are de-acetylated to a small 
degree, and the percentage of liberated sul-
phonamide which is excreted unchanged in the urine 
does not exceed 5-6% of the dose. The results are 
summarized in Table 2. 
A second group of ^-acetylsulphonamide 
derivatives exhibits a Tv, of elimination of 10-25 h 
and a renal clearance of about 10 ml/min. Members 
of this group are: 
Nj-acetylsulphafurazole, N4-acetylsuIphaethidole, 
Nj-acetylsulfisomidme, N4-acetylsulphadoxine) N4-
acetylsulphamethoxydiazine. 
Probenecid co-medication still reduced the renal 
clearance from 10 ml/min to 3 ml/min, as shown for 
N4-acetylsulphafurazole (Table 1) derived from the 
parent compound sulphafurazole. 
The N4-acetylsulphonamide derivatives with a 
long Ту, also showed a small degree of de-acetylation. 
The metabolite could be observed in plasma, but not 
in the urine in all cases, except sulphaethidole 
derived from N4-acetylsulphaethidole, as shown in 
Fig. 4. The results are summarized in Table 3. 
Discussion 
From the experiments of Despopoulos (1965) it was 
concluded that the centre at the N, atom in sul­
phonamides was the dominating group for binding at 
the tubular anion transport mechanism. 
! W -N-R 
Sulphonamides and their corresponding N4-acetyl 
derivative metabolites both have this group in com­
mon. Substitution at the N, atom influences the 
centre by means of charge délocalisation, and thus 
affects the pKa value. Of the parent sulphonamides 
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investigated, only sulphamethizole and sulphathi-
azole had the high renal clearance of 40-100 ml/min, 
which was reduced to 30-15 ml/mm under the influ­
ence of probenecid co-medication This behaviour 
indicates that the main pathway of renal excretion for 
these compounds is active tubular secretion It may 
be concluded that with these sulphonamides, the N,-
atom is the principal centre for binding to the anion 
transport mechanism The remaimng parent sul­
phonamides had renal clearances of less than 10 ml/ 
mm, indicating considerable reabsorption from the 
kidney tubules, as shown by their dependence on 
unne flow and unne pH (Detth et al 1967, Vree et 
al 1978) 
N4-acetylsulphonamides 
N4-acetyIsulphonaimdes with almost identical T,/g 
values have similar renal clearances The influence of 
the substituent at the Ν,-atom has now vanished and 
the most important molecular moiety must be the N 4-
atonu 
In fact there are two competing groups m the 
molecule, which may eligible as leading centres for 
active tubular secretion by the anion transport 
mechanisms 
4-^QA^ H^"<><. PAH 
0 
ctntre 2 o n l r · ! 
For all N4-acetylsulphonamides, centre 2 is 
dominant over centre 1 To demonstrate this it was 
shown that N4-acetylsulphamethizole and N4-acetyl-
sulphathiazole showed a T,h of elimination of 4 5 h 
and a renal clearance of 40-60 ml/mm 
Centre 2 shows structural similarities to para-
aminohippunc acid (PAH), as depicted by 
Despopoulos This behaviour of N4-acetyl substi­
tuted drugs has been observed not only for sul­
phonamides, but also for paraaminohippunc and -
like compounds, such as procainamide Procainamide 
shows a T,/, of about 2 h and a renal clearance of 
300-400 ml/mm (Dreyfuss et al 1972) In contrast, 
N4-acetylprocauianude has a T,,, of 6 h and a renal 
clearance of 200 ml/mm By analogy with the sul­
phonamides, the centre at the N4-atom dominates 
over the centre at the Ν,-atom as far as active tubular 
secretion is concerned The renal excretion of N4-
acetylsulphonamide derivatives can be inhibited by 
probenecid, which proves that the major mechanism 
is active tubular secretion (Beyer 1954) 
The renal clearances of N4-acetylsulphonamide 
derivatives can be divided mto two groups 
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Nj-acetylsulphonamide derivatives with a Τι, of 
4-6 h show a renal clearance of 30-60 ml/mm N4-
acetylsulphonamides with a Τ,
Λ
 of 10-25 h show a 
clearance of less than 10 ml/mm The latter com­
pounds shows higher protein binding (70-90%) than 
the first group N4-acetylsulphonamide derivatives 
with the longer T,,., values and low renal clearance 
are. N4-acetylsulphaethidole, Nj-acetylsulphafura-
zole, N4-acetylsulphadoxine> N4-acetylsuIfisomidine 
and N4-acetylsulphamethoxydiazine 
Structural Requirements m the N, Heterocyclic Ring 
for Active Tubular Secretion 
Despopoulos (1965) stated that substitution at the N, 
position results in charge localisation, thus affecting 
the pKa value of the sulphonamides The principle of 
charge localisation and its resulting influence of the 
pKa has been the subject of many studies, which have 
speculated on the relationship between the antimi­
crobial effect and pKa (Bell and Robhn 1942, Seydel 
1968, Struller 1968) The wide variation in pKa (pKa 
4—8) of the sulphonamides causes a variation in the 
degree of tubular reabsorption of the parent com­
pounds but the similarity m the renal excretory 
behaviour of N4-acetylsulphonamides reduces the 
likelihood that the pKa is a variable which seriously 
influences the renal behaviour of the N4-acetyl-
denvatives 
Substituents at the N, position have a very 
marked influence on the mechanism of excretion 
Three sulphonamides, namely sulphamethizole, sul-
phathiazole and sulphaethidole, show active tubular 
secretion Those three sulphonamides have a struc­
tural moiety in common 
N ' N Ν N N 
-Ihiazol« melhizofe -elhidole 
It seems to be essential for a sulphur atom to be 
located at a site which is 2 atomic bond distances 
from the N, atom 
Replacement of sulphur by oxygen gives struc­
tures like sulphamoxole and sulphafurazole, which 
show a very low renal clearance, tubular reabsorption 
phenomena (unne flow and unne pH dependency), 
and no inhibition of renal clearance by co-medication 
with probenead 
lurazole -moxole 
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When the sulphur atom is replaced by a nitrogen 
atom, the compounds also show low renal clearance 
and tubular reabsorption, for example sulphapy-
ndine, sulphadiazine, sulphadmudine, sulfisomidine 
and sulphamerazine 
•# ^> -Ц -Ц -ν) 
с с 
-Pyridin diazine dimidine isoimdine -merazme 
Sulphametrole possesses a sulphur atom at almost 
the right place for binding to the anion transport 
mechanism, and thus for high renal clearance charac­
teristics, but it appears to be shielded by an adjacent 
nitrogen atom Sulphametrole has a low renal clear­
ance, like sulphamethoxazole In sulphamethoxazole, 
the oxygen atom is too far away from the N, atom 
and is also shielded by a nitrogen atom There can be 
no active tubular secretion of either of these com­
pounds, as their renal clearance cannot be lowered by 
probenecid co-medication 
11 l l o < II Π 
metrate -methoxazole 
It may be concluded from the structure-excretion 
mechanism relationship that only the -S- group 
located two atomic bond distances from the N,-atom 
seems to be important, and it is the leading centre for 
binding at the anion transport site 
The structure of sulphamethizole (pKa 5 40, Kr 
= 100 ml/min) comes closest to the preferred struc­
ture, with an extra nitrogen atom m the 5-membered 
nng system, which increases the negative inducing 
effect 
Sulphathiazole (pKa 7 12, Kr = 50 ml/min) lacks 
this extra negative inducing effect of the nitrogen, 
and for this reason its clearance may be lower 
Sulphaethidole (pKa 5 50, Kr = low), a com­
pound with the preferred structure, shows a low renal 
clearance (5 ml/min at pH 5 and 11 ml/min at pH 7) 
as a result of tubular reabsorption The renal clear­
ance can be reduced to 30% of its original value by 
co-administration of probenecid, as shown in Table I 
(Lundquist 1945) 
Sulphaethidole is a compound with high protein 
binding - 90-99% (Struller 1968) 
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A tendency to considerable protein binding and 
the resultant small percentage of free drug does not 
influence tubular secretion, but it does reduce the 
overall capacity of the excretory mechanism. 
The 'true' renal clearance values of the sul­
phonamides will be the subject of further investiga­
tion 
DeacetylaUon 
Deacetylation is a pathway in the acetylation-
deacetylation equilibrium (Weber 1971, Hearse and 
Weber 1973) Krebs et al. (1947) showed the possi­
bility of deacetylation for N4-acetylsulphadimidine. 
The volunteer who was able to deacetylate N^acetyl-
sulphadimidine in this study was a 'slow' acetylator 
It is not yet certain whether and how the acetylator 
phenotype is influenced by the rate of deacetylation 
and the rate constants of the equilibrium The rates 
of acetylation and deacetylation, too, will be the sub­
ject of further studies 
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BIOPHARMACEUTICS AND DRUG DISPOSITION, 1983, IN PRESS 
PHARMACOKINETICS, ACETYLATION-DEACETYIATION, RENAL CLEARANCE AND 
PROTEIN-BINDING OF SULFAMERAZINE, N4-ACETYLSULFAMERAZINE AND N4-
TRIDEUTEROACETYLSULFAMERAZINE IN 'FAST' AND 'SLOW' ACETYLATORS. 
Tom B. Vree, Chiel A. Hekster, Margriet Baakman, Tom Janssen, Marijn 
Oosterbaan, Eraiel Termond, and Marian Tijhuis. 
Department of Clinical Pharmacy, Sint Radboud Hospital 
University of Nijmegen, The Netherlands 
Summary 
Sulfamerazine shows a clear acetylator phenotype. The halflife of 
elimination of sulfamerazine is 12 h in 'fast' and 24 h in 'slow' 
acetylatore. N.-acetylsulfamerazine is eliminated biphasically, 
characterized by halflives of 5 and 12 h in 'fast' and 5 and 24 h in 
'slow' acetylators. 
Protein binding of sulfamerazine( 86%) and N.-acetylsulfamerazine 
(92%) is independent of acetylator phenotype or the origin of the 
compound, whether it is present in the body as parent compound or 
metabolite. The renal clearance of sulfamerazine ( 20 ml/min) and 
N.-acetylsulfamerazine ( 300-500 ml/min) is independent of the 
acetylator type and the origin of the compound. 
The existence of an acetylation-deacetylation equilibrium in the 
metabolism of sulfamerazine has been demonstrated with the test drug 
N.-trideuteroacetylsulfamerazine. 
N.-trideuteroacetylsulfamerazine inhibits the renal excretion and 
the clearance of N4-acetylsulfamerazine. 
Introduction 
The bimodal acetylaton of a number of drugs has been well known 
since 1964 (1). Drugs which show this phenomenon of 'fast' and 
'slow' acetylation have a variety of chemical structures, like 
Isoniazid(2,3,4)»Procainamide (5), Hydralazine (6), Dapsone (7), and 
the sulfonamides Sulfadimidine, Sulfapyridine (1), and Sulfadiazine 
(8), but all have the para-aminophenyl group in conmon. As well as 
acetylation, deacetylation has been demonstrated in the cases of 
monoacetyldapsone (7), N--acetylsulfadimidine (9), N-acetyl-
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procainamide (10),N4-acetylsulfadiazine (11) and the ^-acetyl-
sulfonamides derivatives in general (8,12,13,14). 
Acetylation and deacetylation must be regarded as an enzymic 
equilibrium (15), which can be demonstrated in man by means of the 
test drug N.-trideuteroacetylsulfamerazine (16). 
N.-trideuteroacetylsulfamerazine is deacetylated into sulfamerazine 
in man, which is acetylated to N.-acetylsulfamerazine, resulting in 
a plasma concentration-time curve with two different half lives of 5 
and 23 h (13,17). The latter half life of N.-acetylsulfamerazine is 
similar to the half life of sulfamerazine as reported by several 
authors( 18,19,20). The bimodal acetylation of sulfamerazine has yet 
not been reported in the literature, although this might be 
anticipated, due to its close structural similarity to 
sulfadimidine. 
In this paper we describe: 
a) the demonstration of two acetylator phenotypes for sulfamerazine 
and the possible existence of a deacetylator phenotype of N.-
acetylsulfamerazine in man. 
b) the protein binding of sulfamerazine and N.-acetylsulfamerazine 
in a series of 'fast' and 'slow' acetylators. 
c) the true renal clearance values of sulfamerazine and of N.-
acetylsulfamerazine in 'fast' and 'slow' acetylators. 
d) the demonstration of an acetylation- deacetylation equilibrium of 
sulfamerazine in man. 
For this purpose sulfamerazine, N.-acetylsulfamerazine and N.-
trideuteroacetylsulfamerazine were ingested by a series of 
volunteers of known acetylator phenotype for sulfadimidine and 
pharmacokinetic properties of parent compound and metabolite were 
measured. 
MATERIALS AND METHODS 
Subjects 
12 Healthy Caucasian volunteers ( 9 males and 3 females, 8 'fast' 
and 4 'slow' acetylators) from the Department of Clinical Pharmacy 
volunteered for the study. All three drugs were administered as fine 
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powder in a gelatin capsule (no 3). 
Drugs 
Sulfamerazine was obtained from Sigma (St.Louis,USA). N4-
acetylsulfamerazine was synthesized according to Vree et al (13). 
Synthesis of N^-trideuteroacetylsulfamerazine 
To 10 mmol of sulfamerazine (2.64 g) was added 25 mmol of (d, 
acetic-anhydride )(2.5 ml) and 10 ml of deuteroethanol (d.). 
The mixture was stirred at 40"C and the reaction followed by HPLC 
After 2 hrs the reaction is complete. 
The reaction mixture was filtered (glassfliter G4) and the 
precipitate is washed several times with distilled water and 
diethyl ether and dried under vacuum over KOH pellets. 
By HPLC thé compound is 100% pure, melting point 238-239eC. 
The Infrared spectrum ( recorded at a Pye Unicam SP 2000 
spectrometer) shows the C=0 band at v= 1680 cm . 
The NMR spectrum was recorded with a Varian Associates Model T-60 
spectrometer and the chemical shifts are reported as б values 
(p.p.m) relative to tetramethylsilane ( TMS) as internal standard. 
NMR (dgDMSO) :δ 10.31 ( broad singlet, 1H,N4H), 8.33 (d,1H,HC),8.0 
(d,2H,HA+HA,), 7.71 (d^HjHg+Hg,), 6.85 (d,1H,HD) and 2.34 (s,3H, 
сн3). 
Sampling procedure 
Blood samples ( 2 ml) were collected at regular time intervals by 
means of fingertip puncture with Monoletr lancets (Monoject, USA). 
Urine was collected on spontaneous voiding. The time periods of 
collecting the urine samples were kept as short as possible. The 
total time of sample collection varied between 60 and 120 hrs. 
Urinary pH was measured immediately after collection from the 
volunteers. Measurements were made with a Radiometer ( Copenhagen 
PHM 61) instrument. 
High Performance Liquid Chromatography(HPLC) 
Apparatus 
A Spectra Physics 3500 В high performance liquid Chromatograph was 
used equipped with a spectrophotometric detector ( model SP 770). 
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A stainless steel column, 10 cm χ 4.6 mn ID, packed with Lichrosorb 
RP 8, particle size 5 Vn, and an injection loop of 100 μ 1 was used. 
Detection of the sulfonamides is effected at 244 nm, the detection 
limit is 0.3 μ g/ml. 
Solvent 
The solvent is a mixture of phosphate buffer and methanol. 
500 ml of 0.067 M KH2P04 were mixed with 10 ml of 0.067 M Na2HP04 
and 100 ml of methanol, final pH 5.9. Flow rate 1.2 ml/min. 
Calibration curves for HPLC analysis 
Calibration curves were made by adding known concentrations of N--
acetylsulfamerazine and sulfamerazine to blank human plasma or urine 
and treated in the same way as the samples. 
The relative retention time (K') and molar extinction (ε ), measured 
in the eluent, of N.-trideuteroacetylsulfamerazine, N4-acetyl-> 
sulfamerazine and sulfamerazine, were calculated . 
There is no difference in the chromatographic and UV absorption 
behaviour between N.-acetylsulfamerazine (K* 7.4; e « 1t90 χ 10 
L.mol cm ) and N.-trideuteroacetylsulfamerazine (Κ' 7.4;ε =1.88 χ 
104 L.mol-1 cm" 1). 
Sample preparation for HPLC analysis 
plasma 
To 100 yl of plasma, 400 μΐ of perchloric acid ( 0.33N) was 
added,the solution mixed thoroughly on a Vortex mixer, and after 
centrifugation at 2600 g for 5 minutes, 100 yl of the supernatant is 
injected on to the column. 
Urine 
The urine is diluted by addition of 0.5 ml of distilled water to 25 
μΐ of urine. The solution is mixed and 100 μΐ is injected on to the 
column. 
Recovery 
Recovery of N.-acetylsulfamerazine added to human plasma in the 
concentration range 1- 200 μg/ml if found to be 91 + 4% . The 
recovery of sulfamerazine added to human plasma is 89 _+ 3 % . 
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Mass spectrometry 
Apparatus 
A Hewlett Packard 5982 dodecapole mass spectrometer was used. 
Operation conditions : electron impact mode, 70 eV electron energy, 
ion source temperature 1620C, ion source pressure 2 χ 10_ Torr, 
analyser pressure 4 χ 10~ Torr. The samples were introduced by the 
direct inlet. 
The mass spectra of sulfamerazine, N.-acetylsulfamerazine and N.-
trideuteroacetylsulfamerazine show the M + 65 ion as base peak. The 
Deuterium/protium (D/H) ratio of N4-trideutero- and N4-
acetylsulfamerazine was measured by Selective Ion Monitoring of the 
respective base peaks m/z 241.3 and m/z 244.3 with an HP 5947 
Multiple Ion Detector. No deuterium exchange took place in the work 
up procedure or in the ion source of the mass spectrometer. 
Calibration curves of the D/H ratio of the plasma and urine 
concentrations of N.-trideuteroacetylsulfamerazine and N.-
acetylsulfamerazine versus the corresponding ratio of the peak 
heights of the ions were constructed. The samples of the calibration 
curve were treated in a similar way as the plasma and urine samples 
with the unknown concentrations. 
Sample preparation for mass spectrometric analysis 
To 300 yl of urine or plasma 100 μΐ of IN HCl and 2 ml of 
dichloromethane was added and mixed on a Vortex mixer. The dichloro-
methane layer was separated and evaporated at 37"C under a stream of 
nitrogen. The residue was dissolved in 50 μΐ diethyl ether, and 3 yl 
of the etheral solution of the sulfonamides transferred to the 
direct insertion probe of the MS. The sulfonamides are evaporated by 
the direct probe heater at a temperature increase rate of 300cC/min. 
The resulting recorded peaks of the evaporation profiles of N.-
acetylsulfamerazine (m/z 241.3) and N.-trideuteroacetylsulfamerazine 
(m/z 244.3) are symmetrical. 
Stability of N.-trideuteroacetylsulfamerazine 
No loss of deuterium content was observed of N^-trideuteroacetyl-
sulfamerazine in the pure compound and in the standard solutions for 
construction of the calibration curves over a time period of 1 year. 
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Renal clearance(Kr) 
The 'apparent' and 'true' renal clearance value of the drugs was 
calculated from the average renal excretion rate, divided by 
respectively the 'total' and 'free' (or 'unbound') plasma 
concentration during the measured time interval. The renal clearance 
(ml/min) was calculated for each urine sample and its corresponding 
plasma sample. 
Protein binding 
Protein binding of sulfamerazine and its metabolite was measured in 
each plasma sample by means of Ultrafreer drug filters, obtained 
from Worthington ( Freehold, USA). 
Creatinine 
Creatinine in plasma and urine samples from each subject was 
measured by a standard procedure ( automated Jaffi method) in the 
Laboratory of Clinical Chemistry, Department of Internal Medicine. 
Statistics 
Regression lines, standard deviations and the Student Τ test were 
calculated according to standard statistical procedures with a 
Hewlett Packard 9810 calculator. 
Acetylator phenotype 
Volunteers were phenotyped according to their ability to acetylate 
sulfadimidine as described earlier ( 8,21). 
RESULTS 
Half lives of elimination 
Figure la shows the pharmacokinetic profile of sulfamerazine and its 
metabolite N.-acetylsulfamerazine and figure lb the profile of N.-
acetylsulfamerazine and its metabolite sulfamerazine in the same 
'fast' acetylator. 
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Figure la: Plasma concentration- and renal excretion rate-time 
profiles of total and unbound sulfamerazine (S) and its metabolite 
N.-acetylsulfamerazine (N4) in a 'fast' acetylator after an oral 
döse of 713 mg of sulfamerazine. 
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Figure 1b:Plasma concentration- and renal excretion rate-time profiles 
total and unbound N¿-acetylsulfamerazine(Nj) and its metabolite 
sulfamerazine (S) in the same 'fast' acetylaCor of figure 1a, after 
an oral dose of 472 mg of N^-acetylsulfamerazine. 
of 
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Sulfamerazine and its metabolite are both eliminated from the body 
with a half life of 12 h. When N.-acetylsulfamerazine is ingested as 
parent compound, the elimination of the parent compound is biphasic, 
the half lives of elimination being 5 and 11 h. 
This pharmacokinetic behaviour is totally different in 
'slow' acetylators which is demonstrated in figures 2a and 2b. 
• a plasma concug/ml 
Figure 2a: Plasma concentration- and renal excretion rate-time 
profiles of total and unbound sulfamerazine (S) and its metabolite 
N.-acetylsulfamerazine (N·) in a 'slow' acetylator after an oral 
döse of 848 mg of sulfamerazine. 
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Figure 2b: Plasma concentration- and renal excretion rate-time 
profiles of total N.-acetylsulfamerazine (N.) and its metabolite 
sulfamerazine (S) in the same 'slow' acetylator of figure 2a, after 
an oral dose of 468 mg of N^-acetylsulfamerazine. 
Sulfamerazine and its metabolite are eliminated in this 'slow' 
acetylator with a half life of 26 h. When N4-acetylsulfamerazine is 
administered to the same 'slow' acetylator the plasma concentration-
time curve is clearly biphasic with half lives of 5 and 23 h. 
The half life of elimination of sulfamerazine and that of its 
metabolite tb-acetylsulfamerazine in 8 'fast' acetylators is 12.1 
1.6 h and in 4 'slow' acetylators 24.3 + 2.8 h (ρ < 0.005), as 
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Pharmacokinetic parameters of Sulphamerazme and its metabolite N -acetylsulphamerazine in 'fast' acetylators 
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94.5І0.9 
93.7І2.8 
88.8І1.5 
12. 
19 
9 
И 
l i l .6 1 2 . l i l . 6 
4 + 1 2 
2 + 9 
5 + 1 1 
16.3І2. 
4.3 
0.1 
0.25 
.9 56.2І6.4 (í 
71.7 
65.2 
74.7 
86.1-3.6 92.4-3.1 13.0-5.3 3.7 
il.5 
10.7 
il.5 
1.55І2.38 70.5І4.9 (SEM) 
S 
N4 
•-S 
Sulpnaraerazine 
N -acetylsulphamerazine 
percent of tne dose excreted as sulphamerazine 
percent of the dose excreted as N -acetylsulphamerazine 
shown in tables 1 and 2. When N^-acetylsulfamerazine is taken as 
parent drug, 'fast' acetylators eliminated the compound in a 
biphasic fashion, with the half lives of 3.7 ± 1.5 h and 10.7 + 1.5 
h (table 1).'Slow' acetylators eliminated the compound also biphasi-
cally, but with half lives of elimination of 4.0 + 0.95 h and 21.2 + 
3.5 h (table 2). 
Protein binding 
The protein binding of sulfamerazine and its metabolite was measured 
in each volunteer in Θ-12 plasma samples. The average values of the 
protein binding of parent drug and metabolite are summarized in 
tables 1 and 2. 
Sulfamerazine is bound to plasma proteins to the extent of 86.2 ± 
2.9% (SEM) in 'fast' acetylators and its metabolite to 92.6 ± 1.9% 
(SEM). In 'slow' acetylators sulfamerazine binds at 87.0 ± 1.5% 
(SEM) and its metabolite to 93.2 ± 1.8% (SEM). It can be concluded 
that protein binding of parent compound and metabolite is not 
different in 'fast' and 'slow' acetylators. 
When N.-acetylsulfamerazine is ingested by 'fast' and 'slow' 
acetylators no difference is observed between the protein binding of 
parent drug or metabolite in the two groups of acetylators. 
The protein binding of sulfamerazine and N.-acetylsulfamerazine is 
independent of the origin of the compound, whether it is present as 
parent drug or as metabolite. 
Renal excretion 
a:total excretion 
'Fast' acetylators excrete 16.3 ± 2.9% (SD) of the dose, as the 
parent compound sulfamerazine while 'slow' acetylators excrete 
25.6 ±2.3% (SD) (p<0.005). 
'Fast' acetylators excrete 56.2 + 6.4% (SD)of the dose as the 
metabolite N.-acetylsulfamerazine ,while 'slow' acetylators 
excreted the metabolite to the smaller extent of 42.3 + 8.6% (SD) 
(ρ < 0.05). 
When N.-acetylsulfamerazine is ingested by 'fast' and 'slow' 
acetylators, only a small percentage of the metabolite 
sulfamerazine is excreted in the urine (about 2%). 70.5 ± 4.9% 
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Pharmacokinetic parameters of Sulphamerazine and its metabolite N -acetylsulphamerazine in 'slow' acetylators 
subject 
T.B.V 
T.J. 
J.R. 
C.S. 
T.B.V. 
T.B.V. 
T.B.V. 
T.J. 
J.R. 
drug 
s 
s 
s 
s 
N4 
N4 
V d 3 
N4 
N4 
dose 
mg 
848 
700 
509 
463 
468 
251 
256 
784 
553 
451 
protein binding 
%S (SD) 
87.3±2.б 
85.4-3.0 
86.3¿2.6 
88.8^0.4 
87.0±1.5 
91.6±0.3 
87.5^1.7 
84.0-2.4 
93.3^0.3 
89.1^4.2 
%N4 (SD) 
90.9-1.5 
92.6^1.3 
94.7^0.9 
94.7І0.2 
93.2^1.8 
94.7±0.4 
94.lío.2 
90.1^4.2 
94.ОІО.5 
93.2І2.1 
Tb S 
h 
26 
26 
20 
25 
24.3І2.8 
23 
26 
23 
25 
18 
23.0І3.1 
ΤΊ 
h 
26 
26 
20 
25 
N4 
24.3І2.8 
5 
3 
3 
3.5 
5 
4.5 
+ 
+ 
+ 
+ 
+ 
4.ОІО.95 
23 
17 
23 
25 
18 
21.2І3.5 
%S 
28.8 
25.4 
23.6 
24.4 
25.6І2.3 
2.7 
1.5 
1.32 
2.2 
2.6І1.6 
% N4 
54.9 
41.0 
36.5 
36.9 
42.3І8.6 
97.3 
75 
59.9 
52.0 N4-d3 
1.97N4 
58.8 
68.0І16.3 
Î 
S sulphamerazine 
N N.-acetylsulphamerazine 
N.-d N -trideuteroacetylsulphamerazine 
Tb halflife of elimination 
%S percent of the dose excreted as sulphamerazine 
%N. percent of the dose excreted as N.-acetylsulphamerazine 
(SD) in 'fast' acetylators and 68.0 ± 16.3% (SD) in 'slow' 
acetylators (p = 0.5) was excreted as N.-acetylsulfamerazine.The 
results are summarized in table 1 and 2. 
btrenal clearance values 
In table 3 the renal clearance values of sulfamerazine and its 
metabolite N^-acetylsulfamerazine are summarized for 'fast' 
acetylators, while in table 4 these values are given for 'slow' 
acetylators. 
The renal clearance of sulfamerazine is influenced by urine flow. 
The renal clearances of sulfamerazine and its metabolite are 
independent of the acetylator phenotype of the volunteer, and of 
the origin of the compounds, whether they are present in the 
body as parent compounds or metabolite. 
Determination of Acetylator Phenotype 
Determination of the acetylator phenotype for sulfamerazine was 
carried out by measuring the plasma concentration of the metabolite 
N.-acetylsulfamerazine as percentage of the total concentration of 
parent drug and metabolite. The percentage of N.-acetylsulfamerazine 
in each plasma sample was plotted against the time after 
administration. Figure 3 shows the difference between the percentage 
N.-acetylsulfamerazine in plasma of 'fast' and 'slow' acetylators. 
The final percentage is 3 5 + 9 % (SD) in 'fast' acetylators and 14 + 
2% in 'slow' acetylators (p < 0.01). 
Acetylator phenotype sulphamerazine 
- slOOH m plasma 
4 3519% fest 
Пав 
,^_5—Ψ—Ψ—δ—-δ—-ο«»«;·« 
Ί Γ 
10 20 
Ί 1 Γ—Τ 
Figure 3 
group of 
(0 M 60 70 h 
Lfameraz 
•4) acetylators. 
: Percentage N.-acetylsul ine-time profiles in a 
'fast' (n=8) and 'slow1 (n-"" 
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Renal clearance values of Sulphamerazine and N -acetylaulphamerazine In 'fast' acetylators. 
subject 
И.О. 
A.M.B. 
Y.A.H. 
W.J. 
T.C. 
M.B. 
N.V. 
Z.Y.L. 
Y.A.H. 
A.M.B. 
M.O. 
drug 
S 
S 
S 
s 
s 
s 
s 
s 
N4 
N4 
dose 
mg 
693 
54Θ 
713 
500 
534 
418 
1012 
684 
472 
618 
439 
urine flow 
ml/min (SD) 
1.36^0.25 
2.83^4.30 
1.31*1.55 
1.83*1.51 
3.71*5.00 
2.25*4.30 
1.69*1.18 
0.88*0.33 
0.89*0.50 
2.46*1.87 
3.88*5.18 
urine pH 
(SD) 
5.60*0.79 
6.21*0.71 
5.92*0.66 
6.08*0.35 
6.02*0.60 
6.20*0.71 
6.00*0.49 
5.80*0.49 
6.54*0.72 
7.09*0.95 
5.71*0.56 
K r S t 
ml/min(SD) 
1.97*0.48 
2.48*0.93 
1.95*0.47 
4.72*2.05 
4.38*3.78 
2.35*1.03 
3.94*1.20 
2.73*0.34 
1.12*0.25 
4.18*1.79 
K r S f 
ml/min(SD) 
16.09*3.81 
15.32*5.36 
19.70±4.72 
33.11*14.37 
30.90*26.67 
17.70*7.79 
21.04*6.49 
26.33*4.74 
7.00*1.59 
23.20*18.50 
K r N 4 t 
ml/min (SD) 
36.55*9.49 
38.95*10.34 
29.63*4.56 
22.87*4.89 
40.97*6.96 
26.00*7.31 
21.39*4.44 
25.90*3.83 
31.62*5.63 
46.09*7.63 
22.40*5.76 
K r N 4 f 
ml/min (SD) 
395*100 
352* 94 
494* 76 
299* 65 
678*115 
409*130 
298* 62 
430* 56 
283* 50 
733*122 
410*107 
Kr Great. 
ml/min 
145*18 
154*29 
152*18 
151*25 
173*25 
127*17 
142*13 
125*16 
156*23 
150*25 
155*39 
(SD) 
î 
4 
Kr 
N 4t 
Great 
sulphamer az ine 
N -acetylsulphamerazine 
renal clearance 
renal clearance based on total plasma concentration 
renal clearance based on total plasma concentration 
not present 
creatinine 
S renal clearance based on unbound plasma concentration 
N. renal clearance based on unbound plasma concentration 
When N4-acetylsulfamerazine is administered as parent compound, the 
plasma concentration of the metabolite sulfamerazine was measured 
and expressed as percentage of the total concentration of parent 
drug and metabolite in each plasma sample of the volunteers. The 
final concentration of the metabolite sulfamerazine is 52 ± 10% (SD) 
in'fast' acetylators and 69 + 9% (p< 0.05, figure 4), in 'slow' 
acetylators. 
Dmcetylator phenotyp· Ni-acttylsulphainfrazin· 
Figure 4: Percentage sulfamerazine-time profiles in a group of 
'fast' (n=3) and 'slow' (n=5) acetylators. 
Kinetics of N.-trideuteroacetylsulfamerazine 
N.-trideuteroacetylsulfamerazine was ingested by one 'slow' 
acetylator in order to demonstrate the existence in man of an 
acetylation-deacetylation equilibrium of sulfamerazine in man,shown 
in figure 5. 
НзС-с-м^-з-м-О
 deacety'Qtlon. 
(Ni-dj-ocetyl-l+IN^-acelyl-) ^. 
ТЦ 5h T)j23h 
sulphamerazine 
T!j23h 
Metabolic pathways of the acetylation-deacetylation 
4" 
Figure 5 : 
equilibriu 
(trideutero)acetyIsu1famerazine 
a  
equilibrium operating In the elimination of N 
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Renal clearance values of Sulphamerazine and N -acetylsulphamerazine in 'slow' acetylators 
subject 
T.B.V. 
T.J. 
J.R. 
CS. 
T.B.V. 
T.J. 
J.R. 
àrug 
S 
S 
S 
s 
N4 
N4 
H, 
dose 
mg 
848 
700 
509 
463 
468 
553 
451 
urine flow 
ml/min (SD) 
1.08-0.53 
1.28І0.19 
1.50-1.95 
3.95^4.98 
1.34^0.96 
4.04^4.66 
1.70І1.35 
urine pH 
(SD) 
6.37-0.30 
6.46-0.45 
6.05^0.67 
5.82І0.37 
6.14^0.80 
6.66І0.73 
5.61±0.60 
КГ s 
ml/min (SD) 
2.30^0.51 
1.45І0.33 
1.71-0.63 
2.32^0.80 
4.52^1.59 
3.76-2.15 
3.75-1.38 
Kr S f 
ml/min(SD) 
19.95^6.78 
11.94^2.53 
12.61І4.94 
20.74^6.93 
27.27Í14.43 
54.80¿18.90 
КГ Ν 
ml/min (SD) 
31.40Í5.68 
24.45^4.87 
17.84^4.29 
22.Θ2-7.24 
37.93^13.32 
23.49^6.73 
17.53І4.46 
**
 N4 f 
ml/min (SD) 
359-80 
341Í75 
335^81 
366^142 
237Í68 
281^68 
Kr Creat 
mi/min (SD) 
166-36 
116-30 
118-22 
127І31 
165^27 
145^20 
123-18 
η 
4 
Kr 
4 t 
Creat 
sulphamerazine 
N -acetylsulphamerazine 
renal clearance 
renal clearance based on total plasma concentration 
renal clearance based on total plasma concentration; N 
not measured 
creatinine 
S renal clearance based on unbound plasma concentration 
4 f renal clearance based on unbound plasma concentration 
Figure б shows the plasma concentration- and renal excretion rate-
time curves of the parent compound N.-trideuteroacetylsulfamerazine 
and its metabolites sulfamerazine and N^-acetylsulfamerazine. 
— ι 1 i—l r — ι — ι — ι — ι 1 1—r—ι ι I 1 1—1 1 — I I I I I-- 1 
« з о і о й і н и п ш ю о і ю uot· 
« 2 pfeMMcm ι φ * 
I « IIO*i 
Figure 6: Plasma concentration- and renal excretion rate-time 
profiles of N.-trideuteroacetylsulfamerazine (N4-d3) and its 
metabolites sulfamerazine (S) and N4-acetylsulfamerazine (N4) in a 
'slow' acetylator after an oral dose of 784 mg of 
trideuteroacetylsulfamerazine. 
N4-
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The half life of elimination of the deuterated compound is 3.5 h, 
while the half lives of its metabolites sulfamerazine and N4-
acetylsulfamerazine are both 25 h. 
Of the ingested dose 52% is excreted in the urine unchanged and 1.3% 
as sulfamerazine and 2.0% as N.-acetylsulfamerazine. It must be 
concluded that the bioavailability of the deuterated compound is 
only 55% as the same volunteer excreted 99% of an oral dose of N.-
acetylsulfamerazine as is shown in figure 2b and table 2. 
Irregular absorption and low bioavailability may be concluded from 
figure 6, which shows that in the period 24-48 h after ingestion, 
delayed absorption from the gastrointestinal tract took place. When 
a mixture of 256 mg of N.-trideuteroacetylsulfamerazine and 251 mg 
N.-acetylsulfamerazine was administered orally to the same 
volunteer, the deuterated compound showed the same irregular 
absorption. 
Renal clearance of deuterated N.-acetylsulfamerazine 
The renal clearance of N.-acetylsulfamerazine (6.84 ± 2.30 ml/min), 
excreted as a metabolite of N.-trideuteroacetylsulfamerazine, was 
much lower than the renal clearance of the deuterated compound 
itself (42.64 + 15.82 ml/min? ρ <0.0125). 
When an equimolar mixture of 256 mg N.-trideuteroacetyl- and 251 mg 
N.-acetylsulfamerazine is administered simultaneously, the renal 
clearance of the deuterated compound (34.79 + 8.55 ml/min) is 
significantly higher (p < 0.05) than the renal clearance of N.-
acetylsulfamerazine (23.51 ± 6.19 ml/min). In this situation, the 
renal clearances were calculated over the time period 0-24 h. 
The renal clearance of N.-acetylsulfamerazine, calculated over the 
time period 30-90 h in which the compound is present as metabolite 
and the deuterated compound is still present, is lower (13.27 +3.17 
ml/min) than in the first time period (p < 0.05). 
When N.-acetylsulfamerazine is administered as parent compound to 
the same volunteer who took the deuterated compound, the renal 
clearance in the first 24 h after ingestion is 40.03 ± 16.50 ml/min 
and in the 30-90 h period , where N.-acetylsulfamerazine must be 
considered as metabolite, 35.21 ± 7.48 ml/min (p= 0.15). 
It must be concluded that these renal clearance values of N.-acetyl-
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suifaraerazine may be used as reference values. 
A second reference value of the renal clearance of N4-acetylsulfa-
merazine can be obtained from the situation wherein N.-acetylsulfa-
merazine is the metabolite of sulfamerazine. The values of the renal 
clearance of N.-acetylsulfamerazine obtained under different 
experimental conditions in one volunteer are summarized in table 5 
and shown in fig. 7. 
renal cl«aranc· N¿-acetylsulphamerazin· 
70 ml/mm 
M 
50 
10 
32 
2° 
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2 
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4 ï 
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Figure 7 : Renal clearance values of N.-acetylsulfamerazine, 
measured under different experimental circumstances, whether the 
compound is present as parent (open dots) compound or metabolite 
(solid dots), plotted against the percentage of deuterated compound 
of the dose ingested by one 'slow' acetylator. The point 50%N4, 50%N«-d3 is separated to show more clearly which clearance belongs 
to wnlcn compound (parents + metabolite). 
In figure 7, the renal clearance values of N.-acetylsulfamerazine 
are plotted against the percentage deuterated compound of the 
ingested dose. 
The solid points represent renal clearance values when N.-acetyl­
sulfamerazine is present as metabolite and the open points the 
situation in which N4-(trideutero)acetylsulfamerazine is the parent 
compound. 
Figure 7 shows that the renal clearance values of N.-trideutero-
acetylsulfamerazine are not statistically different from the renal 
clearance values of N.-acetylsulfamerazine as parent drug or 
metabolite of sulfamerazine. When N^-trideuteroacetylsulfa-merazine 
231 
Renal clearance values of sulphamerazine, N -acetylsulphamerazine and N.-trideuteroacetylsulphamerazine In 
one 'slow' асеtylator. 
subject drug dose 
mg 
KcS^ Kr Ν, 
't — 4 t 
ml/min (SD) ml/min (SD) 
^
 N4 d3 t 
ml/min (SD) 
time period + Th 
T.B.V. N.-d, 7Θ6 4 3 1.97^1.13 
η - 37 
6.84^2.30 η=2β 42.64-15.Θ2 n-16 0-120 h Τ"! 3.5 + 25 h 
ώ T.B.V. N.-d, 256 
ю 4 3 
Ν. 251 
T.B.V. Ν. 468 
4 
1.45-0.44 
η=32 
4.52^1.59 
η=24 
23.51^6.19 η=8 
13.27Í3.17 η»24 
40.03^16.50 η-14 
35.21І 7.48 η-10 
34.79^8.55 η=18 0- 40 h Tb 3-5 h 
40- 80 h T'a 26 h 
0- 30 h Tb 5 h 
30- 60 h Th 23 h 
Î 
S 
T.B.V. 848 2.25-0.62 32.24Í4.81 n=38 0-125 h T1! 26 h 
N4-d3 
N 
N.-trideuteroacetylsulphamerazine 
N acetylsulphamerazine 
4 
S sulphamerazine 
Kr renal clearance calculated based on total plasma concentrations 
time period time after ingestion of the drug 
η number of urine samples and clearance calculations in a certain time period. 
and N^-acetylsulfamerazine are excreted simultaneously by the kidney 
tubules, the renal clearance of N.-acetylsulfamerazine is 
significantly lower than that of the deuterated compound. 
N4-trideuteroacetylsulfamerazine inhibits the renal clearance of 
N.-acetylsulfamerazine when this is present as metabolite of N 4-
trideuteroacetylsulfamerazine alone (p< 0.00125) or in the mixture 
(p < 0.05) of 50% N4-trideuteroacetyl- and 50% N4-acetylsulfa-
merazine. 
DISCUSSION 
The acetylation-deacetylation equilibrium 
When N.-acetylsulfamerazine is administered to volunteers, 
sulfamerazine can be detected in blood and urine as shown in figures 
1b and 2b. 
This is the first indication that an equilibrium exists for this 
drug as has already been shown for sulfadimidine by Krebs et al (9). 
A second indication of the existence of the equilibrium can be 
derived from the plasma concentration-time curves and half lives of 
elimination of parent drug and metabolite. The plasma concentration 
of the metabolite is described by the equation: 
C^· constant. (A.e"km't-B.e~Icel*t) 
were C ^ is the plasma concentration at time t, A and В are 
constants, L· is the rate of acetylation of the parent compound 
and/or the rate of formation of the metabolite, к , the rate of 
elimination of the metabolite and t the time. 
When the rate of the elimination of the metabolite is higher than 
its rate of formation, then the elimination term diminishes faster 
than that of formation, which then becomes the rate limiting factor, 
and the plasma concentration-time curves of parent compound and 
metabolite are parallel. 
When sulfamerazine is eliminated by 'fast' and 'slow' acetylators 
the plasma concentration-time curves of parent drug and metabolite 
show similar half lives, being 12.1 + 1.6 h in 'fast' and 24.3 + 2.8 
h in 'slow' acetylators. The parallel plasma concentration-time 
curves indicate that N.-acetylsulfamerazine is eliminated faster 
than the parent compound, independent of the acetylator status of 
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the volunteer. When N.-acetylsulfamerazine is administered, the 
compound is initially eliminated with a half life of 4 h in both 
'fast' and 'slow' acetylators. This elimination is caused 
predominantly by the high renal clearance of N.-acetylsulfamerazine 
(300-500 ml/min). In the course of time when the half lives of 
parent drug N.-acetylsulfamerazine and metabolite sulfamerazine 
become identical, the plasma concentration of N.-acetylsulfamerazine 
is controlled by that of its metabolite sulfamerazine· In this 
situation, the N.-acetylsulfamerazine present must be considered as 
the metabolite of sulfamerazine and it may be called the 'apparent 
parent compound' because it has got the same structure as the 
compound that is initially administered (14,15). 
A final demonstration of the equilibrium was obtained when N.-
trideuteroacetylsulfamerazine was administered to a volunteer and 
N.-acetylsulfamerazine detected in blood and urine,shown in fig.6. 
The deuterated compound from the gastro-intestinal tract shows delay 
absorption on the second day of the experiment. This delayed 
absorption is not caused by the relatively high dose of 784 mg,as it 
is also seen when 256 mg of N.-trideuteroacetylsulfamerazine is 
taken, but not when 468 mg N.-acetylsulfamerazine is administered 
(see figure 2b). 
The acetylator phenotype 
When N.-acetylsulfamerazine, as metabolite of sulfamerazine, is 
expressed as percentage of the total concentration of sulfonamide in 
plasma and plotted versus the time course of the experiment (8,21) 
the differences between 'fast' and 'slow' acetylators is clearly 
shown(figure 3). Since the early report of Earle (18) that 
sulfamerazine is eliminated with a half life of 23 h,no further 
investigations have been performed on the possible polymorphic 
acetylation of sulfamerazine. The existence of phenotypic 
differences have been reported for the structurally related compound 
sulfadimidine (1). Träeger et al (19) have used sulfamerazine as a 
test compound for kidney function in children and elderly people. 
They reported a variation in the observed half life of 12-25 h. 
It is interesting to see whether a 'deacetylation phenotype' could 
be discovered for N.-acetylsulfamerazine. When the plasma 
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concentration of the metabolite suifamerazine, expressed as 
percentage of the total concentration of sulfonamide is plotted 
versus time, as shown in figure 4, it can be observed that the 
difference between 'fast' and 'slow' acetylators is much smaller 
than that in figure 3. 
Deacetylation of N.-acetylsulfamerazine is a minor process in its 
elimination compared with its renal clearance. The curves in figure 
4 are initially parallel and steeper than in figure 3, due mainly to 
the high renal clearance. 
The difference in half life of sulfamerazine in 'fast' and 'slow' 
acetylators arises from differences in the rate of acetylation, as 
the renal clearances of sulfamerazine and metabolite in both 
acetylator groups are identical. 
Renal clearance: 
The renal clearance of sulfamerazine is low (about 20 ml/mini, due 
to its high protein binding (86%) and extensive tubular 
reabsorption, and is independent of the rate of acetylation and 
acetylator phenotype. 
The renal clearance of N.-acetylsulfamerazine is high (300-500 
ml/min,based on unbound plasma concentrations)»despite the high 
protein binding (92%) and is caused by its high affinity for the 
active tubular transport mechanism (22,23). It has been shown that 
the N.-acetyl group binds to the active site of the tubular 
secretion mechanism (22). 
When N.-trideuteroacetylsulfamerazine and N.-acetylsulfamerazine are 
excreted simultaneously by the active tubular transport mechanism, 
the renal clearance of N.-acetylsulfamerazine is reduced from the 
normal value of 30-40 ml/min to 6 ml/min (based on total plasma 
concentrations). This inhibition of the renal clearance of N.-
acetylsulfamerazine by the deuterated compound may be due to a 
higher binding affinity and/or a much higher concentration at the 
binding site. 
When an eguimolar mixture of deuterated and protonated N.-
acetylsulf amerazine are simultaneously presented to the active 
transport mechanism, the deuterated compound elicits a 
higher(normal) renal clearance of 34.95 + Θ.55 ml/min, than the non-
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deuterated analogue, 23.51± 6.19 ml/min,(ρ<0.05). 
The renal clearance of N.-acetylsulfamerazlne in the final 
elimination process, where it is present as metabolite of both 
compounds, is 13.27 +3.17 ml/min, which is significantly lower 
(p < 0.0025) than the renal clearance of the parent drug N^-acetyl-
sulfamerazine (23.51 +6.19 ml/min; table 5). 
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S I G N I F I C A N C E O F A P P A R E N T H A L F - L I V E S O F A M E T A B O L I T E 
W I T H A H I G H E R E L I M I N A T I O N R A T E Appendix ι 5 
T H A N I T S P A R E N T D R U G 
by Tom B. Vree, Chiel A. Hekster, and Eppo van der Kleijn 
MANY BiocENOus SUBSTANCES and drugs exerting 
physiological and pharmacological effects are con­
verted into metabolites with almost identical effects 
or into substances without any pharmacological ac­
tivity. The plasma concentration time curve of a 
metabolite can be described by an equation of at least 
two e-functions: that of the formation (k,,,) and that 
of the elimination (k,,). 
The plasma concentration time equation of the 
metabolite may read: 
(:,„, = constant· ( А ' е - к » , 1 - В ' е · -к..|М) Eq. 1 
where C,„, is plasma concentration of the metabolite 
of a drug at time t, following the administration of the 
parent drug at time t = 0; A and В are constants; k
n
, is 
rate constant of metabolism (acetylation or glucuroni-
dation); and k,. is rate constant of elimination. (This 
may consist of the rate constant of metabolism [k,,,] 
and the renal excretion [k
r
].) 
If the elimination rate of the metabolite is faster 
than the rate of formation, then the term of the elimi­
nation diminishes faster than the term of the forma­
tion. Consequently, the rate of formation becomes 
the rate-limiting factor. This statement is valid in all 
situations in which one particular metabolic reaction, 
parent drug—»metabolite, is considered, independently 
of many parallel pathways of elimination. Thus, when 
the intrinsic elimination of the metabolite is faster than 
that of the parent compound, the plasma concentration 
time curves of both compounds must run parallel.1 
This behavior is seen with sulfonamide drugs and 
their Ν,-acetylsulfonamide metabolites as well as with 
many other compounds undergoing glucuronidation. 
To determine the intrinsic rate of elimination of the 
TOM B. VREE, Ph.D., is Head, Laboratory of Clinical 
Pharmacokinetics; CHIEL A. HEKSTER, Pharm.D., is 
Head, Section of Ward Service; and EPPO VAN DER 
KLFI.IN, Ph.D., Pharm.D., is Head, Department of 
Clinical Pharmacy, all at the Sint Radboud Hospital, 
University of Nijmegen, Nijmegen, The Netherlands. 
126 
metabolite, this compound must be administered as 
a parent compound, preferably by intravenous admin­
istration.2 For example, it has been shown that N,-
acetylsulfamethoxazole as a metabolite of sulfameth­
oxazole elicits a half-life of 9 to 11 hours, similar to 
that of the parent compound; but as a parent com­
pound it shows a half-life of 3 hours.9 * In general, 
conjugates exert a higher rate of elimination than 
their parent compounds. 
A special situation may exist when the metabolite 
formed is metabolized back into the parent compound: 
parent compound •»- : metabolite 
This equilibrium is a result of the metabolic trans­
formation of one or more enzymes. When a one-way 
reaction is assumed, it appears that the half-life of the 
metabolite will be similar to that of the parent com­
pound, when the metabolite's intrinsic half-life is 
much shorter. 
The question arises whether the plasma concentra­
tion time curves of a parent drug and its metabolite 
still run parallel when both drugs are involved in a 
metabolic equilibrium, but with a still greater overall 
elimination rate of the metabolite. Two metabolic 
reactions that show equilibria are, for example, acety­
lation"' and glucuronidation.' For N^acetylsulfona-
mides, two phases (a, /?) in the plasma concentration 
lime curve have been reported.7 In the case of the 
benzodiazepine glucuronides, oxazepam glucuronide 
and 3-hydroxydiazepam glucuronide, it has been re­
ported that the half-life varies from 3 to 60 hours." 
A second question that arises is whether the ap­
parent variability in the half-lives of, for instance, 
oxazepam and 3-hydroxydiazepam has any clinical 
significance. Nj-acetylsulfonamides can be synthesized 
relatively easily and may act as model compounds for 
the investigation of this problem. However, the syn­
thesis of glucuronides, especially of benzodiazepine 
glucuronides, is much more difficult, if not impossible. 
Reprinted with permission. Copyright 1982 
Drug Intelligence & CUnicaL Pharmacy, Inc. 
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The shape of the plasma concentration time curves 
and corresponding half-lives of benzodiazepine glu-
curonides are comparable to those of N^-acetylsul-
fonamides. So the problem of the significance of the 
apparent and variable half-lives of a relatively fast 
metabolite in the special circumstance of a metabolic 
equilibrium of benzodiazepine glucuronide can be 
studied and explained with the model of Ν,-acetyl-
sulfonamides. 
Nt-Acetykulfonamides 
Figure 1 shows the plasma concentration time and 
renal excretion rate time curves of Nj-acetylsulfa-
methoxazole as a parent compound.4 The short half-
life (3 h) of the compound is clear. No deacetylation 
and no sulfamethoxazole can be detected. 
Figure 2 shows the elimination of Nj-acetylsulfa-
methoxazole as a metabolite of sulfamethoxazole. The 
half-life of each sulfonamide is now 11 hours. With 
different N^-acetylsulfonamides that have been admin­
istered to man as parent compounds, the plasma con­
centration time curve in the final stage of the elimina­
tion was less steep.7 This leveling off of the curve 
results in a much longer half-life. 
Because the plasma concentration of the N4-acetyl-
sulfonamides in the final part of the elimination was 
just above the sensitivity limit of high pressure liquid 
chromatography (HPLC) analysis, no absolute proof 
existed of the occurrence of the biphasic character of 
the elimination curve. N^-acetylsulfadoxine and N«· 
acetylsulfamerazine show the two phases of elimina­
tion curve distinctly, and the plasma concentration 
measured in the final elimination stage of the curve is 
well above the sensitivity limit of the HPLC analysis.7 
Social drugs such as caffeine and nicotine and their 
metabolites do not interfere with the analysis. 
Figure 3 shows the elimination pattern of Nj-acetyl-
sulfamerazine. The compound is metabolized into 
Drug Intelligence and Clinical Pharmacy VOL 16 FEB 82 127 
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sulfamerazinc. N4-acetylsu]famerazine first shows an a 
phase (і г = 5 h ) and ends with a β phase (tVi = 2 3 h ) 
similar to that of its metabolite sulfamerazine. Sulfa-
merazine itself elicits a half-life of 20 to 23 hours. 
Dcacetylation has been known since 1940, but the 
ability to analyze processes and curves was not optimal 
at that time." Deacetylation results in the formation of 
sulfamerazine, which again becomes acetylated into 
Nj-acetylsulfamerazine as soon as it is formed. 
When one considers a particular metabolic equilib­
rium, the result is the following series of metabolic 
oscillations: 
N48' 
N^S'+N.S'-' + N ^ ' + N^S' '^ 
Μα ΟΔβ 
— 5 1 + 52 + 5я + 8п 
ν ' 
tVi/S 
The parent compound (N45') changes, as time and 
the number of metabolic oscillations proceed, from 
pure parent compound into a composition of original 
parent compound and metabolites with similar molec­
ular structures, or into parent compound of the first, 
second, third, and nth generation; the term apparent 
parent compound may be used. Thus, the term par­
ent compound is used for each drug molecule that has 
been administered. 
Given the occurrence of the metabolic oscillations, 
it is incorrect to state that X percent of the ingested 
dose is excreted unchanged as parent compound and 
Y percent as the metabolite. It may be better to state 
that X percent is excreted in a molecular structure 
similar to that of the compound that has been in­
gested, parent + apparent parent, and Y percent as 
metabolites of one particular, defined molecular struc­
ture. The metabolic oscillations imply that the per­
centage of parent compound of the total concentration 
of parent and apparent parent compounds decreases 
and finally disappears. The metabolite regenerates 
the parent compound of the second and nth genera­
tions, and so on (apparent parent compounds). The 
total generation of metabolites (Ist-nth) governs the 
pharmacokinetics of the apparent parent compound, 
and a second phase in the plasma concentration time 
curve will appear as time proceeds. 
It may be stated that the slowest compound governs 
the pharmacokinetic behavior of the fastest compound, 
even when parent compound and metabolite are part 
of a metabolic equilibrium. 
The position of the equilibrium of acetylation and 
deacetylation and the sensitivity of the analytical pro-
Figure Э. Pliinu concentration uid renal excretion rate time proflies 
of N,-acctylsiilfamcr«zljie (N 4 ) and lu metabolite luiraincrazlne (S) 
In a volunteer after an oral dose of Ni-Bcetylsuirameraxlne 468 mg. ТЪе 
ttt of N,.acetylsulfamera2lnc Is 3 h, but Increases to 23 h because of 
the acetylation of the metabolite sulfamerazine with Its Intrinsic tVi of 
23 b.s 
cedure determine whether one is able to demonstrate 
and measure these processes. An example to illustrate 
this statement is shown in Figure 4. Ν,-acetylsulfa-
methoxazole in healthy volunteers is excreted very 
rapidly (Figure 1). Sulfamethoxazole, as the result of 
deacetylation, cannot be detected. When sulfameth­
oxazole is administered to treat an infection in a pa­
tient with severely impaired kidney function, it will 
be acetylated at the normal rate, characterized by the 
half-life of 10 to 12 hours.10 l l The metabolite N4-
acetylsulfamethoxazole is eliminated predominantly by 
renal excretion; but in this patient, renal excretion is 
drastically reduced, as expressed by the creatinine 
clearance of S ml/min. 
Deacetylation of Nj-acetylsulfamethoxazole is a 
process that always takes place as part of the equilib­
rium. With poor kidney function and the resultant 
high plasma concentration of the metabolite Nj-acetyl-
sulfamethoxazole, deacetylation becomes visible. The 
amount of sulfamethoxazole formed from the metab-
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Figure 4 Plasma concentration and renal excretion rate time profile of 
sulfamethoxazole <S) and Its metabolite N(-acetylsuiramctlioxazoIe (N,) 
In a patient with poor kidney function (creatinine clearance S ml/min) 
after being treated for two weeks with co-tnmoxazole 1200/240 mg tld. 
Sulfamethoxazole shows a ttt of 12 h after the administration of the 
last dose, mainly due to acelylalion The metabolite N
r
acetylsulfameth-
oxazole is excreted very slowly and the process of deacetylalion becomes 
visible, changing the I'/i of sulfamethoxazole from 12 h to 40 h, 
identical to the tl4 of N4-BCetylsulfamclhoxazole * 
Figure 5. Plasma concentration and renal excretion rate time profiles of 
Э-hydroxydiazepam (oxydiazepam. temazepam) and its metabolites 
3 hydroxydiazcpam glucuronlde, oxazepam and oxazepam glucuronide in 
a volunteer after an oral dose of J-hydroxydiazcpam JS mg 3-Hydroxy-
diazepam shows a Vá of Э h initially, which becomes identical to the 
l b of 3-hydroxydiazepam glucuronide, due to the process of deglucuro-
nldatlon m the final part of the elimination process l t 
olite N4-acety]sulfamethoxazole visibly influences the 
concentration of the amount of sulfamethoxazole orig­
inally administered to this patient. Furthermore, N 1-
acetylsulfamethoxazole, with a half-life of 40 hours, 
now governs the final elimination of sulfamethoxazole 
itself, with the accompanying half-life of 40 hours 
instead of the normal half-life of 10 to 12 hours, 
which is shown in the first part of the elimination." 
Sometimes special circumstances are required to 
recognize and prove existing processes and equilibria. 
After this exercise with the sulfonamides, one can 
describe and explain the equilibrium between glu-
curonidation and deglucuronidation of benzodiazepine 
glucuronides. 
GIucuronidation-Deglucuronidation 
Drug glucuronides become deglucuronidated by 
plasma and liver /8-deglucuronidase activity.' Glu­
curonides and Nj-acetylsulfonamides are excreted 
mainly in the urine, and they are almost totally de­
pendent on this excretion mechanism for their elimi­
nation. Glucuronides of compounds with a higher 
molecular weight may be partly excreted by the bile, 
deglucuronidated in the gut lumen, and reabsorbed 
again. Deglucuronidation, however, cannot be proven 
easily. For example, as stated before, benzodiazepine 
glucuronides cannot yet be synthesized. To overcome 
the problem of synthesis, it has been shown recently 
that oxazepam glucuronides can be separated and 
purified by means of ion exchange chromatography.12 
The shape of the plasma concentration time curve of, 
for example, oxazepam, 3-hydroxydiazepam, and 
lorazepam makes it possible to describe the processes 
that take place as being analogous to those of sulfona­
mides. 
In the literature, the reported half-life of oxazepam 
ranges from 3 to 60 hours; that of 3-hydroxydiazepam 
ranges from 3 to 30 hours.1·1 This variability in half-
life cannot be understood easily. It may be deter­
mined erroneously, or the measurement may have 
Drug InleUigence and Clinical Pharmacy VOL 16 FEB 82 
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been correct, but different phases of the elimination 
are described, or an apparent half-life is obtained. 
Consider 3-hydroxydiazepam (oxydiazepam, temaze-
pam), which is metabolized predominantly by glucuro-
nidation and only S percent into oxazepam.1'1 Glu-
curonidation is the main process during the first five 
hours after administration of 3-hydroxyd'iazepam, re-
sulting in a half-life of three hours (Figure 5) . Formed 
3-hydroxydiazepam glucuronide is eliminated mainly 
by renal excretion but is, in part, also deglucuronidated 
into 3-hydroxydiazepam of the second generation 
(apparent parent compound). In this case, metabolic 
oscillations also occur. At a given moment, the 
amount of 3-hydroxydiazepam reformed becomes sim-
ilar to or greater than the remaining amount of origin-
ally administered dose of 3-hydroxydiazepam, and the 
3-hydroxydiazepam plasma concentration time curve 
will adopt the half-life of 3-hydroxydiazepam glucuro-
nide, which is ten hours. The two phases in the plasma 
concentration time curve of free 3-hydroxydiazepam 
are not caused by a pharmacokinetic two-compartment 
model, but by the metabolic equilibrium between glu-
curonidation and deglucuronidation. The same proc-
esses are observed for oxazepam and lorazepam.14 
Figure 6 shows the elimination of oxazepam after a 
steady-state level of diazepam, which is replaced by 
clorazepate in the treatment of tetanus in a patient. 
Desmethyldiazepam, as a metabolite of diazepam and 
clorazepate and with a half-life of 40 to 60 hours, 
determines the half-life of oxazepam, while the rate 
of glucuronidation and renal excretion of oxazepam 
glucuronide determines the steady-state concentration. 
In Figure 7, the elimination of diazepam and its 
metabolites, 3-hydroxydiazepam, with its intrinsic 
half-life of three hours, and 3-hydroxydiazepam glu-
curonide, with its intrinsic half-life of ten hours, is 
shown. Both metabolites adopt the half-life time of 
diazepam, 31 hours (in the same patient as shown in 
Figure 6) . 
Two metabolic pathways and the relative rate con-
stants are given in the following schemes. 
faner 
diazepam -
•low 
renal eacretion 
I 
dlazepun -
- ^-hydroxydiuepam^^^^^^l-hydroKydlazepam 
glucuronide 
I 
renal excretion renal excretion 
I \ 
•low fast 
renal 
excretion 
\ 
-N-desmethyl--
diazepam 
renal 
excretion 
I 
renal 
excretion 
\ 
•low 
oxazepam 
glucuronide 
renal 
excretion 
Preliminary results of the calculation of the absolute 
rate constants of acetylation and deacetylation of sul-
fonamide with the NON-LIN program will be pub-
lished elsewhere.15·10 
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Figure 6 Plasma concentration lime profiles of desmethyldiazepam and oxazepam, and renal excretion rate time profile of desmethyldiazepam In a 
palieni treated for teianus with diazepam, which wai later changed to clorazepate (300 mg/24 h. Infusion) After stopping the clorazepate Infusion, 
desmethyldiazepam and its metabolite oxazepam show similar half-lives of 50 h, while the intrinsic tli of oxazepam is 1 and 10 h 
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both adopt the t1? of diazepam, which is 31 h in this patient. 
Practical Consequences 
Impaired Kidney Function. The formation of the 
parent compound from the metabolite may increase 
the half-life of the parent compound in patients with 
extremely impaired kidney function. This increase in 
half-life is not caused by inhibition of the renal excre­
tion of the compound itself, but results from the fact 
that the metabolite cannot be excreted. The inhibition 
of the renal excretion of the metabolite may shift the 
metabolic equilibrium. Knowledge of the occurrence 
of these processes is important for compounds that are, 
for instance, acetylated or glucuronidated and show a 
metabolic equilibrium. 
Formulary Choice. Recently, it has been recog­
nized that benzodiazepines with short half-lives are 
preferred to benzodiazepines with long half-lives for 
the short-term treatment of fear and stress situations, 
thus preventing cumulation of the drug in plasma, re­
sulting in drug dependency. The knowledge of the 
apparent half-lives of the benzodiazepines is impor­
tant. The metabolites of diazepam, oxazepam, and 
3-hydroxydiazepam, with their short intrinsic half-lives 
of three and ten hours, are presented in many tables 
and reviews as the most suitable benzodiazepines for 
short-term treatment. 
As long as oxazepam is administered as the parent 
drug, these half-lives are correct, except when oxaze­
pam acts as the final metabolite of diazepam, chlor-
diazepoxidc, camazepam, clorazepate, medazepam, or 
prazepam in the body. In these cases, the half-life of 
oxazepam is governed by the slow metabolic precursor 
desmcthyldiazepam and then becomes 40 (o 60 hours. 
The conclusion that oxazepam will be present in mi­
nute concentrations as the result of its short intrinsic 
half-life is not justified (Figure 6). Furthermore, it 
may be said that oxazepam has many apparent states 
of appearance, with accompanying half-lives, depend­
ing on its pharmaceutical formulation or pro-drug. It 
is necessary to define the apparent state of oxazepam 
in the body when referring to the half-life of oxaze­
pam.^ 
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Renal Excretion of Sulphamethoxazole and Its 
Metabolite A^-Acetylsulphamethoxazole in Patients 
with Impaired Kidney Function 
*T. B. Vree, *Y. A. Hekster, *J. E. Damsma, tR. van Dalen, 
XÌ. С. M. Hafkenscheid, and §W. T. Friesen 
'Department of Clinical Pharmacy, ^ Intensive Care Unit, and tLaboratoty of Clinical Chemistry, 
Department of Internal Medicine, Sml Radboud Hospital, University of Nymegen, Nymegen, The 
Netherlands; and iSchool of Pharmacy, University of Tasmania, Hobart, Australia 
Summary: Plasma and unne concentrations of creatinine, sulphamethoxazole 
and its metabolite N4-acetylsulphainethoxazole were measured in patients with 
varying degrees of kidney impairment. The plasma elimination half-life of 
sulphamethoxazole is not influenced by the kidney function, while the half-life 
of the metabolite is fully dependent on the kidney function. The renal clear­
ances of the metabolite and that of the parent compound under alkaline unne 
conditions are linearly related to the creatinine clearance Kidney impairment 
affects only the renal clearance of the metabolite, whereas sulphamethoxazole 
is metabolized (acetylated) independently of kidney function. Key Words: 
Kidney impairment — Pharmacokinetics — Sulphamethoxazole — iV,-
Acetylsulphamethoxazole — Renal clearance — Creatinine — Acetylabon. 
The two pathways of elimination of sulphon-
amides from the human body are metabolism by 
acetylation and renal excretion (1). The presence 
of acetyl-coenzyme A and N-acetyltransferase in 
the reaction sequence (2,3) makes acetylation a 
vital condition for life, and it has been shown that 
the overall reaction of acetylation of a sul-
phonamide is the same in patients with terminal 
renal function as in healthy volunteers (4). It has 
been shown earlier that the renal clearance of sul­
phamethoxazole is small (0.5-5 ml/min) and, more­
over, dependent on unne pH and urine flow (5). As 
a consequence, the main route of elimination of 
sulphamethoxazole is metabolism, predominantly 
by acetylation. The metabolite JV4-acetylsulpha-
Address correspondence and rtpnnt requests to Dr Vree at 
Department of Clinical Pharmacy, Suit Radboud Hospital, Uru-
vemty of Numcgen, Geert Grooteplein Zuid 10, Nymegen, The 
Netherlands 
methoxazole is eliminated predominantly by renal 
excretion, and its renal clearance is much larger 
than that of sulphamethoxazole itself (40-60 ml/ 
min) (5,6). 
In general, kidney function is quantitated by the 
glomerular filtration rate, expressed as creatinine 
clearance, a substitute of inulin clearance. In kidney 
impairment, entire nephrons may be deteriorating 
(7), but the ratio between the maximal excreting 
capacities of the glomeruli and tubuli remains con­
stant (8). The fixed ratio between the two mecha­
nisms of excretion allows only one mechanism (i.e., 
glomerular filtration) to be used as a quantitative 
measure of kidney function. 
The objective of this study is to investigate the 
influence of kidney impairment on the renal clear­
ance and pharmacokinetics of sulphamethoxazole 
and its metabolite №4-acetylsulphainethoxazole, as 
well as the relationships between the renal clear-
¡29 
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anees of sulphamethoxazole and its metabolite and 
the renal clearance of creatinine. 
It will be shown that impaired kidney function 
affects mainly the renal clearance of the metabolite 
and to a much smaller extent that of the parent 
compound. 
MATERIALS AND METHODS 
Drug Analysis 
The sulphonamides in plasma and urine were 
measured by means of high pressure liquid chro­
matography as described earlier (5,6). 
Creatinine concentrations in plasma and urine 
were measured by an automated Jaffé method. No 
interference of sulphonamides with this method was 
observed. 
Subjects 
Thirteen Caucasian patients from the intensive 
care unit (ICU) were treated for bacterial infection 
with co-trimoxazole (dose, 400-1,200 mg of sul-
phamethoxazole twice daily). 
Sampling Procedures 
Plasma samples were taken every 3 hr by an 
intra-arterial catheter (as part of treatment in the 
ICU) during steady state and during the final elimi-
nation phase of sulphamethoxazole after discon-
tinuation of medication. The time period of sam-
pling varied between 40 and 120 hr. 
Urine samples were collected every 3 hr by 
means of an indwelling bladder catheter. Urine vol-
ume and urine pH were measured upon receipt 
of the urine sample (Copenhagen-Radiometer 
PMH61). 
Calculations 
Renal clearance (Kr) was calculated from the 
average renal excretion rate in each urine sample 
divided by the mean plasma concentration during 
the measured time interval. The renal clearance 
(ml/mm) was calculated for each pair of urine sam-
ple and corresponding plasma sample. The renal 
clearance data of the patients were averaged (± SD) 
over the time periods wherein one of the following 
urinary excretion parameters was constant: creat-
inine clearance, urine pH, or urine flow. 
Ibtrapeutic Drug Momtonng. Vol. 3, No. 2,1911 
Statistics 
Regression lines and correlation coefficients were 
calculated according to standard procedures with a 
Hewlett-Packard 9810 calculator. 
RESULTS 
Figure 1 shows the pharmacokinetic profiles of 
sulphamethoxazole and N4-acetylsulphamethox-
azole in a patient with severely impaired kidney 
function (average creatinine clearance, 1.8 ml/min) 
in a post-steady-state period after being treated with 
400 mg sulphamethoxazole (co-trimoxazole) twice 
daily for 5 days. 
Sulphamethoxazole has a half-life of 11 hr, 
whereas the plasma concentration of the metabolite 
hardly declines over a time period of 60 hr. The 
renal excretion rate of sulphamethoxazole is about 
10 times higher than that of the metabolite. 
Figure 2 shows the pharmacokinetic profile of 
sulphamethoxazole and Λ/,-acetylsulphamethox-
azole in a patient with severely impaired kidney 
function (average creatinine clearance, 5 ml/min) 
in a post-steady-state situation after being treated 
for 2 weeks with 1,200 mg sulphamethoxazole 
(co-trimoxazole) three times a day. 
Sulphamethoxazole in this patient showed a 
half-life of elimination of 12 hr after the medication 
was stopped; but at about 50 hr later, the Ti of 
elimination changed to 40 hr. The metabolite Nt-
acetylsulphamethoxazole showed a half-life of 
elimination of 40 hr throughout the entire sampling 
period. The renal excretion rates of both com­
pounds started relatively high; but in the time 
course of the post-steady-state situation, they 
gradually decreased with decreasing urine produc­
tion, until after 80 hr almost complete anuria had 
developed. Each urine sample and its correspond­
ing plasma sample were used to calculate the renal 
clearance values of sulphamethoxazole, N4-acetyl-
sulphamethoxazole, and creatinine, and these are 
plotted versus each other in Fig. 3. It is clear that 
the renal clearance of sulphamethoxazole is not de­
pendent on the creatinine clearance (Fig. 3L); the 
renal clearance of the metabolite N4-acetylsulpha-
methoxazole, however, is dependent on the creati­
nine clearance (r = 0.921). The urine pH of the 
patient in Figs. 2 and 3 was strongly acidic through­
out the period of the measurement (5.51 ± 0.07). 
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FIG. 1. Plasma concentration- and renal excre­
tion rate-time profiles of sulphamethoxazole (S) 
and its metabolite A^-acetylsulphamethoxazolc 
(Λ/,) in a panent with severely unpaired kidney 
function (average creatinine clearance, Ι В ml/min) 
in a post-steady-state period after being treated 
with 400 mg sulphamethoxazole (co-tnmoxazole) 
twice daily for 5 days. The Г, of elimination (=» 
acetylation) of sulphamethoxazole is the same as in 
healthy volunteers (4.3,8). The plasma concentra­
tion of the metabolite hardly declines due to its 
continuous formation and the severely impaired 
renal excretion 
This particular relationship between the renal 
clearance of both parent compound and metabolite 
with creatinine was found in all 13 patients and is 
shown in Fig. 4. The average renal clearance values 
of sulphonamides and creatinine, obtained over 
sampling periods over which urine pH is constant 
are plotted in Fig. 4 and summarized in Table 1. 
Figure 4L shows that the renal clearance of the 
metabolite A^-acetylsulphamethoxazole is linearly 
related to the creatinine clearance (r = 0.94), irre­
spective of urine pH or flow. The renal clearance of 
Ñ4-acetylsiilphamethoxazole (NAcS) is 0.54 times 
that of creatinine (Cr) according to the follow-
ing equation: 
*гЛАс8 = 0.543 K
r
.
a
 - 4.501 (r = 0.939). 
When the renal clearance of sulphamethoxazole is 
plotted versus that of creatinine, two situations 
can be distinguished (Fig. 4R). It can be seen that 
with acidic urine (pH 5.26 ± 0.45), there is no re­
lationship between the clearances of the two com­
pounds (r = 0.039); however, with alkaline urine 
(pH 7.13 ± 0.61), the relationship is apparent (r = 
0.48). 
The renal clearance of sulphamethoxazole (S) 
under alkaline urine conditions is still low and only 
0.036 times the renal clearance of creatinine, ac­
cording to the equation: 
К
г
л = 0.036 K
r-Cr + 0.959 (r = 0.478). 
DISCUSSION 
Acetylation 
Sulphamethoxazole is still metabolized in pa­
tients with severely impaired kidney functions. 
Rieder et al. (4) examined the Г, of elimination of 
sulphamethoxazole in 37 patients with varying 
creatinine clearances (122-0 ml/min). The average 
Г( for the drug in these patients was 11.1 ± 5.1 
hr, with an average total clearance of 20.1 ± 8.2 
ml/min. From this value, only 1-5 ml/min accounts 
for renal clearance (ref. 5, and Fig. 4R). Baethke et 
TKrrapeutlc Drug Monilortag. Vol. 3, No. 2,19S1 
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FIG. 2. Plasma сопселігаіюп- and renal excretion 
rate-üme profiles of sulphamethoxazole (S) and its 
metabolite N.-acctylsulphamethoxazole (NJ in a pa-
tient with severely impaired kidney function (average 
creatinine clearance, 5 ml/mm) in a post-steady-state 
situation after being treated with 1,200 mg sul-
phamethoxazole (co-tnmoxazole) three times a day for 
2 weeks Sulphamethoxazole is eliminated (metabo-
lized) initially with a half life of 12 hr, which is compa-
rable to the T, of sulphamethoxazole in healthy volun-
teers (4,5,8), out SO hr after stopping medication, the 
7", of sulphamethoxazole changes to 40 hr and be-
comes similar to that of A/4-acetylsulphamethoxazole 
The rate of deacctylation of the metabolite ultimately 
governs the elimination of sulphamethoxazole 
renal clearance(ml/min) 
20 sulphamethoxazole 
15. 
Мд- acetyl sulphamethoxazole 
15. r . 0 1 7 5 
- 1 — 
10 
— I 
15 
. / y.0279x-0128 
1 ^ 
10 
- 1 -
15 
creatinine clearance ( m l / m m ) 
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FIG. 3. Left: The renal clearance (ml/rmn) 
of sulphamethoxazole plotted versus the 
corresponding renal clearance values of 
creaumne The values are obtained from the 
patient shown m Fig 2 The renal clearance 
of sulphamethoxazole under circumstances 
of metabolic acidosis is not linearly related 
to the creatinine clearance (r = 0 175) 
Right: The renal clearance (ml/mm) of 
the metabolite Ni-acetylsulphamethoxazole 
plotted versus the corresponding renal 
clearance values of Creatinine The renal 
clearance of N4-acetylsulphamethoxazole is 
linearly related to the creaumne clearance (r 
= 0 921) 
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Кг N¿-acetylsulptameth<Mazole-
eOtnl/min 
Kr sulphamethoxazoli 
Bml/min 
сгеоііпіпе clearance ml/mm 
ПС. 4. Left· Th« renal clearance values of the melabolite N.-acetylsulphamethoxazole plotted venus the conesponduig creabmne 
clearance values Both clearances are linearly related (r - 0 94) Variation in the unne pH has no influence on this relationship (see 
Table I) Right: The renal clearance values of sulphamethoxazole, calculated from patients with acidic or alkaline unne pH plotted 
versus the renal clearance of creatinine Under acidic unne conditions, sulphamethoxazole is almost completely reabsorbed, resulting in 
low (and constant) renal clearance values There is no relationship with the creatinine clearance (r - 0 039) Under alkaline unne 
conditions, tubular reabsorption is minimal, and glomenjlar filtration is the predomniant process, resulting in a better correlation (r ~ 
0 48) with the renal clearance of creatinine 
TABLE 1. Renal clearance values of sulphamethoxazole Sfacetyhulphamethoiazole and Creatinine и patients with normal and 
impaired kidney function during treatment with co-tnmoxazole 
Subject 
Creatinine clearance 
(ml/nun) 
122 7 
103 1 
984 
946 
M l 
83 5 
780 
73 1 
62 3 
59 0 
53 1 
512 
42 5 
37 6 
37 4 
10 0 
3 35 
230 
100 
086 
050 
± 2 6 5 
•35 4 
± 860 
± 3 4 3 
± 3 2 0 
± 1 9 2 
± 3 2 7 
± 1 7 4 
± 1 4 8 
± 1 7 0 
± 726 
± 7 27 
± 7 26 
± 904 
± 946 
± 2 55 
± 131 
± 0 91 
± 0 65 
± 0 61 
± 0 47 
*гл 
(ml/nun) 
4 7 7 ± 3 9 8 
5 88 ± 1 24 
0 74 ± 0 30 
6 79 ± 3 14 
0 30 ± 0 12 
2 19 ± 2 05 
0 79 ± 0 51 
2 05 ± 0 63 
4 28 ± 2 08 
4 60 ± 2 27 
1 56 ± 0 71 
1 96 ± 1 45 
3 92 ± 2 22 
— 
— 
0 50 ± 0 2 0 
0 50 ± 0 19 
1 16 ± 0 46 
0 35 ± 0 28 
0 58 ± 0 38 
1 16 ± 0 94 
К rJtAeS 
(ml/nun) 
67 3 
563 
16 9 
684 
292 
469 
365 
278 
19 1 
215 
16 3 
254 
19 9 
14 2 
5 91 
277 
0 73 
0 17 
002 
0 18 
0 18 
± 2 0 3 
± 5 14 
± 5 82 
± 1 3 9 
± 7 35 
± 2 2 1 
±18 7 
± 8 28 
± 4 31 
± 1 2 5 
± 300 
± 890 
± 326 
± 382 
± 1 37 
± 0 71 
± 0 19 
± 007 
± 0 01 
± 0 14 
± 0 14 
Unne pH 
6 76 ± 0 62 
7 31 ± 0 57 
5 06 ± 1 72 
β 59 ± 0 45 
5 02 ± 0 05 
6 16 ± 0 25 
5 05 ± 0 05 
7 16 ± 0 49 
7 65 ± 0 19 
728 ± 0 5 0 
7 13 ± 0 46 
7 34 ± 0 6 8 
6 76 ± 0 45 
5 34 ± 0 13 
5 22 ± 0 25 
551 ± 0 0 7 
581 ± 0 4 0 
451 ± 0 2 0 
4 55 ± 0 15 
5 83 ± 0 29 
6 50 χ 0 78 
Unne flow 
(ml/nun) 
1 93 ± 1 22 
179 ± 0 81 
1 11 ± 0 5 1 
173 ± 0 51 
1 12 ± 0 14 
0 97 ± 0 45 
2 60 ± 1 39 
193 ± 0 6 8 
1 62 ± 0 37 
0 62 ± 0 16 
2 60 ± 0 8 9 
0 90 ± 0 6 6 
2 15 ± 1 21 
1 62 ± 0 66 
1 50 ± 0 43 
0 46 ± 0 10 
0 31 ± 0 15 
0 12 ± 0 07 
0 13 ± 0 05 
0 19 ± 0 09 
0 09 ± 0 12 
Data shown are for 13 patients observed for 21 sampling periods of 15-40 hr in which one of the urinary parameters was constant 
Abbreviations Kr¿, renal clearance of sulphamethoxazole, Krj,ict, renal clearance of the metabolite Λί,-acetyliulphamethoxazolc The 
dash indicates that no measurement was taken 
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al. (8) found an average Ti of elimination of sul-
phamethoxazole of 12.6 ± 3.9 hr in a group of 22 
patients with creatinine clearances varying from 119 
to 11 ml/min. The Ti of elimination of sulpha-
methoxazole (11 and 12 hr) shown in Figs. 1 and 
2, respectively, confirms their data and demon­
strates that metabolism (acetylation) is not de­
pendent on the kidney function of the patient. 
Kidney function affects the renal excretion of the 
metabolite N4-acetylsuIphamethoxazole primarily 
and only secondarily affects the acetylation-
deacetylation equilibrium, presumably as shown in 
Fig. 2. Figure 2 shows the interesting phenomenon 
of similar 7") values (40 hr) of the metabolite and 
parent compound. This result may be explained by 
the assumption that AVacetylsulphamethoxazole is 
deacetylated to sulphamethoxazole (9). This phe­
nomenon is not seen in volunteers, since with nor­
mal kidney functions the renal clearance of N4-
acetylsulphamethoxazole is about 60 ml/min (6) and 
the fraction of N4-acetylsulphamethoxazole which 
is deacetylated to sulphamethoxazole is too small to 
contribute significantly to the total plasma concen­
tration of sulphamethoxazole. 
In the extreme situation of severely impaired kid­
ney function and strong reduction (10-fold) of the 
renal clearance of N4-acetylsulphamethoxazole, 
with resultant high plasma concentrations, it may be 
possible that the amount of sulphamethoxazole, de­
rived from deacetylation of the metabolite, contrib­
utes significantly to the original concentration of 
sulphamethoxazole. 
In volunteers, the rate of acetylation governs the 
plasma concentration-time curve of the parent 
compound. In the patient with extremely poor kid­
ney function and metabolic acidosis, the rate of 
deacetylation of the metabolite governs the final 
elimination of sulphamethoxazole. For the data 
shown in Fig. 2, the acetylation-deacetylation 
equilibrium of a sulphonamide becomes evident for 
sulphamethoxazole (9). The phenomenon of the 
acetylation equilibrium should have been visible 
in Fig. 1, but the plasma concentration of N,-
acetylsulphamethoxazole is much lower than that 
given in Fig. 2 and the time course of sampling was 
too short. 
Renal Clearance 
It can be deduced from Figs. 3L and 4R that sul­
phamethoxazole is excreted in the presence of se-
IheraptuUc Drug Monitoring, Vol. 3. No. 2. 1981 
verely impaired kidney function to a small extent 
(0.5 ml/min). The renal clearance of sulpha­
methoxazole is still dependent on the urine pH, 
as shown previously in volunteers (5). With con­
stant alkaline urine, the renal clearance of sul­
phamethoxazole is related to the creatinine clear­
ance because of the minimal reabsorption and re­
sulting predominance of glomerular filtration. With 
acidic urine, reabsorption of sulphamethoxazole is 
maximal, thus obscuring the partial contribution 
of the glomerular filtration of sulphamethoxazole. 
Λ/,-acetylsulphamethoxazole is excreted predomi­
nantly by active tubular secretion, since the renal 
clearance can be reduced under probenecid co-
medication from about 60 to 15 ml/min (10). 
Glomerular filtration and tubular reabsorption of 
/Yj-acetylsulphamethoxazole are minor processes. 
When plotting the renal clearance of N4-
acetylsulphamethoxazole versus the renal clearance 
of creatinine, two distinct mechanisms are repre­
sented in Fig. 4 (e.g., clearance of A^-acetyl-
sulphamethoxazote = active tubular secretion and 
creatinine = glomerular filtration). The ratio between 
the tubular secretion of /V4-acetylsulphamethox-
azole and glomerular filtration of creatinine is 0.54. 
This ratio is different from the ratio of PAH/inulin 
(= 5.19) and the ratio of PAH/creatinine ( = 
4.76) (8). The PAH/inulin ratio expresses the ratio 
between maximal tubular secretion and maximal 
glomerular filtration. The different ratio of N4-
acetylsulphamethoxazole and creatinine may be 
explained by differences in the affinity of the com­
pound for the transport mechanism. 
, CLINICAL IMPLICATIONS 
When patients with impaired kidney function are 
treated with sulphamethoxazole, the rate of me­
tabolism of the parent compound is not affected, 
but the renal clearance of the metabolite N4-
acetylsulphamethoxazole is severely reduced. Im­
paired excretion capacity of the metabolite may re­
sult in accumulation of the compound in plasma and 
may give rise to crystallisation of the metabolite in 
the nephrons at the site of the transport mechanism 
(11). Therefore, it would be safer for the patient if 
an effective sulphonamide derivative, one which is 
only slightly acetylated, if at all, and which has a 
short Ti of elimination, is chosen since the /V4-
acetylsulphamethoxazole itself (or N4-acetylsulph-
onamide derivatives in general) has no anti-
250 
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bacterial effect Thus, when using a sulphonamide 
to treat infections in patients with impaired kid­
ney functions, a change to a derivative of this class 
of drug (one which has the above-mentioned 
properties, and which is equieffective against the 
pathogen) seems to be more appropnate for the pa­
tient than an adjustment of the dosage regimen 
of sulphamethoxazole, since its elimination does 
not depend on the kidney function but only on the 
rate of acetylation. 
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SOME CONSEQUENCES OF DRUG CHOICE AND DOSAGE REGIMEN 
FOR PATIENTS WITH IMPAIRED KIDNEY FUNCTION 
by Tom B. Vree, Chiel A. Hekster, and Roelof van Dalen A p p e n d i x I 7 
ABSTRACT' The object of this article a to discuss difficulties in 
extrapolating the performances of a drug for which the kinetic 
parameters are derived in healthy volunteers, to patients with 
severely impaired kidney function The theoretical background of 
some actual or probable background is given, and a possible 
solution for these problems is offered, that is, choosing another 
drug from the same drug group 
In patients without kidney function, metabolism is the only 
pathway of elimination. When the elimination of the metabolite 
formed occurs by means of renal excretion only, this metabolite 
accumulates in patients with impaired or absent kidney function. 
When a metabolic pathway of the parent drug is part of a 
metabolic equilibrium, the metabolic return reaction results in an 
"apparent parent compound," with a half-life identical to that 
of the accumulated metabolite In this way, the concentration of 
the "apparent" parent compound increases and the half-life of 
the sum of parent and "apparent" parent drug will change 
Examples of this drug behavior are given for sulfamethoxazole, 
sulfametrole, sulfamethizole, procainamide, and 
N,-acctylprocamamide 
KEY WORDS: impaired kidney function, parent drugs; metabolites, 
drug choice, drug regimen 
IN DRUG THERAPY, three variables are important: drug 
selection, drug dose, and the dosage interval. The 
specific properties of the drug, such as its intrinsic activ­
ity and mechanisms of elimination from the body, 
define its dose and the dosage interval in an individual 
patient. 
When a particular drug has to be administered to a 
patient in whom a specific mechanism of drug elimina­
tion has deteriorated, partly or totally, as a result of 
a disease, one must understand the elimination pathways 
of this drug. This allows anticipation of the behavior 
of the drug in the actual condition of the patient and 
prevents side effects resulting from accumulation of the 
parent drug and, possibly, its metabolite(s). Adaptation 
of the dosage regimen administered to patients with im­
paired kidney function seems advisable.1"' Besides a 
reduction of dose and/or an increase in dosage inter­
val, the use of another drug is a third possibility for 
preventing overdosage in patients with, for instance, 
impaired kidney function. 
Using selected examples, this article describes a 
TOMB. VREE, Ph.D., and CHIEL A. HEKSTER, Pharm.D., 
are with the Department of Clinical Pharmacy; ROELOF 
VAN DALEN, M.D., is with the Department of Intensive 
Care, Sint Radboud Hospital, University of Nijmegen, 
Geert Grooteplein Zuid 10, Nijmegen, The Netherlands. 
number of mechanisms of drug elimination and the con­
sequences of changing the dosage regimen or choosing 
a drug from a class of compounds that are eliminated 
by the acetylation-deacetylation equilibrium and in 
which the renal excretion of the formed metabolite is 
governed by active tubular secretion. The object of this 
article is to describe difficulties in extrapolating the per­
formance of a drug that has been used only in patients 
with normal kidney function to patients with severely 
impaired kidney function. The theoretical background 
of some actual or probable problems is given and a 
possible solution for these problems is offered, that is, 
choosing another drug from the same drug group. If 
this is not feasible, another drug that has similar activ­
ity but whose elimination is not dependent on kidney 
function and whose formed metabolites do not exert 
serious side effects may be chosen. 
Pathways and Combination Pathways of 
Drug Elimination 
The elimination of a drug (Ay from the body may 
occur via mechanisms listed in Table 1. In all of these 
possible pathways of drug elimination, one pathway is 
not absolute, but usually one is relatively predominant 
over other pathways. From these various possibilities, 
the minor pathways have to be neglected temporarily 
while attention is focused on the major route of 
elimination. 
The sum of the metabolic rate constants (EATJ and 
the renal excretion rate constants (ΣΚ,) determines the 
total elimination rate constant (K
a
) and the total clear­
ance (CI) of each drug: K
a
 = ΣΚ„ + ΣΚ, and К, = 
"llMnmitar nhnuon "^ "tubul«i ястаюл — ^tubular гежЬипиюп· І п С Г а і С 
of elimination and the corresponding half-life of com­
pounds that are eliminated predominantly by renal 
excretion depend on kidney function and can be de­
scribed as follows: 
Леі 
which becomes: 
Л = Off3 when ΣΚ,>>ΣΚ„ Eq. 1 
Examples of drugs that are eliminated predominantly 
by renal excretion are the aminoglycosides and some /3-
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lactam antibiotics, such as ampicillin and amoxicillin.* 
In patients with renal failure, the contribution of renal 
clearance to total elimination may be reduced or may 
even disappear altogether, depending on the degree of 
kidney impairment.4"* 
Plasma Concentration of Drug 
Depending on therapy and the drug of choice, it may 
be necessary or desirable to achieve and maintain a 
steady-state plasma concentration (e.g., with sulfameth­
oxazole/trimethoprim). It is important for drugs such 
as sulfonamides and trimethoprim, which interfere in 
the folate metabolism of bacteria, to achieve a constant 
plasma concentration. Conversely, in other situations, 
it might be necessary to strive for peak and trough con­
centrations (e.g., with aminoglycosides). 
A constant plasma concentration of drug can be 
achieved via a continuous infusion or by intermittent 
intravenous and oral administration of the drug. By 
minimizing the variation in the steady-state condition 
(С„) with intermittent dosing, for instance, to allow a 
variation of 20 percent, the dosage interval can be de­
rived from Equation 2. (The percentage of allowed 
variation in the steady-state concentration depends on 
the judgment of the physician regarding the patient's 
well being, his response to the drug, and the occurrence 
of side effects. Here, the value of 20 percent is used as 
an example.) 
M = t™, + t(0l) ) Eq. 2 
where At is the dosage interval and t
ma
 (t 1 0 № = t, 0) is the 
time, in hours, between the administration of the drug 
and the attainment of the maximal plasma concentra­
tion . The value of !„,, is zero after an intravenous bolus 
injection and is variable after oral dosing, intramuscular 
dosing, or piggyback infusion (depending on the rate 
of infusion). Further, t«, represents the time period (h) 
at which the plasma concentration has been decreased 
by 20 percent (C,(Km)) from the maximal plasma concen­
tration, when the drug elimination follows one-compart­
ment pharmacokinetics, with linear elimination. The 
maximal plasma concentration is C,^ = Ct<iom,i = 
Ct(, 0 ) after an intravenous bolus injection. 
Where C,(o 8, = C1(1 m-e - ^ ·4ο ч> 
then ^•'"Ч = 0 . 8 = e-*«i"(08> Eq. 3 
Cm οι 
When/С = " ' Φ " and Equation Bare substituted in 
tVi 
Equation 2, the following equation is derived: 
ΔΙ - 1/3· tW + t„„ Eq. 4 
Similarly, it can be calculated that when 50 percent 
variation in the plasma concentration is allowed, at 
intermittent dosing, the dosage interval will be: 
at = 1/1 •tVi + t™,, Eq. 4a 
From Equation 4, it can be inferred that the dosage 
interval is linearly related to the elimination half-life of 
the drug, when a steady-state condition, with intermit­
tent dosing, must be achieved. 
For the steady-state plasma concentration, the follow­
ing equation can be derived: 
where C„ represents the steady-state plasma concentra­
tion, D the dosage, Vd the volume ofdistribution,^ the 
rate of elimination, at the dosage interval, and F the 
bioavailability. 
When К* = 0 6 P 3 is substituted in Equation 5, the 
t'/i 
equation of C„ becomes: 
c =
 1 . 4 4 . F . D . t ' 4 Eq. 6 
ν , . Δ Ι 
This means that the steady-state plasma concentration 
can be maintained (at a fixed value) only by increasing 
the dosage interval, ΔΙ, or by reducing the dose if the 
half-life increases due to impaired kidney function. 
From Equation 4, it becomes obvious that compounds 
with a short half-life of - 60 minutes are not suitable 
for achieving a steady-state plasma concentration via 
intravenous bolus injection, because ΔΙ will be very short 
(20 min). This situation necessitates a continuous 
infusion. 
With many antibiotics, it is difficult to attain a steady-
state plasma concentration. This is due, in part, to 
associated side effects (ototoxic and nephrotoxic) of the 
aminoglycosides, for example, when maintaining a high 
peak and/or trough level7'' and, in part, to the concept 
that the antibiotic must be present in high concentra­
tions only in the logarithmic growth phase of the 
pathogen, to keep the risk of resistance as low as 
possible.10 
In the presence of impaired kidney function, with 
resultant increased half-life of /Э-lactam antibiotics 
and/or aminoglycosides (t'/j for both groups increases 
up to 40 h"), a new steady-state plasma concentration 
can be attained with a longer time span, with higher and 
even toxic plasma concentrations, when the dosage is 
not adjusted. Suppose that the kidney function of a par­
ticular patient decreases considerably (i.e., the creatinine 
clearance diminishes from 120 to 20 ml/min). Using 
cefuroxime as an example, the renal clearance of the 
antibiotic declines, proportionately, from 500 to 75 
ml/min, while its half-life increases from 2 to 12 hours, 
assuming that the volume of distribution is not altered.9 
According to Equation 6, the steady-state plasma con­
centration is linearly related to the half-life, which may 
change gradually and continuously as kidney function 
deteriorates or improves. In general, a new steady state 
will be reached after a period that is five times the ac­
tual half-life (97 percent C„). In this situation, the 
variable half-life, as a consequence of reduced elimina-
Table 1. Some Pathways and 
Pathway Combinations of Drug Elimination 
Renal elimination (K
r
) only 
Metabolic elimination (A'
m
) only 
Metabolic and renal elimination of the parent drug (A'
m
 + K,) 
Metabolic elimination of the parent drug and renal elimination 
of the metabolite 
Metabolic and renal elimination of the parent drug and renal 
élimination of the metabolite 
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tion, should be taken into account. The measurement 
of a new apparent half-life is possible only when more 
samples, over a longer time, are taken and determined. 
Adjusting the dosage regimen on the basis of one 
measurement would be questionable, because in serious, 
life-threatening situations, patient status can change 
rapidly and dosage is usually instituted empirically." 
Examples 
Elimination by Metabolism Only. Drugs eliminated 
solely by metabolism are few. The metabolic degrada­
tion process results in carbon dioxide and water, and 
one of the formed metabolites may conjugate with 
glycine or glucuronic acid and, thus, be excreted by the 
kidneys. Theophylline, for example, disappears in the 
xanthine chain and is excreted - 5-15 percent unmetab-
olized.13 " Ethanol is oxidated into acetaldehyde, acetic 
acid, and, further, into carbon dioxide and water and 
only about 5 percent is excreted unchanged in the 
urine." 
Elimination by Metabolic and Renal Clearance. The 
ratio between the metabolic (Cl
m
, K
m
) and renal 
clearance (CI,, KT) of a drug determines the decrease in the 
total clearance of the parent compound when the renal 
clearance deteriorates in part or in total. (The two ex­
tremes of a 100-percent renal or 100-percent metabolic 
clearance have been discussed previously.) 
Elimination of the Parent Drug by Metabolic 
Clearance and the Metabolite by Renal Clearance. An 
example of this situation is a sulfonamide derivative that 
is metabolized by acetylation, and, subsequently, the 
metabolite is excreted by active tubular secretion or by 
a compound with a hydroxy! or carboxyl group (e.g., 
oxazepam, chloramphenicol) that can be glucuronidated 
and subsequently excreted by active tubular 
secretion.1417 Acetylation and glucuronidation are high 
capacity functions and do not depend on liver or kidney 
function; these reactions proceed until the moment of 
death. 
Ю0 ptasma cone ug/lri 
: rtnal ncr row ид/ят 
20 
1 ^ 
40 eoti 
Figure 1 РІаалш concemration and renal елсгепоп rale noie profiles оГ іиІГатсігок 
(S) and ils metabolite Ν,-acetylsiiirametrole (Ν,), in a patient with severe renal im­
pairment (creatinine clearance, I Bml/min) Administration of sulramctrolcaOOtng 
and tnmcthopnm 80 mt bid. under these éntreme circumslances, results in an accum-
ulation of the metabolite, the parent drug's normal halMife is eight hours " 
In Figure 1, sulfametrole is administered twice daily 
and has its normal half-life of eight hours as a result of 
acetylation, as observed with healthy volunteers.1' The 
metabolite Ν,-acetylsulfametrole cannot be excreted fur­
ther, due to poor kidney function (Cl„, 1.8ml/min)and 
accumulates in the plasma until an equilibrium is reached 
between the rates of acetylation, deacetylation, and the 
residual small renal clearance of the metabolite.1910 
Sulfametrole possesses antibacterial activity, but its 
Na-acetylsulfametrole metabolite has none. In this situa­
tion, a question to consider is whether a reduction of 
the dose or an increase of the dosage interval will be 
meaningful or whether sulfametrole can be admini­
stered, with no adjustment, without any patient risks. 
Table 2. Some Pharmacokinetic Parameters of a Series of Sulfonamides" 
COMPOUND 
Sulfacthidole 
Suiramelhizole 
Sulfadiazine 
Sulfameraane 
Sulfadimidine 
Sulfathiazole 
Sulfamethoxazole 
Sulfametrole 
Sulfafurazole (sulfuoxazole) 
Sulfisomidinc 
Sulfamethomidine 
Sulfadimeihoxine 
Sulfadoxine 
HALF-LIFE 
OF SULFONAMIDE (h) 
12 
1.5 
10 
12 
11 
24 
2 
7 
3 
»-12 
9-12 
6*9 
6 
28 
40 
110 
HALF-LIFE OF 
N, METABOLITE (h) 
_ 
3 
10 
15 
11 
24 
6 
8 
3 
9-12 
9-12 
18 
9 
48 
56 
110 
N, METABOLITE 
EXCRETED IN URINE ( * ) 
0 
3 
10 
10 
55 
40 
90 
80 
30 
50 
40 
30 
20 
7 
10 
10 
N. METABOLITE 
IN PLASMA ( * ) · 
0 
3 
20 
15 
35 
14 
90 
60 
20 
20 
40 
90 
50 
15 
10 
10 
ACETYLATOR 
PHENOTYPE 
— 
_ 
fast 
slow 
fast 
slow 
fast 
slow 
— 
- t 
- t 
— 
— 
_ 
— 
— 
*(N, / N, + S) · 100 percent in plasma 
tlnfluence of urinary pH 
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The half-life of the parent drug is independent of the 
kidney function, inasmuch as it depends solely on the 
metabolic route (Table 2). Thus, with an unchanged 
dosage regimen of sulfametrole 400 mg bid, there will 
be a steady state of sulfametrole with about SO percent 
variation (Figure 1, Equation 4a). The intrinsic half-life 
of the metabolite N4-acetylsulfametrole is 3.5 hours,"
J1 
but it will increase to 40 hours under these circum­
stances. In anurie patients, the half-life of the metab­
olite Ν,-acetyIsulfametrole amounts to 70 hours, as 
demonstrated in Figure 2 . " 
The rates of acetylation and deacetylation are inde­
pendent of the renal excretion process, so the metabolite 
Ν,,-acetyIsulfametrole is infused virtually at the rate of 
the acetylation of the parent compound. This is true also 
for sulfamethoxazole and its metabolite N4-acetylsulfa-
methoxazole and, in general, for sulfonamides (com­
pounds) that are extensively acetylated (metabolized). 
With severely impaired kidney function, the metabo­
lite accumulates to a steady state identical to that of the 
parent compound. Unless the rate of acetylation is inde­
pendent of kidney function, sometimes an increased 
half-life of sulfamethoxazole is observed in patients with 
severely impaired kidney function."" This can be ex­
plained as follows: Acetylation is part of the acetylation-
deacetylation equilibrium.10 Deacetylation depends on 
the structure of the N^acetylsulfonamide derivative. It 
is low for sulfametrole and sulfamethoxazole but high 
for sulfadiazine, sulfamerazine, and sulfadoxine." " 
When the metabolite N.-acetylsuIfamethoxazole cannot 
be excreted, the deacetylation influences the half-life of 
0 
Г 1 
V 
" τ ­
ο 
π 
' • — Í N , tV4 70 h 
- ^ - ï - i -
*"· . 8 tW 70 h 
T -
- r - i - τ - - 1 — 1» ~r KOh 
Figure 2 Plasma concenlnuion-time curves of sulfametrole (S) and its metabolite 
N,.acetylsulfametro]e (N«), in an anurie patient after one dose of sulfametrole 600 
mg iv О represents the period of hemodialysis In a period ОГ4О-220 hours, the perfect 
acetylation-deacetylation equilibrium between sulfametrole (I И, 70 h) and N«-acetyl-
sulfametrole (tW, 70 h) is shown * · " 
the parent compound, which adopts the half-life of the 
metabolite."J 0 M The same phenomenon is shown in 
Figure 3, for sulfametrole, when it is administered to 
an anurie patient. One of the reasons for keeping the 
plasma concentration of the N<-acetylsulfonamide low 
is that it may help in avoidance of side effects such as 
crystalluria." " 
The risk of crystalluria may be lowered by alkaliniza-
tion of the patient's urine, but, with an unchanged 
dosage regimen, this procedure works only for a cer­
tain time, because the metabolite will accumulate fur­
ther and will finally reach its solubility product at pH 
7. Furthermore, in life-threatening situations, frequently 
metabolic acidosis will be encountered. 
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Figure 3 Plasma concentration and renal excretion ratctime profiles of tnnuthoprim (TMP), sulfamethoxazole (S), and its metabolite N,'acctylsulfaniethoxazole (N,), in a 
patient with unpaired kidney function (creatinine clearance, 26 ml/mm), during a ste»dy-state situation of S 400 mg and TMP SO mg bid and during the post steady-state 
situation TTie similarity between the half-lives of S and TMP has been lost The claimed synergistic plasma concentration S TMP ratio of 20-10 I still seems to be present 
In the steady sute period of 0-30 hours but becomes 2 I during the final elimination process The TMP (tW, 2£ h)and N« (t 1 ^, 26 h) plasma concentration-time profiles run 
parallel, because both compounds are eliminated predominantly by renal excretion 
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To obtain a lower concentration of the metabolite 
Nj-acetylsulfametrole (or N.-acetylsulfaraethoxazole), 
the parent drug has to be administered in a lower daily 
dose. Thus, to achieve a lower concentration of the in-
active compound, the dose of the active compound must 
be reduced. With compounds such as sulfonamides, 
which have a large series of structural analogs with a 
large diversity of half-lives and rates of acetylation, this 
dilemma can be avoided. It is advisable to select a 
sulfonamide derivative that will be acetylated minimal-
ly (e.g., < 10 percent) when accumulation of a metabo-
lite and the occurrence of crystalluria must be avoided. 
Sulfamethizole (t'/i, 2 h) and sulfaethidole (t'/i, 9 h) 
are metabolized to a very small extent or not at all.14 
Sulfamethizole is not acetylated, due to its extremely 
high renal clearance and relatively high rate of deacety-
lation," nor is sulfaethidole, due to its high rate of 
deacetylation." In patients with impaired kidney func-
tion, sulfamethizole may be the obvious drug of choice 
and can replace sulfamethoxazole, sulfametrole, and 
sulfisoxazole (sulfafurazole). 
The half-life of sulfamethizole may, depending on the 
degree of kidney impairment, increase from 2-24 hours 
and, in anurie patients, up to 75 hours.12 Even under 
these circumstances, sulfamethizole is acetylated only 
slightly (about 5 percent). In anurie patients, the perfect 
acetylation-deacetylation equilibrium can be attained, 
without interference and disturbance of the renal 
elimination phenomenon, as demonstrated in Figure 2." 
Sulfaethidole also may be used, though the dosage in-
terval must be adapted, depending on the resulting half-
life, due to the severity of the kidney impairment (see 
Table 2). 
Synergism of Trimethoprim and Sulfonamides in Pa-
tients with Impaired Kidney Function. Sulfonamides are 
used mainly in combination with trimethoprim, because 
of the claimed synergism of both compounds (e.g., Bac-
trim, Eusaprim, Lidatrim, Septuryl). This synergistic 
action appears to be maximal when the dosage ratio of 
sulfonamide and trimethoprim is 5:1, and the plasma 
concentration ratio is 10-20:1."2" The proportionality 
factor of the steady-state concentrations is related to the 
ratio of the actual half-lives of sulfonamide and tri-
methoprim, according to Equation 6: 
CufTMP) "dSLF F T M P ' D T M P A ' S L F t 1 ' 2 ™ ? 
constant . Eq. 7 
t /2TMP 
where the subscript SLF refers to the sulfonamide (e.g., 
sulfamethoxazole, sulfametrole, sulfadiazine) and the 
subscript TMP to trimethoprim, in patients with nor-
mal kidney function. 
By coincidence, the rate of acetylation ( + deacetyla-
tion) of sulfamethoxazole and sulfametrole and the 
renal clearance of trimethoprim result in almost iden-
tical half-lives of — 9-12 hours.141" This similarity in 
half-lives of the active compounds dissipates in patients 
with impaired kidney function, due to a different under-
lying mechanism in the elimination process. 
Figure 3 shows similarities in the half-lives of the 
metabolite N4-acetylsulfamethoxazole and trimethoprim 
(t'A, 26 h), in a patient with impaired kidney function, 
because both compounds are eliminated predominantly 
by renal clearance."19 Sulfamethoxazole elicits its nor-
mal half-life of 13 hours, due to the unaffected rate of 
metabolism (acetylation).1* 
Therefore, in patients with impaired kidney function, 
the claimed optimal synergistic ratio of the plasma con-
centration of sulfonamide and trimethoprim of 10-20:1 
changes gradually into a 2:1 ratio in the final elimina-
tion process. 
The question of whether the 10-20:1 ratio for optimal 
synergism is valid in vivo arises. When clinical results 
of the sulfonamide/trimethoprim combination are ex-
cellent in all patients, even in those with impaired kidney 
function, the rationale for the fixed-dose ratio seems 
questionable. A change in the half-lives of sulfamethox-
azole and trimethoprim results in a related change in 
the steady states of the plasma concentration, according 
to Equations 6 and 7, which leads to a new ratio of the 
steady-state concentration, according to Equation 8: 
Q K S L F ) . . "^SIF „ 
r = constant . -¡p Eq. 8 
^-в(ТМР) l /2TMP 
where the subscript SLF represents sulfamethoxazole 
and TMP represents trimethoprim, in patients with im­
paired kidney function. The difference between the half-
lives of sulfamethoxazole and trimethoprim, in patients 
with impaired kidney function, with a twice-daily dosage 
regimen of sulfamethoxazole and trimethoprim in a 5:1 
ratio, according to Equation 2, results in a steady-state 
concentration with a variation of 20 percent for trimeth­
oprim and 50 percent for sulfamethoxazole. The required 
plasma concentration ratio for the synergistic action of 
sulfamethoxazole and trimethoprim, due to the varia­
tions in steady state, will be achieved only a few times 
per day instead of being constant throughout therapy. 
In general, when two compounds exhibit similar half-
lives, under normal elimination, the plasma concentra­
tion-time curves run parallel. The effects related to this 
plasma concentration will be constant and predictable. 
This is true for sulfamethoxazole, sulfametrole, and 
trimethoprim (t'/i, 9-12 h). In patients with kidney im­
pairment, the parallelism between the active compound 
sulfamethoxazole and trimethoprim will disappear, so 
the synergistic effects will no longer be predictable. If 
synergism between a sulfonamide and trimethoprim is 
required for treatment of a patient with impaired kidney 
function, it is better to choose a sulfonamide that is 
eliminated mainly by renal excretion and shows, in that 
particular patient, the same half-life as trimethoprim. 
The sulfonamide of choice, for this circumstance, may 
be sulfamethizole. The use of trimethoprim alone may 
be considered; however, this drug has been used primar­
ily in the treatment of simple urinary infections." " 
Elimination of the Parent Drug by Metabolic and 
Renal Clearance and of the Metabolite by Renal Clear­
ance. Procainamide is exemplary of this situation. 
Kidney impairment reduces the contribution of renal 
clearance to the total clearance of procainamide, but 
the metabolic clearance by acetylation remains un­
changed. The half-life of procainamide may increase 
from 2 to 11-14 hours, with kidney impairment.111110"" 
The intrinsic half-life of N,-acetylprocainamide is 6 
hours, affected predominantly by renal excretion, and 
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may increase to 40 hours, depending on the degree of 
kidney impairment " " 3 0 " The rate of formation of 
the metabolite N.-acetylprocainamide, or more specifi­
cally the acetylation-deacetylation equilibrium, con­
tinues unaffected Thus, its renal clearance is reduced 
and its plasma concentration increases " ^ *· An un­
changed dosage regimen of procainamide, in patients 
with impaired kidney function, causes an increase of the 
plasma concentration of both the parent drug and the 
metabolite When the dosage regimen of procainamide 
is changed, based on the actual half-life of 14 hours in 
patients with severely impaired kidney function, there 
still will be a strong accumulation of the metabolite 
(t1/j,40h) 
A further complicating factor, which makes the 
plasma concentration of procainamide and its metabo­
lite unpredictable, is the existence of an acetylator 
phenotype in the metabolism 3 0 3 3 3 ' The phenotype of 
one patient may produce a different parent drug metab­
olite ratio in plasma than in another patient The rate 
of deacetylation does not depend, however, on a pheno­
type, but only on the species (dog > man) and is recog­
nizable and measurable only in patients with severely 
impaired kidney function as shown for sulfamethox­
azole,"2 0 for sulfametrole in Figure 2, and for N«-
acetylprocainamide " 
A question that must be raised, independent of kidney 
function, is whether a mixture of two compounds with 
very similar effects but with different half-lives and fluc­
tuating plasma concentrations, can produce stable 
and/or predictable effects Based on the previous obser­
vations, it may be advisable not to administer procain­
amide to patients with impaired kidney function but to 
administer, instead, its metabolite Ni-acetylprocaina-
mide, which is eliminated predominantly by renal excre­
tion and from which the dosage regimen can be adapted 
easily " These problems may be circumvented by the 
use of quimdine and/or disopyramide, because renal im­
pairment does not affect the half-lives of these com­
pounds " " 3 ' However, the kinetics of these drugs and 
their metabolites also must be considered when dosing 
a patient with severe renal impairment " 
Summary 
In patients with impaired kidney function, reduction 
of the dose and/or an increase in the dosage interval 
seem to be the most appropriate methods of avoiding 
(toxic) accumulation of a drug and/or its metabolite 
A thorough knowledge of metabolic and renal clearance 
of the administered drug is necessary 
The kinetics of both the parent drug and its metabo-
lite(s) must be considered when dosing a patient who 
has renal impairment For instance, dosing a patient 
solely with sulfamethoxazole and neglecting to consider 
the kinetics of its metabolite could be dangerous and 
is technically wrong " Conversely, avoidance of the side 
effects of its metabolite, via a dosage reduction of sulfa­
methoxazole, may represent undertreatment of the pa­
tient and may lead to therapeutic failure In this in­
stance, a change in the choice of drug to a structural 
analog with almost identical intrinsic effects but with 
more suitable kinetic parameters is a third alternative 
for compensating for the reduction of one pathway of 
elimination If none of the foregoing is plausible, a last 
alternative may be to select a drug from a completely 
different class of compounds, taking into account the 
previously mentioned precautions However, the bene­
fit risk balance of each drug used in individual treat­
ment should be known so that problems can be avoided, 
as explained with the sulfonamides and procainamide. 
In each case, the certainties on which a decision is bas­
ed must be questioned and evaluated a 
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SUMMARY 
A review of the recent literature on acute urinary tract infections reveals some 
unresolved problems and considerable discussion and reappraisal of the current 
diagnostic and therapeutic methods 
In this review, the rationale for the diagnostic confirmation of the presence, 
extent and site of infection is presented Recent developments in the treatment 
of acute urinary tract infections are discussed Factors affecting the choice of 
drug and recent studies concerning the duration of therapy are detailed Studies 
concerning the treatment of urinary tract infections with trimethoprim alone are 
reviewed and results of the treatment of acute urinary tract infection with a 
single dose of trimethoprim at St Radboud Hospital are presented 
INTRODUCTION 
The high incidence of urinary tract infections, in both hospitalized and ambulatory 
populations, accounts for the considerable discussion on this topic in scientific and 
medical literature Several unresolved problems in the assessment and treatment of 
urinary tract infections (UTI) justify a reappraisal of the current therapeutic principles 
Incidence 
The age and sex distribution of patients with UTI indicates that women are more often 
affected and that men generally only suffer from these infections later in life Epidemiolo-
gical studies have shown that UTI's are the most common type of infection in females (1) 
School-age girls have an incidence rate of about 1% and it is estimated that 10-20% of 
females will have at least one UTI m their lifetime (2) The incidence in males below the 
age of 50 is extremely low, but increases after this age due to prostatic obstruction which 
interferes with unnary flow An estimated 30% of hospital-acquired infections are in the 
urinary tract and the overwhelming majonty of these are related to urethral cathetenza-
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tion (3). In children UTI are often associated with structural abnormalities which place 
them at risk of developing renal damage if the infections are not recognized early enough. 
The assessment and treatment of patients with a suspected urinary tract infection 
remains somewhat of a clinical dilemma, for UTI's can range from straight-forward 
bacteriuria restricted to the lower urinary tract to potentially more damaging upper UTI. 
Furthermore, both upper and lower UTI's can be asymptomatic (1) and, paradoxically, 
about 50% of women with symptoms have sterile urine when cultured (4). Accurate 
diagnosis is necessary both for initial confirmation of a UTI and for the follow-up which is 
essential in many patients. 
Quantitation of bacteriuria 
A urinary tract infection can be defined simply as the presence of significant numbers of 
pathogenic micro-organisms multiplying anywhere within the urinary tract (5). However, 
it is the careful assessment of the extent of tissue involvement which is important in 
determining the site of the infection. The female distal urethra is normally frequently 
invaded by perineal flora so that the collection and culturing of urine is the most 
important initial diagnostic step. Although a specimen obtained by the use of a catheter 
would minimize the possibility of a false positive result, it is unjustified for routine use and 
aside from its obvious discomfort and the time required, it carries the risk of introducing 
bacteria into the bladder. A technique of suprapubic aspiration of the distended bladder 
has been promoted as a rapid, efficient and accurate method of diagnosing urinary tract 
infections (6). However, the clean-catch mid-stream urine (MSU) procedure is still the 
most widely used method. Many variations in the MSU procedure are known; in most 
cases some contamination is inevitable in this method. Therefore, the quantitation of 
bacteria in urine has become a generally accepted method for the assessment of the 
significance of bacteriuria. 
The original criteria established by Kass (7) were to distinguish between contamination 
and true gram-negative bacterial infection of the urine. Kass argued that statistically, a 
single MSU specimen with a count of greater than 105 gram-negative colony-forming 
organisms per ml of the same species represented an 80% confidence level in the diagnosis 
of UTI. 
This means of course that there is at least a one in five chance of a false positive result 
due to gross contamination. In practice this rate is reported to be much higher (1) due to 
poor preparation of equipment or lack of patient supervision and the difficulty in 
sampling with children, the elderly, etc. Because of the limitations in laboratory facilities, 
several commercially available dip-inoculum techniques have been developed and have 
been reported to be as accurate as routine bacteriological counts (8) for the diagnosis and 
assessment of urinary tract infections. 
It is now recognized that many patients with UTI have MSU counts of less than 105 
organisms per ml and in some cases of high urine flow, less than 10'' organisms per ml (1). 
Site of infection 
Identifying the site of infection is important since symptoms of infection of the upper 
and lower urinary tracts often overlap. 
The location and extent of infection can be important considerations in the choice of 
treatment. Some techniques for determining the location of the UTI include a bladder 
washout procedure (9), ureteral catheterization, follow-up urine cultures to see if relapse 
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occurs (more likely with an upper UTI) and, more recently, the detection of antibody-
coated bacteria (ACB). Thomas et al. (10), Jones et al. (11) and Fang et al. (12) have 
reported the latter technique to be reliable in determining whether infection is in the upper 
UTI (antibody-coated bacteria) or lower UTI (no antibody coating of bacteria). Haw-
thorne et al. (13) stated that the ACB technique reliably detected infections in patients 
with upper UTI but that an unacceptable rate of false positive results occurred in patients 
with lower UTI. 
Since the publication of these reports some further controversy has developed about 
the reliability of this technique. Hellerstein et al. (14) reported no correlation between the 
presence of ACB in urinary sediments and infection of the upper urinary tract. Riedasch 
et al. ( 15) claimed that lower urinary tract infections can also be associated with antibody 
coating of bacteria presumably as a result of bacterial invasion of the bladder. Clearly 
some further assessment and refinement of the ACB technique is indicated before 
absolute criteria for its use can be established. 
Causative organisms 
The most common organisms entering the bladder via the urethra are the normal flora 
of the rectum. E. coli accounts for about 80% of community-acquired infections while a 
small fraction are caused by proteus species and Klebsiella-Enterobacter and a few other 
gram-negative enteric species (5). In the hospital environment the situation is more 
complex and highly variable. In general, however, E. coli is still the predominant 
pathogen but more resistant strains of this and other gram-negatives such as Klebsiella 
spp. are also encountered. 
TREATMENT 
Conventional therapy of acute urinary tract infections has usually consisted of three or 
four daily doses of a given antimicrobial agent for a period of 5-14 days. Recently, there 
has been some reappraisal of this convention for a variety of reasons. Firstly, there is a 
substantial tendency for patients to discontinue their therapy after 2 or 3 days due to the 
disappearance of the symptoms or to the difficulty in administering drugs to apparently 
well children. Decline of urinary symptoms within hours is commonly experienced by 
patients (16) and this decline in symptoms has been correlated with a decline in urinary 
bacterial counts (17). Our results (Fig. 1) confirm this finding. Poor patient compliance 
with longer treatment regimens can also be attributed to the occurrence of side effects such 
as diarrhoea or skin rashes (18). The improved cost-benefit ratio resulting from a 
shortened treatment regimen is obvious. Furthermore, there are several types of patients 
for whom minimizing drug intake is important: pregnant and breast-feeding women, 
patients with renal-failure, hepatic-dysfunction patients, patients already receiving multi-
ple drug treatment, young children, etc. 
Drug of choice 
The principal questions in the treatment of acute UTI include: which drug to choose, 
duration of treatment and whether adjunctive treatment is necessary. Regardless of the 
choice of antibacterial agent, the goal of treatment is the sterilization of the urinary tract 
that is eradicative therapy. Often the efficacy of treatment is more dependent on host 
factors such as the condition of the urinary tract and underlying disease states than on the 
choice of drug. 
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Fig. 1. Pharmacokinetic and microbiological profile of a 400 mg single-dose trimethoprim 
treatment of an acute urinary £'. coli infection 
Most of the commonly used antibacterial agents have a similar success rate of about 
70-85%, in individuals with otherwise normally functioning urinary tracts ( 12) and many 
UTI's resolve without treatment. A fundamental principle in selecting from drugs of 
similar efficacy would be to use the cheapest and least toxic agent possessing suitable 
pharmacokinetic characteristics. Several agents have been traditional first-line drugs in 
out-patient practice: sulphonamides, ampicillin or amoxycillin, nitrofurantoin, nalidixic 
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acid, tetracyclines and the trimethoprim/sulphonamide combination. There has been 
much discussion in the literature regarding the relative merits of particular drugs. Clearly, 
there are no simple answers to the best choice of drug. Individual patient variables must be 
considered. 
Factors such as age, sex, incidence of allergy, renal and hepatic functions, immunologi-
cal status and previous history of urinary tract disease or other disease states can all 
influence the selection of drug therapy. The sensitivity characteristics of the infecting 
organism is of paramount importance. Although about 80% of UTI are caused by E. coli 
which is sensitive to the commonly used antibacterial drugs and whose sensitivity pattern 
has changed little over the past few years, the patient's previous history and the likelihood 
of the organism being resistant must be taken into account. 
A distinction must also be made between the choice of drug for upper and lower UTI. 
For upper UTI, where sufficient drug concentration in the kidney parenchyma is required, 
only drugs which reach adequate tissue levels such as ampicillin, amoxycillin, co-trimoxa-
zole or cephalexin are suitable (19). Drugs which only concentrate in the urine and do not 
reach adequate tissue levels, such as nalidixic acid and nitrofurantoin, must only be used 
in infections confined to the lower urinary tract. 
Duration of therapy 
Besides the selection of a particular agent perhaps the most controversial question in 
the treatment of uncomplicated UTI is the duration of therapy. Since several studies have 
shown that urine is sterile within 48 h or less after appropriate therapy and since longer 
term treatment is not without its problems there has been a movement to shorten the 
generally accepted 5-14-day course to a regimen of much shorter duration. Until recently, 
the effectiveness of shorter treatment courses has been unknown and some opposition to 
this approach has been voiced because of the significant number of uncomplicated 
infections which clear spontaneously. It is precisely this rapid sterilization of the urine and 
the significant number of spontaneously remitting UTI which indicate a need to evaluate 
short term or even single dose therapy of urinary infections in clinical practice. Satisfac-
tory results have been reported for amoxycillin (12, 20, 21), short-acting sulphonamides 
(22), co-trimoxazole (23), streptomycin and sulphamethopyrazine (24), cephaloridine 
(25), kanamycin (26) and doxycycline (27). Baily & Abbott (21) have suggested that single 
dose therapy may actually identify patients who require more intensive treatment, 
investigation and follow-up. 
Trimethoprim treatment 
Recently several studies (28-35) have shown trimethoprim to be effective in the 
treatment of urinary tract infections. These studies further indicate that, in most cases of 
acute UTI, the combination of trimethoprim and a sulphonamide probably offers no 
demonstrable advantage over trimethoprim alone. 
Trimethoprim is available in Britain, Finland, and the U.S.A. as a single agent for the 
treatment and prophylaxis of UTI. 
Elsewhere trimethoprim is still only available combined with a sulphonamide. There 
has been considerable discussion on the clinical significance of the claimed synergy 
between trimethoprim and sulphonamides in UTI and other infections. Other questions 
concern the relative toxicity of trimethoprim and the combination and whether trimetho-
prim alone is more likely to facilitate the emergence of bacterial resistance. 
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Although after conventional doses of the combination concentrations of both trimeth-
oprim and sulphonamide exceed the MIC of either drug on its own, the trimethoprim 
component is dominant in the urine and no synergy with sulphonamide has been 
demonstrated (28, 29, 36-38). 
The combination appears to be predominantly bacteriostatic (28) and any bactericidal 
activity is probably due to trimethoprim alone (29). 
In studies comparing the efficacy of co-trimoxazole with trimethoprim on its own both 
treatments have been shown to be at least bacteriologically and clinically equivalent 
(28-35). 
When toxicity occurs with the use of the trimethoprim/sulphonamide combination it is 
likely to be due to the sulphonamide component (35, 39, 40) and the incidence of 
crystalluria due to sulphonamide and its metabolites has been recently re-emphasized 
(41). Although further study of the toxicity of trimethoprim is indicated, published 
studies show that trimethoprim is tolerated as well as, or better than the combination 
(28-33, 35, 40). 
Perhaps the greatest concern expressed in the use of trimethoprim alone, is that this 
treatment will encourage the emergence of resistant strains. Few controlled studies have 
been carried out to investigate this possibility but it has been suggested that the combina-
tion might actually induce more resistance than single-agent therapy (38). 
Lacey et al. (35) reported that few trimethoprim-resistant pathogenic bacteria were 
isolated when trimethoprim alone was used for both acute respiratory and urinary tract 
infections and concluded that the combination of a sulphonamide with trimethoprim to 
prevent resistance seemed unnecessary. Busk and Körner (42) reported no increase in 
trimethoprim resistance over a 10-year period in an area where both the combination and, 
more recently, trimethoprim alone have been in use. Since about 30% of enterobacteria 
are sulphonamide-resistant (43), many patients treated with the sulphonamide/trimetho-
prim combination may essentially be receiving trimethoprim alone. 
Maskell & Pead (44) claimed that trimethoprim alone is more likely to select resistance 
in Staphylococcus albus UTI than co-trimoxazole. This view is disputed by Lacey (45) who 
concluded that the data indicated that cross-infection and not trimethoprim-resistance 
was responsible for the increased levels of infection. 
Figure 1 shows the result of a single 400 mg dose of trimethoprim in the treatment of an 
acute urinary tract infection in a 56-year-old male with creatinine clearance of 65· 1 μg/min. 
Bacterial counts were assessed by means of MICUR-C dip slides which have been shown 
to be as reliable as serially diluted plate bacterial counts in the assessment of UTI (8). 
It can be seen that the bacterial count declined from well over IO7 E. coli organisms per 
ml to a state of urine sterility within 24 h of the trimethoprim dose. 
The patient's urine was kept alkaline (pH 7· 18 ± 0· 53 s.d.) during the entire 80 h period 
by the ingestion of 8 g of sodium bicarbonate per day in order to maximize the tubular 
reabsorption of trimethoprim, thus maintaining the highest concentration in the urinary 
tract. The renal clearance of trimethoprim was 48-62 /ig/min. 
The ti of the decline in E. coli bacterial count in the urine was found to be approxima­
tely 3 h while the t^ of the trimethoprim in the plasma and urine was 9 h. After 24 h the 
plasma trimethoprim concentration was well within the range of the MIC reported for E. 
coli and several other gram-negative bacteria (46). Follow-up urine cultures for a week 
and after 6 weeks showed no recurrence of bacteriuria. 
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CONCLUSION 
The results of single-dose therapy of acute UTI have been generally encouraging, though 
because of the higher incidence of treatment failure in upper UTI, single dose therapy 
should probably only be used to treat infections of the lower urinary tract 
Adjunctive therapy and advice such as improved personal hygiene, increased fluid 
intake during an infection, double micturation and frequent voiding are important aids in 
the eradication of an infection and to prevent recurrence which is still unacceptably high 
Alkalinizing the urine may give some symptomatic relief but this should not be done 
routinely and should only be considered when it may substantially improve the pharma­
cokinetic properties of the drug, bearing in mind that alkalmized urine may encourage 
proteus growth 
In the treatment of acute UTI several studies have indicated that in terms of efficacy and 
the emergence of resistant strains combining a sulphonamide with trimethoprim offers no 
advantage over the use of trimethoprim alone Furthermore there are definite benefits to 
be gained from single agent therapy These include fewer side effects, less cost and greater 
ease of administration In patients with reduced renal function, trimethoprim would be 
preferable because it does not cause crystalluna which is commonly seen with the 
sulphonamide in renal failure patients There would seem to be a case for the use of 
trimethoprim alone in preference to its combination with a sulphonamide, in the treat­
ment of acute urinary tract infections However, the correct dosage and dosage regimen 
have yet to be established (35) Some caution m the use of trimethoprim for long-term 
therapy would be advisable pending further studies and heeding recent reports of 
increased resistance to trimethoprim m Scandinavia (43, 47) and Britain (48, 49) 
REFERENCES 
1 Bailey, R.R. (1972) Urinary tract infection some recent concepts Canadian Medical Association Journal, 
107,316-330 
2 Kunin, СМ., Deutcber, R. & Paquin, A. (1964) Unnary tract infections m school children epidemiological, 
clinical and laboratory study Medicine, 43, 91-130 
3 Stamm, W E. (1975) Guidelines for prevention of catheter-associated unnary tract infections Annals of 
Internal Medicine, 82, 386-390 
4 Gallaghar, D.J. Α., Montgomerie, J.Z. A North, J.D.K. ( 1965) Acute infections of the unnary tract and the 
urethral syndrome in general practice British Medica/Journal, 1,622-626 
5 Johnson, J.E.( 1978) Unnary tract infections In ClmicalConceplsof Infectious Diseases (eásh E ClufTand 
J E Johnson III), 2nd edn, pp 310-321 Williams & Willems Co , Baltimore 
6 Bailey, R.R & Little, Ρ J. (1969) Suprapubic bladder aspiration in diagnosis of unnary tract infection 
British Medical Journal. 1, 293-294 
7 Kass, E.H. ( 1956) Asymptomatic infections of the unnary tract Transactions of the Association of American 
Physicums, » , 56-63 
8 Kunin, C M . (1975) New methods in detecting unnary tract infections Urology Clinics of North America, 2, 
423-432 
9 Falrley, K.F., Bond, A.G., Brown, R.B. & Habenberger, P. ( 1967) Simple test to determine the site of urinary 
tract infection Lancet, U, 427-428 
10 Thomas, V., Skdokov, A. & Foriand, M. ( 1974) Antibody-coated bactena in the unne and the site of unnary 
tract infection New England Journal of Medicine, 290, 588-590 
11 Jones, S.R., Smith, J.W. & Sanford, J.P. (1974) Localization of unnary tract infections by detection of 
antibody-coated bactena in unne sediment New England Journal of Medicine, 290, 591-593 
12 Fang, L.S.T., Tolkoff-Rubin, N.E. & Rubin, R H. (1978) Efficacy of single-dose and conventional amoxicil­
lin therapy in urinary-tract infection localized by antibody-coated technique New England Journal of 
Medicine, 298,413-416 
267 
8 IV. T. Friesen et al. 
13 Hawthorne, N.J., Kurtz, S.B., Anhalt, J.P. & Segura, J.W. (1978) Accuracy of antibody-coated bacteria test 
in recurrent urinary tract infections Mayo Clmic Proceedings, 53, 651-654 
14 Hellerstein, S., Kenndey, E., Nussbaum, L. & Rice, К. (1978) Localization of the site of urinary tract 
infections by means of antibody-coated bacteria in the urinary sediments Journal of Pediatrics, 92,188-193 
15 Riedasch, G., Ritz, E., Mohring, K. & Bommer, J. (1978) Antibody coating of urinary bactena relation of 
site of infection and invasion of uroepithehum Clinical Nephrology. 10, 239-244 
16 Cattell, W.R., Sardeson, J., Sutcliffe, M.B. & O'Grady, F. ( 1968) Kinetics of unnary bacterial response to 
antibacterial agents In Urinary Trad Infection (eds F O'Grady and W Brumfítt), pp 212-226 Oxford 
University Press, Oxford 
17 Prat, V., Bohuslav, V. & Hatala, M. ( 1979) Daily bacteriological examination of unne during antimicrobial 
treatment of unnary tract infections International Urology and Nephrologv, 11, 3-10 
18 Fairley, K.F. & Whitworth, J.A. (1980) Problems in the treatment of unnary tract infections Drugs, 19, 
190-194 
19 (1979) Acute urinary tract infection in general practice Drug and Therapeutics Bulletin, 17, 81-83 
20 Anderson, J.D., Aird, M.Y., Johnson, A.M., Ree, R., Goresky, D., Bnimwell, C.A. & Percival, R.K.L. (1979) 
The use of a single Ig dose of amoxycillin for the treatment of acute urinary tract infections Journal of 
Antimicrobial Chemotherapy, 5,481-483 
21 Bailey, R.R. & Abbott, G.D. (1978) Treatment of unnary tract infection with a single dose of amoxycillin 
Nephron, 18, 316-318 
22 Kallenius, G. & Wlnberg, J. (1979) Unnary tract infections treated with a single dose of short-acting 
sulphonamide British Medical Journal, 1, 1175-1176 
23 Bailey, R.R. & Abbott, G.D. (1978) Treatment of unnary tract infection with a single dose of tnmethopnm-
sulphamethoxazole Canadian Medical Association Journal, 118, 551-552 
24 Williams, J.D. & Smith, E.K. (1970) Single-dose therapy with streptomycin and sulphamethopyrazine for 
bacterium during pregnancy British Medical Journal, 4, 651-653 
25 Brumfitt, W., Faiers, M.C. & Franklin, I.N.S. (1970) The treatment of urinary infection by means of a single 
doseofcephalondine Postgraduate Medical Journal, 46, (suppl Oct ), 65-69 
26 Ronald, A.R., Boutros, P. & Mourtada, H. (1976) Bactenuna localization and response to single-dose 
therapy in women Journal of the American Medical Association, 235, 1854-1856 
27 Sabath, L.D. (\919) Changing concepts in urinary tract infections Presented as a scientific exhibit at the 19th 
interscience conference on antimicrobial agents and chemotherapy, Boston, October 1-5, 1979 
28 Anderson, J.D., Lacey, R.W., Lewis, E.L. & Sellin, M.A. (1974) Failure to demonstrate an advantage in 
combining sulphamethoxazole with trimethoprim in an experimental model of the unnary tract Journal of 
Clinical Pathology, 27, 619-622 
29 Lewis, E.L., Anderson, J.D. & Lacey, R.W. (1974) A reappraisal of the antibacterial action of co-tnmoxa-
zole m vitro Journal of Clinical Pathology, 27, 87-91 
30 Brumfitt, W. & Pursell, R. (1972) Double blind trial to compare ampicillin, cephalexin, co-tnmoxazole and 
trimethoprim in treatment of unnary infection British Medical Journal, 2, 673-675 
31 Kasanen, Α., Kaasalo, E., Hiltunen, R. & Soini, V. (1974) Companson of long term low dosage nitrofuran­
toin, methanamine hippurate, trimethoprim, sulphamethoxazole and the combination of both on the 
control of recurrent urinary tract infections Annals of Clinical Research, 6, 285-289 
32 Koch, V.J., Schumann, K.P., Küchler, R. & Kewitz, H. ( 1973) Efficacy of tnmethopnm, sulphamethoxazole 
and the combination of both in acute unnary tract infections Chemotherapy, 19, 314-322 
33 Kasanen, Α., Sundquist, H. & Junnila, S.Y.T. (1979) Trimethoprim in the treatment of acute unnary tract 
infection Current Therapeutic Research, 25, 202-209 
34 Pancoast, S. J., Hyams, D.M. & Neu, H.C. ( 1980) Effect of tnmethopnm and tnmethopnm-sulphamethoxa-
zole on development of drug-resistant vaginal and fecal floras Antimicrobial Agents and Chemotherapy, 17, 
263-268 
35 Lacey, R.W., Lord, V.L., Gunasekera, H.K.W., Ueberman, P.J. & Luxton, D.E.A. (1980) Comparison of 
tnmethopnm alone with trimethoprim sulphamethoxazole in the treatment of respiratory and urinary 
infections with particular reference to selection of tnmethopnm resistance Lancet, i, 1270-1273 
36 Greenwood, D. & O'Grady, F. (1976) Activity and interaction of tnmethopnm and sulphamethoxazole 
against Escherichia coll Journal of Clinical Pathology, 29, 162-166 
37 Greenwood, D. ( 1979) Relevance of in vitro synergy to therapy does synergy between diaminopynmidmes 
and sulphonamides operate at concentrations available in unne9 Journal of Antimicrobial Chemotherapy, 5 
(suppl B), 85-89 
268 
Acute urinary tract infection 9 
38. Licey, R.W. (1979) Mechanism of action of trimethoprim and sulphonamides: relevance to synergy m vwo. 
Journal of Antimicrobial Chemotherapy, 5 (suppl. B), 75-83. 
39. Bailey, R.R. & Little, P.J. (1976) Deterioration in renal function in association with co-trimoxazole 
therapy. Medical Journal of Australia, 1, 914-918. 
40. Clark, A.J.L., Mouchizadeh, J., Faunch, R. & McMichael, H.B. ( 1980) Trimethoprim alone Lancei.i, 1030. 
41 Vree, T.B., Hekster, Υ. Α. & Van Dalen, R. ( 1981 ) Het meten van de concentratie van Sulfonamiden in bloed 
en urine van patiënten met gestoorde nierfunctie. Folia Chemotherapeutica (in press) 
42. Busk, H.E. & Körner, В. ( 1980) Trimelhopnm resistance in Finland. British Medical Journal, 1, 1054-1055. 
43. Burman, L.J. (1980) Resistance to Trimethoprim. Lancet, i, 1409. 
44. Maskell, R. Л Pead, L. (1980) Trimethoprim alone. Lancet, U, 144-145. 
45 Lacey, R.W. (1980) Trimethoprim alone. Lancet, IL, 256-257. 
46. Garrod, L.P. (1980) Principles and practice of antibacterial chemotherapy. In: Drug Treatment: Principles 
and Practice of Clinical Pharmacology and Therapeutics second edition (éd. G. S. Avery), 2nd edn, pp. 
1122-1141. ADIS Press, Sydney and New York. 
47. Huovinen, P. & Tolvanen, P. (1980) Trimethoprim resistance in Finland after five years' use of plain 
tnmethopnm. British Medical Journal, 1, 72-74. 
48. Grey, D., Hamilton-Miller, J.M.T. & Brumfitt, W. (1979) Incidence and mechanisms of resistance to 
trimethoprim in clinically isolated gram-negative bacteria. Chemotherapy, 25, 147-156. 
49. Brumfitt, W., Hamilton-Miller, J.M.T. & Gooding, A. (1980) Resistance to trimethoprim. Lancet, I, 
1409-1410. 
269 

TRIMETHOPRIM: CLINICAL USE AND PHARMACOKINETICS 
by W.T. Friesen, Y.A. Hekster, and T.B. Vree 
Appendix I I 2 
Qoal 
The goal of this article Is to review the properties of 
trimethoprim that make It suitable for use as a 
single-agent antimicrobial drug and to acquaint the 
reader with the clinical uses and pharmacokinetics 
of trimethoprim. 
Objective« 
After reading this article, the reader should be able 
to: 
1. outline the history of the development of tri­
methoprim, 
2. describe the antibacterial properties of 
trimethoprim, 
3. describe the relative merits of trimethoprim com­
pared to trimethoprim/sulfonamide combina­
tions, 
4. discuss the established, as well as possible, 
clinical uses of trimethoprim, 
5. discuss the significance of adverse effects of 
trimethoprim and probability of the development 
of bacterial resistance, and 
6. describe the pharmacokinetic properties of 
trimethoprim and appreciate their clinical 
significance. 
TRIMETHOPRIM (2,4-diammo-5- [3',4',5',-trimethoxy-
benzylj-pyrimidinc) (Figure 1) was first synthesized 
in the Wellcome Laboratories. Trimethoprim (TMP) 
possesses some antiprotozoal activity, but the main 
interest in TMP was due to its inherent antibacterial 
activity, acting in the folic acid metabolic chain. TMP 
was thought to act sequentially with sulfonamides in 
antagonizing folic acid synthesis, at the stage imme­
diately following that blocked by sulfonamides.' This 
sequential blockage was promoted as a basis for syn­
ergism and a wider spectrum of activity. Therefore, 
TMP was marketed as a combination with a medium 
long-acting sulfonamide, sulfamethoxazole, because 
the two compounds had similar rates of absorption and 
elimination. The combination (co-trimoxazole) was 
released for general therapeutic use in Britain in 1968 
and in the U.S.A. in 1973. More recently, other in­
dividual sulfonamides (sulfadiazine and sulfamctrole) 
have been combined with TMP and promoted for 
therapeutic indications similar to those for which co-
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Figure I. Chemical structure of trimethoprim. 
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trimoxazole is used. Until 1978, TMP has only been 
available for use as a fixed combination with a sulfon­
amide.* More recently however, TMP has been in­
troduced in some other countries for use as a single 
drug or in combination with drugs other than the sul­
fonamides. 
Mode of Action and Antibacterial Activity 
Trimethoprim is a folic acid antagonist which in­
hibits the enzyme dihydrofolate reductase, preventing 
the transformation of dihydrofolic acid to tetrahydro-
folic acid.- This enzyme system exists in both bac­
terial and mammalian cells; however, it is estimated 
that the bacterial enzyme is up to 50000 times more 
sensitive to TMP than is the mammalian enzyme. 
The proposal that sulfonamides, acting at a differ­
ent site (i.e., dihydrofolate synthetase), induced a 
sequential antibacterial activity with TMP has been 
challenged. It has been suggested that sulfonamides 
and TMP actually act independently at the same 
dihydrofolate reductase enzyme site.' Whether this 
simultaneous binding to bacterial dihydrofolate re­
ductase is a basis for synergism is uncertain. Griinc-
berg suggested that any observed increase in effect of 
the TMP/sulfonamide combination over the individual 
components is probably merely additive.1 Greenwood 
could not demonstrate a synergistic effect of co-tri­
moxazole at concentrations available in the urine.'' 
Thus, there is some doubt as to one of the suggested 
major advantages of combining TMP with a sulfona­
mide, that is, the production of synergy. 
A second suggested advantage of the combination 
of TMP and a sulfonamide, over the individual com­
ponents, is a bactericidal effect. Anderson et al. have 
shown that TMP alone produces some bactericidal 
activity in urine, but perhaps more significantly, the 
bactericidal effect of TMP was actually antagonized 
by the sulfonamide, rendering the combination (co-
trimoxazole) merely bacteriostatic." If the sulfona­
mide acts first in the folic acid synthesis sequence at 
•Finland is the exception, there trimelhopnm alone has been 
registered since 1973 for urinary tract infections. 
Reprinted with permission. Copyright 1981 
Drug Intelligence & Clinical Pharmacy, Inc. 
MA Y SI P O Box 42435. Cincinnati, OH 45242 
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the same or a diflercnt enzyme site, TMP cannot be 
expected to act in a damaged metabolic chain Green-
wood further demonstrated a potent antibacterial ef-
fect for TMP alone, and it now appears that the 
combination in vitro is bacteriostatic more often than 
it is bactericidal, and that any bactericidal effect mav 
be due to TMP alone " TMP is active against a wide 
variety of bacteria (Table 1 ), ' " it would be expected 
to be clinically useful for infections caused by or-
ganisms showing a low minimum inhibitory concen-
tration (MIC) (< 5 ,.g/ml) 
Clinical Uses 
Until recently, TMP has been employed clinically 
almost exclusively in combination with a sulfonamide 
derivative, thus, studies reporting the use of TMP 
tend to present results for the use of the TMP sulfon-
amide combination (usually co-tnmoxazole) Clinical 
investigations of the use of TMP alone are scarce, 
and there is some evidence that TMP as a single drug 
is equal or superior to co-tnmoxazole for many infec-
tions Kasanen et al have published a review on the 
clinical pharmacokinetics and efheacy of trimethoprim 
alone, describing the use of this drug in 40 000 patient 
years, but the data are restricted to its use in urinary 
tract infections " 
Prostatitis Chronic prostatitis responds poorly lo 
chemotherapeutic treatment, but co-tnmoxazole has 
been reported to be useful in this disease1" and in pre-
venting bactenuna after prostatectomy" Because 
sulfamethoxazole does not actually reach therapeutic 
levels in the prostate"' while TMP levels are equal to 
or higher than serum levels, TMP alone may be effec-
tive in the treatment of prostate conditions (Table 2) 
Uiinaiv Tract Infections Recently, several studies 
have investigated TMP as a single agent for the treat-
ment of some specific infections TMP has been 
shown to be effective in the treatment or prevention of 
recurrent urinary tract infections as multiple-dose 
therapy'1 ^'' ' or as single-dose therapy1" In most 
cases of acute lower urinary tract infection, there ap-
pears to be no advantage m the use of co-lrimoxazole 
over TMP alone '" " 
Lifnç ami Respiratory Infections TMP concentra-
tions in lung tissue and sputum have been shown to 
be higher than that required to inhibit common respi-
ratory pathogens,1" and upon investigating this phe-
nomenon clinically, Laccy et al showed that TMP 
had a similar cure rate to co-tnmoxazole, with fewer 
side effects, in both respiratory and unnary tract in-
fections Since co-tnmoxazole is frequently prescribed 
for the treatment and prophylaxis of respiratory and 
urinary tract infections, Laccy et al recommend the 
use of TMP for general use in place of TMP -'sulfona-
mide combinations ^ 
Otitis Media This disease is most commonly 
caused by Hemophilus influenzae and Streptococcus 
pneumoniae, both of which are sensitive to co-trun-
oxazole or TMP It has been suggested that co-tnm-
oxazole is a useful alternative to penicillin in the case 
of penicillin allergy or where pemcillinase-producing 
H influenzae have been isolated '" This would appear 
to be yet another situation for which TMP should be 
investigated as an alternative treatment 
Gonorrhea Treatment of gonorrhea with co-trim-
oxazolc is feasible,1" but the adverse effects associated 
with the relatively high dosage make it generally un-
acceptable for single-dose therapy Austin et al sug-
gested greatly increasing the TMP/sulfamethoxazole 
ratio to improve efficacy and to reduce sulfamethoxa-
zolc-related toxicity -'" With the increasing incidence 
of resistant Neisseria gonorrhea strains, TMP, either 
alone or in a modified combination with a sulfona-
mide, may have a role in treating gonorrhea without 
the disadvantage of masking incubating syphilis 
Typhoid Co-tnmoxazole has been used successfully 
in the treatment of typhoid fever, including chlor-
amphemcol-resistant infections -' The resistance to 
chloramphenicol is mediated by an R plasmid, which 
Table 1 In Vitro Antibacterial Activity of Tnmethopnm* 
MINIMUM INHIBITORY CONCENTRATION („g ml) 
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also confers resistance to sulfonamides as well as to 
other antibiotics In this situation, the patients may be 
benefiting from the effects of TMP alone, suggesting 
thjt TMP may be effective for typhoid fever-' 
Rivstami' The fears thai the use of TMP alone 
would promote the emergence of resistant strains ap­
pears to be largely unfounded, and the suggested 
ability of the combination to decrease the rate of 
emergence of resistance to the individual components 
has been questioned Gruneberg stated that no con­
vincing evidence exists that indicates that co-tnmoxa-
zole prevents the emergence of bacterial resistance4 
Darrcll et al reported that the TMP/sulfonamide 
combination delayed the emergence of resistant 
strains,— although Brumfitt and Pursell could not 
demonstrate such an effectлі Lacey et al suggested 
that resistance to co-trimoxazole is on the increase, 
and that the combination might actually provoke 
more resistance than single-agent therapy They fur­
ther reported that few TMP-resistant pathogenic bac­
teria were isolated when TMP alone was used to treat 
respiratory and urinary tract infections and concluded 
that the combination of TMP with a sulfonamide to 
prevent resistance seemed unnecessary " Busk and 
Körner reported no increase in TMP resistance over 
a ten-year period,-' and Burman suggested that, since 
about 30 percent of enterobactena are sulfonamide-
resistant, many patients receiving the TMP 'sulfona-
mide combination probably receive, essentially, TMP 
alone -"' Kasanen et al showed that the development 
of resistant strains after long-term administration of 
trimethoprim is less frequent than during treatment 
with sulfonamides or during ampicillin treatment " 
Trimethoprim Combination with Other Drugs The 
common usage of TMP with a sulfonamide derivative 
has stimulated investigation of combinations of TMP 
with other antimicrobial agents primarily in the hope 
of demonstrating synergy 
TMP has been reported to act synergistically with 
nfampicin against a wide vanety of bacteria 2'' It has 
been suggested that TMP prevents rapid emergence of 
rifampicin-resistant organisms·"1 and that the TMP/nf-
ampicm combination (Rifapnm®) is superior to ceph-
Table 2 Distribution of Trimethoprim into Body 
Tissues and Fluids (Blood = I ) 4 2 
prostate tissue 
prostate fluid 
saliva 
bronchial secretions 
sputum 
cerebrospinal fluid 
vaginal secretions 
synovial fluid 
milk 
felal plasma 
aqueous humour* 
bile· 
seminal fluid* 
bone marrow* 
bone tissue* 
2 
1-2 
2 
2 
2 
1 
5 
1 
1 
1 
01 
0 2-0 8 
0 5 
0 7 
0 2 0 7 
'Potentially therapeutic concentrations 
radine in treating recurrent unnary tract infections " 
TMP has also been reported to be synergistic with 
amikacin-" and gentamicm·"' against a wide vanety of 
gram-negative bacteria including Escherichia coli, 
Klebsiella pneumoniae, Serratia marcescens but not 
Pseudomonas aeruginosa 
Adverse Effects of Trimethoprim 
Most reports of adverse reactions involving TMP 
concern toxicity of co-trimoxazole, and little effort has 
been made to distinguish between adverse reactions by 
the two components individually 
Skin Effects Skin reactions develop in about 3 
percent of patients receiving co-trimoxazole 1" Several 
cases of erythema, urticaria, and a wide variety of 
maculopapular, purpuric, or morbilliform lesions have 
been caused by co-tnmoXazole," as well as at least 
28 cases of Stevens-Johnson syndrome (including 2 
fatalities) " Although it is probable that most if not 
all, of these cases have been caused by sulfamethoxa-
zole, Brumfitt et al advised caution that TMP cannot 
be ruled out as a cause of skin reactions 12 
Blood Effects Hematological side effects were an-
ticipated for TMP because of its mode of action Con-
cern that TMP interferes with human folate metabo-
lism, and hence hematopoesis, appears to be largely 
unfounded " Only in patients with potential preexist-
ing deficiencies in folic acid or vitamin B, . (alcoholics, 
malnourished individuals, pregnant women, patients 
receiving phenytom or folate antimetabolites), could 
some problems with TMP be anticipated ^ In view 
of the high selectivity of TMP for bacterial enzyme 
systems and the potential for prevention or reversal of 
any effects by the administration of folimc acid, hema-
tological problems with TMP are probably not a 
senous clinical threat 
Renal Effects A recurring problem with co-tn-
moxazole therapy is the deterioration of renal function, 
which appears to be associated with acute tubular 
necrosis 'M It has been suggested that this necrosis 
may be due to sulfonamide hypersensitivity114 and/or 
crystalluna associated with sulfonamides and their N,-
acetyl metabolites 39 
Although there have been reports of reduced cre-
atinine clearance associated with TMP,He there does 
not appear to be any senous danger of nephrotoxicity 
with the use of TMP alone β ,л '" Several studies have 
now concluded that fewer side effects and adverse 
reactions occur with TMP than with co-trimoxa-
20І£ В 12 15 30-ЗН 
Pharmacokinetic Properties 
Absorption Figure 2 shows the pharmacokinetic 
profile of a 151 mg oral dose of TMP administered to 
a healthy volunteer TMP is absorbed rapidly and 
almost completely After a single oral dose, the peak 
level of TMP occurs between the first and fourth 
hour,·19-41 the plasma concentration being propor­
tional to the dose 
Drug Intelligence and Clinical Pharmacy VOL 15 MAY 81 327 
273 
Distribution. Approximately 45-50 percent of TMP 
is protein bound." TMP is distributed to body tissues, 
and the apparent volume of distribution (Vd) is esti­
mated to be 69-130 L,"" suggesting adequate tissue 
uptake. The level of TMP in many tissues and fluids 
has been reported to be equal to or to exceed the 
serum concentration (Table 2). Significantly, when 
co-trimoxazole is used, TMP concentration in the 
prostate secretions and tissues equals or exceeds 
plasma levels, whereas sulfamethoxazole does not ap­
pear to reach therapeutic concentrations in the pros­
tate.42 Lower, but potentially therapeutic concentra­
tions have also been reported in other tissues and 
fluids (see Table 2). Significant concentrations of 
TMP also have been reported in breast milk, amniotic 
fluid, and fetal plasma.42 The significance of these 
concentrations as a potential hazard to the breast-fed 
or unborn child has not been determined. 
Metabolism. After absorption, TMP is about 20 
percent metabolized,4·,·4·г, and the metabolites do not 
possess antimicrobial activity. Weinfeld and Macasieb 
have studied the metabolism of TMP using high pres­
sure liquid chromatography techniques,40 and five 
metabolites have been identified.42 
Mechanism of Excretion and Influence of Urine pH. 
Sharpstone first observed that the renal clearance of 
TMP was increased by a decrease in urine pH, but 
not by increasing urine flow.47 Bergan and Brodwall 
confirmed the pH dependency on TMP renal clear­
ance;4" however, the actual mechanisms of TMP ex­
cretion have been the subject of some speculation 
TMP is a weak base (pKa 7.3), and in its undissoci-
ated form at alkaline pH, TMP undergoes passive 
tubular reabsorption. Under alkaline urine conditions, 
the renal excretion rate of TMP exhibits a constancy 
over ± 2 0 hours, before it parallels the plasma concen­
tration. This behavior indicates that, at alkaline 
conditions, other processes such as active tubular 
reabsorption might occur (see Figure 2). 
The more-or-less constant correlation between the 
renal clearance of TMP and the renal clearance of 
creatinine shown by Sharpstone47 and Bergan and 
Brodwall4'1 indicates that glomerular filtration might 
be the predominant mechanism of TMP excretion 
Sharpstone showed that TMP clearance substantially 
exceeds creatinine clearance at acidic urine pH and 
speculated that some active process, possibly tubular 
secretion, accounted for the excess TMP excretion.47 
Our own findings (Vree et al., unpublished data) in­
dicate that there is no major tubular secretion process 
involved in the elimination of TMP at acid pH The 
renal clearance of TMP under control conditions 
(without probenecid co-medication) is 87.61 ± 30 55 
ml/min, while the renal clearance of TMP under the 
influence of probenecid co-medication is 90.39 ± 
27.72 ml/mm (at pH 5.6). 
Figure 3 shows the relationship between the renal 
clearance of TMP and creatinine based on the data of 
Bergan and Brodwall4" plus additional data (Vree ТВ 
et al., unpublished data). The pH dependency of 
TMP renal clearance is clearly evident. At acidic pH 
- trlmMhoprlm 
Figure 2 Pharrnacokinettc pronte of orally administered trimethoprim 
showing plasma concentrations (Mg/ml) and renal excretion rates 
(fig/mui) under conditions of alkaline and acidic urine. The dotted 
lines represent acidic urine conditions (pH 5 44 ± 1 2 5 ) and the solid 
lines represent alkaline urine conditions (pH 7.34±:0 78). The pH 
dependency of trimethoprim eRcretion is clearly evident in the half-life 
(114) values. 
values, passive tubular reabsorption would be mini­
mal, so glomerular filtration must be the predominant 
excretion parameter, while at alkaline pH values re-
absorption would be maximal and would reduce the 
total renal clearance of TMP. From Figure 3 it may 
be observed that the pH dependency is virtually non­
existent at creatinine clearance values below 50 
ml/min. The linear relationship between the renal 
clearances of TMP and creatinine and the absence of 
active tubular secretion, as shown by the probenecid 
co-medication, validates the conclusion of Sharpstone 
and Bergan that renal excretion of TMP is predomi­
nantly achieved by glomerular filtration. 
Trimethoprim and Kidney Function. TMP is only 
about 20 percent metabolized and is excreted in the 
active and unchanged form up to 80 percent in the 
urine; therefore, the half-life of elimination of TMP 
is dependent on kidney function. Kasanen et al. 
showed a linear correlation between the creatinine 
clearance and the half-life of trimethoprim in 11 pa­
tients with various degrees of renal impairment.0 Renal 
clearance of TMP is primarily via glomerular filtra­
tion.47·4" Tubular reabsorption of TMP is pH de­
pendent for kidney functions represented by creatinine 
clearance values of more than 50 ml/min. It would, 
therefore, be feasible to alkalinize the urme with 
sodium bicarbonate to enhance the rcabsorption of 
TMP, and thus, possibly lengthen the dosage interval 
in patients with normal or near-normal kidney func­
tions. 
The main advantage of TMP alone over the 
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TMP'sulfonamide combinations, in the presence of 
renal impairment, is the reduction of the risk of renal 
toxicity, most notably crystalluria caused by sulfona­
mides and or their Nj-acetyl metabolites It should 
be noted that in patients with advanced renal impair­
ment, even when the dosage of TMP is appropriately 
reduced, urinary concentrations of TMP still exceed 
the MIC for most urinary pathogens 0 " - « » A 
KEV WORDS inmethopnm pharmacokinetics, co-tnmoxazole 
ABSTRACT 
The recent marketing of trimethoprim (TMP) as a single drug 
has resulted in interest in the use of this drug to treat com­
mon infections The history and antibacterial properties of 
TMP are reviewed Indications for the clinical use of TMP 
are presented, and possible new uses for the drug are con­
sidered The significance of adverse effects is discussed The 
pharmacokinetic properties of TMP are reviewed with par­
ticular emphasis on the renal handling of the drug and its 
advantages over TMP/sulfonamide combinations in relation 
lo renal function and toxicity 
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SUMMARY 
The development and maintenance of an Integrated Clinical Pharmacy 
Department Is described. 
The use of a computerized system as a tool to manage drug use, turn 
over monitoring and total costs of drug therapy In the central and 
decentral pharmacy proved Its utility. The compliance to the the-
rapeutical Formulary 1s clearly shown. The Intensified contacts 
between the Health care workers has led to the Involvement of the 
Clinical Pharmacy Department In patient care. 
INTRODUCTION 
One of the main objectives In treating hospitalized patients with 
medications, should be the guarantee, that the right patient gets 
the right drug 1n the right amount. In the right way and at the 
right time, and assuring the expected effect of the chosen medica-
tion. The recognition that frequently this 1s not reached, has led 
to a revolution 1n Hospital Pharmacy from the traditional, conven-
tional form to a more clinically oriented Pharmacy. 
As those revolutions have also constructive elements, many indivi-
duals and Institutions have recognized the new perspectives of 
pharmacists, nurses, physicians and other health care workers. 
Some of them have reorganized their system. One of the key objec-
tives in Clinical Pharmacy is to assure rationa! drug therapy and 
drug utilization control, identified by assuring optimal safety in 
the distribution and use of medication. 
The most important criterium of utility of a distribution system 
1s the consideration of absence of medication errors, that must 
be balanced against cost. 
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However, It Is an extremely difficult task to compare costs among 
several different pharmacy departments (1). 
Absence of medication errors: 
Observations In a 300 plus bed general hospital with a conventional 
drug distribution system Indicate that omissions and commissions 
may occur as often as once In every seven opportunities (2). 
Other studies compared medication errors In hospitals, showing per-
centages of omission and commission between 8 and 20, In conven-
tional distribution systems. (3,4) 
The categories of medication errors are listed below as 
1. Omission 
2. Commissions. 
2.1. Wrong dose 
2.2. Extra given dose 
2.3. Unordered drug given 
2.4. Wrong dosage form 
2.5. Wrong time 
Studies In hospitals with unit-dose systems show results of lower 
total observed errors of about 3.52 (3,4). 
In those systems the Hospital Pharmacy Department Is part of the 
medication distribution system, or better, health delivery system, 
where Improved patient care Is promoted through a closer profes-
sional relationship between pharmacists, nurses and physicians. 
More nursing time for patient care will be the result. In most of 
these newer medication systems, the use of a unit-dose or unit to 
use packed and formulated drug 1s an Important component. In fact, 
It Is becoming more and more evident to pharmacists, medical doc-
tors, nurses and administrators that effectively used unit-dose 
packed drugs can allow economic, hygienic and more reliable ser-
vices. 
In fact every hospital in the world Is practising unit-dose, i.e. 
all medications are ultimately reduced to an Individual dose before 
a drug is administered to a patient. So. it Is better to consider 
at what point in the chain from manufacturer to patient unit-dose 
must be implemented. Our opinion is that this should be done at the 
level of manufacturer or next best at the Hospital Pharmacy level. 
The industry has recognized the need for unit-dose packaging as 
required by the total therapeutic regimen within the hospital, but 
has not yet conducted action for the european market. 
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In the meantime there are a few possibilities for obtaining drugs 
in single unit dose packages (5). 
1. Manufacturer and drug-importer 
2. Wholesalers 
3. Contract packaging companies 
4. Hospital Pharmacy Departments 
In the beginning of UDP in The Netherlands there was no possibility 
of obtaining the prepacked drugs from the manufacturers neither 
from wholesalers, probably because of economic reasons and small 
divergent market. Meetings to stimulate collaborative efforts were 
not very succesful. In addition the dutch drug supply and pharma-
cy practice act prohibited till 1976 the forwarding of bulk drugs 
to packaging companies for transformation Into unit-dose. This was 
considered as dispensing of drugs and according to the law the 
pharmacist in hospitals may only dispense drugs to patients admit-
ted to the hospital and to resident nurses. 
So it was decided to develop manufacturing facilities at our own 
hospital. The possibilities of producing single unit-dose packages 
of solid oral drugs on a large or medium scale in Europe have been 
demonstrated by Amacker, van der Kleijn, van der Kuy and Phaf and 
others, (ref. 5,6, 7 ) . 
The procedure for the repacking of drugs by the Hospital Pharmacy 
Is based on a protocol, that contains the following five elements: 
1. order processing 
2. entrance control 
3. packing 
4. final control 
5. registration 
1. On the orderform the number of units, dosage form, name of pro-
duct, edp code and supplier are reglstrated. 
2. The entrance control contained the name of manufacturer, the 
lotnumber, the expiration date, the result of quality control 
and the entrance check by a technician. 
3. The packing procedure contained the name of the person who 
packed and checked, the date of padcing, examples of labels, 
used for unit dose packs and the cartons, and the final check 
by a technician. 
4. The Identity control is basis for the Final Quality control • 
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5. Regi stration of the number of units received, the number of 
units going into stock and the difference (= waste) are regi-
strated. 
So hospital pharmacists utilizing complete unit-dose drug distri-
bution systems at the present time, have been forced to package 
many of the items themselves but surely they will gladly give up 
this packaging role, merely because of economic reasons. 
HOSPITAL'S REPACKING COSTS PER UNIT 
The hospitals annual costs of repacking solid oral dosage forms 
from bulk containers into unit-dose aluminium backed pressure re-
lease packs, have been calculated. (5). 
This calculation takes into account all costs for labour, equip-
ment ( 1.
 e. annual depreciation costs and average interest costs), 
accomodation, costs of packaging materials, engineering, cleaning 
and the costs of cooling water, pressurized air and electricity 
supply. 
The total costs of repacking 1.5 million oral dosage forms amounted 
to Df 1 . 75.000,-- in 1975, which equals a cost per unit o.f 5 cents 
of a guilder. 
It has to be emphasized that these costs per unit are related to 
the procedures that are valid for our hospital and the costs as re-
lated to the level of labour costs in Holland. The costs per unit 
depend to a large extend on procedures requiring great labour con-
test, such as the frequent controling steps during manufacturing 
and the manually packing of strips of 5 units in a row into cartons. 
The batch size being small on an average and the fact that only 25 
percent of the machine capacity has to be used to cover our needs, 
affects the costs per unit too. 
Undoubtedly pharmaceutical companies can manufacture these u.d.p 's 
at a lower cost level as a consequence of larger batch sizes and 
automated control steps. Besides that the pharmaceutical companies 
are far more better equipped for the manufacturing of u.d.p 's in 
a controlled environment than hospital pharmacies. 
Last year the transfer of bulk drugs to a contract packaging compa-
ny was accepted by law as a legal procedure. The legal aspects of 
this solution make differences between the possession and the owner. 
ship of the ordered drug. 
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The responsibility for the pharmaceutical quality is now for the 
ordering Pharmacy and the responsibility for the homogeniety of the 
batch is for the contract packaging company. 
In the Sint Radboud Hospital all oral Formulary drugs are me-
chanically blister packed in single self adhesively labelled unit 
dosages to allow identification, hygiene and easy registration of 
drug intake. 
In close cooperation with the nursing staff the choise in our hos-
pital was to use a "push through" blister pack as this is the 
easiest package to handle. Nowadays, only those items are repacked, 
that cannot be obtained unit-dose packed by manufacturer or whole-
saler. Then packaging is performed on a Klöckner EAST- unit dose 
blister packing machine. The external dimensions of the blisters 
are fixed at 25x50mm for ergonomie ease and standardization. ( see 
figure 1 ) . 
figure 1 
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Un1t-dose Is Just one component In the development of a more cli­
nically oriented pharmacy. 
In a previous paper (8) the methods to establish and monitor In­
dividual medication profiles and dosage regimens In pharmacothe­
rapy are described. 
The development of the Clinical Pharmacy Department 1n our hospital 
has been approached along essentially five main pathways. 
1. Drug management procedures 
2. Prescription processing 
3. Drug dispensing 
4. Drug utilization research 
5. Clinical pharmacokinetics 
However, 1t Is Important to realise the coherence between these 
paths as shown In figure 2. 
Several of the connecting links will be discussed more 1n detail. 
Kardex 
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J 
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1. DRUG MANAGEMENT PROCEDURES 
A. Therapeutical Formulary 
Together with the Introduction of the unit-dose package there 
has been a limitation of the number of several, therapeutically 
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ITEM REDUCTION BY HOSPITAL FORMULARY SYSTEM 
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identical drugs by means of the so-called Radboud Hospital For­
mulary. The compulsory character of this drug list was stimu­
lated by the medical and hospital boards. The effect of this For­
mulary is shown in figure 3,4 and 5. (9). 
Hypnotics : (fig. 3,4). 
Although the guidelines for hypnotics were applicable to dispensing 
of hypnotics since 1973 it appeared much more difficult to limit 
the use of this group of drugs in the hospital. In fact introduc­
tion of the unit-dose system and the improved authority by the phar­
macy to propose change of medication orders has strongly contribu­
ted to the item reduction and the relative increase of use of For­
mulary choices. 
Ascorbic acid ( Vitamine С ) , (fig. 5 ) . 
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The usefulness of ascorbic acid in therapy with the exception of 
scorbut Is arbitrary. Its large turnover in tablets of 50mg with 
citric acid has raised considerable doubt. Its harmlessness and 
inexpensiveness may explain the use in hospitals by both patients 
as well as personnel. The introduction of the unit-dose system for 
Formulary drugs led to a disproportionate increase of costs per 
unit. Therefore Instructions were given to the Pharmacy personnel 
to limit the distribution of ascorbic acid. This has led to a re­
duction in use and a steady level. This level was, however, con­
sidered still too high for the possible incidences of Vitamin С 
deficiency. The decision of the Formulary Committee to take Ascor­
bic Acid 50mg tablets out of the Formulary and the application of 
the Formulary guidelines to the 5Orag tablets led to an almost com­
plete elimination from the statistics. 250mg tablets and compounded 
formulations remain available for clinical indications. 
Although such measures were carried out the steep increase in cost 
of drug therapy remained. The hospital management decided to review 
the drug distribution from pharmacy to patient Including all 
administrative procedures. 
The purpose of the study was to determine the feasibility of a 
computerized system for the 
- turnover monitoring and inventory control 
- medication order processing 
- pharmacotherapeutic monitoring 
The Introduction of EDP systems for drug management has been care­
f u l l y analysed. Scenario's for the development of such a system 
starting from different sections In the distribution model ( f i g . 6) 
DRUG DISTRIBUTION IN A HOSPITAL 
Production 
Facility 
Ward 
Inventory 
figure 6 
Supplier 
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have been elaborated (10). Then It turned out that for our hospi-
tal the automation of drug management should start 1n the pharmacy. 
This result has been confirmed by the Implementation of GENESYS, an 
offline pharmacy management system. (11). 
This system has demonstrated the utility of modern Inventory con-
trol 1n a hospital pharmacy. In addition the system allowed for 
a considerable improvement of the quality of drug management 
through the hospital by Its detailed turnover surveys. 
The cholse of starting the EDP system 1n the Pharmacy has led to 
consequences on the Prescription processing and will give pos-
sibilities for the control of drug utilization. This system will be 
extended stepwise to inventory control on the wards and finally 
to medication order processing and drug monitoring. 
2. PRESCRIPTION PROCESSING 
The initial step 1n any drug distribution system is the decision 
of the physician to order a drug for his patient. This activates 
a chain of events till the medication Is administered. 
In 1962, the published investigations by Barker and HcConnell 
on the serious problem of medication errors stimulated the 
réévaluation of conventional drug distribution systems. (12). 
A significant source of medication error proved to be the trans-
scrlptlon of the order. The development of new forms for the 
prescription processing was necessary, not only for the safer 
arrangement of the physical drug distribution, but also to Im-
prove compliance and confidence In medication records. 
The processing routine 1n these newer distribution systems con-
sists 1n general of the following steps: 
1. Written Physician's medication order 
2. Unambiguous transfer of the order or a copy to the medication 
Record Chart, and a copy of the order sent to the Pharmacy. 
3. Checking of the Integral medication. 
4. Charting dosages given. 
5. Accounting for rendered services. 
In all these steps it is necessary to built in security and control. 
Especially just before administration the identity of the patient, 
matching of the original order with the chosen drug should be con-
firmed. Medication monitoring Itself wil! be discussed later. 
In many hospitals the change of a conventional drug distribution 
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system to unit-dose required stepwise implementation by interim 
systems. To start, pilot trials were proposed to incorporate unit-
dose into Pharmacy Services. In those proposals there are mainly 
two essential differences between several hospitals, being the 
use of a Centralized Pharmacy or a Decentralized Pharmacy. 
The criteria for the best strategy may be different for each indi­
vidual hospital, depending among others on distance from the cen­
tral pharmacy, availability of a pneumatic tube system, vertical and 
horizontal transportation facilities etc. 
In the St. Radboud Hospital the pilot study started on a surgical 
ward located at a considerable distance from the central pharmacy. 
Because of the lack of intensive transportation facilities at that 
time, peripheral pharmacy services were chosen. 
It was kept in mind that several functions could be centralized 
as a "drug catering" service. "On the spot" judgement by 
pharmaceutically authorized personnel on the wards is considered 
to remain indispensable. 
The system that is worked out for the St. Radboud Hospital uti­
lizes the following elements: 
a. Serial medication order form with one or two NCR copies kept 
in a Multo^ r' ring binder. One of the copies is self adhesive, 
and is used in the Medication Record Chart. The other is used 
in special occasions (pediatric department). 
b. Medication Order Form. 
с Cumulative dispensing order and medication record chart. 
d. Medication record extension form. 
Chart for treatments extending the preprinted 14-day period. 
e. The Kardex, containing all medication record charts of the 
ward. (fig. 7 ) . 
Now, the medication order and registration procedure has been im­
plemented succesively using the Kardex as the integral medication 
sheet for Medication Monitoring. This system is used on all the 
wards, with the exception of the Intensive Care. Because of the 
frequent changing of medication profiles dependent on clinical 
and chemical data, it is considered difficult to schedule here 
the medication. 
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The pediatric department is using the same system. In addition a 
second copy of the medication order, is transfered to a form with 
a Scotch* ' ATG dispenser with adhesive transfer tape and sent to 
the central pharmacy. 
Here controlling of dosage regimen in respect to age and weight is 
carried out. Compounding is often necessary and taken from this 
order. 
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3 . DRUG DISPENSING 
3.1. Monitoring 
Checks before, during and after medication are necessary 
as a routine. This can be concentrated on the individual 
patient when all medication orders, using a copy of the 
original, will be received in the Central Pharmacy. Auto­
matic monitoring by the computer gives evidence of a fre­
quency of severe interactions, requiring action of the 
Pharmacy Department to alert the prescriber of about 0.2% 
(13,14). 
Monitoring the medication profile on the wards by pharma­
cists or technicians supervizing the medication orders, 
allows the checks of integral medication together with 
clinical information about the patients. 
3.2. Preparation for dispensing 
The unit-dose packed drugs are taken from the ward stock 
and placed in the drawers of a medicationcart (fig. 8 ) , in 
ΙΐΐΓΓ' 
figure 8 
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the compartment designated to the administration times. 
There Is a fixed time schedule, depending on the frequency 
of administration. Every Individual patient has Its own 
drawer. These carts have been developed 1n collaboration 
with TNO, Delft and manufactured by Stalo, St. Oedenroede., 
The Netherlands. The medication carts contain essentially: 
a. Trays that can be Individually labelled and divided Inte 
sections for the various administration times of the day. 
b. Room for l.v. utensils and disinfection materials. 
c. Disposal bag. 
d. Room for the Kardex folder system. 
e. Lock for preservation of the contents. 
At the proper time the carts are wheeled to the room and the 
drugs are administered by a nurse to the patient. This handling 
Is recorded by initialing. Although each unit-dose Is provided 
with a self-adhesive label, that can be removed after administra-
tion of the drug and placed on a medication form, this system 1$ 
not used because of Its time-consuming, complicated handling as 
experienced by the nurses. This procedure of dispensing scheduled 
medication and charting the administration 1s worked out for all 
oral solid drugs, suppositories, oral liquids and parenteral ad-
ministrations. For unscheduled medication a separate field 1s re-
served on the form. The preparation and dispensing routine by 
pharmacy technicians on the wards before administration of the 
drugs and charting by nurses is still under study at one ward. 
3.3. I.V. additive support 
Another aspect of Individualized drug dispensing can be seen 
in the preparation and dispensing of sterile fluids for Im-
mediate use. The I.V. additive support, considered a task of 
the Hospital Pharmacy, Is gradually extending. Spedai pro-
cedures as screening for compatibilities and stability and 
the use of strict aseptic techniques are In development. 
Nowadays the pediatric and gastroenterology department are 
obtaining their tota! parenteral nutrition, prepared by the 
Central Pharmacy. 
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3.4. Information Centre 
With the extension of professional services in the hospital 
to supply information on drugs and poisons, a special centre 
has been created. Information on use, dosage, adverse reac-
tions, interactions, stability and compatibility can be re-
ceived from this centre. This centre has access to several 
information systems, some using computer procedures to update 
their information like Medline, Toxline etc. 
The gathered information is also used to update the Hospital 
Formulary. The questions and answers are filed for retrospec-
tive survey and later use. Although the Centre can depend on 
national centers for drug information (Royal Dutch Pharma-
ceutical Association) adverse reactions (Ministery of Health, 
Leidschendam) and Drug Intoxications (National Poison Centre, 
Utrecht) it has been proven necessary to have a local center 
operational for coordination. 
4. DRUG UTILIZATION 
For the drug turnover monitoring and inventory control of the 
Pharmacy and the hospital wards an EDP system has been intro-
duced in the St. Radboud Hospital (11). 
It has been clear that regular reporting on drug utilization 
would require some degree of computerization. Using computerized 
stock, turnover administration, inventory control and accounting 
programmes it is possible to get information about: 
1. Compliance to the hospital formulary 
2. Stock in pharmacy and the wards 
3. The use of drugs by various groups and individuals 
4. Total cost of drug therapy 
4.1. Compliance to the Hospital Formulary 
The development, maintenance and evaluation of methods to 
improve drug distribution, including the use of a hospital 
formulary, are described elsewhere. (9). 
Although the medical and hospital board have stimulated the 
compulsory character of these drug lists, compliance to the 
291 
94 
formulary is depending on the relationship between the phy-
sician, nurse and pharmacist. In a retrospective analyses 
of four wards, representating the hospital, the compliance 
in 1975 and 1976 was studied, (fig. 9 ) . 
Compliance to the Formulary in '75 and '76 
ward 
year 
items 
compiiance 
in % 
I 
75 
399 
97,7 
76 
387 
977 
II 
75 
399 
96,7 
76 
451 
9817 
III 
75 
491 
96.1 
76 
422 
98,3 
IV 
75 
496 
96,4 
76 
500 
962 
totals | 
75 
967 
76 
97,7 
figure 9 
These results indicate an acceptation of the therapeutic Formulary 
within the hospital. However, a reduction in items has not been 
observed in this period, but compared to the number of items in 
1974, there is a reduction of 15%. 
4.2. Stock of drugs in the Pharmacy and on the Wards 
In a Pharmacy all drugs are supposed to be available in 
sufficient quantities. A system to compute the optimum 
stock of each drug and the optimum order quantity (11) has 
proved its usefulness by the improved inventory control. 
(see figure 10). 
RATE OF TURNOVER 
months 
.theor computed rate 
1 \ 
1972 1973 
figure 10 
1974 1975 1976 
The savings exceed the costs of additional manpower and 
maintenance of the EDP systems. 
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4.2. Stock on the wards 
2. The number of Items on the hospital wards varied from 150-
250 drugs per ward. Starting from the assumption that this 
number was too high it was tried to reduce it. In a pilot 
study on three wards intensive monitoring of turnover sta­
tistics showed the possibility to reduce this number to 
100-140 Items. Many items were available on the ward, with 
none or little turnover. This Is likely due to the nature 
of a university teaching hospital, with Its rapid change of 
medical and nursing staff and admission policy. 
In this pilot study the rate of turnover of the stocks on 
the wards expressed in months, varied between 1,2 and 2,8. 
The computer data of dispensing of drugs to the wards with 
the actual use are compared now every three months. From 
these data updating of the order sheets 1s carried out. 
Every ward has now its own 100 items order sheet, depending 
on their actual use figures. If an item 1s not used during 
this 3 months period, it 1s returned to the central Phar­
macy. The influence of such actions showed its useful effect 
during the integral switch over to unit-dose package in the 
. central and decentral pharmacy in 1974. 
As a result of this action a decrease in units of drugs 
and drugvalue on the wards has been obtained, (fig. 11). 
conventional 
packaging system 
units 
224000 
value in 
D.F1 
55.500 
UDP 
system 
units 
125500 
value In 
D.F1 
ЗЭ800 
% 
decrease 
units 
44 
value 
39,IX 
figure 11 
4.3. Utilization of drugs 
3. The increase of use of blood, bloodcomponents and blood 
substitutes, can be seen in figure 12. As the actual pri­
ces and the prices in 1974 are comparable, there has been 
an increase 1n use. Figure 13 shows this results with the 
use of antibiotics. The Increase of use has not led to a 
proportional increase of costs. On the contrary, a relative 
decrease can be observed. 
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Thli dtcretie of coiti ein bt accounted for by tht Improved 
condition· of purchaie. 
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Such data supply valuable statistics for the Formulary com­
mi ttee. 
4.4 Total costs of drug therapy 
The costs of drug therapy have been increased rapidly as seen 
in figure 14. 
The dip between 1972 and 1974 is almost exclusively due to the 
introduction and maintenance of the hospital formulary by its 
item reduction of drugs. This has led to better merchandise 
possibilities. 
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The extension of the Intensive Care and Coronary Care Unit In 
1974 has contributed to the rapid Increase in costs in 197S. 
These two wards with 14 beds accounted for about 20Ϊ of the to­
tal drug budget in the period of 1974-1976. 
However the steep increase of expensive drugs as blood prepara­
tions, antibiotics, antineoplastic agents etc. have led to the 
Increase in cost of drug therapy per day of hospitalization. It 
is necessary to solve this problem, by domestic management pro­
cedures and guidelines for priority judgement for expensive, 
scarce or epldemiologically hazardous drugs. 
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5. CLINICAL PHARMACOKINETICS 
The support of an analytical research team is indispensable for 
a department of clinical pharmacy, to enable continuous adapta-
tion of the hospital formulary to the views of those, responsa-
ble for the prescribing, compounding, preparation, dispensing 
and administration of drugs. Drug analyses in biological fluids 
are carried out for several different intentions. 
1. Accompaniment of drug choice and therapy, 
2. Clinical Toxicology, 
3. Research. 
5.1. Accompaniment of drug choice and therapy 
The choice of an adequate therapy in hospitalized patients 
is to be considered with many variables in mind. 
1. Bioavailability study. 
These studies are necessary to choose the right drug 
formulation and preparation in order to obtain the de-
sired efficacy. The choice between a sustained release 
preparation and a preparation with rapid release such 
I r) 
as Depakine v , Procainamide etc. can be made. 
2. Monitoring of pharmacotherapy 
The use of plasma concentration values to monitor phar-
macotherapy has been well established for anti-epilep-
tics, antiarrythmics,digital i s glycosides, theophylline 
and antibiotics. Consequences for the therapeutic regi-
men can be expected as a result of the analyses. When 
"therapeutic" concentrations of the drug are not ob-
tained: 1. Correction of the dosage regimen, or 2. adap-
tation of the route of administration, or 3. changes to 
other formulations, are the result. 
3. Interactions 
The influence of comedication on the therapeutical ef-
ficacy of drugs is unanimously recognized. The influence 
of these kind of interactions on plasma concentrations 
may have consequences on drug therapy and dosage regi-
men, to maintain patients on the desired plasma concen-
trations. Interaction with drugs may also occur with food 
often resulting in a sustained absorption of the drug. 
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For some drugs
 s u c h as antibiotics this may result In Inade-
quate plasma levels. 
Clinical Toxicology 
For the treatment of patients with an overdose of drugs, the 
Identification of the drugs of course is a guideline for the-
rapy. Sometimes quantitative data for drugs as paracetamol 
are required prior to the use of a rather toxic antidotum as 
cysteamine. In many cases of barbiturate overdosing the moni-
toring of plasma concentration tells the physicfan how the 
metabolic enzym systems are coping with the problem. Taking 
care of patient and enzym systems may solve the problem. 
Research 
Extensive research 1s necessary to Investigate kinetics and ef-
fects for a proper handling of the drug. Subjects to be in-
vestigated are metabolism, placenta transfer, dosage regimens 
in neonates, children and adults and kinetics in disease sta-
tes as Impairment of renal or liver functions. A scientific 
unit in a clinical pharmacy department can not be seen as a 
separate unit. It is placed at the end of pharmaceutical 
handling and serves the feed back of drug fate 1n patients, 
into the pharmacy policy and subsequently in the hospital for-
mulary. 
As a result of the development of the Clinical Pharmacy De-
partment, the professional contacts between nurses, physi-
cians and pharmacists have been Intensified within the hospi-
tal. 
Pharmacists and pharmacy technicians are now, as a consequence 
of the choise of Clinical Pharmacy, also Involved In patient 
care. A dally contact between the Pharmacy Department and the 
Intensive Care Unit has been established. This cooperation has 
led to interesting results (15) and do show the usefulness of 
strong cooperation. 
In other departments as neurology, biological psychiatry and 
pediatry such a contact is once a week, when the Clinical 
Pharmacy Department is contributing In the weekly patient 
rounds. Also the therapy subcommittees can be seen as examples 
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of th· 1nttni1f1>d conticti bttwein th» participant! In health 
car·. 
Eiptelally th· comltt··! on adequate us« of ant1«p11aot1ct and 
antlneoplaitlc agenti «.g. Mithotraxat« (MTX) proved thalr uti­
lity. All thai· contact* may lad to a batter undantandlng of 
the mutual problemi and may Improve patient care. 
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SUMMARY 
The widespread use of antibiotics has led to the formation of multireslstant 
strains. Guidelines and instructions for the use of antibiotics on a surgical 
ward were prepared to reduce antibiotic utilization. Application of these 
generally accepted guidelines resulted In a reduction of overall costs of anti­
microbial therapy by 25%. This study proves the necessity of rational antibiotic 
treatment and Its effects on costs of treatment, without interfering In the 
quality of patient care. 
INTRODUCTION 
The widespread use of antibiotics has led to the formation of multireslstant 
bacterial strains. This is especially the case In a hospital environment. 
Administration of antibiotics possibly gives rise to development of resistance, 
to more or less harmful side effects and can even lead to decrease of the 
patients own defence . 
The only way in which the sensitivity of micro-organisms can be restored or at 
least maintained Is by rationalization of the prescription habits and by a well 
considered use of the most suitable antibiotic in the most appropriate dosage, 
2 
taking a time-limit into consideration . 
The aim of this study Is to show that rationalization will not only result In 
ecological but also In economical profits, without Interfering in the quality 
of treatment of the patient. 
A working group of the Veterans Administration Ad Hoc Interdisciplinary 
Advisory Committee on Antimicrobial Usage has published a serie of articles 
about the conditions to be fulfilled In order to reach a sufficient policy for 
the use of antibiotics3- . 
35 
A p p e n d i x I I I 1 
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The most important criteria in selecting antibiotics are : 
1. Efficiency (from literature data) 
2. Toxicity 
3. Costs of treatment per day 
k. Mode of administration 
5. Bacteriogram of the hospital and the department. 
Based on the above mentioned articles a rationalized policy for antimicrobial 
usage has been adopted In the Department of General Surgery of the Sint Radboud 
Hospital. 
This policy (practiced In the department of general surgery for male patients) 
was evaluated for an one year period, and was compared with a period preceding 
the introduction of guidelines. 
GUIDELINES FOR A RATIONALIZATION OF ANTIMICROBIAL USAGE. 
1. The medication chart of each patient should contain the following data: 
- the Indication of the medical problem for which the antibiotic Is being 
used 
- the dosage 
- the mode of administration 
- a time 1 imit. 
Especially the setting of a time-limit "nay result In a decrease of excessive 
utilization of antibiotics. 
Asking the physician to mention the Indication makes him aware of the used 
dosage, the contra-indications and the mode of administration. In addition this 
Information can also be used by consultants, other attending physicians ( in 
large institutes)and by the pharmacist. 
2. Differentiate between prophylaxis and therapy. Give a definition of prophy-
laxis and restrict the Indications. Prophylactic usage of antimicrobial 
agents in surgery is efficient when optimal blood-levels are obtained just 
before, during and shortly after the operation. 
As appears from different studies, prophylaxis can be started one or two 
hours before the operation. The woundconcentratIons of used antibiotics will 
be optimal then. Prophylactic usage for trauma-patients can be started as 
soon as possible after the arrival of the patient . 
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3. Prophylaxis means : 
A start before the operation, administration of all antibiotics intravenously 
and a stop within 2k - 't8 hours. 
k. Treatment with antibiotics is started after obtaining blood-, urine-, sputum-
and pus samples for bacterial culture. 
5. All antibiotics are administered intravenously. This leads to higher blood 
levels. It is a fool-proof mode of administration and there are no problems 
In the resorption of the used antimicrobial agents. 
6. Antibiotics used for therapeutical purposes should not be administered any 
longer than 10 - 14 days, except in chronic osteomyelitis, endocarditis, 
tuberculosis, staphylococcal sepsis and lung abcess. 
7. The patient rarely needs more than a combination of two antimicrobial agents 
to fulfill a therapeutic goal. Make a choice between antibiotics of the same 
class. Duplication leads to confusion, requires an excessive Inventory by 
the pharmacy and rises the costs. 
6. Therapy with a particulary antibiotic should be discontinued or adjusted when 
side effects occur, or when the micro-organism Is sensitive to a less toxic 
or a less expensive antibiotic. 
3· Infections of the urinary tract should not be treated with antibiotics while 
an indwelling urinary catheter Is used, except when this catheter is to be 
removed within 2k hours or in patients with a pyelonephritis or urosepsis. 
10.Consultation of a bacteriologist Is needed before starting treatment with an 
expensive or hazardous antibiotic or in case of prolonged treatment. 
RESULTS 
In comparison with other University Hospitals the usage of antimicrobial 
agents In the Department of General Surgery of the Sint Radboud Hospital prior 
to this study showed to be fairly low. 
TABLE I. 
ANTIMICROBIAL USE IN SURGICAL DEPARTMENTS 
W.E. Scheckler e.a. 1970 In 7 conmunity hospitals 22,3 - ks % 
A.W. Roberts e.a. 1972 non-Gov. comm. hospital 20 % 
Duke Univ. Med. Center 1977 kS % 
Sint Radboud Hospital 1977 25 % 
25% of all the admitted patients received antibiotics compared to kS% in the 
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Dukes University Medical Center . Due to intensive monitoring of these guide­
lines only 20% of the admitted patients were treated with antibiotics after the 
introduction of the guidelines. 
TABLE 2. 
RESULTS OF A RATIONAL ANTIBIOTIC TREATMENT 
92 (25 » 
81 (20 %) 
78 (20 %) 
f 
ƒ 
/ 
Total 
32.143.-
25,34ο.-
25,505.-
/ 
f 
f 
Average 
87.60 
65.50* 
66.59** 
Period Number of Number and percentage Total and average costs of 
patients of patients treated antibiotic treatment/per 
admitted with antibiotics patient/per hospitalization 
Jan - Jun 77 368 
Jan - Jun 78 387 
Jul - Dec 78 383 
* { - 25%) 
M ( - lk%) 
The number of patients receiving long-term antibiotic treatment (more than 10 
days) decreased from 25 ¡n the control period to 13 and 15 in the two studied 
periods (see Table 3)> though the number of admissions Increased. 
TABLE 3. 
EFFECT OF RATIONAL UTILIZATION OF ANTIBIOTICS ON THE NUMBER 
OF PROLONGED TREATMENT, AS RELATED TO THE NUMBER OF PATIENTS 
ELIGIBLE FOR PROLONGED TREATMENT. 
Period Number of patients Number of patients receiving 
eligible for antibiotics over more than 
prolonged treatment 10 days. 
25 (119 * ) 
13 ( 37 * ) 
15 ( 37 * ) 
The number of large bowel-operations and the number of admissions for chronic 
osteomyelitis was also significantly higher in the two periods studied. 
Jan - Jun 77 
Jan - Jun 78 
Jul - Dec 78 
21 
35 
41 
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TABLE h. 
INDICATIONS FOR ANTIBIOTIC TREATMENT IN DIFFERENT PERIODS 
Period Colon/rectum Osteomyelitis Sepsis 
operations chronica 
Jan - Jun 77 15 2 Ί 
Jan - Jun 78 21 7 7 
Jul - Dec 78 Zk 7 Ю 
The higher incidence of sepsis In the study could not be attributed to the 
change in policy. Some patients were referred from elsewhere with an already 
existing sepsis. In addition, a more agressive approach was used In patients 
with a so-called persistent abdominal sepsis. Laparotomies were carried out 
12 
repeatedly in these patients with a better than usual rate 
However a long stay in the hospital, partly in the intensive care unit Is 
required in these cases and the incidence of sepsis is significantly higher. 
An important aspect of the introduction of the guidelines for antibiotic usage 
Is that the number of antimicrobial agents as Indicated on the order list for 
the pharmacy was reduced. The number of topical antibiotics and antiseptics 
could be reduced from 22 to Ί . 
TABLE 5. 
EFFECT OF RATIONAL UTILIZATION OF ANTIBIOTICS ON THE NUMBER 
OF ITEMS ON THE ORDERING LIST OF THE HOSPITAL PHARMACY. 
Period Antibiotics Antiseptic solutions and 
AB for local treatment 
Jan - Jun 77 20 22 
Jan - Jun 78 10 5 
Jul - Dec 78 10 4 
The use of cephalosporlnes was decimated while the use of gentamiclne and 
llncomycine increased. This could be mainly attributed to the Initiation of a 
prophylaxis in cases of spilling during abdominal surgery (figure 1). 
The Influence of Introduction of guidelines on the usage of antibiotics Is 
shown in figure 2. There Is a decrease In the number of patients that received 
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antibiotic treatment for a long-term period. 
In addition there Is a clear change to short term therapy. 
Figure 3 shows the Influence of the guidelines explicitly for gentamicin 
utilization. Gentamicin is used for short-term prophylaxis in abdominal surgery. 
CONCLUSION 
A rational policy for the usage of antimicrobial agents was adopted and 
could be evaluated in practice due to an intensive collaboration between the 
departments of Clinical Pharmacy and General Surgery. 
This results in a decreased utilization of antibiotics and antiseptics associ­
ated with a saving of 25*. There were no adverse effects, interfering with the 
quality of treatment of the patient. 
Figure 1. 
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Figure 2. 
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Rational Antimicrobial Prophylaxis on a Urologica1 Ward. 
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St. Radboud Hospital, Catholic University of Nijmegen, 
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ABSTRACT 
The development of a policy for antimicrobial use on a urological ward 
is presented. 
The introduction of guidelines and the monitoring of Its effects for 
rational antimicrobial usage are described. As a result, of the imple­
mentation of this policy, a reduction in antibiotic consumption of 
over 50% was achieved, without interfering with the quality of patient 
care. 
These results were achieved by intensive collaboration between the 
departments of Urology and Clinical Pharmacy. 
INTRODUCTION 
The administration of antimicrobial drugs in and outside the hospital 
often occurs on a large scale and with insufficient indication . 
About 30% of the patients admitted to the hospital will be treated with 
2 
one of more antibiotics . 
It has been shown that excessive use of antimicrobial agents can lead 
to changes in the microbial ecological balance . In addition, anti­
biotics may change the intestinal flora, resulting in a selection of 
resistant microorganisms. This disturbance is now known as colonization 
4 
resistance . As bacteria from the intestinal flora are the primary 
source of infection of the urinary tract, it is obvious that resistant 
microorganisms resulting from a disturbance in the fecal flora produced 
by antibiotics can be the cause for urinary tract infections. 
When antimicrobial agents are used in conjunction with corpora aliena 
(catheters and splint catheters) in the urinary tract, the risk of the 
producing of resistant microorganisms is greatly increased. 
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Only rationalization of antibiotic prescribing policies will solve 
the problem of germ selection. 
The measures that must first be taken on the long and laborious path 
back to an ecological balance involves carefully considering which is 
the most appropriate antimicrobial drug to be administered, what is 
the appropriate dosage regimen and how long should the drug be ad-
ministered. 
Not only ecological but also economical benefits can be realized 
without loss of present day quality of patient care. 
6 
This has been described in a recent study . 
Considering the results, obtained on a surgical ward, the decision 
was made to introduce a rationalized antimicrobial prescribing policy 
in the Department of Urology. In implementing this policy, allowance 
has been made for differences in patient's population and in surgical 
approaches. 
The audit information of the Veterans Administration Ad Hoc Interdis-
ciplinary Advisory Committee on Antimicrobial Drug Usage was used as 
a guide . 
METHODS 
Drug Data Recording 
All drugs delivered by the pharmacy to the different departments of 
the hospital were recorded using a computerized inventory control 
Q 
system . All computer data are stored on tapes. 
The actual drug intake by the patients has been registered in the 
9 10 
nursing stations using individual patient registration sheets (Kardex ' ). 
The individual patient medication data are kept in the pharmacy per 
time period(yearly- quarter) and per department after dismissal of the 
patient from the hospital. This makes it possible to make separate re-
trospective studies on the ward level of drug usage for special groups 
* 4.· 4. ^ j 6/11 of patients and drugs 
Patient Data Recording 
Medical records and medication records of the patients admitted to the 
department of Urology were collected. 
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Group I 
Group II 
Group III 
Group IV 
a, b 
a, b 
a, b 
a, b 
Data of males (a) and females (b) were separated. Both these groups 
were further categorized according to age. The following distinction 
was made: 
< 25 years 
25-50 years 
50-60 years 
> 60 years 
The following data were collected: 
1. number of antimicrobial agents used per patient 
2. antimicrobial drug(s) used per patient 
3. sort of operation performed 
4. occurrence of post operative wound infections after gland dissections 
Rationalization of antimicrobial drug grescribtion 
Before discussing the administration of antibiotics in general, in 
cases of urological affections, in particular a clear distinction should 
be made between therapy and prophylaxis. 
Therapy with antimicrobial drugs is directed against an existing infec-
tion. This infection must be clearly defined: otherwise no comparison 
12 
can be made among the results obatained from different studies 
An infection is considered to exist when there is either a local or a 
systemical increase in microorganisms that is followed by a clinical 
reaction. Although this clinical reaction can express it self as pain, 
usually a rise of body temperature is seen. A clear bacteriemia with 
shock symtoms (urosepsis) is the most severe kind of infection. 
A urinary tract infection was considered to be present when from a 
single clean-catch midstream urine (MSU) sample a count of more than 
10 gram-negative colony forming organisms per ml of the same species, 
was obtained . 
In urological operations two approaches can be distinguished: 
1. The so called "open" urological surgery (abdominal-retroperitoneal, 
abdominal-intraperitoneal and the scrotal route). 
2. The "closed" transurethral route varying from singular catheteriza-
tion up to the elaborated endoscopic surgery of prostate and bladder 
tumors. 
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Guidelines, as agplied to the Department of Urology 
For urological indications the following guidelines were used: 
1. Closed transurethral operations. 
If the urine is preoperatively sterile, no antibiotics will be 
administered. If the urine is preoperatively infected, amoxycillin, 
4x1 gram intravenously per 24 hours, during 48 hours (starting when 
the premedication is administered). 
If an antibiogram is known, the most appropriate antibiotic is chosen, 
taking toxicity, potency and expense into account. 
2. Open non-transurethral operations. 
When opening the infected urinary tract, amoxycillin, 4x1 gram per 
24 hours, will be administered intravenously during 48 hours. If an 
antibiogram is available, the most appropriate drug is chosen. 
When serious manipulations of the intestines occur or when spilling 
of intestional contents is to be expected, gentamicin, 3x80mg in-
travenously in combination with lincomycin, 3x600mg per 24 hours 
is started. 
As an alternative for lincomycin metronidazol, 3x500mg has been used. 
Duration of prophylaxis was 48 hours. 
3. Catheter and/or splint in situ. 
In cases of a catheter and/or splint in situ, no antibiotics will be 
administered, except in situations when a urosepsis or pyelonefritis 
is present. 
4. Profylaxis is justified when a long disease or a valvular prothesis 
is present. General guidelines for prophylaxis have been described 
recently (6). 
Prophylaxis was always started one hour prior to the operation. 
5. Treatment of infections. 
Treatment of confirmed infections was based on an antibiogram. 
The choice of the most appropriate drug according to the antibiogram 
was based on efficiency, safety and expense. 
Study gerlods 
In the study, three periods were considered: 
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I Period January - June 1979 
II Period January - June 1980 
III Period July - December 1980 
period without guidelines 
period with guidelines 
consolidation of policy procedures 
Introduction of guidelines 
Prior to the introduction of the guidelines the medical staff of the 
Department of Urology discussed them at length and a general approval 
was obtained, 
RESULTS 
1. Patients admitted at the ward 
In figure 1 and table 1, the number of patients, admitted to the 
urological ward during each of the three study periods, is given. 
In table 1, these patients are categorized according to age and sex. 
ANTIMICROBIAL TREATMENT ON A UROLOGY WARD 
PATIENTS ADMITTED 1 
¿00 
300 
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53V. m 26·/. 
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Figure 1 
Number of patients admitted to the urological ward, separated in total, 
male and female. 
The percentage of the patients treated with antimicrobial agents is 
given in this figure for each study period, classified for the total 
group, the males and the females. 
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TABLE 1 
PATIENTS ADMITTED TO THE DEPARTMENT OF UROLOGY 
Age 
<25 
25 - 50 
50 - 60 
>60 
Total 
MALES 
Period I 
η % 
151 (49.8) 
67 (22.1) 
62 (20.5) 
23 ( 7.6) 
303 100 
Period II 
η % 
165 (55.2) 
51 (17.0) 
54 (18.1) 
29 ( 9.7) 
299 100 
Period III 
η % 
179 (52.3) 
56 (16.4) 
77 (22.5) 
30 ( 8.8) 
342 100 
FEMALES 
Period I 
η % 
55 39.8 
47 34.1 
23 16.7 
13 9.4 
138 100 
Period II 
η % 
58 45.7 
43 33.8 
11 8.7 
15 11.8 
127 100 
Period III 
η % 
46 41.8 
42 38.2 
10 9.1 
12 10.9 
110 100 
2. Percentage of patients treated with antimicrobial drugs 
Figure 1 and table 2 show the percentage of patients, separated 
by sex, who were treated with antimicrobial agents during their 
hospitalization. 
In the combined group of patients, a reduction is seen from 63% 
in the period without guidelines (period I), to 31% in the conso-
lidation period (period III). 
Both the average percentage of applied antimicrobial drugs in males 
and females are given (fig. 1) as well as per individual age group 
(table 2). 
In the combined male group a decrease frem 55% to 26% can be noticed. 
In the fçmale group, a decrease from 80% to 49% is seen. 
3. Changes in prescribing policy 
In the male groups of over 50 years, a striking reduction in anti-
microbial drugs used of about 70% has been established. 
This reduction is a result of the prophylaxis protocol, where no an-
timicrobial agents are applied in endoresections of the prostate in 
patients with preoperatively sterile urine. 
Such endoresections are especially prevalent in the age group of 
over 50 years. 
Drugs of choice 
In table 3 the number of males and females are given, per study period 
who were treated without antibiotics, those treated with single drug thera-
py and those treated with combined antimicrobials agents. 
From the groups treated with antimicrobial agents (both monotherapy as 
well as combined therapy) the pattern of use was determined. 
Figure 2 shows this pattern of drugs used in the three different study 
periods. 
Amoxycillin is the drug of first choice on this urological ward. 
The drug was used for respectively 75, 69 and 53% of patients treated 
with antimicrobial agents. 
The use of gentamicin and lincomycin increased gradually once this 
combination for prophylaxis in abdominal surgery, was selected. 
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TABLE 2 
PERCENTAGE OF PATIENTS TREATED WITH ANTIMICROBIAL AGENTS 
Age 
<25 
25 - 50 
50 - 60 
>60 
total 
HALES 
I 
74.8 
43.3 
33.9 
38.5 
55.4 
II 
46.1 
43.1 
29.6 
20.7 
40.1 
III 
36.9 
19.6 
10.4 
10.0 
25.7 
FEMAT.ER 
I 
83.6 
Θ3.0 
73.9 
61.5 
79.7 
II 
48.3 
51.2 
45.5 ι 
60.0 . 
50.4 , 
III 
52.1 
42.9 
50.0 
58.3 
49.1 
TABLE 3 
PATIENTS AND ANTIMICROBIAL DRUG USAGE 
no antibiotics 
monotherapy 
combined use 
total patients 
MALES 
Period I 
η « 
135 44.6 
143 47.2 
25 8.2 
303 
Period II 
η % 
179 59.9 
80 26.7 
40 13.4 
299 
Period III 
η % 
254 74.3 
61 17.8 
27 7.9 
342 
FEMALES 
Period I 
η % 
28 20.3 
80 58.0 
30 21.7 
138 
Period II 
η % 
63 49.6 
43 33.9 
21 16.5 
127 
Period III 
η % 
56 50.9 
33 30.0 
21 19.1 
110 
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Figure 2 
Percentage of the patients treated with antimicrobial agents, for each 
individual drug in each study period. In this figure total use of each 
drug is given, (both combined as single agent use). 
The number of patients treated with antimicrobial agents are respectively 
for these periods 278, 184 and 142. 
Monotheragy 
From the groups of patients treated with antimicrobial agents, also the 
pattern of single agent antimicrobial drug use was determined. 
From figure 3, it can be noticed that amoxycillin is most frequently 
used as a single drug. 
Its use was reduced considerably in the periods of introduction of the 
guidelines. Its use, based upon the total number of patients trea­
ted with antimicrobial agents decreased form 58% (period I) to 33% 
(period III). 
Infection rates 
Closed transurethral surgery 
The number of post operative urinary tract infections after endoresections 
shows a constant percentage of 25% in patient with preoperatively sterile 
urine. 
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Prom our (limited) data, no difference could be observed between pro­
phylaxis with antimicrobial agents and no special prophylaxis. 
Open non-transurethral surgery 
In 1979 a radical cystectomy with lymph and gland dissection was 
performed 14 times, 
A clear wound infection was observed in four cases, requiring surgical 
drainage. 
In one case, sepsis with a proteusstrain as causative microorganism 
was seen. 
In 1980, this operation was carried out 19 times under protection of 
gentamycin and lincomycin. 
No wound infections were observed. 
ANTIMICROBIAL TREATMENT ON A UROLOGY WARD 
•/.TREATED PATIENTS 
80 
60 
І 0 
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Jan-Jun 1979 no guidelines η=27β 
[ jQn-Jun1980 Introduction n=194 
Ш 
¡Я Ш Jul-Dec 1980 stabilisation n=139 
SINGLE AGENT USE 
A Amoxycillin 
T- Tnmethoprim-
S Sulfamethoxazol 
D Doxycyclin 
N Nitrofurantoin 
С Cephalosporin 
T-5 
Figure 3 
Percentage of the patients treated with antimicrobial agents, for each 
individual drug in each study period. In this figure only single agent 
drug use is given. The number of patients treated with antimicrobial 
agents are respectively for these periods 278, 184 and 142. 
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DISCUSSION 
In 1979 it was observed that 63% of the patients admitted to the de-
partment of Urology of Sint Radboud Hospital were treated during their 
hospitalization with antimicrobial agents. This percentage was considered 
as relatively high. 
It was suggested that the introduction of a rational antimicrobial policy 
could improve the quality of drug usage, and could lead to a reduction 
of drug usage. The guidelines of the Veterans Administration were used 
as a guide. Guidelines for appropriate antimicrobial usage were introduced 
and retrospectively reviewed to determine their effects. 
It is clear that the introduction of guidelines had significant effects 
on the prescribing policy of antimicrobial agents as have been shown 
in the figures 1,2 and 3 and table 2. 
A total reduction could be observed of over 50% of the percentage of 
patients that were treated with antimicrobial agents. 
This reduction of drug usage was combined with a reduced incidence of 
postoperative infections after open non-transurethral surgery. 
With the new guidelines no infections were observed in 19 cases of re-
triperitoneal lymph gland dissections. In contrary, before the guidelines, 
infections were observed 4 times in 14 cases. In one case, sepsis occured. 
It is however difficult to prove that the introduction of guidelines 
has been the only determining factor. Attention focussed on asepsis, 
technique improvement and wash-out techniques,(silent improvements of 
surgical handling)along with pre- and post operative parenteral nutri-
tion, could also contribute to lowering the percentage of wound infections. 
In the "closed" surgery a rather constant infection incidence was ob-
served. 
Here, the effects of prophylaxis however seem to be questioned even 
in patients with preoperatively infections of the urinary tract. 
(13, 14, 15, 16). 
Post operative infections have been treated with drugs such as nitro-
furantoin and trimethoprim (17). 
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However, as have been observed by several authors, prophylactic use 
of antimicrobial agents did hardly influence the incidence of post 
operative infections complications. (14, 15, 16, 19, 20). An increased 
urine flow with a diuretic such as furosemide has been promoted to prevent 
infections (21). 
Recently, pre- and post operatively bladder irrigation with povidone -
iodine solutions, has been mentioned as a means of prophylaxis in uri-
22 
nary tract infections 
Well controlled prospective studies are needed to determine the efficien­
cy of antimicrobial agents in these fields, before a more definitive 
policy can be prepared. 
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GUIDELINES FOR THE USE OF ANTIMICROBIAL AGENTS IN THE SINT RADBOUD 
HOSPITAL. 
H.L.H.Muytjens , R.J.Α. Goris , F.W.J. Gribnau , У.А. Hekster ,and 
C.G. van Oostrom . 
1 2 
From the departments of Medical Microbiology , General Surgery , 
Clinical Pharmacology , Clinical Pharmacy , and Pediatrics . 
Sint Radboud Hospital, University of Nijmegen, The Netherlands. 
SUMMARY 
In 1981 guidelines for the rational use of antimicrobial agents were 
introduced in the hospital. These guidelines were prepared in close 
cooperation with many responsible physicians. 
The manuscript covers the following topics: 
THERAPY general considerations 
meningitis 
endocarditis lenta 
sepsis 
deep fungal infections 
infections of the lower respiratory tract 
gastrointestinal infections 
eye infections 
surgical infections 
ear, nose and throat infections 
viral diseases 
toxoplasmosis 
urinary tract infections in adults 
urinary tract infections in children 
skin infections 
sexually transmitted diseases 
gynaecological infections 
obstetrical infections 
parasitic diseases 
323 
PROPHYLAXIS endocarditis lenta 
rheumatic (heart)diseases 
radiodiagnostic tests 
neutropenic patients 
gynaecological interventions 
surgical interventions 
urological interventions 
indwelling catheter 
malaria 
GENERAL INFORMATION drug interactions 
drug dosage in renal failure 
drug dosage in children 
drug use in pregnancy 
cross index of listed antimicrobial drugs 
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RECORD-LINKED AUDIT OF DRUG UTILIZATION DATA IN A 
HOSPITAL: ANTIMICROBIAL USE ON A UROLOGY WARD 
Y. A Hekster*, W. T. Friesen§ and J. B. J. Boeremaf 
Departments of Clinical Pharmacy* and Urology.^ St. Radboud Hospital, University of Nijmegen, The 
Netherlands and School of Pharmacy,§ University of Tasmania, Hobart, Australia 
SUMMARY 
Antimicrobial drug utilization patterns were studied on a urology ward with a 
view to establishing base-line data and subsequently determining drug usage 
data during the implementation of antimiúrobial prescribing guidelines. 
Methods of data collection, storage and interpretation are described. The 
results of therapeutic audit of the use of antimicrobial agents over a period of 
time during which discussion, constitution and acceptance of guidelines took 
place, are described. The effectiveness of a multidisciplinary approach in 
rationalizing drug prescribing and the effects of intensive monitoring on 
prescribing patterns are illustrated. 
INTRODUCTION 
In the last 50 years there has been a remarkable increase in the number of drugs used in 
medical practice (1). Furthermore, cost and prescription figures have shown a vast 
increase in drug utilization. It has become evident that drugs are frequently not used to 
their full potential nor according to generally accepted therapeutic criteria (2). This can be 
accounted for at least in part by the overwhelming array of prescription items which are 
available for use. It is therefore most important to study the manner in which drugs are 
prescribed; for what reasons, for which patients and with what results, in order to 
establish a base-line from which actual drug utilization data can be determined. Such 
therapeutic audits can only be carried out in close co-operation with all interested 
participants, using relatively small but representative samples. 
Drug Utilization Research (DUR) has been carried out on an international basis (3,4), 
and on a national basis comparing regional differences (5-7). For purposes of establishing 
prescribing guidelines with which medical practitioners can identify and influence it is best 
to study drug utilization patterns on a hospital-wide scale (8), or for purposes of 
establishing guidelines on particular wards or specialties, studies can be done on a ward or 
even individual patient level (8-10). 
Drug utilization has been defined as the marketing, distribution, prescription and use of 
Work carried out at: The St. Radboud Hospital, University of Nijmegen, The Netherlands. 
Paper presented at the European Society of Clinical Pharmacy workshop. 
Correspondence Y. A. Hekster, Department of Clinical Pharmacy, St. Radboud Hospital, Catholic 
University of Nijmegen, Geert Grooteplein Zuid no. 10, 6525 GA Nijmegen, The Netherlands. 
0143-3180/81/1200-0277S02.00 © 1981 Blackwell Scientific Publications 
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drugs in a society with special emphasis on the resulting medical, social and economic 
consequences (11). Drug utilization studies should be carried out taking these elements 
into account. 
This paper describes the techniques of data collection and the effectiveness of a 
multidisciplinary approach to improve the utilization pattern of drugs employing 
record-linked data collection, both computer-based and gleaned from individual patient 
records. 
METHODS 
In any hospital drug distribution system the following elements can be found and 
recorded in a variety of ways: 
1. Purchase 
2. Production 
3. Inventory stock 
4. Ward stock 
5. Patient record 
Collection and storage of data 
In the St. Radboud Hospital the pharmacy inventory is seen as the record of all 
deliveries to the central pharmacy and all drugs dispensed to individual wards, including 
all drugs returned to the pharmacy. These transactions are all recorded as drug item, 
quantity and date. The present computer-linked system thus records all drug transactions 
to and from particular wards but at present does not include recording individual patient 
drug consumption data. This patient medication data is collected using the individual 
medication registration sheet. 
These medication sheets are stored in the pharmacy department per time period 
(quarter) and per ward. Storage of the patient medication sheets in this manner facilitates 
the rapid collection of drug utilization data by manual methods. 
All computerized data are stored on tapes and printed on request. 
Selection of data 
Routinely the selection and printing of computer-stored data is carried out by Fortran 
when it concerns the drug surveys per period. Selection of individual drug data and other 
non-routine data is carried out using a compiling packet called 'Easy Trieve'. This packet 
allows the selection and printing of data using punchcards, time sharing and other entry 
systems. Selection of data can be for particular groups of drugs, individual drug items and 
individual wards based on turnover use of units, costs, drug handling, drug code, drug 
name, etc. Data on the administration of particular types of drugs to individual patients is 
collected manually from the patient medication sheets after the criteria for the study have 
been established. 
Units of comparison 
Several units of comparison for drug utilization are possible. For example, the total 
weight of a particular substance (e.g. albumin) can be determined. The costs of therapy 
can be assessed, the use in units can be determined or an estimate of the consumption 
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based on therapeutic criteria can be used. This latter approach is based on the Defined 
Daily Dose (DDD) developed by Lunde et al. (7). 
An adaptation of the DDD to reflect the consumption of individual drugs in a hospital 
or on a particular ward is necessary. To establish the adapted DDD the following data are 
taken into account: 
—Bed occupancy 
—Number of beds per unit studied (e.g. ward) 
—Period in days 
—Total DDD consumed 
The equation total DDD χ 100%/days χ beds χ (% occupancy) is regarded as the adapted 
DDD expressed as the probability that a patient is treated with the particular drug item, 
or the percentage of patients who are treated with that particular drug item. 
% patients 
70. 
ANTIMICROBIAL THERAPY 
UROLOGY 
1977(oct-dec) 
190 patients 
1979(oct-dec) 
233 patients 
1980(oct-dec) 
303 patients 
1 2 3 
drugs per patient 
Fig. 1. Proportion of urology patients receiving antimicrobial treatment and number of 
antimicrobial drugs per treated patient. Note the steadily improving situation during the 
discussion, constitution and implementation of prescribing guidelines. 
3 2 7 
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Investigations on the urology ward 
The ward which was chosen for investigation was a twenty-four bed urology ward on 
which the following sequence was to take place. Firstly, base-line data of antimicrobial 
drug utilization was to be collected. Secondly, prescribing practices on the ward were to be 
considered and discussed. Thirdly, guidelines for the prescribing of antimicrobial agents 
for prophylactic use and treatment of confirmed or suspected infections were to be 
formulated. Fourthly, once the guidelines were accepted, intensive monitoring of 
antimicrobial drug utilization was to take place. Throughout the study period, from 1977 
to 1980, continuous audits of drug usage were to be performed using both patient records 
and drug distribution data. 
RESULTS 
In a survey of antibiotic utilization patterns on a urology ward, it was found that the 
number of urology patients receiving antibiotic treatment, as determined by direct counts 
of patient records, declined steadily from 71-5% in 1977 to 63-5% in 1979 and to 38-6% in 
1980 (Fig. 1 ). The figure also shows that the majority of treated patients received only one 
antimicrobial drug and that the proportion of patients receiving single-agent treatment 
also steadily declined over the study period. The pattern of multiple drug antimicrobial 
therapy is also shown in this figure. 
Figure 2 shows that for single-agent antimicrobial treatment, amoxycillin was the drug 
of first choice in the large majority of cases in the study years 1977 and 1979. 
. SINGLE-AGENT ANTIMICROBIAL THERAPY 
i urology 
% treated patients 
100. 
D 1977(oct-dec) 
105 patients 
Ш 1979(oct-dec) 
121 patients 
amox ' tmp- •doxy ' ntn · s f z ^ ^ c e f p 
smx 
sTz ' c pfi 'noi oc • gent 
single drug item 
Fig. 2. Utilization pattern of single-agent antimicrobial treatment on a urology ward. 
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AMOXYCILLIN THERAPY 
urology 
% patients 
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94 patients 
— 1979(oc»-dec) 
108 patients 
1-2 3-4 T T 11-12 >12 Ί 5-6 ' 7-8 ' 9-10 
duration in days 
Fig. 3. Duration in days of amoxycillin treatment on a urology ward Discussions intended to 
standardize prescribing practices have resulted in two distinct periods of treatment duration by 
1979, representing prophylaxis and treatment 
80-
60. 
«X. 
20L 
AMOXYCILLIN-UROLOGY 
% probability (ODD/100 
bed-days) (oct-dec quarter) 
77 ' 78 ' 79 ' 80 
Fig. 4. The probability of a urology patient receiving amoxycillin treatment over a 4-year penod 
Antibiotic prescribing guidelines were established in 1980 The data are expressed as defined daily 
doses (DDD) per 100 bed-days 
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Co-trimoxazole use showed a slight increase from 1977 and 1979. The duration of 
amoxycillin therapy showed an interesting pattern between 1977 and 1979 (Fig. 3). 
Whereas there was no apparent pattern to the duration of therapy in 1977, the data for 
1979 showed two distinct peaks, one after two days and a second one at 9-10 days 
duration. 
Figure 4 shows the percentage probability of a urology patient receiving amoxycillin 
treatment computed from the ward drug distribution data and expressed in terms of the 
defined daily doses per 100 bed-days. This data shows an initial decline in the probability 
from 1977 to 1978, followed by an increase between 1978 and 1979. The most significant 
fall in the DDD value is seen between 1979 and 1980. 
DISCUSSION 
The results presented here, for the drug utilization of antimicrobial agents on a urology 
ward, show clearly that data can be collected and expressed in a variety of ways using both 
computer-assisted and manual techniques. 
The patterns of antimicrobial drug use per patient before, during and after the 
discussion, constitution and implementation of antimicrobial prescribing guidelines are 
seen from the data. The dramatic drop in antibiotic prescribing is illustrated by a 
continuous decline in the number of patients receiving antimicrobial treatment from 1977 
to 1980 (Fig. 1). The formation of duration of therapy data into two distinct peaks (Fig. 3) 
represents evidence that attempts to standardize treatment periods into prophylaxis (the 
first peak), and treatment of an established infection (the second peak) were largely 
successful. Whereas the data presented for the number of antimicrobial drugs per patient 
and duration of therapy were acquired directly from the patient records, the use of the 
hospital-adapted DDD expresses drug utilization data differently, i.e., as a probability 
based on units distributed to the ward (Fig. 4). This method is useful when direct data 
from patient records is difficult to obtain or when a rapid estimate of drug utilization 
patterns is desirable. The DDD utilizes pooled computer-stored data on the delivery of 
drugs to and the return of drugs from the ward stock. Thus it gives an indication of the 
overall drug consumption on the ward, expressed per 100 bed-days, adjusted for bed 
occupancy. In the case of amoxycillin utilization, the data revealed an overall reduction of 
the DDD per 100 bed-days over the study period. 
The various methods used to determine the patterns of antimicrobial drug use on a 
urology ward in this study all reveal a common trend. The decline in the number of 
patients receiving antimicrobial treatment, the evidence -of some standardization in 
treatment duration and the pattern of DDD consumption all correspond to (a) 
establishment of baseline data in 1977, (b) a period of discussion of antibiotic prescribing 
practices in 1978, (c) a transition period during which prescribing guidelines were being 
formulated and consitituted in 1979 and (d) the acceptance of the guidelines and 
monitoring of the adherance to those guidelines in July 1980. 
Some of the studies showed an increase in drug consumption between 1978 and 1979. 
This serves to illustrate how quickly prescribing practices can revert to pre-monitoring 
patterns. Prescribing guidelines were developed in 1979 and implemented in 1980. During 
this 2-year period intensive monitoring and extensive discussions took place and the 
beneficial results are obvious. 
The decline in antibiotic utilization on the urology ward is partially a result of a 
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limitation of the indications for the prophylactic use of antimicrobial agents prior to 
urological surgery as well as the implementation of guidelines to rationalize antibiotic 
treatment criteria (9) 
The results of this drug utilization survey and medical audit on a urology ward serves 
to show the benefits of a multidisciplmary approach to the rationalization of drug 
prescribing m a hospital These studies are of particular value because they concern small 
co-operating groups of investigators who are concerned about drug usage The 
data provides objective evidence of particular drug usage patterns and provides an 
opportunity for discussion of the situation and to formulate alternative or improved 
systems or procedures 
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SUMMARY 
Growing awareness of problems arising from over-use of antimicrobial agents 
has led to attempts to develop policies or guidelines for rational treatment To 
follow the effects of guidelines, the percentage of patients receiving anti­
microbial drug therapy, acquired from patient records, has been a frequently 
used parameter. In this paper the Defined Daily Dose (DDD) per 100 bed-days 
has been used instead. This parameter can be calculated by converting the 
number of units of antimicrobials, delivered to individual wards, to defined 
daily doses per bed-day. This parameter determines the probability of treating 
a patient with a particular drug, based on pooled data. The DDD per 100 bed-
days has been used to follow changes in prescribing habits arising from the 
acceptance of and adherence to guidelines over a period of 5 years in a Univer­
sity Hospital. 
INTRODUCTION 
Growing awareness of the problems arising from the use of antimicrobial agents has stimu­
lated many attempts to develop policies to control and improve their usage (1). A Working 
Group, the Veterans Administration ad hoc Interdisciplinary Advisory Committee on Anti­
microbial Usage, has published a series of articles about the conditions to be fulfilled in 
order to achieve an efficient policy for the use of antibiotics (2) and in recent years 
increased attention has been focused on the use of antimicrobial agents in hospitals (3-9). 
As a result of such attention, reports of significant decreases in antibiotic use and costs 
have appeared (5). Changing patterns in antimicrobial drug use have also been recognized. 
Some authors have shown that a reduction in antibiotic usage did not affect the number 
of infections nor the length of hospital stays due to infectious diseases (10). 
Advantges of rational anti-infection strategies on an Intensive Care Unit have also been 
described (11) and reduction in post-operative wound infections on a General Surgical 
Ward has been reported to follow such improved control (8). Most of the data on the use 
Correspondence: Y. A. Hekster, Department of Clinical Pharmacy, St Radboud Hospital, Catholic University 
of Nijmegen, Geert Grooteplein Zuid no. 8, 6925 GA Nijmegen, The Netherlands. 
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of antimicrobials in hospitals are recorded from medical records, or individual patient medi­
cation charts. These data are in general examined by a multi-disciplinary team. 
A main general problem, however, is the lack of uniformity in how drug information 
data are recorded. In the U.S.A. current national estimates of the extent of hospital drug 
use are based primarily upon pharmaceutical marketing data. Such information is insuf­
ficient for more detailed studies since it measures drug flow many steps away from actual 
patient 'consumption', and represents, at best, a crude approximation of hospital drug use 
(12). 
Scandinavian researchers have been at the forefront in expressing concern for the marked 
increase in drug consumption and related costs. Their statistics of sales are not represented 
in terms of cost or volume. Instead, the Defined Daily Dose was developed as a unit of 
comparison. 
The Defined Daily Dose (DDD) is not a recommended dose, but simply a technical 
unit of measurement. It gives by means of dose statistics reported in relation to population 
and time, (DDD per 1000 inhabitants per 24 h) an indication of the size of the population 
receiving a particular drug treatment. For hospital use, Bergman et ed., (13) have intro­
duced the number of DDDs per bed-day concept and recently, the DDD per 100 bed-days 
has been chosen as a unit of comparison between hospitals by the WHO, Drug Utilization 
Research Group. The DDD per 100 bed-days has been shown to be a suitable measure 
of drug-use in a hospital and as a parameter for therapeutic audit (13, 14). Corresponding 
results were observed between record-linked data, both computer-based and taken from 
individual patient records (14). 
In this paper the effects of guidelines and audit procedures of antimicrobial drug use 
in a hospital at ward levels over 5 years are described using the Defined Daily Dose as 
the unit of comparison. 
METHODS 
Collection of data 
The drug distribution system of any hospital has elements such as purchase, inventory 
stock, ward stock and patient records, for which records are kept by various methods. At 
the St Radboud Hospital the Pharmacy Inventory is seen as the record of all deliveries 
and returns to the central pharmacy and all drugs dispensed to the wards. These trans­
actions are all recorded as drug item, quantity and date. The present computer linked sys­
tem (IBM 158) records all drug transaction to and from individual wards, but at present 
does not yet include recording individual patients drug consumption data. This patient 
medication data is collected using the individual medication registration sheet. These medi­
cation sheets are stored in the pharmacy department per time period (quarter) and per 
ward. Storage of the patient medication sheets in this manner facilities rapid collection of 
drug utilization data by manual methods. All computerized data are stored on tapes and 
printed on request. 
Selection of data 
Routinely the selection and printing of computer-stored data is carried out by means 
of COBOL® language. Selection of individual data and other non-routine data is carried 
out using a compiling package called 'Easy Trieve®'. This package enables the selection 
for particular groups of drugs, individual drug items and individual wards based on turn­
over of units, costs, drug-handling, drug-code, drug-name etc. 
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Una of comparison 
In Drug Utilization Research several units of comparison can be used, for instance: (a) 
total weight of a particular substance, (b) units dispensed (c) total cost of therapy (d) per­
cent of the patients receiving a particular treatment and (e) defined daily dose. All the 
items can be calculated for the whole hospital, and for each department, ward or bed indi­
vidually. 
It is not always possible to quantitate all individual drugs and the number of units does 
not take the strength into consideration. Price variations with time and between prep­
arations and countries are also the norm and would suggest that only Defined Daily Dose 
should be used in Drug Utilization Research. 
Defined Daily Dose 
The Defined Daily Dose is the average maintenance dose for the main indication of a 
drug, per day (15). In general, it is also the most frequently prescribed dose. For example, 
the DDD of gentamkin is 240 mg (3 χ 80 mg/day), of metronidazole 1500 mg 
(3 χ 500 mg/day) parenteral administration), and lincomycin 1800 mg (3 χ 600 mg per day). 
The DDDs for antimicrobial agents were used according to the values listed in the 
Nordic statistics on medicine (15), and in Legemiddel forbruket i Norge 1980 (16). 
For some drugs, the DDD was not yet available. For these drugs the DDD was as 
follows: amikacin l-5g, azlocillin 15g, cefamandole 4g, cefotaxime 4g, cefoxitin 4g, 
cefuroxime 3 g, miconazole l-2g, netilmicin 0-4g, nitroxoline 0-4g and sulphametrole 
+trimethoprim like co-trimoxazole, trimethoprim 0-4 g. 
Qassification of antimicrobial drugs 
The antimicrobial agents from which the DDD has been calculated were classified in 
the following groups: penicillins, cephalosporins, lincomycin group, macrolides, tetra­
cyclines, chloramphenicole group, sulphonamides (including co-trimoxazole), urinary tract 
agents (including trimethoprim alone), aminoglycosides, antimycodcs, and metronidazole. 
Bed-day and DDD per 100 bed-days 
Bed-day is defined as: the average number of patients in the hospital or each ward per 
day; the days of admission and the discharge were counted as one bed-day. DDD per 100 
bed-days was used as previously described (13). 
Data on drug use 
Data on drug use were collected from the described wards of the St Radboud Hospital 
(956 beds). The following medical specialities were chosen: General Intensive Care Unit, 
seven beds; Cardiosurgical Intensive Care Unit, eight beds; General Surgery, thirty-two 
beds and Urology, twenty-four beds. On these wards, efforts were put to develop a rational 
antimicrobial drug policy. 
Introduction of guidelines 
The following sequence was adopted. Firstly, the 1976 base-line data for antimicrobial 
drug utilization was retrospectively collected. Secondly, current prescribing practices on 
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the wards were considered and discussed. Thirdly, guidelines for the prescribing of anti-
microbial agents for prophylactic use and treatment of confirmed or suspected infections 
were formulated. These guidelines were based upon literature data, susceptibility data and 
data on the pharmacodynamic and pharmacokinetic properties of the drugs. The guidelines 
were introduced at ward level and were followed by staff instruction. Evaluation of the 
clinical effects were based for instance on the number of post-operative wound infections. 
On the departments of General Surgery and Urology a reduction of this complication could 
be observed, although the type of operations became more complicated, and the number 
of operations increased. Some of these results have been described elsewhere (8), and some 
are in press. 
Fourthly, once the guidelines were accepted, intensive monitoring of antimicrobial drug 
utilization was carried out. Throughout the study period, from 1976 to 1980, continuous 
audits of drug usage and clinical results were performed using both patient records and 
drug distribution data. The data were examined by a multidisciplinary team. Based on this 
work, guidelines for the use of antimicrobial agents for the hospital have been introduced 
and were authorized by the Board of Directors of the hospital (17). 
RESULTS 
Collection and conversion of utilization data as described in the Methods section led to 
a DDD/100 bed-days-time profiles for each ward and drug sub-group. A description of 
the most relevant changes in drug use on different hospital wards is given in the following 
figures. 
Figure 1 shows the total number of Defined Daily Doses of antimicrobial agents per 
100 bed-days for the General Intensive Care Unit, Cardiosurgical Intensive Care Unit, 
and the departments of Urology, General Surgery and the total hospital during the years 
1976-1980. For all the groups a reduction in the number of DDDs of antimicrobial drugs 
per 100 bed-days can be observed to follow changes in antimicrobial policy and of the 
acceptance of guidelines and audit procedures. 
Figure 2 shows the pattern of use of antimicrobial agents as a group and the penicillins 
and the cephalosporins as subgroups in the hospital, expressed as the number of DDD/100 
bed-days, during the period 1976-1980. 
As with Figure 2, Figure 3, shows similar data for additional subgroups of antimicrobial 
agents. In this figure the increase in the use of aminoglycosides, and drugs used for the 
prophylaxis and treatment of anaerobic infections (lincomycin group, metronidazole) can 
be noticed. 
Besides the use of antimicrobials in general, Figure 4 shows the patterns for penicillins, 
cephalosporins and sulphonamides on the Cardiosurgical Intensive Care Unit. A rapid de-
crease in the use of antimicrobials from 300 to 117 DDD/100 bed-days has been achieved 
during 1976-1980. The introduction of newer cephalosporins has led to the replacement 
of ampicillin and fludoxacillin by a cephalosporin derivative in 1975-1976, for prophylactic 
purposes in open heart surgery. The effect of the replacement is clearly shown by the de-
crease in penicillin DDD/100 bed-days from 260 to 32 and a corresponding increase for 
the cephalosporins from 15 to 140 during the same period. In 1979 the duration of prophy-
laxis was reduced from 5 to 2 days. This effect can be seen in the reduction of DDD/100 
bed-days during 1979-1980. 
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Fig. 1. The decrease in use of antimicrobial agents, eipresaed as Defined Daily Doses per 100 
bed-days is given for the General Intensive Care, Cardiosurgical Intensive Care, Urological ward, 
General Surgical ward and total Hospital. 
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Fig. 2. Pattern of use of total antimicrobials, penicillins and cephalosporins is shown, expressed 
as DDD/100 bed-days for the total hospital. Λ reduction from 44 to 33 DDD/100 bed-days can 
be observed. 
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Fig. 3. Panero of use of some antimicrobial groups «pressed as DDD/100 bed-days for the total 
hospital. Note the introduction of cephalosporins. Amino-glycosides and metrozidazole use is 
increased as a result of drug policy. 
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Fig. 4. Pattern of use for the Cardiosurgical Intensive Care. A decrease can be observed from 300 
to 117 DDD/100 bed-days, for antimicrobial agents. The replacement of penicillins by cephalospor­
ins is clearly shown. 
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Figure 5 shows the patterns of antimicrobial drug-use in the General Intensive Care 
Unit. Ampicillin and fludoxacillin were also replaced by a cephalosporin derivative. A 
reduction from about 280 to 90 DDD/100 bed-days can be noticed for the penicillins and 
was paralled by a reduction in the total number of DDD/100 bed-days for antimicrobial 
drugs from 381 to 198 DDD/100 bed-days. 
Similar data were obtained for the General Surgical ward, where after the introduction 
of guidelines the DDD of penicillins decreased from 47 in 1976 to 16 DDD/100 bed-days 
in 1980, as shown in Figure 6. A total reduction from 64 to 29 DDD/100 bed-days was 
achieved, while the quality of patient care was improved based upon the number of post­
operative wound infections. There was no change in admission policy on this ward during 
the period of study. 
Figure 7 shows the data for the Urologica! ward. The total number of DDD/100 bed-
days has been reduced from 94 to 41 during the years 1976-1980. The reduction is obvious 
during 1979-1980 as a result of the introduction and audit of guidelines for prophylaxis. 
These mainly affected the use of amoxycillin. Although more complicated operations have 
been performed, the incidence of post-operative wound infections was reduced. 
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Fig. 5. Panera of use of antimicrobial drugs for the General Intensive Care. Total antimicrobial 
use u reduced from 381 to 198 DDD/100 bed-days. The penicillin reduction is a result of a change 
ш drug policy. 
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Flf. 6. Pattern of use for the General Surgical ward. IntroducDon of guidelines and audit of the 
guidelines have resulted in a decrease of total antimicrobials from 64 to 29 DDD/100 bed-days. 
In particular, penicillin use for ргорЬуІажіа ta» been limited. 
100· 
eo-
6 0 -
4 0 -
20" 
Urology 
Defined Daily Doses per 100 bed-days 
Τ 1 Γ 
1976 1977 1978 1979 Ι9Θ0 
Total 
antimicrobials 
'· Penicillins 
.«'¿SUpUnamides 
^ •^Cephalosporin 
Year 
Flf. 7. Pattern of use of antimicrobial drugs in the Urological ward. A reduction from 95 to 41 
DDD/100 bed-day* can be noticed. During 1979 an audit procedure has resulted in the rapid 
decrease for penicillin. 
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DISCUSSION AND CONCLUSION 
There are known differences in patterns of drug utilization within different hospitals (18, 
19). Also, the patterns of use of antimicrobial agents vary between hospitals and between 
medical specialties (3, 7, 8). It has become evident that antimicrobial drugs are frequently 
over-used (1, 2). Criteria for proper use of antimicrobial agents have been established by 
several authors with a view to rationalize prescribing policies (8, 9, 20). This is an import-
ant task, as the danger of over-use of antimicrobial agents does not only have a direct effect 
on the individual patient but also, as is now generally accepted, on the development of 
organisms causing 'hospital' infections. Many attempts have therefore been focused on the 
rational prescribing of antimicrobial agents in hospitals. It has been demonstrated that such 
approaches are very effective. Besides reductions in the cost of drug therapy, it has also 
been shown that appropriate drug therapy is of value in improving the quality of patient 
care (8, 11). 
In this study, the parameter DDD per 100 bed-days was used to monitor the effect of 
guidelines on antimicrobial drug-use. This· method is useful when direct data from patient 
records is difficult to obtain or when a rapid estimate of drug utilization patterns is desir-
able. The DDD per 100 bed-days utilizes pooled (computer-stored) data of the delivery 
of drugs to the wards. So, it will give an indication of the overall drug consumption on 
the ward, and does not give information of the use of antimicrobial agents per individual 
patient. It determines the probability that a patient might be treated, with a particular drug 
or drug group. The data obtained show the value of antibiotic guidelines as well as of the 
DDD per 100-bcd-days as a unit of comparison. 
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STELLINGEN 
behorend bij het proefschrift van Chiel Hekster, Selection Criteria 
for Antimicrobial Drug Utilization, 
Ni]megen, 3 juni 1983 
1. Indien de ratio tussen de plasma concentraties van Sulfamethoxazol 
en trimethoprim maatgevend is voor de werking, dient het gebruik 
van een kombinatiepreparaat waarbi] de komponenten in een vaste 
verhouding aanwezig zijn, bi] patiënten met verminderde nier-
funktie te worden ontraden. 
2. De mate van acetylering van para-aminofenyl groepen bevattende 
verbindingen zoals Sulfonamiden wordt bepaald door de ligging van 
het acetylenngs-deacetylerings evenwicht. Dit evenwicht is 
struktuur en species afhankelijk. 
Leibman,K.C., and Anaclerio,A.M. In: Metabolic factors controlling 
duration of drug actions, Pergamon Press, (1962), 91-96. 
Nawaz,M. Zentralblatt für Veterinärmedicin,27A (1980),75-80 . 
Vree, T.B., et al. Pharmaceutisch Weekblad, Scientific Edition 
5 (1983),49-56. 
3. Hondachtigen kunnen, tot zover bekend als enige diersoort in de 
schepping, 'schijnbaar' niet acetyleren. Dit fenomeen is te 
verklaren door een hogere snelheid van deacetylering ten opzichte 
van acety1ering. 
Vree, T.B., et al. Journal of Veterinary Pharmacology and Thera-
peutics, (1983) in press. 
4. Het begrip totale lichaamsklaring van een geneesmiddel geeft de 
indruk dat het geneesmiddel ook werkelijk uit het lichaam wordt 
verwijderd, en legt alle nadruk op het kinetisch gedrag van de 
moederverbinding. Metabolisme leidt echter niet tot verwijdering 
van stof. Meer aandacht dient gegeven te worden aan het werken met 
renale klaringen van zowel moederverbinding als ( alle) metabo-
lieten en de uiteindelijke massabalans. 
5. Een bifasisch verlopende plasmaconcentratie-tijd kurve moet niet 
automatisch beschreven worden met behulp van een twee komparti-
menten model. Ook metabole evenwichten kunnen leiden tot een 
bifasisch verlopende kurve. 
6. De gemeten verschillen in de halfwaardetijden van oxazepam, 
variërend van 3 tot 60 uur, kunnen verklaard worden op basis van 
het kinetisch gedrag van de langzaamste voorganger. 
7. Het bifasisch verloop van de plasmaconcentratie-tijd kurven van 
oxazepam,lorazepam, en temazepam kan worden toegeschreven aan een 
glucuroniderings-deglucuromderings evenwicht. 
Greenblatt, D.J., et al. Journal of Pharmaceutical Sciences, 68 
(1979), 57-63. 
8. Beperking van het assortiment van geneesmiddelen leidt niet 
vanzelfsprekend tot kostenbesparing. Voor een rationele benadering 
van de kosten dient de aandacht gericht te worden op gebruiks-
beperking. 
9. Nu het vergelijken van het gebruik van geneesmiddelen zowel op 
lokaal,regionaal als Internationaal nivo mogelijk wordt, aangezien 
zowel de internationaal via de WHO vastgestelde gemiddelde dag-
doseringseenheid (DDD) als de klassifikatiekode (АТС) aan een 
nationaal bestand van geneesmiddelen gegevens worden toegevoegd, 
dient de aandacht gericht te worden op het vinden van een 
consensus over de te vergelijken kenmerken. Deze gegevens maken 
het mogelijk tot een ijkbeleid te komen. 
10. Strukturering van het medisch handelen leidt in het algemeen tot 
een verbetering van de kwaliteit van dit handelen. Door invulling 
van individuele omstandigheden van de patient aan de uiteinden van 
de takken van de bealisboom kunnen een aantal bezwaren tegen 
protocollaire geneeskunde ondervangen worden. 
11. Gezien de beschreven interferenties van geneesmiddelen met 
klinisch-chemische laboratorium bepalingen, verdient het aanbeve­
ling een koppeling te maken tussen toegediende geneesmiddelen en 
klinisch-chemische laboratoriumuitslagen. 
Hansten,P.D. Drug Interactions, (1979), 301-491. 
Young,D.S., et al. Clinical Chemistry 21 (1975), 1D-432D. 
12. De gegevens over struma, afkomstig van de Stichting Medische 
Registratie (SMR) over de jaren 1965-1981, samen met de gegevens 
over het gemiddeld broodgebruik per hoofd van de bevolking in 
Nederland, tonen niet aan dat de daling van het broodgebruik heeft 
geleid tot een toename van struma. Toevoeging van extra jodium aan 
brood is niet te verdedigen op grond van vermeende strumatoename. 
13. Vormen van volksgeneeskunde (in niet-westerse landen), gebaseerd 
op holistisch denken en leven, kunnen nooit beoordeeld worden aan 
de hand van cartesiaanse maatstaven van de westerse officiële 
geneeskunde. 
14. Wetenschap maakt niets beter. 


